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Malaria has been a major driving force in the evolution of the human genome. In 
sub-Saharan African populations, two neighbouring polymorphisms in the 
Complement Receptor 1 (CR1) gene, named Swain-Langley (Sl2) and McCoy (McCb), 
occur at high frequencies, consistent with selection by malaria. This thesis 
investigates the association between these two polymorphisms and severe malaria. 
Previous studies into this area have produced conflicting findings.  
Using a large case-control study of severe malaria in Kenyan children and statistical 
models adjusted for confounders, I found that the Sl2 polymorphism was associated 
with markedly reduced odds of cerebral malaria and death, while the McCb 
polymorphism was associated with increased odds of cerebral malaria. I also 
identified an interaction between Sl2 and α+thalassaemia, with the protective 
association of Sl2 greatest in children with normal α-globin.  
Following these epidemiological findings, I explored potential biological hypotheses 
which might explain them. The first approach examined whether the Sl2 and McCb 
polymorphisms affected how CR1 forms clusters on erythrocyte membranes, a 
process which is key in the binding and transfer of immune complexes from 
erythrocytes to macrophages. Using erythrocytes from Kenyan children, I 
performed immunofluorescence assays (IFAs) with confocal microscopy to quantify 
CR1 cluster number and volume. I found no association between the Sl2 and McCb 
polymorphisms and either the number or volume of CR1 clusters formed.  
The second approach investigated whether the cerebral malaria-specific 
associations seen with Sl2 and McCb might be due to expression of CR1 by human 
brain endothelial cells (HBEC). The immortalised cell line HBEC-5i was investigated 
for expression of CR1 using IFA, flow cytometry, western blotting, functional C3b 
degradation assays, mass spectrometry, immunoprecipitation and siRNA 
knockdown experiments. A pool of α-CR1 monoclonal antibodies recognised an 
intracellular antigen in permeabilised HBEC-5i cells which was a similar molecular 
weight to CR1 on western blotting. However, when the α-CR1 monoclonal 
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antibodies were tested individually, only E11 recognised an HBEC-5i antigen. 
Further investigative approaches did not support the presence of CR1 on HBEC-5i 
cells, instead suggesting that E11 was not specific for CR1 and was instead 
recognising a protein in the Golgi apparatus.  
The final approach was to examine whether the Sl2 and McCb polymorphisms might 
influence the binding of the complement components mannose binding lectin, C1q 
and L-ficolin to the LHR-D region of CR1. I aimed to generate recombinant proteins 
of the LHR-D region which included the polymorphisms. Site-directed mutagenesis 
of the region was successful and subcloning and expression of the mutant 
amplicons will be performed at a later date.  
In summary, I have identified opposing associations between the Sl2 and McCb 
polymorphisms and cerebral malaria, which do not appear to be due to differences 
in CR1 clustering or expression of CR1 by human brain endothelial cells. My 
investigation into whether the polymorphisms might influence complement 








II. Lay Summary 
Malaria kills over half a million children in sub-Saharan Africa every year. 
Mosquitoes infected with malaria parasites spread them to humans when they bite. 
Once inside a human, the parasites infect the red blood cells. In severe cases, these 
red blood cells can stick to the walls of small blood vessels supplying the brain and 
hinder the flow of oxygen, causing a coma. This is called cerebral malaria and can be 
fatal. 
Small changes (called polymorphisms) in certain human genes can protect against 
malaria. Over time, polymorphismsthat protect people living in Africa from dying 
from malaria have been passed down through generations. Finding new 
polymorphisms that protect against malaria help scientists understand how severe 
malaria happens and eventually develop new drugs and vaccines against the 
disease. Some studies have found that polymorphismsin a gene called complement 
receptor 1 (CR1) may be protective against malaria, although others have disagreed. 
I set out to investigate this further in this thesis. 
Firstly, I analysed genetic and health information on more than 5,500 children in 
Kenya to see if the severity of malaria differed depending on whether they had a 
CR1 polymorphism. I found that children with one of these CR1 polymorphismswere 
a third less likely to get cerebral malaria and half as likely to die as children without 
the polymorphism. I also found that the CR1 polymorphismwas only protective 
against severe malaria when the child does not have another malaria-protective 
polymorphismcalled α-thalassemia. In children with α-thalassemia, the CR1 
polymorphismdoes not make a difference.  
I then tried to work out how this polymorphismmight protect against cerebral 
malaria and death. I looked at whether it might affect how CR1 molecules on red 
blood cells bunch up or “cluster” when they bind foreign particles, e.g. bits of 
microorganisms (which is one of the key jobs of CR1). I used blood samples from 
Kenyan children with and without the polymorphismand looked at the CR1 clusters 
which formed on them. I found that the mutation made no difference to the 
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number or the size of CR1 clusters, making this unlikely to be involved in the how 
the polymorphismprotects against cerebral malaria.  
After this, I wondered if brain blood vessel cells might have CR1 on their surface. If 
this was the case it could explain why the polymorphismprotected only against 
malaria in the brain and not elsewhere. I used human brain blood vessel cells that 
had been modified so that they could survive in a laboratory and employed many 
different scientific techniques to try and detect CR1 on these cells. However, I could 
not find any evidence that there was CR1 on the surface of brain blood vessels, 
making this unlikely to be how the polymorphismprotects against cerebral malaria. 
Finally, I decided to make some protein that contained the polymorphism myself so 
I could study it more closely and see how it might influence other parts of the 
immune system. I did this by taking a section of CR1 DNA (the genetic recipe which 
tells the body how to make CR1) and putting it into a bacteria, which I then used as 
a tiny factory to make more CR1 DNA. I used enzymes (biological molecules that 
carry out chemical reactions) to make the polymorphism in the CR1 DNA. My next 
project will be to use the bacteria to make CR1 with and without the polymorphism, 
so that I can see if it affects how CR1 interacts with other parts of the immune 
system.  
In summary, I have shown that Kenyan children with a polymorphismin CR1 are 
protected against cerebral malaria and death and that this doesn’t appear to be due 
to the polymorphismmaking CR1 cluster differently or due to brain blood vessels 
having CR1 on their surfaces. I am in the process of making CR1 proteins with and 
without the polymorphismin order to study them further and work out what the 
effect might be. If I can do that, further down the line, this may lead to a new drug 
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“What is wanted is not the wish to believe, 
 but the will to find out,  
which is the exact opposite.” 





1.1 The genetic arms race between man and malaria 
The greasy fingerprints of malaria run through the length of the human genome. For 
tens of thousands of years, each species has been attempting to outwit the other 
through the mutation, shuffling and repurposing of their genes, both with the 
ultimate goal of survival. Many of these genetic changes are not without cost. It is a 
sign of the magnitude of the threat from malaria that potentially fatal genetic 
mutations such as sickle cell have become firmly established in some populations as 
the payoff – protection against death from malaria – is so great. In return, the 
parasite expends huge amounts of energy in evading and subverting the human 
immune system. It is over 70 years since Haldane first suggested that the high 
frequency of β- thalassaemia in an Italian population was due to selection by 
malaria (Haldane, 1949) and we are still unearthing new human genetic 
polymorphisms that protect against the disease. More recently, we have begun to 
consider how individual human polymorphisms tessellate and interact to shape an 
individual’s susceptibility to malaria.  
This thesis explores two polymorphisms in the complement receptor 1 (CR1) gene 
whose role may have been inappropriately discounted in the genetic skirmish 
against malaria. These polymorphisms may yet provide a valuable window into 
alternative ways to protect against or treat malaria, if, as is so often the case, 







1.2 General background  
1.2.1 Global prevalence of malaria 
The World Health Organisation (WHO) estimated a global burden of 216 million 
cases of malaria including 445,000 deaths worldwide in 2016 (WHO, 2017).  Ninety 
percent of these cases occurred in sub-Saharan Africa, with the majority of deaths 
occurring in children under five years. The decline in malaria seen between 2010 
and 2014 has stalled, acting as a stark warning against complacency. The lack of an 
effective vaccine and the persistent threat of resistance to antimalarial drugs and 
insecticides ensure it is still a major challenge (Ashley et al., 2014; Sokhna et al., 
2013). The global distribution of malaria is detailed in Figure 1-1.  
 
 
Figure 1-1. Global burden of malaria cases and deaths from 2013. 
Age-standardised malaria incidence (top panel) and death (bottom panel) rates in 2013. 




1.2.2 The life cycle of Plasmodium falciparum 
Malaria is due to infection by Plasmodium parasites, of the phylum Apicomplexa. 
Five Plasmodium species can cause malaria in humans. Plasmodium falciparum is 
responsible for 99% of cases of malaria in Africa and the majority of global mortality 
(WHO, 2017) and is thought to have originated from the zoonotic transfer of P. 
praefalciparum from gorillas to humans approximately 10,000 years ago (Liu et al., 
2010). This thesis investigates genetic polymorphisms found almost exclusively in 
African populations and focuses entirely on P. falciparum. 
P. falciparum is transmitted when a human is bitten by an infected female 
Anopheles mosquito, which acts as the obligate host for parasite sexual 
development. Sporozoites are injected via the mosquito’s salivary glands during a 
blood meal. This initial injection usually contains less than 100 sporozoites, which 
travel through the circulation to invade hepatocytes (reviewed in (Prudêncio et al., 
2006)). Invasion is followed by intense mitosis and merozoites (exoerythrocytic 
forms of the parasite) are packaged into merosomes (Sturm et al., 2006). The 
parasite induces liver cell death and release of the merosomes into the circulation 
approximately six days after the mosquito bite.  
 
Figure 1-2. Life-cycle and developmental stages of P. falciparum.  
Image taken directly from (Rowe et al., 2009). 
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Once in the blood, merozoites invade erythrocytes via a complex process involving 
multiple receptor-ligand interactions (reviewed in (Cowman et al., 2012).  These 
interactions include complement receptor 1 (CR1) on the erythrocyte and the 
parasite adhesin P. falciparum reticulocyte-binding homologue 4 (PfRh4, see section 
1.7.2) 
The merozoite develops from ring stage to a mature pigmented trophozoite and 
finally to a schizont (Figure 1-3). During this process, the infected erythrocyte (IE) 
undergoes modification by the parasite including the digestion of haemoglobin to 
haem (toxic to the parasite) and then to haemozoin (non-toxic, reviewed in (Egan, 
2002)). As the parasite matures, the erythrocyte becomes increasingly rigid 
(Suwanarusk et al., 2004) and multiple parasite proteins are exported to the surface 
of its membrane. Each schizont gives rise to 8-36 daughter merozoites on rupture 
and the invasion process begins again (Garg et al., 2015). This cycle repeats every 48 
hours, with merozoites free in the circulation for only a matter of seconds. 
 
Figure 1-3. Intra-erythrocytic blood stages of P. falciparum.  
Ring stage (6-22 hours), trophozoite stage (22-38 hours) and schizont stage (38-48 hours).  
Merozoites can be seen at 48 hours prior to erythrocyte rupture and new invasion. 
 (Figure taken directly from (Radfar et al., 2009). 
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Not all merozoites follow this cycle, with some committing to differentiate into 
male or female gametocytes after invading an erythrocyte (Silvestrini et al., 2000). 
These forms are responsible for the transmission of the parasite from the human 
host to a new insect host. The male and female gametocytes are ingested during a 
mosquito blood meal and form a zygote in the insect’s midgut. The zygote forms an 
ookinete which infiltrates the midgut wall to form an oocyst, in turn producing 
thousands of sporozoites (reviewed in (Kuehn and Pradel, 2010)). The oocyst bursts 
releasing the sporozoites which migrate to the mosquito’s salivary gland, allowing 
the cycle to begin again. 
1.2.3 Clinical sub-phenotypes of malaria 
Infection with P. falciparum can result in a wide range of clinical symptoms ranging 
from asymptomatic parasitaemia to severe malaria. While diagnosis previously 
relied on detection by microscopy, antigen-based rapid diagnostic tests (RDTs) are 
now the standard of care in many settings, with an estimated 312 million RDTs 
carried out globally in 2017 (WHO, 2017).  
1.2.3.1 Uncomplicated malaria 
Although repeated infection with malaria results in acquired natural immunity, 
sterile immunity does not occur (reviewed in (Doolan et al., 2009; Hviid, 2005)). As 
such, some individuals are parasitaemic with no symptoms of the disease 
(asymptomatic malaria). In susceptible individuals, symptoms of uncomplicated 
malaria (UM) include fever and vomiting with rigors, headaches, malaise, muscle 
and joint pains and diarrhoea. Children can also present with a cough or difficulty 
breathing. Fevers coincide with schizont rupture and the release of merozoites from 
IEs, occurring every 48 hours (Golgi, 1886). However, the cluster of symptoms is 
often non-specific. First-line treatment for UM varies with local resistance, but 
involves three days of artemisinin-based combination therapy, which combines an 
artemisinin derivative (artemether, artesunate or dihydroartemesinin) with a 
longer-acting antimalarial with a different mechanism of action (lumefantrine, 
amodiaquine, mefloquine, piperaquine or sulfa-doxine-pyrimethamine) (World 
Health Organization and Global Malaria Programme, 2015). 
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1.2.3.2 Severe malaria 
Patterns of severe malaria vary with transmission intensity. In areas of stable, high 
transmission (e.g. sub-Saharan Africa), infants and young children are most at risk of 
severe disease (Carneiro et al., 2010; Snow et al., 1997)). However, in areas of 
unstable or low transmission (e.g. South East Asia), older children and adults are 
more likely to be affected (Dondorp et al., 2008a). In sub-Saharan Africa, the 
median age of patients with severe malaria is inversely proportional to transmission 
intensity, i.e. infants and young children suffering most in areas of high transmission 
(Modiano et al., 1998; Snow et al., 1994). In populations with year-round high 
transmission, the commonest manifestation of severe malaria is severe malarial 
anaemia (very young children), whereas in areas of lower or seasonal transmission, 
the picture is more of cerebral malaria (older children) (Modiano et al., 1998; Snow 
et al., 1994). While WHO collects data on UM cases and deaths, the burden of 
severe disease is harder to ascertain. However, the WHO estimates that “1-3% of 
uncomplicated cases were assumed to have moved to the severe stage” (WHO, 
2017).  
In areas of continual exposure, natural immunity to malaria increases with age. 
Immunity against severe disease is acquired rapidly, followed by immunity against 
mild malaria and finally, most malaria infections in adulthood are asymptomatic 
(Figure 1-4, (Marsh and Kinyanjui, 2006; White et al., 2014)). A prospective study of 
882 Tanzanian children revealed that most cases of severe malaria occurred after 
having one or more episodes of UM, rather than during their first infection 
(Gonçalves et al., 2014). In addition, although 102 children developed severe 
malaria over the study period, only 15 of these had a second episode. Examining the 
parasite densities of study participants revealed that this naturally acquired 





Figure 1-4. Severity of malaria varies with age in an area of moderate transmission.  
Repeated exposure results in development of protection against severe malaria, followed by mild 
malaria and finally some protection against asymptomatic malaria. 
(Image taken directly from (White et al., 2014), which is modified from (Marsh and Kinyanjui, 2006)). 
In sub-Saharan Africa, severe malaria is predominantly a disease of children, with 
the most common symptoms being impaired consciousness, seizures, respiratory 
difficulties, severe anaemia and jaundice with laboratory findings including 
hypoglycaemia, high lactate and metabolic acidosis (Marsh et al., 1995; WHO, 
2014). In particular, the presence of impaired consciousness or respiratory distress 
was found to predict 84% of deaths in Kenyan children admitted to hospital with 
malaria (Marsh et al., 1995). These symptoms are classically categorised into the 
(sometimes overlapping) syndromes of cerebral malaria (CM), severe malarial 
anaemia (SMA) and respiratory distress (RD, outlined below). Severe malaria can be 
difficult to diagnose as the symptoms and laboratory findings are similar to other 




1.2.3.3 Cerebral malaria 
Cerebral malaria (CM) is diagnosed when a patient is in an unrousable coma 
(Blantyre coma score ≤2) in association with P. falciparum parasitaemia and after 
the exclusion of other causes of coma (including prolonged seizure activity, 
hypoglycaemia and meningitis) (World Health Organization and Global Malaria 
Programme, 2015). However, even when this definition was strictly applied, an 
autopsy series of Malawian children diagnosed with “cerebral malaria” found that 7 
of the 31 children had actually died of other causes (Taylor et al., 2004). This 
misclassification was improved by an additional retinal examination which identifies 
retinal features that mirror the infected microvasculature in the brain. These 
include retinal whitening, retinal haemorrhages, vessel changes and papilloedema 
(reviewed in (Beare et al., 2006)). The mortality rate of CM in Africa varies from 15-
30% (Marsh et al., 1995; Molyneux et al., 1989; Oluwayemi et al., 2013; Walker et 
al., 1992; Waller et al., 1995), with 9-14% of survivors suffering from neurological 
sequelae (Molyneux et al., 1989; Oluwayemi et al., 2013). Current therapy for CM is 
sub-optimal, relying on the same anti-malarial medications as for UM together with 
supportive treatment and high quality nursing care (WHO, 2014).  
Intravenous artesunate has been the standard of care in severe malaria (World 
Health Organization and Global Malaria Programme, 2015) since an open-label 
randomised controlled trial across nine African countries comparing parenteral 
artesunate and quinine. Artesunate was associated with reduced mortality (OR 
0.75, 95% CI 0.63-0.90) (Dondorp et al., 2010). However, even in the arm receiving 
intravenous artesunate under trial conditions, CM mortality was still 18%.  
1.2.3.4 Severe malarial anaemia 
In children, severe malarial anaemia (SMA) is diagnosed as a haemoglobin of ≤5 
g/dL with a parasitaemia of >10,000/μL (World Health Organization and Global 
Malaria Programme, 2015). SMA is more common in younger children and in areas 
of stable malaria transmission (Snow et al., 1997). SMA has a mortality rate of 4-
16% when occurring alone which rises when presenting in combination with other 
syndromes (Marsh et al., 1995; Slutsker et al., 1994). SMA is multifactorial and 
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involves the destruction not only of deformed IEs by the spleen, but also uninfected 
bystander cells (Abdalla, 1988; Waitumbi et al., 2004) as well as dysregulation of 
erythropoiesis (Abugri et al., 2014; Dörmer et al., 1983). Nutritional status and 
intestinal parasites are also likely to be important in predisposition to SMA (Calis et 
al., 2008). In addition to anti-malarial treatment, SMA requires the transfusion of 
virus-screened fresh whole blood, which is often in short supply (World Health 
Organization and Global Malaria Programme, 2015). 
1.2.3.5 Respiratory distress  
In African children, respiratory distress is the manifestation of metabolic acidosis 
and represents the attempt to compensate for this through expellation of carbon 
dioxide. Metabolic acidosis is primarily due to the accumulation of lactic acid and 3-
hydroxybutyric acid (Sasi et al., 2007) and is strongly associated with increased 
mortality (Dondorp et al., 2010; Marsh et al., 1995). In some cases, respiratory 
distress can be due to concomitant pneumonia or cardiac failure due to severe 
anaemia (World Health Organization and Global Malaria Programme, 2015). Specific 
treatment is difficult, with the role of intravascular fluid replacement particularly 
unclear after a large study of febrile African children admitted to hospital with 
impaired tissue perfusion found that giving fluid boluses actually increased 
mortality when compared to maintenance fluids (Maitland et al., 2011). 
1.2.3.6 Malaria acute kidney injury 
Another severe life-threatening complication is malaria acute kidney injury (MAKI) 
clinically manifesting as oliguria, encephalopathy, cardiac dysrhythmias and acidosis 
(WHO, 2014). MAKI has also been associated with increased risk of neurodisability 
in African children and biomarkers of renal injury (cystatin C, blood urea nitrogen 
and urinary chitinase-3-like 1) also correlate with mortality (Conroy et al., 2016, 
2018; von Seidlein et al., 2012).  
MAKI is particularly common in adults in low malaria transmission areas of Asia and 
historically was not commonly reported in paediatric populations in sub-Saharan 
Africa (reviewed in (Mishra and Das, 2008)). A retrospective study from Nigeria 
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reported that MAKI only accounted for 3% of all paediatric severe malaria (Okpere 
et al., 2017). However, the prevalence of MAKI may be under-reported as children 
may not suffer overt clinical signs or they may be overshadowed by the more 
clinically evident symptoms of cerebral malaria. Indeed, one Gambian study found 
that 25% of children with cerebral malaria also had evidence of renal impairment 
(Weber et al., 1999). Another recent study examining the renal function of 180 
Ugandan children with severe malaria found 46% met the diagnostic criteria for 
MAKI (Conroy et al., 2016).  
The pathogenesis of MAKI is incompletely understood. Unlike CM, MAKI does not 
appear to be due to cytoadherence or sequestration of infected parasites 
(MacPherson et al., 1985; Nguansangiam et al., 2007). Instead, the pathological 
process may include malarial immune complex deposition in the glomerular 
capillaries, pro-inflammatory cytokines, reactive oxygen intermediates together 
with intravascular haemolysis, hypovolaemia and hypoxia  (reviewed in (Mishra and 
Das, 2008)). More recently, both haem and haemopexin have been implicated in 
the pathogenesis of AKI, possibly through the triggering of endothelial dysfunction 
and subsequent impairment of renal perfusion (Elphinstone et al., 2016). 
1.2.4 P. falciparum virulence factors 
The P. falciparum parasite has an extensive repertoire of virulence factors which 
result in cytoadherence and immune evasion. A hallmark of P. falciparum infection 
is the absence of mature parasite stages from the peripheral circulation. This is due 
to their adhesion to the endothelium of capillary venules, resulting in sequestration 
in multiple organs including the brain, heart, lung and gut (Milner et al., 2015) in 
order to avoid destruction by the liver and spleen (Mebius and Kraal, 2005). 
Pigmented trophozoites use three adhesion mechanisms; rosetting (adhesion to 
uninfected erythrocytes), cytoadherence to endothelial cells and platelet-mediated 
clumping (Figure 1-5 and reviewed in (Rowe et al., 2009)). IEs can assume one or 




Figure 1-5. Adhesion mechanisms of P. falciparum-infected erythrocytes to endothelial cells, platelets 
and other erythrocytes. 
 Image taken directly from (Rowe et al., 2009). 
Sequestration of parasitized erythrocytes may lead to obstruction of the 
microvasculature (Dondorp et al., 2004, 2008b), with the downstream effects of 
acidosis, hypoglycaemia and inflammatory mediator release (reviewed in (Planche 
and Krishna, 2006; Schofield, 2007)). 
1.2.4.1 P. falciparum variant surface antigens 
In order to evade the immune system, P. falciparum expresses hundreds of variant 
surface antigens (Miller et al., 2002; Scherf et al., 2008). Many variant antigens also 
mediate adhesion to host cells. The P. falciparum genome contains multi-gene 
families which include var genes (Baruch et al., 1995; Smith et al., 1995; Su et al., 
1995), the repetitive interspersed family (rif) (Cheng et al., 1998; Fernandez et al., 
1999; Kyes et al., 1999) and subtelomeric variant open reading frame (stevor) 
(Kaviratne et al., 2002). 
Parasite adhesion is predominantly mediated by P. falciparum erythrocyte 
membrane protein 1 (PfEMP1), a transmembrane protein expressed on the surface 
of IEs. Each parasite genome contains approximately 60 var genes, each encoding 
variants of PfEMP1 (Baruch et al., 1995; Smith et al., 1995; Su et al., 1995). One 
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PfEMP1 variant is expressed at any given time, and the parasite can switch var gene 
transcription with each erythrocytic cycle to avoid immune system recognition 
(Chen et al., 1998; Roberts et al., 1992). These var genes are classified into Group 
A,B, C and E, with Group A and B/A being associated with severe malaria and 
showing a non-CD36 binding phenotype, whereas Group B, C and B/C are associated 
with non-severe disease and CD36 binding (Avril et al., 2013; Claessens et al., 2012; 
Jensen et al., 2004; Kyriacou et al., 2006).  
PfEMP1 ligands include endothelial receptors (e.g. CD36, intracellular adhesion 
molecule 1 (ICAM-1), chondroitin sulfate A and endothelial protein C receptor 
(EPCR)), receptors on the erythrocyte surface (e.g. blood group antigens A and B, 
heparan sulfate and complement receptor 1 (CR1)) and serum components 
(including IgM, reviewed in (Bull and Abdi, 2016; Rowe et al., 2009)).  
1.2.4.2 Cytoadherence to endothelial cells 
The cytoadherence of IEs to endothelial cells is of particular interest in CM, where 
sequestration is implicated both in direct obstruction of the cerebral 
microvasculature and associated inflammation and coagulopathic changes (see also 
section 1.2.5) (Dondorp et al., 2004, 2008b; van der Heyde et al., 2006; Milner et al., 
2008). The endothelial binding receptors for PfEMP1 in CM are still to be fully 
elucidated. Some parasite strains can bind to ICAM-1 expressed on endothelial cells 
(Berendt et al., 1989) which may be upregulated by TNF stimulation in CM 
(Wassmer et al., 2011).  
A recently described P. falciparum binding receptor in brain endothelium is 
endothelial protein C receptor (EPCR) (Turner et al., 2013). EPCR binds specific 
adhesion domains (domain cassettes or DC) of PfEMP1; DC 8 and DC 13 (Lau et al., 
2015; Turner et al., 2013) which are associated with cerebral and severe malaria 
and also bind to human brain endothelial cells (HBECs) (Bertin et al., 2013; Lavstsen 
et al., 2012). There is also evidence that IEs use a combination of ICAM and EPCR to 
bind to HBECs (Avril et al., 2016). These findings were predominantly based on 
PfEMP1 recombinant protein experiments. However, recent work using parasite 
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lines expressing the same PfEMP1 variants as previously reported found they bound 
to HBEC and expressed DC 13, but did not bind to EPCR, questioning the biological 
relevance of EPCR in parasite sequestration in CM (Azasi et al., 2018). 
1.2.4.3 Rosetting 
A rosette is formed when an IE binds to two or more uninfected erythrocytes, a 
process which occurs spontaneously at various rates in field isolates 
(Udomsangpetch et al., 1989). Together with cytoadherence to endothelial cells, 
rosetting is a key mechanism in the obstruction of the microvasculature (reviewed 
in (Wahlgren et al., 2017)). In studies of African children, all sub-phenotypes of 
severe malaria have been associated with high rates of rosetting and larger rosettes 
when compared to cases of UM (Doumbo et al., 2009; Kun et al., 1998; Rowe et al., 
1995, 2002a, 2007; Treutiger et al., 1992). However, the association does not 
extend to south east Asia (Angkasekwinai et al., 1998; Ho et al., 1991), implying 
geographical differences in pathogenesis.  
PfEMP1 mediates rosetting (Rowe et al., 1997), with P. falciparum field isolates 
showing a strong association between rosetting frequency and Group A var gene 
transcription (Bull et al., 2005; Kyriacou et al., 2006; Warimwe et al., 2012). The best 
characterised rosetting receptor is complement receptor 1 (CR1), which is discussed 
in detail in section 1.7.1. In addition to erythrocyte receptors, serum components 
play a role, with decreased rosette frequency seen when parasites are cultured in 
serum-free media (Somner et al., 2000). Some rosetting parasites bind non-immune 
IgM, a property associated with increased severity of disease (Ghumra et al., 2008; 
Rowe et al., 2002a). IgM binding appears to reinforce rosettes by cross-linking 
PfEMP1 molecules (Stevenson et al., 2015a). α2-macroglobulin has also been 
reported as a serum rosetting factor, with the ability to cross-link PfEMP1, working 
synergistically with IgM in the development of rosettes (Stevenson et al., 2015b). 
1.2.4.4 Platelet-mediated clumping 
The auto-agglutination of IEs into clumps is mediated by platelets (Pain et al., 2001). 
In addition to contributing to microvascular obstruction, platelet clumping may 
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function as a bridge between IEs and activated endothelium (Wassmer et al., 2004). 
Platelet clumping has not been as extensively studied as rosetting and there is 
conflicting evidence as to the role it plays in the development of severe malaria in 
Africa (Arman et al., 2007; Mayor et al., 2011; Pain et al., 2001; Wassmer et al., 
2008). 
1.2.5 Cerebral malaria pathogenesis 
Despite decades of research, the pathogenesis of CM remains incompletely 
understood. Sequestration of mature P. falciparum IEs is one of the hallmarks of 
CM, with multiple autopsy studies reporting a higher level of parasite sequestration 
in the brain than in other organs (MacPherson et al., 1985; Milner et al., 2014; 
Pongponratn et al., 1991, 2003). Sequestration is associated with mechanical 
obstruction of the blood flow and impaired tissue perfusion and localised hypoxia 
(Dondorp et al., 2008b), with both infected and uninfected erythrocytes becoming 
less deformable (Dondorp et al., 1997). Importantly, a recent paper has reported 
that neurovascular sequestration of IEs can be directly observed at the bedside as 
orange discolouration of the retinal vessels on indirect ophthalmoscopy of 
Malawian children with CM (Barrera et al., 2018). Monocytes containing malaria 
pigment and fibrin–platelet thrombi have also been reported to sequester in the 
brain of African children with CM, particularly in those with HIV co-infection 
(Dorovini-Zis et al., 2011; Hochman et al., 2015). 
A series of detailed autopsy studies in Malawian children with CM defined two 
discrete phenotypes, those with sequestration alone (CM1) and those with 
additional intravascular and perivascular pathology (CM2), including ring 
haemorrhages and extra-erythrocytic pigment (Dorovini-Zis et al., 2011; Milner et 
al., 2014). These changes were associated with permeability of the blood-brain 
barrier (BBB) in African children, with evidence of fibrinogen extravasation 
associated with ring haemorrhages (Dorovini-Zis et al., 2011). This is in contrast to a 
large study of Thai adults with CM which found the BBB to be intact and CSF 
opening pressures to be lower in cases of fatal CM than in CM survivors (Warrell et 
al., 1986). However, a magnetic resonance imaging (MRI)-based investigation of 168 
1-15 
 
Malawian children with CM found that 84% of children who died with CM had 
evidence of severe brain swelling on admission, compared to 27% of CM-survivors, 
suggesting increased brain volume with raised intracranial pressure may influence 
CM outcome (Seydel et al., 2015). Following this, a detailed MRI study of CM in 
India (5 adults, 6 children) showed results consistent with vasogenic oedema in all 
patients, with 5 also showing venous congestion, which was considered to be due to 
the sequestration of IEs in the cerebral microvaculature (Mohanty et al., 2017). A 
recent Zambian MRI study of children with CM using a stronger magnetic field 
further supported this hypothesis that the cerebral oedema was vasogenic rather 
than cytotoxic in nature and that results were consistent with parasite 
sequestration, local inflammation and vascular congestion (Potchen et al., 2018).  
Other studies suggest activation and dysfunction of the cerebral microvascular 
endothelium are key in CM, occurring through a combination of direct interaction 
with IEs  and the effect of pro-inflammatory cytokines (reviewed in (Medana and 
Turner, 2006)). The rupturing of schizonts releases parasite toxins into the 
bloodstream, with the subsequent activation of monocytes and neutrophils and 
cytokine secretion (reviewed in (Gazzinelli and Denkers, 2006)). Pro-inflammatory 
cytokines IL-1β, IL-6 and IL-8 are raised in malaria-infected individuals and correlate 
with disease severity (Day et al., 1999; Lyke et al., 2004). Patients with CM have 
increased levels of both TNF-α and soluble TNF-α receptors, with high levels of the 
cytokine correlating with increased mortality (Kwiatkowski et al., 1990; Molyneux et 
al., 1993). TNF-α activates endothelial cells resulting in upregulation of surface 
receptors including ICAM-1, whilst stimulation of HBEC in vitro with TNF increases 
cytoadherence of parasitized erythrocytes (Wassmer et al., 2005). In addition, 
microvascular endothelial cells from the subcutaneous tissue of Malawian children 
with CM or UM showed differential reactivity to stimulation with TNF-α, with cells 
from CM patients showing higher ICAM-1 upregulation, IL-6 production and 
microparticle shedding (Wassmer et al., 2011). A pro-coagulant state is also seen in 
CM, with localised coagulopathy characterised by fibrin deposits reported in the 
brains of African children with CM (Dorovini-Zis et al., 2011). 
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1.2.6 Models of cerebral malaria  
In disentangling the pathology of any disease, a suitable model is necessary.  
1.2.6.1 Human model  
Historically, CM has been studied in humans using autopsies. By their nature, 
autopsy studies provide a static view of the disease end-point, with the disease 
process itself needing to be inferred. Access to patients who have died is limited 
and cultural and ethical issues pertaining to post-mortem studies must not be 
underestimated, particularly regarding children in resource-poor settings (Lewis et 
al., 2018; Lishimpi et al., 2001). Autopsy studies also compare brains with CM 
against those from patients who died from other causes, rather than against 
healthy individuals. The brains of survivors are, by definition, unavailable for 
comparison. 
There a number of complementary methods to investigate CM during life. These 
approaches include ocular fundoscopy, which has described a unique malaria 
retinopathy, increasing specificity in CM diagnosis (reviewed in (Beare et al., 2006)). 
In addition, neuroimaging enables sequential visualisation throughout the disease 
process and during follow up of CM survivors. Computed tomography (CT) has been 
crucial in establishing the increase in brain volume seen in CM (Mohanty et al., 
2011; Newton et al., 1994; Patankar et al., 2002) and the technology is more widely 
available than magnetic resonance imaging (MRI). However, the detail afforded by 
MRI together with the ability to perform functional MRI (fMRI) scans makes this 
modality the current neuroimaging of choice (Looareesuwan et al., 2009; Mohanty 
et al., 2014) However, the availability of MRI scanners in malaria-endemic areas has 
limited this approach to a few key research centres.  
Microcirculatory studies provide another dynamic route of investigation, with 
orthogonal polarization spectral imaging used to examine accessible areas of 
microcirculation during severe malaria as a proxy for the disease process in the 
brain (Dondorp et al., 2008b; Hanson et al., 2012, 2015). However, heterogeneity of 
endothelial cells means findings may not be extrapolatable to the brain (Aird, 2012). 
1-17 
 
1.2.6.2 Murine models 
While the use of mouse models has been indispensable in the investigation of many 
diseases, their place in CM is a subject of heated debate. As P. falciparum does not 
infect mice, alternative rodent parasites are required, including P. chabaudi, P. 
berghei and P. yoelii. In particular, the P. berghei ANKA infection in CBA or CB57BL/6 
mice is a commonly used model with mice genetically resistant or susceptible to CM 
(reviewed in (Lou et al., 2001)). However, this model results in markedly different 
histopathological features to human CM. The major difference is in sequestration of 
IEs in the cerebral microvasculature, which is a hallmark of post-mortem studies of 
human CM (e.g. (Barrera et al., 2018; Dorovini-Zis et al., 2011; Seydel et al., 2006; 
Turner et al., 1994) but not consistently reported in murine CM studies, which are 
instead associated with the accumulation of leucocytes in the brain vessels and 
varying levels of IEs in multiple organs (Cabrales et al., 2010; Franke-Fayard et al., 
2005; Riley et al., 2010). Indeed, these differences have led one researcher to quip: 
“(…) one cannot have cerebral malaria without cerebral sequestration (unless, of 
course, you are a mouse)…” (Milner, 2010).  Some researchers consider the 
processes in murine CM to be so different from human CM that the “(…) 
pathological and therapeutic interpretations derived from it were largely irrelevant 
for the understanding and treatment of HCM (human CM) (Craig et al., 2012).” 
Findings from murine CM studies must be interpreted with caution. 
1.2.6.3 In vitro models 
A number of endothelial cell lines have been used in the investigation of CM. 
Human umbilical vein endothelial cells (HUVECs) are primary cells which can easily 
be obtained at birth. HUVECs have historically been used in studies of malaria 
pathogenesis (Nash et al., 1992; Udeinya et al., 1981) but have significant 
limitations. In addition to their variability between donors, HUVECS are 
macrovascular cells, and are not the usual target for IE sequestration. Primary 
human brain endothelial cells (HBEC) circumvent one of these issues and have been 
used widely in the study of CM (e.g. (Adams et al., 2014; Avril et al., 2012, 2016; 
Claessens et al., 2012)), however genetic and environmental differences between 
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donors may again influence findings and their reproducibility (reviewed in (Bouïs et 
al., 2001). In addition, both primary cell lines are limited by the length of time they 
can be cultured and the potential for contamination with unwanted cells from the 
donor.  
Immortalised human brain endothelial cell lines, which include the HBEC-5i 
(Dorovini-Zis et al., 1991; Wassmer et al., 2006) and hCMEC/D3 lines (Weksler et al., 
2013), provide a reproducible cerebral microvascular environment which can be 
cultured with parasitized erythrocytes. Although many additions can be made to 
this approach, for example co-culturing with peripheral blood mononuclear cells 
(PBMCs) (Khaw et al., 2013), or platelets (Wassmer et al., 2006), the approach is 
inherently limited by the absence of the immune system. In addition, the 
immortalisation process may result in unanticipated changes to the properties of 
these cells (Urich et al., 2012) and as such, findings require replication in primary 
HBEC experiments.  
It is evident that no perfect model of CM exists, however immortalised HBEC-based 
models may provide the clearest starting point for investigating cellular level 
hypotheses in CM.  
1.3 Host genetic resistance against malaria 
Host genetic factors play a large role in an individual’s susceptibility to severe 
malaria with one Kenyan study estimating 25% of the variation in malaria 
hospitalisation rates was attributable to genetic factors (Mackinnon et al., 2005). Of 
particular interest are erythrocyte polymorphisms. Two of the most widely reported 
polymorphisms in sub-Saharan Africa are sickle cell trait and α+thalassaemia, whose 
geographical distributions closely mirror the incidence of malaria (Figure 1-6) (Flint 




Figure 1-6. Approximate distributions of malaria, HbS and α+thalassemia in sub-Saharan Africa. 
Deletions of the −α3.7 type are the most common cause of α+thalassemia in Africa. 
 Image taken directly from (Wellems and Fairhurst, 2005) 
  
1.3.1 Sickle cell trait 
The sickle cell polymorphism was the first point mutation to be associated with 
malaria over 50 years ago (Allison, 1964). The polymorphism comprises a glutamic 
acid to valine substitution in the β-globin gene on chromosome 11, resulting in the 
unstable haemoglobin variant HbS (Serjeant and Serjeant, 2001). The heterozygous 
form (HbAS, sickle cell trait) is clinically silent, but confers a high degree of 
protection against all forms of severe and UM (Taylor et al., 2012; Williams et al., 
2005a). The strength of association is staggering, with results from a recent large 
multi-centre study into severe malaria across 12 locations in Africa, Asia and 
Oceania reporting that HbAS was associated with reduced odds of all severe malaria 
(OR 0.14, p = 1.6 × 10−225), CM (OR 0.11, p = 4.7 × 10−88) and SMA (OR 0.11, p = 9.3 × 
10−65) (Rockett et al., 2014). Sickle cell represents a classic example of a balanced 
mutation, with protection against malaria for heterozygotes, whilst homozygotes 
(HbSS) suffer from severe sickle cell disease, which is fatal without modern medical 
input. The protective mechanisms of HbAS have not been confirmed but may 
involve the early removal of IEs (Ayi et al., 2004), lower levels of rosetting (Carlson 
et al., 1994; Udomsangpetch et al., 1993), decreased cytoadherence and a 




α+thalassaemia arises from a deletion in the α-globin gene on chromosome 16, 
resulting in inadequate synthesis of α-globin (reviewed in (Weatherall and Clegg, 
2001). The most common polymorphism responsible for α+thalassaemia in African 
populations is the 3.7-kb α-globin deletion. (Flint et al., 1998). Both heterozygous     
(-α, αα) and homozygous (-α,-α) forms have been reported to protect against 
severe malaria (Taylor et al., 2012; Williams et al., 2005b). A metanalysis examining 
the relationship between α+thalassaemia and severe malaria reported an odds ratio 
of 0.63 (95% CI 0.48-0.83) for homozygotes and 0.83 (95% CI 0.74-0.92) for 
heterozygotes (Taylor et al., 2012). In contrast, the polymorphism did not influence 
parasite density or protect against UM (Taylor et al., 2012; Williams et al., 1996, 
2005b). 
The protective mechanisms for α+thalassaemia may include the formation of 
smaller, weaker rosettes (Carlson et al., 1994), reduced cytoadherence (Butthep et 
al., 2006; Krause et al., 2012) and the spreading of haemoglobin across a higher 
number of smaller erythrocytes (Fowkes et al., 2008). Protection offered by 
α+thalassaemia may not be limited to malaria, with a report from Papua New 
Guinea associating the polymorphismwith protection against severe non-malaria 
disease such as respiratory infections, gastroenteritis and meningitis (Allen et al., 
1997). 
1.3.3 Polymorphisms associated with protection against cerebral 
malaria  
1.3.3.1 Southeast Asian ovalocytosis 
Southeast Asian ovalocytosis (SAO) causes erythrocytes to be ovoid instead of 
biconcave discs and is caused by a deletion mutation in the erythrocyte membrane 
protein band 3 (SLC4A1Δ27), with heterozygosity specifically associated with 
protection against CM in Papua New Guinea (Allen et al., 1999; Genton et al., 1995). 
Not a single individual with SAO was found to suffer from CM across these two 
studies. P. falciparum infected SAO erythrocytes showed a marked increase in 
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binding to the endothelial receptor CD36 under flow conditions (Cortés et al., 2005). 
As CD36 is only sparsely expressed on brain endothelial cells (Turner et al., 1994), 
CD36 on endothelium out-with the brain may act as a decoy increasing 
sequestration outside of the cerebral microvascularture. Indeed, a clinical trial of 
exchange transfusions from donors with SAO has recently been suggested as a 
treatment for CM (Jajosky et al., 2017).  
1.3.3.2 HbC 
Another example of a red blood cell polymorphism with reported CM-specific 
protection is the structural variant of haemoglobin, HbC (May et al., 2007). 
Although the heterozygous state (HbAC) had been previously associated with 
protection against other forms of severe malaria in other smaller studies (Agarwal 
et al., 2000; Mockenhaupt et al., 2004), this larger study by May et al. carefully 
stratified patients by clinical outcome to identify the association of HbAC with a 
reduced OR of CM (0.64, 95% CI 0.45-0.91, p=0.03). This specificity may be due to 
the finding that P. falciparum infected HbAC erythrocytes express ~30% less PfEMP1 
on their membranes, potentially altering their ability to bind to cerebral 
endothelium (Fairhurst et al., 2005).  
1.3.3.3 Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
An alternate model for protection against CM can be seen in the X-linked condition 
glucose-6-phosphate dehydrogenase (G6PD) deficiency. Recently, evidence has 
been building that increasing levels of G6PD deficiency are associated with 
decreased odds of CM but increased risk of severe malaria anaemia (Clarke et al., 
2017; Rockett et al., 2014; Uyoga et al., 2015). A working hypothesis for this CM-
specificity is lacking at present, with evidence suggesting more global effects of the 
polymorphism on early phagocytosis of ring-stage infected G6PD erythrocytes 
(Cappadoro et al., 1998) and inhibition of P. falciparum growth inside G6PD 




1.4 The complement system 
1.4.1 Complement activation and function 
The complement system is a network of almost 60 fluid-phase and membrane-
bound proteins (Elvington et al., 2016). Complement activation produces three 
main effectors: the anaphylatoxins C3a and C5a, which result in leucocyte activation 
and recruitment, the opsonins C3b, iC3b, and C3d, which bind to and identify target 
cells and immune complexes (ICs) for removal by phagocytes and the terminal 
membrane attack complex (MAC, C5b-9) which causes direct cell lysis (reviewed in 
(Noris and Remuzzi, 2013)). Complement activation is triggered by danger signals 
via three major pathways; the classical (CP), alternative (AP) and lectin pathways 
(LP), which all lead to the production of a C3 convertase.  
In the CP, the initiator molecule C1q binds to antigen-antibody complexes 
containing IgG or IgM or to other molecules including C-reactive protein and 
apoptotic/necrotic cells (Nauta et al., 2003), with sequential activation of C1r and 
C1s. Activated C1s then cleaves C4 (to C4a and C4b) and C2 (to C2a and C2b). 
C4bC2a, a C3 convertase, is then formed (reviewed in (Orsini et al., 2014)).   
The LP produces the same C3 convertase, but via a different mechanism. Mannose 
binding lectin (MBL, structurally and functionally similar to C1q), collectins or 
ficolins act as the initiator molecules by recognising carbohydrate patterns including 
N-acetylglucosamine or mannose (reviewed in (Garred et al., 2016)), providing 
specificity for altered endogenous and exogenous surfaces (reviewed in (Takahashi 
and Ezekowitz, 2005)). This binding activates MBL-associated serine proteases 
(MASP-1, MASP-2 and MASP-3), cleaving C4 and C2 to form the C3 convertase 
C4b2a in a manner reminiscent of the classical pathway (Ehrnthaller et al., 2011; 
Vorup-Jensen et al., 2000). Regardless of whether the C3 convertase C4b2a has 
originated from the LP or CP, it is then able to cleave C3 to C3a and C3b. C3b 
subsequently complexes with C4b2a to form C4b2a3b, a C5 convertase. 
Activation of the AP is slightly different and is due to the slow, spontaneous 
hydrolysis of C3 in the circulation to form C3(H2O), known as “tick-over.” C3(H2O) 
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binds factor B which is cleaved by factor D to form C3(H2O)b, which is the C3 
convertase of the AP, cleaving C3 into C3a and C3b. This C3b has three fates; 
amplification of the pathway by creating more C3 convertase (C3bBb), binding to an 
existing molecule of C3bBb to form the C3bBb3b complex (which is a C5 
convertase), or inactivation by factor I and a cofactor. 
Both C5 convertases (C4b2a3b and C3bBb3b) cleave C5 to C5a (anaphylotoxin) and 
C5b, which interacts with C6, C7, C8 and C9 to form C5b–9, the membrane attack 
complex (MAC), which is inserted into the target cell membrane, creating a pore 
which leads to cell lysis (reviewed in (Morgan, 1999)). In addition to the MAC, 
complement activation produces the opsonins C3b, iC3b, and C3d and C3a and C5a 
fragments. The latter are potent anaphylatoxins with roles in leucocyte chemotaxis, 
adhesion and up-regulation of vascular adhesion molecules on the endothelium 
(Albrecht et al., 2004; Hugli, 1981). Thrombin, plasmin and factors IXa, Xa, and XIa 
can also cleave C3 and C5 (Amara et al., 2010). A simplified overview of these 
pathways and their downstream effects is shown in Figure 1-7. 
1.4.2 Complement regulation 
The destructive abilities of complement are powerful but fairly non-specific and 
excessive complement activation on self tissue can have severe effects. To counter 
this, a number of complement regulators help to restrict inappropriate activation 
and amplification. Two functions are key; inactivation of C3b (and C4b) and 
acceleration of the decay of the C3 and C5 convertase complexes. Factor I is 
necessary for the inactivation of C3b and C4b, but requires the presence of a 
cofactor. Five complement regulators perform the tasks of decay acceleration and/ 
or cofactor activity; the membrane-bound regulators complement receptor 1 (CR1), 
membrane cofactor protein (MCP) and decay accelerating factor (DAF), and the 
soluble regulators factor H (FH) and C4 binding protein (C4BP). These homologues 
belong to the regulators of complement activation (RCA) family which are made up 
of complement control protein (CCP) modules (reviewed in (Kirkitadze and Barlow, 
2001). The regulatory protein CR1 is discussed in detail in section 1.6 and its points 




Figure 1-7. Overview of the pathways of complement activation.  
See text for details. 
 Points marked CR1 indicate where complement receptor 1 acts to inhibit complement activation.  
In addition, CR1 acts as a cofactor with factor I to bind and degrade C3b. 




1.4.3 Exploitation by microorganisms 
Subversion of the host immune system is a common strategy used by pathogens 
and the wide variety of complement receptors and regulatory proteins provides 
fertile ground for such subterfuge. Immune evasion includes the acquisition or 
mimicking of complement regulators, for example the expression of a factor H-
binding protein by strains of Neisseria meningitidis (Biagini et al., 2016; Schneider et 
al., 2009). Another approach is to degrade complement proteins, e.g. Pseudomonas 
aeruginosa which produces elastase to break down C3 (Schmidtchen et al., 2003).  
Other pathogens voluntarily activate the cascade, allowing themselves to be 
opsonised, interact with complement receptors and gain entry to the host cells 
(reviewed in (Lambris et al., 2008)). Many pathogens use CR1 as an invasion 
receptor, including Mycobacteria tuberculosis and M. leprae into monocytes and 
macrophages (Schlesinger and Horwitz, 1990; Schlesinger et al., 1990), Legionella 
pneumophila into monocytes (Payne and Horwitz, 1987) and Leishmania spp. into 
macrophages (Da Silva et al., 1989). 
1.5 Complement and malaria 
An association between malaria and complement activation was first described 100 
years ago, when it was noted that erythrocytes from an infected individual were 
able to activate complement in vitro (Thomson, 1918). Evidence of complement 
activation has been consistently reported in malaria, with depletion of complement 
components C3, C4 and C1q (Ade-Serrano et al., 1981; Greenwood and Brueton, 
1974; Neva et al., 1974; Phanuphak et al., 1985; Srichaikul et al., 1975) and an 
increase in the level of soluble MAC (sC5b-9) (Berg et al., 2015; Roestenberg et al., 
2007). Complement activation correlates with severity of disease with level of 
activation associated with increased production of IL-6, IL-8, monocyte chemotactic 
protein 1 and macrophage inflammatory protein 1β (Berg et al., 2015; Nyakoe et al., 
2009). Parasite components have been reported to activate complement, including 
merozoites (Korir et al., 2014), the digestive vacuole (Dasari et al., 2012, 2014), 
haemozoin and haematin (Berg et al., 2015; Pawluczkowycz et al., 2007). 
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Infection with P. falciparum is associated with all three pathways of complement 
activation.  Elevated levels of C1rs-C1inh were found in experimental human P. 
falciparum infection (Roestenberg et al., 2007), together with an increased 
clearance of radiolabelled C1q in natural P. falciparum infections (Srichaikul et al., 
1975), implicating CP involvement. An increased level of C3bBb has also been 
reported in malarial infection (Roestenberg et al., 2007; Wenisch et al., 1997), 
suggesting concurrent AP involvement. The LP has also been linked with malaria, 
with three studies reporting MBL’s ability to recognise malarial antigens (Garred et 
al., 2003; Klabunde et al., 2002; Korir et al., 2014). Complement activation was 
investigated using a case-control study of Kenyan children with UM or SMA and a 
functional complement activity ELISA (Nyakoe et al., 2009). The authors reported 
100% consumption of the LP, 90% consumption of the CP and 63% consumption of 
the AP in children with SMA. Over half of the children with SMA had no measurable 
activity across all three complement pathways, suggesting complete consumption. 
1.5.1 Complement and cerebral malaria 
Of particular interest to this thesis is the role of complement in the development of 
CM. Complement activation was originally suspected when adult CM patients were 
found to be hypocomplementaemic with higher levels of the complement activation 
product C3d than patients with UM (9 CM cases, 23 UM cases) (Adam et al., 1981). 
Other reports of complement activation in severe malaria have included small 
numbers of CM cases alongside other severe phenotypes (Helegbe et al., 2007; 
Phanuphak et al., 1985; Srichaikul et al., 1975), or give no details on CM cases 
(Nyakoe et al., 2009). One such report included 23 adult Thai patients with severe 
malaria of whom 18 were diagnosed with CM (Wenisch et al., 1997). This study 
reported a marked increase in the complement activation products MAC, C4d (C4b 
degradation product) and Bb (product of factor B cleavage by factor D) in cases 
compared to healthy controls, indicating CP and AP activation in a group of 
(predominantly) CM cases. A small study of Ugandan children (n = 64) also reported 
significantly higher in C5a levels in children with CM than UM (Kim et al., 2014).  
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Direct histopathological investigation of complement activation in CM is distinctly 
lacking. Staining for complement components or receptors was not included in the 
major autopsy studies of Malawian children with CM (Dorovini-Zis et al., 2011; 
Hochman et al., 2015; Milner et al., 2014). The first direct histopathological 
evidence of complement activation in the brains of patients with CM was reported 
from an autopsy series of eight Malawian children with CM, which showed high 
levels of intravascular α-C5b-9 staining (membrane attack complex, MAC) in 
association with sequestered IEs (Brown et al., 2001). A more recent study 
investigating complement deposition on erythrocytes in P. falciparum infection also 
presented brief data on complement deposition on the brain of seven Thai adults 
with CM (Dasari et al., 2014). Brain paraffin sections were stained with α-C3d and α-
C5b-9, with cortical capillaries staining for both complement components. The MAC 
may have a modulatory role in CM as administration of MAC to endothelial cells has 
been reported to upregulate expression of ICAM-1 (Kilgore et al., 1995), a receptor 
involved in the parasite sequestration (discussed in section 1.2.4). 
A causal role for complement activation in the pathogenesis of malaria has been 
difficult to establish. As with much of the data on CM pathogenesis, the role of 
complement in the disease has been examined in greater detail in mouse rather 
than human studies. The role of complement in murine CM has been well reviewed 
(Biryukov and Stoute, 2014; Schmidt et al., 2015). In brief, the data suggests a large 
role for C5a, with susceptibility to murine CM correlating to the ability to produce 
functional C5a or C5a receptors and treatment of mice with CM with C5a-blocking 
antibody providing partial resistance (Kim et al., 2014; Patel et al., 2008). Others 
have questioned this need for C5a and suggested a role for MAC, with the finding of 
C9 deposits in the brains of mice with CM and treatment with an α-C9 antibody 
reducing mortality (Ramos et al., 2011). Whilst murine data are important, it should 
be recalled how different murine CM (with a strong role for inflammation) is from 
human CM (with a strong role for sequestration, section 1.2.6). It appears the role 
of complement in human CM is unclear, not because studies are conflicting, but 
because they are so scarce.   
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1.6 Complement receptor one (CR1) 
1.6.1 Expression and structure  
Complement receptor 1 (CR1, also known as CD35) is a large transmembrane 
glycoprotein and a key regulator of complement activation. CR1 is expressed on the 
membrane of most peripheral blood cells including erythrocytes, monocytes, 
neutrophils and B lymphocytes but is absent from platelets, natural killer cells and 
most T cells (Fearon, 1980; Tedder et al., 1983). Although leucocytes express up to 
100 times more CR1 than erythrocytes, the absolute number of erythrocytes means 
that they account for >85% of CR1 in the peripheral blood (reviewed by (Moulds, 
2010)). CR1 is also expressed by follicular dendritic cells (Reynes et al., 1985), retinal 
pigment epithelial cells (Fett et al., 2012)  and glomerular podcytes (Fischer et al., 
1986). Soluble CR1 (sCR1) is found in the circulation from cleavage of CR1 on the 
surface of leucocytes (Danielsson et al., 1994) and urinary CR1 from cleavage of 
glomerular CR1 (Pascual et al., 1994a). 
CR1 is encoded by the CR1 gene at the 1q32 locus, spans approximately 133 kb and 
comprises 39 exons (Vik and Wong, 1993). The CR1 gene is part of the regulation of 
complement activation (RCA) cluster of genes, with RCA proteins sharing structural 
similarity and consisting of repeating blocks of 60-70 amino acids referred to as 
complement control proteins (CCP) or short consensus repeats (SCR) (reviewed in 
(Hourcade et al., 1989)). The ectodomain of the most common form of CR1 (CR1*1, 
see section 1.6.3) comprises 30 CCPs, with the first 28 grouped into four long 
homologous repeats A-D (LHRs A-D) each consisting of seven CCPs (Klickstein et al., 
1987). Significant homology is seen between CCPs occupying the same position 
across LHRs. The last two CCPs (29 and 30) are not part of the LHRs and are 
followed by a transmembrane domain and a cytoplasmic tail. The structure of 




Figure 1-8. Diagram of the most common Complement Receptor 1 size variant (CR1*1) 
The ectodomain of CR1 is composed of 30 Complement Control Protein (CCP) domains which are 
organized into four “Long Homologous Repeats” (LHR). The single nucleotide polymorphisms 
determining the Sl and McC antigens of the Knops blood group system are found in CCP 25 in LHR-D 
(red). Various functions have been mapped to different regions of CR1, including Site 1 (decay 
accelerating activity for C3 convertases; binding of the complement components C3b and C4b and the 
P. falciparum invasion ligand PfRH4), and Site 2 (cofactor activity for factor I; binding of C3b and C4b 
and P. falciparum rosetting). LHR-D is thought to bind C1q and Mannose Binding Lectin (MBL), but 
the specific binding sites have not been mapped. TM, transmembrane region; CYT, cytoplasmic tail.  
Image and legend taken directly from (Opi, Swann et al, 2018). 
1.6.2 CR1 Function 
The two major functions of CR1 are regulation of complement activation and 
immune adherence. Specific complement regulatory functions have been mapped 
to the first three CCPs of LHRs A, B and C; LHR-A contains CCPs 1-3 which comprise 
site 1 while CCPs 8-10 and 15-17 in LHRs B and C respectively comprise two (almost 
identical) copies of site 2 (Figure 1-8). Site 1 binds C4b (strongly) and C3b (weakly) 
(Kalli et al., 1991; Klickstein et al., 1988; Krych et al., 1991). Site 1 is also the 
predominant location for decay accelerating activity (enhancing the breakdown) for 
the C3 convertases (C4b2a and C3bBb) and C5 convertases (C4b2a3b and C3Bb3b), 
thus regulating both the classical and alternative pathways (Iida and Nussenzweig, 
1981; Krych-Goldberg et al., 1999).  
Site 2 binds both C3b and C4b efficiently and also cooperates with site 1 to enhance 
binding of these ligands (Klickstein et al., 1988; Tetteh-Quarcoo et al., 2012; Tham 
et al., 2011). Site 2 is also the major site for cofactor activity in the cleavage of C3b 
to iC3b in conjunction with factor I and subsequently the cleavage of iC3b to C3dg 
and C3c (described in section 4.4.14.1) (Medof et al., 1982; Ross et al., 1982). iC3b 
and C3dg are ligands for CR2 on B cells, providing an immunostimulatory role and a 
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bridge between innate and adaptive immune responses (Dempsey et al., 1996; 
Hannan, 2016; Weis et al., 1984). The function of the LHR-D region is less clear, with 
potential binding sites for C1q, mannose binding lectin and ficolins (Ghiran et al., 
2000; Jacquet et al., 2013; Klickstein et al., 1997), discussed in section 5.2.1. 
CR1 on erythrocytes is also responsible for immune adherence, the binding of C3b- 
and C4b-opsonised matter (primarily antigen-antibody ICs but also bacteria and 
viruses). ICs are shuttled to CR1 on resident macrophages in the liver and spleen 
and phagocytosed (Emlen et al., 1992; Schifferli and Taylor, 1989). CR1 is dispersed 
on the resting erythrocyte membrane but forms clusters on binding a ligand 
(Chevalier and Kazatchkine, 1989; Ghiran et al., 2008; Paccaud et al., 1988, 1990). 
The functions of CR1 are outlined in Figure 1-9. 
1.6.3 CR1 size polymorphism 
CR1 exhibits an unusual size polymorphism, with four allelic variants whose 
molecule weights increase in 30 kDa increments under reducing conditions; CR1*3 
(190 kDa), CR1*1 (220 kDa), CR1*2 (250 kDa) and CR1*4 (280 kDa) (reviewed in 
(Krych-Goldberg and Atkinson, 2001). The CR1*1 variant is the most common and 
contains four LHRs (A-D). The 30 kDa size difference between these variants 
corresponds to the deletion or duplication of a LHR, with CR1*2 containing an extra 
LHR between LHR-A and LHR-B and CR1*3 lacking LHR-B (Wong and Farrell, 1991; 
Wong et al., 1989). CR1*4 is anticipated to have 6 LHRs, although this has yet to be 
confirmed (Birmingham and Hebert, 2001). The frequencies of the variants are not 
well characterised, but CR1*1 has been reported to occur at a frequency of 86% in 
Caucasians, 75-78% in African Americans and 96-98% in Asians studied, whereas 
CR1*2 occurred at 13%, 20- 21% and 1-2% respectively and CR1*3  and CR1*4 being 





Figure 1-9. Overview of the functions of CR1.  




1.6.4 CR1 copy number polymorphism 
In addition to the size polymorphism, the level of CR1 on erythrocytes, known as 
the CR1 copy number, is also under genetic control. In healthy individuals, the CR1 
copy number on erythrocytes has been reported to vary from 50-1200 molecules 
per cell (Cockburn et al., 2004; Wilson et al., 1986). In Caucasian and Asian 
populations, CR1 copy number correlates with a HindIII restriction fragment length 
polymorphism (RFLP) in intron 27 of the CR1 gene (Herrera et al., 1998; Wilson et 
al., 1986). The polymorphism results in two co-dominant alleles, the H allele (high 
expression) and the L alleles (low expression). Homozygotes for the L allele typically 
have CR1 copy numbers of <200, while homozygotes for the H allele have 3-10 
times this amount (Wilson et al., 1986). A number of other candidate 
polymorphisms have been identified in exons 19, 22 and 33 of the CR1 gene, which 
are in linkage disequilibrium with the HindIII RFLP (Herrera et al., 1998; Xiang et al., 
1999). However, in African populations, the HindIII RFLP does not correlate with low 
CR1 copy number and the mechanism controlling copy number in this setting 
remains to be elucidated (Herrera et al., 1998; Rowe et al., 2002b). 
1.6.5 CR1 as a therapy 
Considering the strong complement regulatory effects of CR1, there has been 
particular interest in developing recombinant soluble CR1 (sCR1) as a therapy. 
Therapeutic sCR1 was originally developed as TP10 by the pharmaceutical company 
Avant and has been trialled for ischaemia-reperfusion in cardiopulmonary bypass 
surgery with some success (Keshavjee et al., 2005; Lazar et al., 2007). In addition, 
pre-clinical studies have investigated a role for sCR1 in the treatment of conditions 
as diverse as spinal cord injury (Li et al., 2010), arthritis (Goodfellow et al., 2000) 
and myasthenia gravis (Piddlesden et al., 1996). The therapeutic possibilities of 
sCR1 have been limited by the size of the molecule. As such, some work has focused 
on the recombinant fragment APT070, which represents the first three CCPs of CR1 
together with a lipopetide that tethers it to the surface of the cell to be protected 
(reviewed in (Smith, 2002)).  
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1.7 CR1 and malaria 
1.7.1 CR1 and rosetting 
Complement receptor 1 (CR1) is the best characterised of the rosetting receptors. 
The original report found that erythrocytes with CR1 copy numbers of <100 showed 
reduced rosetting frequency with P. falciparum laboratory strains, with soluble CR1 
(sCR1) inhibiting rosette formation (Rowe et al., 1997). CR1 deficient erythrocytes 
also showed reduced or absent binding to the DBL1α domain of PfEMP1 from the 
R29 strain when expressed on COS-7 cells. The same group used recombinant CR1 
deletion mutants and α-CR1 antibodies to map the region required for rosetting to 
site 2 in LHR B (CCPs 8-10) and LHR C (CCPs 15-17) (Rowe et al., 2000) (Figure 1-8). 
Further investigation revealed that only the J3B11 antibody was able to reverse 
rosetting. The predicted binding sites for J3B11 are CCPs 3, 10 and 17 (Nickells et al., 
1998), suggesting CCPs 10 and 17 are critical for rosetting. In addition to laboratory 
strains, J3B11 was also found to reverse rosetting in clinical P. falciparum isolates 
from Kenya (13 out of 14) and Malawi (5 out of 10), suggesting the role of CR1 in 
rosetting may vary with geographical location.  
From the parasite perspective, the site of CR1 binding in DBLα has been further 
refined using deletion constructs of DBLα from laboratory strain R29 expressed on 
COS-7 cells (Mayor et al., 2005). The authors compared the binding of erythrocytes 
with normal or low CR1 copy numbers to the constructs to isolate the CR1 binding 
residues to cysteines C5 to C12 in the central region of DBLα. However, it should be 
noted that there is currently no direct evidence for the binding of PfEMP1 to CR1. 
Indeed one study using both recombinant short CR1 proteins and sCR1 was unable 
to detect any binding between these proteins and immobilized recombinant 
versions DBLα from R29 using surface plasmon resonance (although data for this 
assertion was not presented) (Tetteh-Quarcoo et al., 2012). While this may be due 
to the use of recombinant protein fragments, it also raises the possibility of an 
intermediate molecule in the binding of CR1 and PfEMP1. 
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1.7.2 CR1 and erythrocyte invasion 
CR1 has been identified as a receptor for the sialic acid-independent invasion of P. 
falciparum into erythrocytes, providing an alternative invasion pathway to 
glycophorins (Spadafora et al., 2010; Tham et al., 2010). Two separate groups 
reported this finding almost simultaneously. Spadafora et al. used neuraminidase-
treated enterocytes (i.e. devoid of sialic acid and hence the glycophorin invasion 
receptors) and found erythrocyte invasion by laboratory strains could be inhibited 
by incubation with sCR1 and α-CR1 antibodies. Similar results were seen for three 
clinical isolates in this study and eight others in a separate investigation (all from 
Kenya), with invasion proportional to the level of erythrocyte CR1 expression 
(Awandare et al., 2011; Spadafora et al., 2010; Tham et al., 2010).  
Tham et al. extended these findings to show that the parasite adhesin P. falciparum 
reticulocyte-binding homologue 4 (PfRh4) was responsible for direct binding to CR1. 
Investigations using recombinant CR1 fragments revealed the PfRH4 binding site to 
be in site 1 of CR1 (CCPs 1-3, see Figure 1-8 (Tham et al., 2011)). Truncation and 
deletion constructs of LHR-A revealed the binding site for PfRh4 to be CCP 1 (Park et 
al., 2013) and a α-PfRh4 monoclonal antibody capable of inhibiting erythrocyte 
invasion has been identified, suggesting therapeutic possibilities (Lim et al., 2015). 
The clinical importance of CR1 as an invasion receptor for P. falciparum is unclear as 
it is rarely employed without prior neuraminidase treatment of erythrocytes 
(Awandare et al., 2011; Mensah-Brown et al., 2015; Spadafora et al., 2010; Tham et 
al., 2010). A study of children in Papua New Guinea reported that antibodies against 
PfRh4 were associated with protection against symptomatic malaria and high-
density parasitaemia, although the CR1 invasion pathway was not directly examined 
(Reiling et al., 2012). Other studies do not support a clinically important role for CR1 
as an invasion receptor, with reports from Brazil and Papua New Guinea finding no 
association between CR1 level and parasite density (Lin et al., 2010; Soares et al., 
2008). It has been suggested that a hierarchy of invasion receptors exists, with CR1-
invasion only becoming clinically important if other receptors have been rendered 
unavailable by antibodies or polymorphisms (Baum et al., 2005). 
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1.7.3 CR1 copy number and malaria 
1.7.3.1 Theories of association 
The association between CR1 copy number and malaria has been much investigated 
but remains unclear. This is partly because the optimal amount of CR1 on 
erythrocytes may differ depending on the outcome required in terms of minimising 
rosetting, reducing C3b deposition on erythrocytes or clearing immune complexes 
(ICs). For example, CM has been associated with high levels of ICs containing IgG 
and IgE and their deposition has also been reported in brain microvasculature 
(Maeno et al., 2000; Mibei et al., 2008). High CR1 expression on erythrocytes may 
allow increased binding and clearance of these ICs (Cosio et al., 1990; Madi et al., 
1991; Schifferli et al., 1989). However, high CR1 might also increase the risk of 
rosetting (Rowe et al., 1997). Conversely, whilst low CR1 copy number may reduce 
rosetting, it might render low-CR1 erythrocytes susceptible to C3b deposition, 
increasing the risk of SMA (Odhiambo et al., 2008; Stoute et al., 2003; Waitumbi et 
al., 2000). Alternatively, erythrocytes with high CR1 levels might carry more ICs, 
interacting with PBMCs and endothelial cells to increase inflammatory mediator 
release (Beynon et al., 1994; Chou et al., 1985).  
1.7.3.2 CR1 copy number and malaria – Studies from Asia and Papua New Guinea 
Most studies examining the relationship between CR1 expression and severe 
malaria come from Asia and Papua New Guinea (PNG); three from eastern India 
(Panda et al., 2012; Rout et al., 2011; Sinha et al., 2009), two from Thailand 
(Nagayasu et al., 2001; Teeranaipong et al., 2008) and one from PNG (Cockburn et 
al., 2004). Two of the case-control studies from eastern India reported high CR1 
copy number SNPs were associated with increased odds of CM (Panda et al., 2012; 
Rout et al., 2011), whilst the third did not break down severe malaria cases by sub-
phenotype (Sinha et al., 2009). In contrast, one Thai study reported a high CR1 copy 
number SNP was associated with an decrease in odds of CM in an endemic area 
(Teeranaipong et al., 2008), contradicting the Indian studies. The study from PNG 
tells a different story, with a low CR1 copy number SNP being associated with 
protection against SMA (Cockburn et al., 2004).  
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These disparities may be due to differences in methodology, parasite strains or 
other host malaria-susceptibility genes. It is also possible that the association 
between disease severity and CR1 copy number could be influenced by the local 
transmission intensity of P. falciparum. For example, severe malaria in Asia affecting 
adults is more commonly a picture of multiorgan failure and metabolic acidosis 
(Dondorp et al., 2008a; White, 1987) than severe malaria in PNG affecting children, 
which is predominantly characterised by CM and SMA (Allen et al., 1996).  
1.7.3.3 CR1 copy number and malaria – Studies from Africa 
The genetic determinant of CR1 copy number has yet to be established in African 
populations (Herrera et al., 1998; Rowe et al., 2002b; Xiang et al., 1999). As such, it 
is unsurprising that a Gambian study based on HindIII genotyping (rather than direct 
quantification of CR1 copy number on erythrocytes) found no association with 
severe malaria (Bellamy et al., 1998). A collection of studies has focused on the 
relationship between CR1 copy number and severe malaria in Western Kenya. The 
level of CR1 varied with age, with the lowest levels of CR1 seen between 6 and 24 
months (Odhiambo et al., 2008; Waitumbi et al., 2004).  The same group reported 
that low CR1 copy number was associated with lower IC binding, higher circulating 
levels of ICs and increased C3b deposition on erythrocytes and subsequent 
phagocytosis in children with SMA than children with UM or asymptomatic malaria 
(Odhiambo et al., 2008; Owuor et al., 2008; Stoute et al., 2003) (Waitumbi et al., 
2000). In further studies, the same group reported that high CR1 erythrocytes which 
had been pre-saturated with ICs stimulated higher levels of TNF-α production from 
macrophages than low CR1 erythrocytes (although this was not statistically 
significant) (Odera et al., 2011). The authors suggested that IC-laden high CR1 
erythrocytes in the sluggish blood flow of CM might stimulate microglial cells 
(resident macrophages) to produce inflammatory cytokines. 
If any conclusion can be drawn as to the relationship between CR1 copy number 




1.8 The Knops blood group polymorphisms in CR1 
1.8.1 Molecular basis of the polymorphism 
The third CR1 polymorphism is the Knops blood group and is independent of both 
copy number and size polymorphisms. The Knops blood group system comprises 
nine antigens; three antithetical pairs (Kna/Knb, McCa/McCb, Sl1/Sl2), one 
conformational epitope (Sl3) and two single antigens (Yka and KCAM+, summarised 
in Table 1-1). All polymorphisms are found in exon 29 (corresponding to CCP 25 in 
the CR1 molecule) (Moulds et al., 1991, 2001, 2002, 2005) except for the York 
antigen (Yka) which is located in exon 26 (corresponding to the linker between CCP 
22-23) (Veldhuisen et al., 2011). This thesis will focus on the antithetical antigen 
pairs McCoy (McCa/McCb) and Swain-Langley (Sl1/Sl2). 
1.8.2  Global prevalence of the Sl and McC polymorphisms 
The global distributions of Sl2 and McCb alleles are striking. The alleles are almost 
absent in Caucasian populations (Covas et al., 2007; Moulds et al., 2004) yet 
occurring at high frequencies in populations of African origin (Figure 1-10). In 
African populations, frequency of the Sl2 allele ranges from 0.32 in Malawi to 0.80 
in The Gambia (Fitness et al., 2004a; Zimmerman et al., 2003). The McCb allele is 
less prevalent than Sl2, but ranges from a frequency of 0.24 in Mali to 0.38 in The 
Gambia (Noumsi et al., 2011; Zimmerman et al., 2003). The distribution of Sl2 and 
McCb in populations of African origin has been hypothesised to be due to selection 
pressure by P. falciparum (Moulds et al., 2000). Interestingly, the Sl2 and McCb 
polymorphisms appear absent from malaria-endemic Asian populations (Gandhi et 
al., 2009; Teeranaipong et al., 2008), either suggesting that the selection pressure 














Amino acid change Phenotype SNP  
KN1 KN2 Kna 29 4681A Val1561 Kn(a+b-) rs41274768 
KN2 KN1 Knb 29 4681G Met1561 Kn(b+a-)  
KN3 KN6 McCa 29 4768A Lys1590 McC(a+b-) rs17047660 
KN6 KN3 McCb 29 4768G Glu1590 McC(a-b+)  
KN4 KN7 Sl1 29 4801A Arg1601 Sl(1,-2) rs17047661 
KN7 KN4 Sl2 29 4801G Gly1601 Sl(-1, 2)  
KN5 - Yka 26 4223C>T Thr1408Met Yk(+) rs3737002 
KN8 - Sl3 29 4801A /4828A>T Arg1601/Ser1610† Sl(1,-2,3) rs4844609 
KN9 - KCAM 29 4843A>G Ile1615Val KCAM(+) rs6691117 
Table 1-1. Antigens of the Knops blood group system.  
Nucleotide positions given in reference to NCBI accession number NM_000573.3 (https://www.ncbi.nlm.nih.gov/nuccore/NM_000573.3). † Arg1601 is also required 
for KN8 (Sl3) expression. The Sl and McC polymorphisms are highlighted in blue ISBT = International Society of Blood Transfusion. Information collated from (Moulds 




Figure 1-10. Global distribution of the CR1 Knops Sl and McC alleles. 
A) Shows the global frequencies of the Sl alleles. Sl1 is represented in blue and Sl2 in red. 
B) Shows the global frequencies of the McC alleles. McCa is represented in green and McCb in purple. 
The two samples in North and South America showing high frequencies of Sl2 and McCb alleles are 
both derived from populations with African heritage. Numbers in parentheses indicate the studies 
from which the Sl and McC allele frequencies were derived. [1] Thathy et al., 2005; [2] Zimmermann 
et al., 2003; [3] Moulds et al., 2004; [4] Noumsi et al., 2011; [5] Fitness et al., 2004; [6] Covas et al., 
2007; [7] Gandhi et al., 2009; [8] Yoon et al., 2013; [9] Hansson et al., 2013; [10] Kariuki et al., 2013; 
[11] Eid et al., 2010.  
(Image and legend taken directly from (Opi, Swann et al, 2018)).  
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1.8.3  Epidemiological studies of the Sl and McC polymorphisms 
relationship with malaria in Africa 
The ten studies examining this relationship are summarised in Table 1-2.  
1.8.3.1 Studies reporting an association between Sl / McC and severe malaria 
Thathy et al. performed a matched case-control study Western Kenya with SMA 
cases recruited from the malaria holoendemic region of Kisumu and CM cases from 
Kisii, an area in the highlands with seasonal malaria transmission (Thathy et al., 
2005). Controls were cases of UM matched for ethnicity, age, sex and location of 
residence with analysis by conditional logistic regression. The study reported the 
Sl2/Sl2 genotype was associated with reduced odds of CM but not SMA. The study 
also examined the Sl and McC polymorphisms together, which makes biological 
sense in terms of proximity (33 bp apart). Surprisingly, this found the genotype 
Sl2/Sl2 McCa/McCb to be associated with reduced odds of CM.  
A large multi-centre study by the MalariaGen group comprised a consortia of case-
control studies across 12 global sites (Rockett et al., 2014). The study was extremely 
powerful, with 11890 cases of severe malaria and 17441 controls. Genotyping was 
performed centrally for 55 malaria candidate SNPs, including Sl and McC. However, 
there was marked heterogeneity across the study sites, including controls used 
(varying from cord-blood samples to matched or unmatched community controls 
with or without minor infections), malaria transmission patterns and disparity in 
sample number from each site (e.g. 2801 from The Gambia and 114 from Nigeria). 
To account for heterogeneity, the authors included a Bayesian approach in their 
detailed statistical analysis (which also adjusted for ethnicity and HbS). The authors 
noted: “(…) it is undoubtedly also the case that authentic genetic associations might 
be missed by multi-centre studies if the effect is weak and there is heterogeneity of 
effect across different study sites.” Considering these points, McCb was associated 
with increased odds of CM on pooled analysis of all sites, a finding which appears to 
contradict that of Thathy et al. 
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Another study reported an association between McCb and seizures in severe malaria 
and was a sub-analysis of data from four of the MalariaGen African sites (Malawi, 
Kenya, Ghana and Tanzania) (Kariuki et al., 2013). The McCb/McCb genotype was 
associated with increased odds of prolonged and repetitive malaria-associated 
seizures (MAS). Much of this signal was driven by data from the Kenyan component 
of the study, reinforcing the problems with heterogeneity in multi-centre studies. 
Together with Rockett et al., the increased odds of CM and MAS with McCb appear 
to suggest a selection pressure other than malaria for this polymorphism.  
Two small case control studies also reported associations between Sl/McC and 
severe malaria (Eid et al., 2010; Tettey et al., 2015). Neither study was clear in the 
recruitment of their participants, making it difficult to assess potential sources of 
bias. Such small studies are also vulnerable to sparse data bias (i.e. leading to a 
considerable upward bias in ORs when there are few study participants at key 
combinations of the outcome and exposure (Greenland et al., 2016)). For example, 
Tettey et al. report that McCb/McCb was associated with protection against severe 
malaria, but this statement was based on only eight controls and a single case of 
SMA and CM (Tettey et al., 2015). As such, the contribution of these studies to the 
body of evidence is limited.  
1.8.3.2 Studies reporting no association between Sl/McC and severe malaria 
 Other studies have reported no association between Sl or McC and severe malaria. 
The first of these was by performed in The Gambia using a matched case-control 
study with controls selected from outpatients with “mild illnesses” (predominantly 
non-malarial infections) (Zimmerman et al., 2003). This choice of controls is 
potentially problematic it has been reported that Knops blood group 
polymorphisms may be associated with infectious disease other than malaria 
(Fitness et al., 2004a; Noumsi et al., 2011). As such, if Sl and McC had a broader 
effect on complement (rather than a malaria-specific effect), the inclusion of 
controls with other infections may obscure an association. This study reports that 




A larger study from The Gambia also reported no association between Sl/McC and 
severe malaria (Jallow et al., 2009). This study had well-defined inclusion criteria 
and used newborn controls. This study was primarily a genome wide association 
study (GWAS) using the Affymetrix 500K array. Neither Sl nor McC were as 
identified using this approach. Twelve malaria candidate SNPs (including Sl) were 
then directly genotyped and their association with severe malaria examined and Sl 
was not significantly associated with severe malaria. 
Two other case control studies from Tanzania and Mali have also reported no 
association between Sl/McC and severe malaria (Manjurano et al., 2012; Toure et 
al., 2012). The studies shared many similarities; both were matched case-control 
studies of a similar size with community controls matched for age, sex and location. 
Both studies included data on children with UM who were used either as additional 
controls or additional cases in different analyses, which may have potentially 
influenced findings.  
A final small study from Ghana reported no association between Sl/Mc 
polymorphisms individually or in combination (Hansson et al., 2013). The controls 
for this study were poorly defined, being community controls from healthy children 
“(…) with or without detectable P. falciparum in a thick blood smear (...)” In 
addition, the number of controls differs throughout the paper (275 controls used in 
some analyses and 448 in others) without explanation. The authors also allude to 
differences in ethnicity between cases and controls, but do not account for this. 
Finally, an analysis using eight Knops haplotypes was undertaken, reducing the 
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McCb/McCb assoc with ↑ 
prolonged MAS 
2.56 (1.41 – 4.67), p = 0.002 
McCb/McC b assoc with ↑ 
repetitive MAS 
1.97 (1.22-3.22), p = 0.005 


































McCb assoc with ↑ CM  
(additive model) 
1.09 (1.02-1.17), p = 0.008 
No signif assoc reported for 
Sl 
Tettey  

















McCa/b assoc with ↑ severe 
malaria 
2.31 (1.03-5.20), p = 0.043 
McCb/b assoc with ↓ severe 
malaria 
0.12 (0.02-0.64), p = 0.013 
Table 1-2. Summary of epidemiological investigations of the Sl and McC polymorphisms relationship with malaria in Africa. 
* Overlapping syndromes.  $ Global sites = Burkina Faso, Cameroon, The Gambia, Ghana, Kenya, Malawi, Mali, Nigeria, Tanzania, Vietnam and Papua New Guinea 
& African sites = Malawi (Blantyre), Kenya (Kilifi), Ghana (Kumasi) and Tanzania (Muheza). UM = uncomplicated malaria. MID = mild infectious disease (outpatients). 
CC = community controls, either healthy or with asymptomatic parasitaemia. NC = neonatal controls. SMA = Severe malarial anaemia. CM = Cerebral malaria.  
RD = Respiratory distress. RFLP-PCR = Restriction fragment length polymorphism-polymerase chain reaction.  




1.8.3.3 A comment on the disparity of findings 
It is clear there is no consensus on whether Sl/Mc are associated with severe 
malaria in Africa. In addition to the methodological differences discussed above, 
there are many other potential explanations for the variation in findings. The 
multiple study settings cover a range of malaria transmission intensities. For 
example, even without information on transmission rates, this is hinted at by 
examining the mean age of CM patients in different studies; e.g. 2.4 years in Thathy 
et al (western Kenya, seasonal transmission) compared to 4.4 years in Tettey et al. 
(Accra, Ghana, low-stable transmission (National Malaria Control Programme et al., 
2013). In addition, differing parasite strains or environmental factors could 
influence associations. Host genetic factors might also interact with Sl and McC. 
Only three studies considered the effect of other malaria-resistance polymorphisms 
in their analyses and this was limited to HbS (Manjurano et al., 2012; Rockett et al., 
2014; Toure et al., 2012). It is also plausible, given the proximity of the two SNPs, 
that an association between Sl and McC and severe malaria is only apparent when 
both SNPs are included in the same model, an approach only taken by three studies 
(Hansson et al., 2013; Thathy et al., 2005; Zimmerman et al., 2003). It must also be 
remembered that Sl and McC may not be causative SNPs, but instead might be 
tagging an unknown mutation that is in linkage disequilibrium with a causative SNP 
in, for example, Kenyan populations but not in Gambian populations.  
A final point to consider is that these ten studies are not all truly independent; four 
use the same data and could be considered sub-analyses of Rockett et al. (Jallow et 
al., 2009; Kariuki et al., 2013; Manjurano et al., 2012; Toure et al., 2012). As such, 
whilst MalariaGen is a large consortium of well-designed and carried out studies, all 
genotyping has been centrally performed, with the potential for multiple studies 





1.9 Aims and hypotheses of this thesis 
1. Chapter 2 investigates the hypothesis that the Sl and McC polymorphisms are 
associated with severe malaria in Kilifi, Kenya. Specifically, I hypothesised that the 
association between CM and Sl2 observed in western Kenya might also be observed 
in eastern Kenya. Investigation was undertaken using a large, well defined case-
control study analysed using mixed effect logistic regression analysis.  
2. Chapter 3 investigates the hypothesis that the Sl and McC polymorphisms 
influence how CR1 molecules cluster on the surface of an erythrocyte. Specifically, I 
hypothesised that the Sl or McC polymorphisms might alter the volume or number 
of CR1 clusters on an erythrocyte, therefore influencing the binding and transfer of 
immune complexes during infection with malaria. Field samples from Kilifi, Kenya 
were used and investigation undertaken using an immunofluorescence assay 
analysed using confocal microscopy and specialised imaging software. 
3. Chapter 4 investigates the hypothesis that human brain endothelial cells can 
express functional CR1. Specifically, I hypothesised that the protective association 
against CM seen with the Sl2 polymorphism was due to direct expression of the CR1 
protein on endothelial cells, potentially influencing parasite cytoadherence, 
immune complex deposition or complement activation. Investigation used 
immortalised human brain endothelial cells, α-CR1 antibody based assays, siRNA 
knock-down, functional complement assays and mass spectrometry. 
4. Chapter 5 investigates the hypothesis that the Sl or McC polymorphisms directly 
influence binding of C1q, mannose binding lectin or L-ficolin to the LHR-D region of 
CR1. Site-directed mutagenesis was performed to introduce the Sl2 and McCb 
mutations into a plasmid containing the LHR-D region with the aim of generating 
recombinant proteins and testing their binding to various complement components. 
Please note that as these chapters each use distinct methodological approaches 
with little overlap, the relevant methods section is found at the beginning of each 




2 Are the Swain Langley and McCoy polymorphisms in 
CR1 associated with severe malaria? 
The body of this chapter is reproduced from the manuscript “Two complement 
receptor one alleles have opposing associations with cerebral malaria and interact 
with α+thalassaemia” published in eLife on 25.04.18 on which I am joint first author 
(Opi, Swann et al, 2018). In accordance with the University of Edinburgh guidelines 
for inclusion of publications in a thesis (Appendix 8.2), the publication is presented 
with an additional introduction and discussion. Abstract, introduction, methods, 
results, discussion, figures, tables and legends are taken directly from the 
publication. The manuscript has been re-formatted to correspond to thesis style. 
Supplementary information has been placed in-line where possible. A PDF of the 
manuscript can be found at https://www.elifesciences.org/articles/31579 and 
corresponding open access licence in Appendix 8.3. 
2.1 Declaration 
I was responsible for the data curation, investigation and statistical analyses of the 
Kenyan and Malian case-control studies which constitute the majority of this 
manuscript. Writing of the manuscript was undertaken by myself with assistance 
from Herbert Opi. The final draft of the manuscript was edited by Alex Rowe and 
approved by all collaborators. Herbert Opi was responsible for the statistical 
analysis of the Kenyan cohort study. Ewen Harrison provided advice on statistical 
methods. Gavin Band provided advice on haplotype analysis and linkage 
disequilibrium. Dominic Kwiatkowski and Kirk Rockett oversaw Sl, McC, HbS and 
ABO blood group genotyping and Sophie Ugoya and Alex Macharia performed the 
α+thalassaemia genotyping for the Kenyan studies. Thomas Williams designed and 
oversaw recruitment of the Kenyan case-control and cohort studies. Carolyne Ndila 
was responsible for data curation. For the Malian case-control study, Sl and McC 
genotyping was performed by Joann Moulds and ABO serotyping and ex vivo 





Malaria has been a major driving force in the evolution of the human genome. In 
sub-Saharan African populations, two neighbouring polymorphisms in the 
Complement Receptor One (CR1) gene, named Sl2 and McCb, occur at high 
frequencies, consistent with selection by malaria.  Previous studies have been 
inconclusive. Using a large case-control study of severe malaria in Kenyan children 
and statistical models adjusted for confounders, we estimate the relationship 
between Sl2 and McCb and malaria phenotypes, and find they have opposing 
associations. The Sl2 polymorphism is associated with markedly reduced odds of 
cerebral malaria and death, while the McCb polymorphism is associated with 
increased odds of cerebral malaria. We also identify an apparent interaction 
between Sl2 and α+thalassaemia, with the protective association of Sl2 greatest in 
children with normal α-globin. The complex relationship between these three 
polymorphisms may explain previous conflicting findings, highlighting the 
importance of considering genetic interactions in disease-association studies. 
2.3 Additional introduction to this manuscript 
The distribution of Sl2 and McCb in populations of African origin has been 
hypothesised to be due to selection pressure by P. falciparum (Moulds et al., 2000). 
However, the evidence is conflicting and varying in quality and has been reviewed in 
depth in section 1.8.3. This chapter sought to examine this hypothesis in a large 
Kenyan case-control study of severe malaria, with detailed analyses which included 
the two polymorphisms in a single model and considered the possibility of 






Complement Receptor One (CR1) plays a key role in the control of complement 
activation and the immune clearance of C3b/C4b coated immune complexes (Krych-
Goldberg and Atkinson, 2001). CR1 is expressed on a range of cells including red 
blood cells (RBCs), leucocytes and glomerular podocytes (Krych-Goldberg and 
Atkinson, 2001). A number of CR1 polymorphisms have been described, including 
four molecular weight variants and variation in the number of CR1 molecules 
expressed on the surface of RBCs (reviewed by (Krych-Goldberg et al., 2002; 
Schmidt et al., 2015)). Missense substitutions of CR1 form the basis of the Knops 
blood group system of antigens, that includes the antithetical antigen pairs of 
Swain-Langley 1 and 2 (Sl1 and Sl2) and McCoy a and b (McCa and McCb) (Moulds, 
2010). The non-synonymous single nucleotide polymorphisms (SNPs) A4828G 
(rs17047661) and A4795G (rs17047660) within exon 29 of the CR1 gene give rise to 
the Sl1/Sl2 and McCa/McCb alleles, encoding R1601G and K1590E respectively 
(Moulds et al., 2001) (Figure 1-8).  
CR1 has been implicated in the pathogenesis of multiple diseases, with 
epidemiological and in vitro data suggesting a role in malaria (reviewed in (Schmidt 
et al., 2015)). The Sl2 and McCb alleles occur at high frequencies only in populations 
of African origin (Figure 1-10) (Covas et al., 2007; Eid et al., 2010; Fitness et al., 
2004a; Gandhi et al., 2009; Hansson et al., 2013; Kariuki et al., 2013; Moulds et al., 
2004; Noumsi et al., 2011; Thathy et al., 2005; Yoon et al., 2013; Zimmerman et al., 
2003), which, given the historical prevalence of the malaria-causing parasite 
Plasmodium falciparum in sub-Saharan Africa, might suggest a possible survival 
advantage against malaria (Rowe et al., 1997, 2000).  CR1 is a receptor for the 
invasion of RBCs by P. falciparum merozoites (Spadafora et al., 2010; Tham et al., 
2010) and for the formation of clusters of P. falciparum-infected erythrocytes (IEs) 
and uninfected RBCs, known as rosettes (Rowe et al., 1997).  The rosetting 
phenotype is associated with severe malaria in sub-Saharan Africa (Doumbo et al., 




blood flow (Kaul et al., 1991). RBCs from donors with the high frequency African 
CR1 Knops mutations bind poorly to the parasite ligand P. falciparum erythrocyte 
membrane protein-1 (PfEMP1) that mediates rosetting by IEs, potentially protecting 
against severe malaria by reducing rosetting (Rowe et al., 1997). Nevertheless, 
epidemiological data supporting this possibility are contradictory, with some studies 
showing an association between Sl and McC genotypes and severe malaria (Kariuki 
et al., 2013; Tettey et al., 2015; Thathy et al., 2005) and others finding none 
(Hansson et al., 2013; Jallow et al., 2009; Manjurano et al., 2012; Rockett et al., 
2014; Toure et al., 2012; Zimmerman et al., 2003). Some previous studies have not 
considered Sl and McC genotypes together in the same statistical model, despite 
their physical adjacency in the CR1 molecule, nor taken into account potential 
interactions with other malaria resistance genes. Given the important biological role 
of CR1 in malaria host-parasite interactions, we aimed to clarify the relationship 
between the Sl and McC alleles and severe malaria in a case-control study of Kenyan 
children. These investigations were supplemented with a separate longitudinal 
cohort study of Kenyan children, examining the associations of these alleles with 
UM and other common childhood illnesses. Finally, we also investigated the 
influence of these alleles on the formation of P. falciparum rosettes, as a potential 
functional explanation for these results through ex vivo laboratory studies. 
2.5 Materials and methods 
2.5.1 Datasets studied 
This study uses data from a Kenyan case-control study of severe malaria, with 
samples collected between 2001 and 2010, a Kenyan longitudinal cohort study, with 
samples collected between 1998 and 2001 and a Malian case-control study 
performed between July 2000 and December 2001. Historic datasets (i.e. >10 years 
old) are widely used in genetic epidemiological studies of malaria due to the 
logistical challenges of sample collection in malaria endemic countries and the 




2.5.2 The Kenyan study area  
All epidemiological and clinical studies in Kenya were carried out in the area defined 
by the Kilifi Health and Demographic Surveillance System (KHDSS), with Kilifi County 
Hospital (KCH) serving as the primary point of care (Scott et al., 2012). Malaria 
transmission is seasonal in this region following the long and short rains. An 
Entomological Inoculation Rate (EIR) of up to 50 infective bites per person per year 
was measured in the late 1990s (Mbogo et al., 2003), but transmission has since 
declined (O’Meara et al., 2008). 
2.5.3 The Kenyan case-control study  
Between January 2001 and January 2008, children aged <14 years who were 
admitted to KCH with severe malaria were recruited as cases, as described 
previously (Rockett et al., 2014), except that children who were resident outside the 
KHDSS were excluded (Figure 2-1).  Severe malaria was defined as the presence of 
blood-film positive P. falciparum infection complicated by one or more of the 
following features: cerebral malaria (CM) (a Blantyre coma score (BCS) of <3) n=943; 
severe malarial anaemia (SMA) (haemoglobin concentration of <5g/dl) n=483; 
respiratory distress (RD) (abnormally deep breathing) n=522 or “other severe 
malaria” (no CM, SMA or RD but other features including prostration (BCS 3 or 4), 
hypoglycaemia and hyperparasitaemia) n=318. Controls (n=3829) consisted of 
children 3-12 months of age who were born consecutively within the KHDSS study 
area between August 2006 and September 2010 and were recruited to an ongoing 
genetic cohort study (Williams et al., 2009). As such, controls were representative 
of the general population in terms of ethnicity and residence but not of age.  The 
use of controls who are considerably younger than cases differs from the classical 
structure of a case-control study. However, this method (using cord blood or infant 
samples as controls) has been widely used in African genetic association studies 
(e.g. (Band et al., 2013; Busby et al., 2016; Clarke et al., 2017)), and is the most 
logistically feasible way of collecting sufficiently large numbers of control samples in 










2.5.4 Sample processing and quality control for the Kenyan case-control 
study 
The Sl and McC polymorphisms were originally typed as part of a larger study by 
Rockett et al. (Rockett et al., 2014), which included case-control data from 12 global 
sites. In Kenya, 0.5ml blood samples were collected into ethylenediaminetetraacetic 
acid (EDTA) tubes and DNA extracted using Qiagen DNeasy blood kits (Qiagen, 
Crawley, UK). DNA was stored at -20oC and shipped frozen to Oxford. Sample 
processing is described in detail in the supplementary methods of Rockett et al. 
(Rockett et al., 2014). Briefly, samples underwent a whole-genome amplification 
step using Primer-Extension Pre-Amplification. Genotyping was performed using 
SEQUENOM® iPLEX® Gold with 384 samples processed per chip. Samples were 
typed for 73 SNPs; 55 of these SNPs were chosen on the basis of a known 
association with severe malaria, 3 SNPs were used to confirm gender and the 
remaining 15 SNPs to aid quality control. Samples were excluded if they did not 
have clinical data for gender or if genotypic gender of the sample did not match 
clinical gender. Samples were included if they were successfully genotyped for more 
than 90% of 65 “analysis” SNPs.  
2.5.5 The Kenyan longitudinal cohort study 
This study has been described in detail previously (Nyakeriga et al., 2004). Briefly, 
this study was established with the aim of investigating the immuno-epidemiology 
of uncomplicated clinical malaria and other common childhood diseases in the 
northern part of the KHDSS study area, approximately 15km from KCH (Williams et 
al., 2005a). The study was carried out between August 1998 and August 2001 
involving children aged 0-10 years recruited either at the start of the study or at 
birth when born into study households during the study period. They were actively 
followed up on a once-weekly basis for both malaria and non-malaria related 
clinical events. In addition, on presentation with illnesses, cohort members were 
referred to a dedicated outpatient clinic for more detailed diagnostic tests. The 




through four cross-sectional surveys carried out in March, July and October 2000 
and June 2001. Exclusion criteria included migration from the study area for more 
than 2 months, the withdrawal of consent and death. Uncomplicated clinical 
malaria was defined as fever (axillary temperature of >37.5°C) in association with a 
P. falciparum positive slide at any density. The most common non-malaria related 
clinical events reported during the study period included upper respiratory tract 
infections (URTIs), lower respiratory tract infections (LRTIs), gastroenteritis, 
helminth infections and skin infections, as defined in detail previously (Williams et 
al., 2005a). Malaria negative fever was defined as an axillary temperature of 
>37.5°C in association with a slide negative for P. falciparum. This analysis includes 
208 children aged <10 years for whom full Sl, McC, sickle cell genotype, 
α+thalassaemia genotype and ABO blood group data were available.  
2.5.6 The Malian case-control study 
This study has been described in detail previously (Lyke et al., 2003). Briefly, 
between July 2000 and December 2001, children ranging from 1 month–14 years of 
age were recruited into a case-control study in the Bandiagara region in East Central 
Mali, an area of intense and seasonal P. falciparum malaria infection. In order to 
address the specific question of whether the Sl2/Sl2 genotype is associated with 
protection against cerebral malaria in Mali, only the subset of children suffering 
strictly-defined cerebral malaria (a BCS of <3, with other obvious causes of coma 
excluded, n=34) or UM (n=184, symptomatic children with P. falciparum 
parasitaemia and an axillary temperature ≥37.5°C, in the absence of other clear 
cause of fever), and for whom Sl and McC genotyping was available were analysed. 
2.5.7 Ex vivo rosetting  
The rosette frequency (percentage of mature IEs forming rosettes with two or more 
uninfected erythrocytes) of P. falciparum isolates from patients recruited into the 
Mali case-control study was determined by microscopy after short term culture (24-
48 hours), as described in detail previously (Doumbo et al., 2009).  Of the 209 




alleles and are analysed here. The rosetting assays were performed before we 
genotyped the study participants, excluding observer bias. The rosette frequency of 
parasites from hosts with differing Sl and McC genotypes were compared by a 
Kruskal-Wallis test with Dunn’s multiple comparisons (Prism v6.0, Graphpad Inc, San 
Diego, California). 
2.5.8 Laboratory procedures 
DNA was extracted either from fresh or frozen whole blood by proprietary methods 
using either the semi-automated ABI PRISM® 6100 Nucleic acid prep station 
(Applied Biosystems, Foster City, CA, USA) or using QIAamp DNA Blood Mini Kits 
(Qiagen, West Sussex, United Kingdom). SNPs giving rise to the Sl and McC alleles 
were genotyped using either the SEQUENOM iPLEX® Gold multiplex system (Agena 
Biosciences, Hamburg, Germany) (Kenyan study) (Rockett et al., 2014) or by an 
established PCR-RFLP method as described previously (Malian study) (Moulds et al., 
2004). Genotyping for sickle cell trait (HbAS) and the common African 
α+thalassaemia variant caused by a 3.7kb deletion in the HBA gene were performed 
by PCR as described in detail elsewhere (Chong et al., 2000; Waterfall and Cobb, 
2001). 
2.5.9  Statistical analysis 
The effects of the Sl and McC alleles were examined in genotypic, dominant, 
recessive and additive models of inheritance, with the best fitting model selected 
based on Akaike information criterion (AIC).  Analyses for the Kilifi case-control 
study were performed in R (R Foundation for Statistical Computing, Vienna, Austria) 
(R Development Core Team, 2010) using the “ggplot2”, “lme4”, and 
“HardyWeinberg” packages (Bates et al., 2013; Graffelman and Camarena, 2008; 
Wickham, 2009), while analyses for the longitudinal study were performed in Stata 
v11.2 (StataCorp, Texas, USA). In both studies, a p value of <0.05 was considered 
statistically significant. Graphs were generated using R or Prism v6.0 (Graphpad Inc, 




For the Kenyan case-control study, Sl and McC genotype were included together in 
a statistical model to examine their associations with malaria susceptibility.  Odds 
Ratios (ORs) and 95% Confidence Intervals (CI) were generated using mixed effect 
logistic regression analysis both with and without adjustment for ethnicity and 
location of residence as random effects, and sickle cell genotype, α+thalassaemia 
genotype, and ABO blood group (O or non-O) as fixed effects (variables which have 
been associated with malaria susceptibility in multiple previous studies on this 
population) (Atkinson et al., 2014; Fry et al., 2008; Malaria Genomic Epidemiology 
Network, 2015; Penman et al., 2009; Rockett et al., 2014; Rowe et al., 2007; 
Williams et al., 2005b, 2005a). The ethnicity variable was compressed from 28 
categories to four; Giriama (n=2728), Chonyi (n=1800), Kauma (n=588) and other 
(n=429).  Binary parameterization of the α+thalassaemia variable was used, i.e. 
comparing those children with no α+thalassaemia alleles against those with one or 
more α+thalassaemia alleles. This division was chosen in accordance with a previous 
report showing that both heterozygous and homozygous α+thalassaemia genotypes 
are associated with protection against severe malaria and death in the Kilifi area 
(Williams et al., 2005b). 2000 bootstrapped iterations were run to give 95% CIs and 
p values.  
For the Kenyan longitudinal cohort study, Incidence Rate Ratios (IRRs) and 95% CIs 
were generated using a random effects Poisson regression model that took into 
account within-person clustering. Data were examined with and without 
adjustment for confounding by McC genotype (for Sl analyses), Sl genotype (for McC 
analyses) sickle cell genotype, α+thalassaemia genotype, ABO blood group, ethnic 
group, season (defined as 3 monthly blocks), and age in months as a continuous 
variable.  
For the Malian case-control study, ORs and 95% CIs were computed using mixed 
effect logistic regression analysis with adjustment for location of residence as a 
random effect and age, ABO blood group (O or non-O) and ethnicity (Dogon or non-




study and sickle cell trait is extremely uncommon in this population, therefore 
neither variable was included in the model. 2000 bootstrapped iterations were run 
to give adjusted ORs.   
Corrections for multiple comparisons were not performed, instead all adjusted odds 
ratios, confidence intervals and p values have been clearly reported. This approach 
has been repeatedly advocated, particularly when dealing with biological data 
(Fiedler et al., 2012; Nakagawa, 2004; Perneger, 1998; Rothman, 1990, 2014).  A 
detailed description of the statistical model fitting for the Kenyan studies is given in 
section 2.7.1. 
2.5.10 Ethical statement 
Human subjects: This work involved analysing blood samples from patients with 
malaria and from healthy controls. Written informed consent was obtained from 
the parents or legal guardians of all participants. The studies received ethical 
approval from the Kenya Medical Research Institute National Ethical Review 
Committee (case control study: SCC1192; cohort study: SCC3149), the University of 
Bamako/Mali Faculty of Medicine, Pharmacy and Dentistry Institutional Review 
Board (which, at the time the study was accepted did not give out approval 






2.6.1 The Sl2/Sl2 genotype is associated with protection against 
cerebral malaria and death in the Kenyan case-control study 
Data were obtained from 5545 children enrolled in a case-control study of severe 
malaria (Figure 2-1). The general characteristics of the cases and controls are shown 
in Table 2-1, and the characteristics of the dataset by Sl and McC genotype are 
shown in Table 2-2 and Table 2-3. The Sl2 and McCb allele frequencies (0.68 and 
0.16 respectively) were comparable to other African populations (Figure 1-10). 
There was no significant deviation from Hardy-Weinberg equilibrium for the Sl or 
McC genotypes among controls (Table 2-4).  
 
 
Controls   
  n = 3829 
All severe malaria cases  
n = 1716 p value 
Gender    
Males   1931 (50.4 %) 862 (50.2 %)  
Females   1898 (49.6 %) 854 (49.8 %) 0.915 
    
Ethnicity    
Giriama  1775 (46.4 %)  953 (55.5 %)  
Chonyi  1365 (35.6 %)  435 (25.4 %)  
Kauma  440 (11.5 %)  148 (8.6 %)  
Others  249 (6.5 %)  180 (10.5 %) <0.001 
    




 6 (5-8) 
 
  28 (15-43) 
 
<0.001 
Table 2-1. General characteristics for the Kenyan case-control study. 






Sl1/Sl1 % Sl1/Sl2 % Sl2/Sl2 % p value 
Clinical status Control 378 9.9 1730 45.2 1721 44.9   
All severe cases 177 10.3 801 46.7 738 43.0  0.403  
CM  95 10.1 457 48.5 391 41.5 0.144 
 Severe no CM 71 10.5 297 44.1 306 45.4 0.804  
SMA  53 11.0 230 47.6 200 41.4 0.319 
 SMA no CM 27 12.1 100 44.8 96 43.0 0.541  
RD 54 10.3 245 46.9 223 42.7 0.630 
 RD no CM 24 12.5 80 41.7 88 45.8 0.407 
 Died 25 13.9 80 44.4 75 41.7 0.203 
 Died with CM 16 12.2 59 45.0 56 42.7 0.659 
 Died no CM 8 19.0 18 42.9 16 38.1 0.148# 
 Died with SMA 9 16.1 24 42.9 23 41.1 0.304  
Died with RD 10 13.7 34 46.6 29 39.7 0.467 
Gender M 270 9.7 1287 46.1 1236 44.3   
F 285 10.4 1244 45.2 1223 44.4 0.637 
Ethnicity Giriama 235 8.6 1223 44.8 1270 46.6   
Chonyi 204 11.3 832 46.2 764 42.4   
Kauma 68 11.6 279 47.4 241 41.0   
Other 48 11.2 197 45.9 184 42.9 0.007 
Sickle Hb AA 489 10.0 2234 45.8 2158 44.2   
Hb AS 60 9.6 282 45.3 280 45.0   
Hb SS 6 14.3 15 35.7 21 50.0 0.660# 
α+thalassaemia   α α 189 9.5 912 45.8 890 44.7   
 α –α 279 10.3 1244 45.8 1196 44.0   
 -α –α 87 10.4 375 44.9 373 44.7 0.892 
Blood group O  287 9.8 1328 45.5 1302 44.6   
Non-O 268 10.2 1203 45.8 1157 44.0 0.855 
Median age Months  







Table 2-2. Characteristics for the Kenyan case-control study by Sl genotype. 
CM, cerebral malaria; SMA, severe malarial anaemia; RD, respiratory distress; IQR, interquartile 
range. Significance testing for each clinical status uses control as the reference group. Age: Kruskal 

















McCb % p value 
Clinical status Control 2700 70.5  1040 27.2 89 2.3  
 All severe cases 1182 68.9  484 28.2 50 2.9 0.278 
 CM  633 67.1  284 30.1 26 2.8 0.122 
 Severe no CM 479 71.1  175 26.0 20 3.0 0.520 
 SMA  346 71.6  128 26.5 9 1.9 0.761 
 SMA no CM 162 72.6  56 25.1 5 2.2 0.791 
 RD 355 68.0  153 29.3 14 2.7 0.488 
 RD no CM 132 68.8  54 28.1 6 3.1 0.626# 
 Died 119 66.1  53 29.4 8 4.4 0.128# 
 Died with CM 83 63.4  44 33.6 4 3.1 0.184# 
 Died no CM 31 73.8  9 21.4 2 4.8 0.304# 
 Died with SMA 38 67.9  14 25.0 4 7.1 0.088# 
 Died with RD 51 69.9  21 28.8 1 1.4 0.934# 
Gender M 1928 69.0  802 28.7 63 2.3  
 F 1954 71.0  722 26.2 76 2.8 0.071 
Ethnicity Giriama 1881 69.0  777 28.5 70 2.6  
 Chonyi 1307 72.6  462 25.7 31 1.7  
 Kauma 410 69.7  160 27.2 18 3.1  
 Other 284 66.2  125 29.1 20 4.7 0.003 
Sickle Hb AA 3404 69.7  1348 27.6 129 2.6  
 Hb AS 444 71.4  168 27.0 10 1.6  
 Hb SS 34 81.0  8 19.0 0 0.0 0.311# 
α+thalassaemia   α α 1398 70.2  551 27.7 42 2.1  
  α –α 1898 69.8  739 27.2 82 3.0  
  -α –α 586 70.2  234 28.0 15 1.8 0.200 
Blood group O  2042 70.0  799 27.4 76 2.6  
 Non-O 1840 70.0  725 27.6 63 2.4 0.879 
Median age Months  8 IQR 5-12 
 8 IQR 5-14 8 
IQR 
5-18.5 0.441 
Table 2-3. Characteristics for the Kenyan case-control study by McC genotype. 
CM, cerebral malaria; SMA, severe malarial anaemia; RD, respiratory distress; IQR, interquartile 
range. Significance testing for each clinical status uses control as the reference group. Age: Kruskal 




Sl1/Sl1 Sl1/Sl2 Sl2/Sl2 χ2 p value 
378 1730 1721 3.43 0.064* 
     
McCa/McCa McCa/McCb McCb/McCb χ2 p value 
2700 1040 89 0.81 0.369 
Table 2-4. Hardy Weinberg equilibrium calculations for controls in the Kenyan case-control study. 
*Although Sl and McC were found to be in Hardy Weinberg Equilibrium (HWE), Sl was of borderline 
statistical significance. HWE calculations for Sl were stratified by ethnicity and found to deviate from 
HWE for the Giriama ethnicity (χ2 = 5.12, p = 0.024), but not for the other ethnic groups. Ethnicity 
was subsequently included as a variable in all analyses performed.  To further investigate whether a 
genotyping error could be responsible for the borderline significant deviation from HWE for Sl in the 
Kenyan population, a subset of samples (n= 2344) were genotyped using a second platform (Illumina 
HumanOmni2.5-4) as previously described (Malaria Genomic Epidemiology Network, 2015).  
The concordancy rates between the two methods were 98.3 % (2304/2344 samples) for Sl and 98.8 % 
(2317/2344) for McC. 
Using a simple logistic regression model containing only Sl and McC genotypes 
(referred to as the unadjusted analysis below), we found a non-significant 
association between the Sl2 allele and severe malaria overall, with the Sl2/Sl2 
genotype being associated with an OR for severe malaria of 0.90 (95% CI 0.79-1.01; 
p=0.07) (Table 2-5). We attempted to refine this signal by fitting a more complete 
model to the data, including the potential confounding factors of ethnicity, location, 
sickle cell trait, ABO blood group and α+thalassaemia genotype, as well as 
considering possible first order interactions between terms (referred to as the full 















malaria (n=1716) 0.90 (0.79 – 1.01) 0.071 1.17 (1.00 – 1.25) 0.056 
CM (n=943) 0.82 (0.71 – 0.95) 0.010 1.21 (1.05 – 1.39) 0.008 
Severe without 
CM (n=674) 1.09 (0.86 – 1.21) 0.829 1.00 (0.84 – 1.18) 0.985 
Died (n=180) 0.80 (0.58 – 1.09) 0.164 1.34 (1.00 – 1.77) 0.046 
Died with CM 
(n=131) 0.82 (0.57 – 1.19) 0.306 1.39 (0.99 - 1.92) 0.052 
Died without CM 
(n=42) 0.74 (0.38 – 1.41) 0.373 1.05 (0.54 – 1.91) 0.881 
SMA(n=483) 0.87 (0.71 – 1.06) 0.177 0.98 (0.80 – 1.18) 0.800 
SMA without CM 
(n=223) 0.94 (0.71 – 1.25) 0.693 0.93 (0.70 – 1.23) 0.620 
Died with SMA 
(n=56) 0.77 (0.43 – 1.24) 0.327 1.40 (0.83 – 2.27) 0.192 
RD§ (n=522)  0.88 (0.72 – 1.06) 0.181 1.16 (0.96 – 1.38) 0.129 
RD without CM 
(n=192) 1.01 (0.74 – 1.37) 0.955 1.10 (0.82 – 1.45) 0.529 
Died with RD 
(n=73) 0.80 (0.48 – 1.29) 0.363 1.05 (0.64 – 1.66) 0.834 
Table 2-5. Unadjusted odds ratios for clinical outcomes for the Kenyan case-control study. 
Model includes only Sl2/Sl2 in recessive form (i.e. vs Sl1/Sl1 and Sl1/Sl2) and McCb in additive form 
(i.e. impact of each additional McCb allele). The data are not adjusted for the potential confounders 
ethnic group, location, sickle cell trait, ABO blood group or α+thalassaemia genotype.  
Confidence intervals by Wald. The 95% CIs and p values are not bootstrapped. 
OR = odds ratio; CI = confidence interval; CM = cerebral malaria; SMA = severe malarial anaemia; RD, 












aORs (95% CI) 
p 
value 
     
All severe malaria§ 
(n=1716) 
 
0.78 (0.64-0.95) 0.011 1.10 (0.97-1.25) 0.108 
CM# (n=943) 0.67 (0.52-0.87)* 0.006 1.19 (1.02-1.38) 0.025 
Severe without CM 
(n=674) 











     
Died with CM (n=131) 
 
0.44 (0.23-0.78)* 0.007 1.34 (0.94-1.88) 0.104 
Died without CM (n=42) 
 
0.73 (0.18-2.30) 0.636 1.00 (0.48-1.94) 0.940 
SMA† (n=483) 
 
0.76 (0.55-1.05) 0.099 0.96 (0.78-1.17) 0.688 
SMA without CM 
(n=223) 
 
0.82 (0.51-1.26) 0.366 0.91 (0.67-1.20) 0.553 
Died with SMA‡ (n=56) 0.65 (0.21-1.67) 0.374 1.35 (0.77-2.20) 0.229 
     
RD$ (n=522)  0.81 (0.59-1.10) 0.181 1.12 (0.92-1.35) 0.225 
RD without CM (n=192) 1.06 (0.66-1.68) 0.805 1.07 (0.80-1.43) 0.615 
     
Died with RD¶ (n=73) 0.39 (0.14-0.88)* 0.027 1.01 (0.59-1.61) 0.948 
Table 2-6. Adjusted Odds Ratios (aOR) for severe malaria by Sl2 (recessive) and McCb (additive) 
genotype in Kenya. 
&Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are presented for the Sl2 genotype in 
the recessive form (i.e. Sl2/Sl2 vs all other Sl genotypes) and McCb genotype in the additive form (i.e. 
change in aOR with each additional McCb allele). Sl and McC genotype were included together in a 
statistical model to examine their associations with malaria susceptibility. aORs displayed are 
adjusted for ethnicity, location of residence, sickle cell genotype, α+thalassaemia genotype and ABO 
blood group. An interaction term between Sl genotype and α+thalassaemia was included in the 
model. Model outputs following 2000 bootstrapped iterations are shown. 
$99 children (7 of whom died) were severe malaria cases whose CM status was not recorded, 
hence these children are included in the numbers for “All severe malaria” and “Died” but not 
in “with CM” or “without CM” categories. 
*Models that showed significant evidence of interaction between Sl2 and α+thalassaemia. 
#CM, cerebral malaria (P. falciparum infection with a Blantyre coma score of <3) 
†SMA, severe malarial anaemia (P. falciparum infection with Hb < 5 g/dl) 
‡34/56 cases who died with SMA also had CM. 
$RD, respiratory distress (P. falciparum infection with abnormally deep breathing) 






Figure 2-2. The Sl2 and McCb alleles have opposing associations with cerebral malaria (CM) and 
death. 
Forest plot showing the associations between Sl and McC polymorphisms and severe malaria in Kilifi, 
Kenya. Filled boxes: adjusted Odds Ratios (aOR) for the Sl2 genotype in the recessive form (i.e. Sl2/Sl2 
vs all other Sl genotypes). Open boxes: McCb in the additive form (i.e. change in odds ratio with each 
additional McCb allele). 
 Sl and McC genotype were included together in a statistical model to examine their associations with 
malaria susceptibility. aORs displayed are adjusted for ethnicity, location of residence, sickle cell 
genotype, α+thalassaemia genotype and ABO blood group.  
An interaction term between Sl genotype and α+thalassaemia is included in the model. 








A significant protective association was observed for Sl2 in the recessive form 
(adjusted Odds Ratio (aOR) 0.78; 95% CI 0.64-0.95; p=0.011), which was most 
marked for cerebral malaria (aOR 0.67; 0.52-0.87; p=0.006, Figure 2-2 and Table 
2-6). The Sl2/Sl2 genotype was also associated with significant protection against 
death from severe malaria (aOR 0.50; 0.30-0.80; p=0.002), and death among 
children admitted with a specific diagnosis of cerebral malaria in the full adjusted 
analysis (aOR 0.44; 0.23-0.78; p=0.007, Figure 2-2 and Table 2-6). Unexpectedly, we 
observed a significant interaction between Sl2 and α+thalassaemia genotype, such 
that the protective associations of Sl2 were only seen in individuals of normal α-
globin genotype (Figure 2-3). We found no evidence for an association between Sl2 
and any other clinical form of severe malaria (Table 2-6), or with P. falciparum 






Figure 2-3. The protective association of Sl2 with cerebral malaria and death is only evident in 
children with normal α-globin. 
Interaction plots showing the interaction between Sl (recessive) and α+thalassaemia for the 
proportion of children suffering (A) cerebral malaria and (B) death. For α+thalassaemia status, 0=wild 
type a-globin; 1= heterozygote or homozygote for α+thalassaemia.  For Sl (recessive) status, 0= 







Figure 2-4. Parasite densities by Sl and Mc genotypes.  
 Geometric mean parasite densities in the Kenyan case-control study (severe malaria) and 
longitudinal disease cohort study (uncomplicated malaria and asymptomatic parasitaemia) by A) Sl 
genotypes and B) McC genotypes. The data on severe malaria includes 1695 children: (Sl1/Sl1 (175), 
Sl1/Sl2 (793), Sl2/Sl2 (727) and McCa/McCa (1167), McCa/McCb (478) and McCb/McCb (50). The data 
on uncomplicated malaria includes 162 children: (Sl1/Sl1 (16), Sl1/Sl2 (75), Sl2/Sl2 (71) contributing 
124, 488 and 461 episodes respectively and McCa/McCa (107), McCa/McCb (49) and McCb/McCb (6) 
contributing 699, 349 and 25 episodes respectively. The data on asymptomatic parasitaemia includes 
57 children: (Sl1/Sl1 (5), Sl1/Sl2 (26), Sl2/Sl2 (26) contributing 6, 35 and 35 episodes respectively and 
McCa/McCa (34), McCa/McCb (20) and McCb/McCb (3) contributing 47, 25 and 4 episodes respectively. 
Differences in parasite densities by genotype were tested by linear regression analysis with 
adjustment for HbAS, age as a continuous variable and ABO blood group in the severe malaria cases, 
HbAS and season (defined into 3-monthly blocks) in the uncomplicated malaria samples and HbAS 
and ABO blood group in the asymptomatic parasitaemia samples. Data were adjusted for within-
person-clustering of events in the uncomplicated malaria and asymptomatic parasitaemia studies. 









2.6.2 The McCb allele is associated with increased susceptibility to 
cerebral malaria and death in the Kenyan case-control study 
The unadjusted analysis showed a borderline significant association between McCb 
and increased susceptibility to severe malaria overall (OR 1.17; 1.00-1.25; p=0.056, 
Table 2-5), and significant associations with increased risk of cerebral malaria (OR 
1.21; 1.05-1.39; p=0.008) and death (OR 1.34; 1.00-1.77; p=0.046, Table 2-5).  
Similar associations were seen in the full adjusted analysis, although this only 
reached statistical significance for cerebral malaria (aOR 1.19; 1.10-1.38; p=0.025 
(additive model), Figure 2-2 and Table 2-6). We found no association between McCb 
and any other clinical form of severe malaria (Table 2-5 and Table 2-6) or with P. 
falciparum parasite density (Figure 2-4).   
2.6.3 Analysis of haplotypic effects and genotype combinations  
We considered whether the observed results for Sl and McC could be consistent 
with the effect of a single haplotype spanning Sl and McC, or with the effect of a 
specific genotype combination. Sl and McC are 33bp apart and are in linkage 
disequilibrium, with only three of four possible haplotypes observed in our data. We 
therefore reanalysed the data under a haplotype model in which the per-individual 
count of each of the three observed haplotypes was included as a predictor along 
with the potential confounding factors, as well as under a genotypic model in which 
the count of each of the six possible Sl/McC genotype combinations was included as 
a predictor (detailed in 2.7). These analyses suggest an additive protective 
association with the Sl2/McCa haplotype (aOR=0.85; 0.75-0.96; P=0.007), with 
broadly consistent results observed for analysis of genotype combinations (Table 
2-7 and Table 2-8). Thus, the opposing effects of Sl2 and McCb observed above 
could plausibly result from the protective association of a single haplotype at the 
locus, although this is difficult to distinguish from the individuals SNPs acting 








CM cases aOR 95% CI p value 
Sl1/Sl1-McCa/McCa 378/95 Ref Ref Ref 
Sl1/Sl2-McCa/McCa 1330/322 0.89 0.59 - 1.41 0.622 
Sl1/Sl2-McCa/McCb 400/135 1.15 0.69 - 1.92 0.606 
Sl2/Sl2-McCa/McCa 992/216 0.70 0.44 – 1.11 0.123 
Sl2/Sl2-McCa/McCb 640/149 0.57 0.33 – 0.96 0.031 
Sl2/Sl2-McCb/McCb 89/26 1.12 0.38 – 2.76 0.749 
Table 2-7. Sl and McC combined genotypes and adjusted odds ratios for cerebral malaria in the 





died aOR 95% CI p value 
Sl1/Sl1-McCa/McCa 378/25 Ref Ref Ref 
Sl1/Sl2-McCa/McCa 1330/57 0.73 0.35 – 1.77 0.383 
Sl1/Sl2-McCa/McCb 400/23 1.04 0.43 – 2.72 0.946 
Sl2/Sl2-McCa/McCa 992/37 0.44 0.19 – 1.10 0.080 
Sl2/Sl2-McCa/McCb 640/30 0.34 0.13 – 0.92 0.034 
Sl2/Sl2-McCb/McCb 89/8 1.17 0.00 – 6.09 0.530 
Table 2-8. Sl and McC combined genotypes and adjusted odds ratio for death in the Kenyan case-
control study. 
For both Table 2-7 and Table 2-8: aOR: adjusted Odds Ratio. aORs were adjusted for ethnicity, 
location of residence, sickle cell genotype, α+thalassaemia genotype and ABO blood group. An 
interaction term between the combined Sl/McC genotype and α+thalassaemia was included in the 









2.6.4 The Sl2/Sl2 genotype was associated with protection against 
uncomplicated malaria in the Kenyan longitudinal cohort study. 
We next examined the association between Sl2 and McCb alleles and uncomplicated 
malaria in a longitudinal prospective study of 208 Kenyan children. General 
characteristics of the cohort study population by Sl and McC genotypes are shown 
in Table 2-9. The number of episodes, incidence and unadjusted Incidence Rate 
Ratios for the diseases studied in the longitudinal cohort are shown in Table 2-10, 
Table 2-11 and Table 2-12.   
After adjusting for variables known to influence malaria susceptibility, the Sl2 allele 
was associated with a >50% reduction in the incidence of uncomplicated malaria 
(additive model) Table 2-13. Once again, a significant interaction was seen with 
α+thalassaemia, such that the protective association of Sl2 was only demonstrated 
in children of normal α-globin genotype (Table 2-14). We found no significant 











































                
Sample size  22 10.6 94 45.2 92 44.2  137 65.9 63 30.2 8 3.9  
Mean age in 
months 
 (95% CI) 















Gender                
 Males 13 10.8 56 46.7 51 42.5  82 68.3 33 27.5 5 4.2  
 Females 9 10.2 38 43.2 41 46.6 0.844 55 62.5 30 34.1 3 3.4 0.594 
Ethnic group                
 Giriama 19 10.8 80 45.5 77 43.8  113 64.2 55 31.3 8 4.6  
 Chonyi 2 10.0 10 50.0 8 40.0  15 75.0 5 25.0 0 0.0  
 Others 1 8.3 4 33.3 7 58.3 0.907 9 75.0 3 25.0 0 0.0 0.877 
Sickle                
 AA 17 9.3 85 46.7 80 44.0  122 67.0 52 28.6 8 4.4  
 AS 5 19.2 9 34.6 12 46.2 0.224 15 57.7 11 42.3 0 0.0 0.228 
α+thalassaemia                
 Normal  (αα/αα) 7 10.5 33 49.3 27 40.3  45 67.2 18 26.9 4 6.0  
 Heterozygote  (-α/αα) 9 8.7 48 46.2 47 45.2  67 64.4 34 32.7 3 2.9  
 Homozygote  (-α/-α) 6 16.2 13 35.1 18 48.7 0.546 25 67.6 11 29.7 1 2.7 0.823 
ABO blood 
group                
 O 11 9.4 56 47.9 50 42.7  81 69.2 30 25.6 6 5.1  
 Non O 11 12.1 38 41.8 42 46.1 0.628 56 61.5 33 36.3 2 2.2 0.189 
Table 2-9. General characteristics of the Kenyan longitudinal cohort study population by Sl and McC genotypes. 
















285 5.77 1052 4.92 1020 5.40 
Uncomplicated 
malaria 
124 2.51 493 2.31 461 2.44 
LRTI† 46 0.93 180 0.84 172 0.91 
URTI¶ 111 2.25 394 1.84 403 2.13 
Gastroenteritis 64 1.30 158 0.74 145 0.77 
Skin infection 37 0.75 196 0.92 176 0.93 
Helminth 
infection 
7 0.14 52 0.24 44 0.23 
Malaria 
negative fever 
104 2.11 301 1.41 233 1.23 
Table 2-10. Incidence of common childhood diseases by Sl genotypes in the Kenyan cohort study. 
Incidence = number of episodes per child-year of follow up. Data were collected from 22 Sl1/Sl1, 94 
Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 cyfu (child-years of follow-up) 
respectively. 
 




episodes Incidence  
No. of 
episodes Incidence  
No. of 




1595 5.42 685 4.78 77 5.38 
Uncomplicated 
malaria 
699 2.37 354 2.47 25 1.75 
LRTI† 273 0.93 117 0.82 8 0.56 
URTI¶ 624 2.12 246 1.72 38 2.66 
Gastroenteritis 252 0.86 101 0.71 14 0.98 
Skin infection 261 0.89 141 0.98 7 0.49 
Helminth 
infection 
74 0.25 28 0.20 1 0.07 
Malaria 
negative fever 
423 1.43 192 1.34 23 1.61 
Table 2-11. Incidence of common childhood diseases by McC genotypes in the Kenyan cohort study. 
Incidence = number of episodes per child-year of follow up. Data were collected from 137 McCa/McCa, 
63 McCa/McCb and 8 McCb/McCb individuals during 294.5, 143.2 and 14.3 cyfu respectively. 

















0.95 (0.76-1.18)  0.638 4 0.72 (0.32-1.63)  0.254 1 
All non-malaria 
clinical visits 
1.03 (0.87-1.22) 0.711 1 0.91 (0.79-1.06) 0.242 4 
LRTI†  1.02 (0.74-1.41) 0.902 1 0.54 (0.21-1.43) 0.217 1 
URTI¶ 1.08 (0.88-1.33) 0.472 1 0.81 (0.65-1.02) 0.077 3 
Gastroenteritis  0.56 (0.34-0.95) 0.031 2 0.87 (0.60-1.26) 0.462 2 
Skin infection 1.24 (0.73-2.12) 0.430 2 0.47 (0.17-1.29) 0.142 1 
Helminth infection 1.63 (0.69-3.86) 0.265 2 0.72 (0.46-1.12) 0.147 4 
Malaria negative 
fever 
0.70 (0.49-1.02) 0.060 2 0.91 (0.70-1.19) 0.486 3 
Table 2-12. Unadjusted Incidence Rate Ratios (IRR) for uncomplicated malaria and non-malarial 
diseases in the Kenyan longitudinal cohort study by Sl and McC genotype. 
Data were collected from 22 Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 
188.8 cyfu (child-years of follow-up) respectively and 137 McCa/McCa, 63 McCa/McCb and 8 
McCb/McCb individuals during 294.5, 143.2 and 14.3 cyfu respectively. Sl2 and McCb alleles were 
tested separately in univariate analyses for their association with the disease outcomes of interest 
using logistic regression in the 1recessive, 2dominant, 3heterozygous and 4additive models. The best 
fitting models as examined using the Akaike information criterion (AIC) were used in the final analysis 
that accounted for within-person clustering of events. §IRRs: (unadjusted) Incidence Rate Ratios; 




















0.49 (0.34-0.72)* <0.001 4 1.24 (0.90-1.70) 0.184 1 
All non-malaria 
clinical visits 
1.13 (0.96-1.32) 0.140 1 0.76 (0.61-0.96)* 0.020 4 
LRTI†  1.09 (0.81-1.47) 0.561 1 0.39 (0.16-0.96) 0.040 1 
URTI¶ 1.21 (0.98-1.50) 0.073 1 0.79 (0.63-0.99) 0.047 3 
Gastroenteritis  0.66 (0.43-1.03) 0.066 2 0.55 (0.31-0.97)* 0.038 2 
Skin infection 1.33 (0.79-2.26) 0.285 2 0.42 (0.16-1.13) 0.086 1 
Helminth 
infection 
1.98 (0.83-4.71) 0.122 2 0.68 (0.43-1.07) 0.094 4 
Malaria negative 
fever 
0.83 (0.58-1.18) 0.293 2 1.03 (0.80-1.33) 0.828 3 
Table 2-13. Adjusted Incidence Rate Ratios (aIRR) for uncomplicated malaria and non-malarial 
diseases in Kenya by Sl and McC genotype. 
Data were collected from 22 Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 cyfu 
(child-years of follow-up) respectively and 137 McCa/McCa, 63 McCa/McCb and 8 McCb/McCb individuals during 
294.5, 143.2 and 14.3 cyfu respectively. Both Sl2 and McCb alleles were tested for their association with the 
disease outcomes of interest using Poisson regression in the 1recessive, 2dominant, 3heterozygous and 4additive 
models. The best fitting models as examined using the Akaike information criterion (AIC) were used in the final 
analysis that included adjustment for McC genotype (for Sl analyses), Sl genotype (for McC analyses) 
α+thalassaemia and sickle cell genotype, ABO blood group, season (divided into 3 monthly blocks), ethnicity, age 
as a continuous variable and within-person clustering of events. 
§aIRRs: adjusted Incidence Rate Ratios 
*Models that showed significant evidence of interaction between either Sl2 or McCb and α+thalassaemia. 
†LRTI: Lower Respiratory Tract Infection 
















 124 2.51 493 2.31 461 2.44 
Normal  
α globin 73 4.18 238 2.87 77 1.64 
Heterozygous  
α+thalassaemia 32 1.58 209 1.92 302 2.88 
Homozygous 
α+thalassaemia 19 1.63 46 2.09 82 2.20 
Table 2-14. Incidence of uncomplicated malaria by Sl genotype and α+thalassaemia status in the 
Kenyan longitudinal cohort study. 
Incidence = number of episodes per child-year of follow up (cyfu). Data were collected from 22 
Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 child-years of follow-up 
respectively. 
 
2.6.5 The McCb allele was associated with protection from common 
non-malarial childhood diseases in the Kenyan longitudinal cohort 
study. 
The data shown above are incompatible with malaria being the selective pressure 
for McCb in the Kenyan population, and suggest that other life-threatening 
childhood diseases may have been responsible for selection of McCb. We therefore 
used the same longitudinal cohort study to investigate whether the McCb and Sl2 
alleles influence the risk of other childhood diseases.  McCb was associated with 
borderline significant protection against several common infectious diseases 
including LRTIs, URTIs and gastroenteritis (Table 2-13). Sl2 was associated with a 
borderline reduced incidence of gastroenteritis (Table 2-13). The association of 
McCb with gastroenteritis was predominantly seen in children of normal α-globin 





2.6.6 The Sl2 allele was associated with reduced ex vivo rosette 
frequency in P. falciparum clinical isolates from Mali. 
A previous in vitro study based on a culture-adapted P. falciparum parasite line 
suggested that RBC from Sl2 genotype donors had a reduced ability to form 
rosettes, providing a possible mechanism for protection against severe malaria 
(Rowe et al., 1997). P. falciparum clinical isolates were not available from the 
Kenyan case-control study to investigate this potential mechanism in that 
population. However, the association of Sl and McC genotypes with ex vivo P. 
falciparum rosette frequency could be examined using 167 parasite isolates from a 
case-control study of children with clinical malaria in Mali (Doumbo et al., 2009).  
To determine if the Mali case-control study was a suitable source of samples to 
examine the effect of Knops genotype on P. falciparum rosetting, we examined 
whether there was any evidence to suggest that the association of the Sl2/Sl2 
genotype with cerebral malaria also occurred in Mali. To do this, we examined the 
cerebral malaria cases (n=34) and uncomplicated malaria controls (n=184) from the 
Malian case-control study Figure 2-5.  General characteristics of the cases and 
controls are shown in Table 2-15 and Table 2-16. α+thalassaemia genotype data 




















(Cerebral malaria) p value 





90 (49 %) 
94 (51 %) 
 
17 (50 %) 









161 (87.5 %) 
23 (12.5 %) 
 
30 (88 %) 















Table 2-15. General characteristics for cases and controls in the Mali case-control study. 











Sl2 %  p  
McCa/ 




McCb % p  
Clinical 
status UM 19 10.3 78 42.4 87 47.3 
 103 56.0 61 33.2 20 10.9  
 
CM 5 14.7 19 55.9 10 29.4 0.135# 16 47.1 15 44.1 3 8.8 0.478# 
Gender M 11 10.3 48 44.9 48 44.9   57 53.3 41 38.3 9 8.4   
F 13 11.7 49 44.1 49 44.1 0.945 62 55.9 35 31.5 14 12.6 0.430 
Ethnicity Dogon 21 11.0 88 46.1 82 42.9  108 56.5 66 34.6 17 8.9   
Non-
Dogon 3 11.1 9 33.3 15 55.6 0.448
# 11 40.7 10 37.0 6 22.2 0.078 
Blood 
group 
O  13 10.0 63 48.5 54 41.5  68 52.3 49 37.7 13 10.0  
 





















Table 2-16. Table of Characteristics for the Malian case-control study by Sl and McC genotype. 
UM = uncomplicated malaria. CM, cerebral malaria. IQR, interquartile range. Significance testing uses uncomplicated malaria as the reference group. Age: Kruskal 






Analysis of this small case-control study suggested a protective association between 
the Sl2/Sl2 genotype and cerebral malaria (aOR 0.35, 95% CI 0.12-0.89, p=0.024) 
and the Sl2/Sl2-McCa/McCa genotype combination was associated with protection 
against cerebral malaria (aOR 0.14, 95% CI 0.02-0.84, p=0.031). As such, we 
considered samples from this population to be appropriate for testing rosetting as a 
potential mechanism of action. The median rosette frequency (percentage of 
infected erythrocytes that form rosettes) was significantly lower in P. falciparum 
isolates from malaria patients with one or more Sl2 alleles than in isolates from 
Sl1/Sl1 donors (Figure 2-6), whereas McC genotype had no significant associations 
with P. falciparum rosette frequency (Figure 2-6).    
 
 
Figure 2-6. The Sl2 allele is associated with reduced ex vivo rosette frequency of P. falciparum clinical 
isolates. 
Parasite isolates were collected from 167 malaria patients in Mali and matured in culture for 12-24 
hours before assessment of rosette frequency (percentage of infected erythrocytes forming rosettes 
with two or more uninfected erythrocytes). Red bars show the median rosette frequency and 
interquartile range (IQR) for each genotype. (A) Rosetting by patient Sl genotype. Sl1/Sl1 (n=22, 
median 20.0, IQR 8.3-36.5), Sl1/Sl2 (n=82, median 4.0, IQR 0-20.3), Sl2/Sl2 (n=63, median 5.0, IQR 0-
17.0); * p<0.05, Kruskal Wallis with Dunn’s multiple comparison test; (B) Rosetting by McC genotype.  
McCa/McCa (n=81, median 9.0, IQR 0-22.0), McCa/McCb (n=73, median 6.0, IQR 0-20.0), McCb/McCb 






2.7 Supplementary information and results 
2.7.1 Statistical model fitting and bootstrapping for the Kenyan case-
control study 
Analyses for the Kilifi case-control study were performed in R (R Foundation for 
Statistical Computing, Vienna, Austria) (R Development Core Team, 2010) using the 
“ggplot2”, “lme4”, and “HardyWeinberg” packages (Bates et al., 2013; Graffelman 
and Camarena, 2008; Wickham, 2009). The dataset was restricted to children who 
were resident in the Kilifi Health and Demographic Surveillance System (KHDSS) 
(Scott et al., 2012) and had full genotyping data for Sl, McC α+thalassaemia, sickle 
cell and ABO blood group. This resulted in 1716 cases and 3829 controls (Figure 
2-1). The ethnicity variable was compressed from 28 categories to four; Giriama 
(n=2728), Chonyi (n=1800), Kauma (n=588) and other (n=429). Binary 
parameterization of the α+thalassaemia variable was used, i.e. comparing those 
children with no α+thalassaemia alleles against those with one or more 
α+thalassaemia alleles. This division was chosen in accordance with a previous 
report showing that both heterozygous and homozygous α+thalassaemia genotypes 
are associated with protection against severe malaria and death in the Kilifi area 
(Williams et al., 2005b). 
A simple unadjusted logistic regression analysis containing only the Sl and McC 
genotypes suggested potential associations with severe malaria (Table 2-5). We 
attempted to refine this signal by fitting a more complete model to the data using 
mixed effect logistic regression analysis. The full adjusted analysis was constructed 
as follows: 
1. Variables associated with malaria susceptibility in multiple previous studies in this 
population (Atkinson et al., 2014; Fry et al., 2008; Malaria Genomic Epidemiology 
Network, 2015; Penman et al., 2009; Rockett et al., 2014; Rowe et al., 2007; 
Williams et al., 2005b, 2005a) were included to give a “base model”. These variables 




α+thalassaemia genotype (as a binary variable, one or more α+thalassaemia alleles 
vs no α+thalassaemia alleles) and ABO blood group (as a binary variable, group O vs 
non-group O). 
2. Both Sl and McC genotype were added in the simplest form (additive).  
3. All possible models for Sl were then examined (genotypic, dominant, recessive, 
heterozygous and additive models of inheritance, Table 2-17). Model selection was 
performed using a criterion-based approach by minimizing the Akaike information 
criterion (AIC) and discrimination (i.e. how well a model separates individuals with 
and without the outcome of interest) was determined using the c-statistic (area 
under the receiver operator curve). The recessive model had the best overall fit for 
Sl across clinical outcomes.  
4. The process of examining all genetic models of inheritance was then repeated for 
McC (Table 2-18), with Sl as recessive included in each model. The additive model 
had the best overall fit for McC across clinical outcomes. 
5. All first order interactions were explored. The interaction with the greatest effect 
on the AIC was included in the final model. This resulted in an interaction term 
between Sl2 and α+thalassaemia being incorporated into the model.  
6. Finally, ethnicity and location of residence were incorporated as random effects 
in order to accommodate population structures which did not require quantification 
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Table 2-17. Adjusted Odds Ratios for different genetic models for the Sl polymorphism in the Kenyan case-control study.  
The “base model” is kept the same throughout (ethnicity and location of residence as random effects; sickle cell genotype, α+thalassaemia genotype and ABO blood 
group as fixed effects. An interaction term for Sl * α+thalassaemia is included). The McCb allele was kept in the additive form for all analyses. 
 CM = cerebral malaria; SMA = severe malarial anaemia; RD = respiratory distress. 
















Table 2-18. Adjusted Odds Ratios for different genetic models for the McC polymorphism in the Kenyan case-control study.  
The “base model” is kept the same throughout (ethnicity and location of residence as random effects; sickle cell genotype, α+thalassaemia genotype and ABO blood 
group as fixed effects. An interaction term for Sl * α+thalassaemia is included). The Sl2 allele was kept in the recessive form for all analyses.  
CM = cerebral malaria; SMA = severe malarial anaemia; RD = respiratory distress.  









McCb genotypic (McCa / McCa = ref) 
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The final model incorporated ethnicity and location of residence as random effects, 
and as fixed effects had Sl2 in the recessive form (i.e. binary variable, Sl2/Sl2 vs 
Sl1/Sl1 or Sl1/Sl2); presence of at least one α+thalassaemia allele vs no 
α+thalassaemia alleles (binary variable);an interaction term between the Sl and 
α+thalassaemia variables; McCb in the additive form (i.e. impact of each additional 
McCb allele); presence/absence of sickle cell trait as a binary variable; O/non-O 
blood group as a binary variable.  
The code used for the final model was: 
fit = glmer (outcome ~ (1|ethnicity) + (1|location) + 
Sl_recessive*thalassaemia_allele + Mc + sickle_trait + non_O, data=data, family= 
binomial) 
Bootstrapping was performed using the “bootMer” function in package “lme4” in R.  
2000 iterations were run of each model to calculate 95% confidence intervals and p 
values. If models did not converge over these 2000 iterations they were inspected 
for singularities (i.e. a level of one of the variables having a value of 0, for example 0 
cases living in the town of Gede). If no singularities were identified, the 
bootstrapping was rerun using the optimiser “bobyqa” with 105 evaluations.  
Corrections for multiple comparisons were not performed in this study, instead all 
adjusted odds ratios, confidence intervals and p values have been clearly reported. 
This approach has been repeatedly advocated, particularly when dealing with 
biological data (Fiedler et al., 2012; Nakagawa, 2004; Perneger, 1998; Rothman, 
1990, 2014). The stringency of multiple comparisons increases the risk of type II 
error, potentially discarding important findings. No single study can be considered 





2.7.2 Comparison between this study and Rockett et al.  
The Sl and McC polymorphisms were originally typed as part of a larger study by 
Rockett et al. (Rockett et al., 2014), which included case-control data from 12 global 
sites. The Kenyan samples studied by Rockett et al. originally comprised 2741 cases 
of severe malaria and 4183 controls. After the quality control of both phenotypic 
and genotypic data described above, 2268 cases and 3949 controls were analysed 
by Rockett et al. which were the starting point for our study. Children living outside 
the KHDSS were excluded, because this allowed us to use “location” as a random 
effect in the final statistical model, which greatly improved model fit. Children with 
missing genotypes (Sl, McC, sickle cell, α+thalassaemia or ABO blood group) were 
also excluded (Figure 2-1). After applying these exclusion criteria, 1,716 severe 
malaria cases and 3829 community controls were available for analysis. 
Hence, the number of severe malaria cases differs between our study and Rockett 
et al. due to differing exclusion criteria. The inclusion of the severe malaria cases 
who lived outside the KHDSS into our statistical models did not alter the findings of 
our analysis (Table 2-19). In both our study and that by Rockett et al., the control 
samples were identical and all came from within the KHDSS. Our study has 120 
fewer controls than Rocket et al. due to missing genotypes, because we only used 
controls for whom full Sl, McC, sickle cell genotype, α+thalassaemia genotype and 
ABO blood group data were available. Our analytical methods differed from Rockett 
et al., in that we included both Sl and McC in the same statistical model and 








aOR (95% CI) p value 
McCb 
aOR (95% CI) p value 
All severe malaria 
(n= 2100) 
0.84 
(0.70 - 1.01) 
0.069 
1.07 





(0.57 – 0.90) 
0.004 
1.18 
(1.03 – 1.34) 
0.016 
Severe without CM  
(n=805) 
1.05 
(0.82 – 1.35) 
0.672 
0.967 





(0.45 – 1.05) 
0.083 
1.16 





(0.72 – 1.24) 
0.693 
0.92 





(0.66 – 1.15) 
0.333 
1.16 
(0.98 – 1.36) 
0.086 
Table 2-19. Reanalysis of Kenyan case-control study including children who lived outside of the KHDSS 
study area. 
Analysis of the dataset including the 386 children who lived outside of the KHDSS study area (407 
children lived outside the KHDSS but only 386 had full data on sickle cell, α+thalassaemia, Sl, McC and 
ABO genotype, thus available for inclusion in this analysis). These children were all severe malaria 
cases and were previously excluded from the main analysis as they did not have location-specific 
controls. 
Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are presented for the Sl2 genotype in 
the recessive form (i.e. Sl2/Sl2 vs all other Sl genotypes) and McCb genotype in the additive form (i.e. 
change in aOR with each additional McCb allele). aORs displayed are adjusted for ethnicity, sickle cell 
genotype, α+thalassaemia genotype and ABO blood group. An interaction term between Sl genotype 
and α+thalassaemia was included in the model. Confidence intervals by Wald. The 95% CIs and p 
values are not bootstrapped. 
In contrast to the main results table in the manuscript, location of residence could not be used in this 
model as the newly included cases had no location-specific controls. Removal of the location variable 
resulted in deterioration of the model fits. 




2.7.3 Exploration of alternative haplotype and combined genotype 
models 
As one of the four possible Sl/Mc haplotype combinations was not seen (Sl1/McCb), 
the Sl2 and McCb alleles are likely to be in complete linkage disequilibrium in this 
population sample (i.e. D’ = 1, no recombination between these two markers). This 
situation makes it difficult to distinguish statistically between a model where Sl and 
McC act independently and additively or a haplotype model. We considered the 
possibility that a haplotype model could provide an alternative explanation for our 
findings, with a separate true protective mutation being positively tagged by the Sl2 
allele and negatively tagged by the McCb allele. Specifically, for each sample we 
computed the count of each of the three possible Sl/Mc haplotypes (assuming only 
three haplotypes are segregating as above).  We then re-fit the logistic regression 
model for cerebral malaria using haplotype counts as predictors, in addition to 
potential confounders included in the full adjusted analysis described above.  This 
model estimates a non-zero protective effect of the Sl2/McCa haplotype (additive 
OR = 0.85; 0.75-0.96; P=0.007), but did not fit as well as the full adjusted analysis 
described above (AIC = 4268.5, versus 4266.8 for the full analysis). 
As both Sl and Mc have sufficient structural effects to alter Knops blood group 
phenotype, it would appear reasonable to examine their function further before 
looking for other nearby mutations. In addition, no other strong effects near CR1 
have been identified by GWAS studies that could explain the association. However, 






2.7.4 Exploration of the negative epistasis between sickle trait and 
α+thalassaemia  
Previous studies have described a negative epistatic interaction between sickle trait 
and α+thalassaemia, reporting that α+thalassaemia homozygotes who also carry the 
sickle trait are not protected from severe malaria (Williams et al., 2005c). We 
wanted to ensure that an unrecognised relationship between sickle cell trait and Sl 
genotype did not account for the interaction between α+thalassaemia and Sl that 
we report in the current study.  
Analysis of our current dataset confirmed the existence of negative epistasis 
between sickle trait and α+thalassaemia in this population (Table 2-20). However, of 
interest, this negative epistatic interaction was only seen in the severe malaria cases 
without cerebral malaria, whereas the α+thalassaemia/Sl interaction was specific to 
cerebral malaria cases (Table 2-20). Therefore, the two interactions appear to be 
mutually exclusive.  
The final adjusted analysis was also re-run on a restricted dataset which excluded 
the 664 children with sickle cell trait or sickle cell disease. The results of this analysis 
remained unchanged and the α+thalassaemia/Sl interaction persisted without any 
influence of sickle trait (Table 2-21).   
Sickle cell trait did not show a statistical interaction with either Sl or McC genotype. 
The sickle cell polymorphism is far less common in the KHDSS population than the 
α+thalassaemia polymorphism (~12% of children have one or more sickle cell 
alleles, compared to ~64% with one or more α+thalassaemia alleles). As such, even 
in a study as large as this one, the power to detect statistically significant 
interactions between all three of sickle, α+thalassaemia and Sl genotypes is greatly 
reduced. However, we found no evidence of a three way interaction between these 
alleles. The raw data for the combined genotypes compromising sickle trait, 
α+thalassaemia and Sl for each clinical outcome is presented in Table 2-22. 




































































































Table 2-20. Investigation of the sickle trait/α+thalassaemia negative epistatic interaction and the 
Sl2/α+thalassaemia interaction by clinical outcome in the Kenyan case-control study. 
Coefficients and p values are for the sickle trait/α+thalassaemia interaction and the Sl2/α+thalassaemia 
interaction by clinical outcome in two separate models (denoted by * or #). The sickle trait/α+thalassaemia 
interaction (examined in the * model) was only significant for cases without cerebral malaria, whereas the 
Sl2/α+thalassaemia interaction (examined in the # model) was only significant for cases with cerebral 
malaria. Both models include ethnicity and location as random effects with additional variables described 
in the * or # paragraphs below (NB, McCb and ABO are not included in these models). 260/483 cases of 
SMA also had CM. 
* This model included the α+thalassaemia variable in recessive form (i.e. α+thalassaemia homozygotes vs 
both α+thalassaemia heterozygotes and those without α+thalassaemia alleles), sickle cell trait (i.e. sickle 
cell trait vs both sickle cell homozygotes and those without sickle cell alleles) and an interaction term 
between these two variables (Williams et al., 2005c). 
# This model included the Sl2 variable in the recessive form (i.e. Sl2/Sl2 genotype vs both Sl1/Sl1 and 
Sl1/Sl2 genotypes) and the α+thalassaemia variable in the dominant form (i.e. one or more α+thalassaemia 
alleles vs no α+thalassaemia alleles). This is the novel interaction identified. 
The logistic regression interaction effect is interpreted as a ratio of odds ratios. For example, there is a 
significant association between α+thalassaemia homozygosity and sickle cell trait for severe malaria. The 
association between α+thalassaemia homozygosity and severe malaria for those WITHOUT sickle cell trait 
is aOR=0.73. The association between α+thalassaemia homozygosity and severe malaria for those WITH 






Clinical Outcome Sl2 
aOR (95% CI) p value 
McCb 
aOR (95% CI) p value 
All severe malaria 
(n= 1665) 
0.75 
(0.61 - 0.93) 
0.009 
1.10 









(1.01 - 1.37) 
0.035 
 
Severe without CM  
(n= 654) 
0.98 










(0.24 - 0.71) 
0.001 
1.33 




















(0.92 - 1.35) 
0.247 
 
Table 2-21. Reanalysis of the Kenyan case-control study excluding all children with one or more sickle 
cell alleles does not alter findings. 
Kilifi case-control dataset restricted to children without sickle cell trait or sickle cell disease (664 
children excluded from analysis).  
Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are presented for the Sl2 genotype in 
the recessive form (i.e. Sl2/Sl2 vs all other Sl genotypes) and McCb genotype in the additive form (i.e. 
change in aOR with each additional McCb allele). aORs displayed are adjusted for ethnicity, location 
of residence, α+thalassaemia genotype and ABO blood group. An interaction term between Sl 
genotype and α+thalassaemia was included in the model. Confidence intervals by Wald. The 95% CIs 
and p values are not bootstrapped.  


























Case no CM 
Proportion 
(%) 
0 0 0 103 68 39.77 35 25.36 27 20.77 29 21.97 
0 0 1 495 325 39.63 186 27.31 94 15.96 120 19.51 
0 0 2 504 275 35.30 133 20.88 81 13.85 131 20.63 
0 1 0 161 85 34.55 51 24.06 24 12.97 28 14.81 
0 1 1 740 356 32.48 205 21.69 107 12.63 131 15.04 
0 1 2 714 363 33.70 207 22.48 95 11.74 132 15.60 
0 2 0 56 22 28.21 7 11.11 2 3.45 14 20.00 
0 2 1 232 101 30.33 55 19.16 26 10.08 39 14.39 
0 2 2 243 80 24.77 42 14.74 20 7.60 32 11.64 
1 0 0 17 1 5.56 1 5.56 0 0.00 0 0.00 
1 0 1 87 5 5.43 4 4.40 0 0.00 1 1.14 
1 0 2 104 7 6.31 4 3.70 1 0.95 3 2.80 
1 1 0 32 1 3.03 1 3.03 0 0.00 0 0.00 
1 1 1 139 9 6.08 6 4.14 2 1.42 2 1.42 
1 1 2 113 6 5.04 2 1.74 2 1.74 4 3.42 
1 2 0 9 0 0.00 0 0.00 0 0.00 0 0.00 
1 2 1 37 5 11.90 1 2.63 1 2.63 4 9.76 
1 2 2 43 7 14.00 3 6.52 1 2.27 4 8.51 
Table 2-22. Raw data for the combined sickle trait, α+thalassaemia and Sl genotype by clinical outcome in the Kenyan case-control study.  
Raw data for each clinical outcome presented by sickle trait status (0 = no sickle trait, 1 = sickle trait), α+thalassaemia genotype (0, 1, 2 = number of α+thalassaemia 
alleles) and Sl2 genotype (0, 1, 2 = number of Sl2 alleles). 





 Sickle α+thalassaemia Sl2 McCb 
Sickle  0.011 0.006 -0.025 
α+thalassaemia 0.011  -0.007 0.002 
Sl2 0.006 -0.007  0.301 
McCb -0.025 0.002 0.301  
Table 2-23. Correlations between the sickle cell, α+thalassaemia, Sl2 and McCb variants in the Kenyan 
case-control study. 
Each variant was coded as 0/1/2 copies of the allele. Shaded area = not applicable. 
2.7.5 Statistical model fitting for the longitudinal cohort study 
Associations between Sl and McC and mild malaria and other non-malarial related 
diseases in the longitudinal cohort study were tested in Stata v11.2 (StataCorp, 
Texas, USA) using a random effects Poisson regression analysis that accounted for 
within-person clustering of events. This analysis was restricted to children under 10 
years old living in the Ngerenya area in the northern part of the KHDSS study area. 
The analysis was carried out on the 208 children from the cohort with full genotype, 
ethnic group, season and age data. The model selection process first involved 
univariate analyses testing for disease associations for Sl and McC independently 
without potential confounders in genotypic, dominant, recessive, heterozygous and 
additive models of inheritance. Models were compared using the Akaike 
information criterion (AIC) for fitness, with the model displaying the minimum AIC 
values for each respective genotype and outcome of interest chosen as the best 
fitting model. The unadjusted Incident Rate Ratios and best fitting models are 
shown in Table 2-12. For each disease outcome, the association with Sl genotype 
was then adjusted for confounding by McC (best genetic model chosen from the 
univariate analysis) and for explanatory variables previously associated with 
outcomes of interest: sickle cell genotype, α+thalassaemia genotype, ABO blood 
group genotype, ethnic group, season (defined as 3 monthly blocks) and age in 
months as a continuous variable. AIC values were compared to identify the best 
fitting genetic model (Table 2-24).  The same process was carried out for the 
association of McC genotype with each disease outcome, with adjustment for Sl 




reporting here, the same explanatory variables are included in the statistical models 
for all disease outcomes in the data presented. Optimized model-fitting for each 
outcome by removing explanatory variables that did not improve model fit, did not 
make any material difference to the results shown here.  
Finally, we tested for interactions between either Sl and McC and α+thalassaemia 
(represented as normal, heterozygous and homozygous genotypes) using the 
likelihood ratio test with a p value of <0.05 indicating statistically significant 







Sl2 recessive Sl2 additive Sl2 heterozygous Sl2 dominant 
Sl2 genotypic (Sl1/Sl1 = ref) 
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Table 2-24. Adjusted Incidence Rate Ratios for Sl disease associations in the longitudinal cohort study by genetic models of inheritance.  
Data were collected from 22 Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 cyfu (child-years of follow-up) respectively. Sl2 was tested for 
association with the disease outcomes of interest in the recessive, additive, heterozygous, dominant, and genotypic models. Adjusted incidence rate ratios and 95% 
confidence intervals (CIs) were generated using Poisson regression analysis, with adjustment for McC, α+thalassaemia and sickle cell genotypes, ABO blood group, 
season (divided into 3 monthly blocks), ethnicity, age as a continuous variable and within-person clustering of events. §aIRRs: adjusted Incidence Rate Ratios. *Models 
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Table 2-25. Adjusted incidence rate ratios for McC disease associations in the longitudinal cohort study by genetic models of inheritance. 
Data were collected from 137 McCa/McCa, 63 McCa/McCb and 8 McCb/McCb individuals during 294.5, 143.2 and 14.3 cyfu (child-years of follow-up) respectively. McCb 
was tested for association with the disease outcomes of interest in the recessive, additive, heterozygous, dominant, and genotypic models. Adjusted incidence rate 
ratios and 95% confidence intervals (CIs) were generated using Poisson regression analysis, with adjustment for Sl, α+thalassaemia and sickle cell genotypes, ABO 
blood group, season (divided into 3 monthly blocks), ethnicity, age as a continuous variable and within-person clustering of events. §aIRRs: adjusted Incidence Rate 





2.8 Discussion  
The data presented here provide epidemiological evidence supporting a role for 
CR1 in the pathogenesis of cerebral malaria. Two neighbouring CR1 polymorphisms 
belonging to the Knops blood group system of antigens had opposing associations 
on risk of cerebral malaria. The Sl2/Sl2 genotype was associated with protection 
against cerebral malaria and death, while the McCb allele was associated with 
increased susceptibility (Figure 2-2 and Table 2-6). The Sl2 allele was also associated 
with significant protection against uncomplicated malaria, whereas the McCb allele 
was associated with borderline protection against several common infections in 
Kenyan children (Table 2-13). The protective association of Sl2 against cerebral 
malaria, death and uncomplicated malaria was influenced by α+thalassaemia, being 
most evident in children of normal α-globin genotype.   
The protective association between Sl2 and cerebral malaria was first reported in a 
small case-control study from western Kenya (Thathy et al., 2005), but has 
remained controversial, especially as most prior studies have been underpowered. 
Hence, our study is the first adequately powered independent sample set that 
replicates the protective association between Sl2 and cerebral malaria.  Other 
studies found no consistent significant associations between Sl genotypes and 
severe malaria (Hansson et al., 2013; Jallow et al., 2009; Manjurano et al., 2012; 
Rockett et al., 2014; Toure et al., 2012; Zimmerman et al., 2003), including a recent 
multi-centre candidate gene study that included the sample set analysed here 
(Rockett et al., 2014). A weak association between McCb and an increased odds 
ratio for cerebral malaria was shown in the multi-centre study (Rockett et al., 2014). 
The complex interactions between Sl2, McCb and α+thalassaemia revealed by our 
study provide possible reasons for the previous inconsistent findings. Although Sl2 
was associated with protection against cerebral malaria in our study, McCb and 
α+thalassaemia both counteracted this effect. The protective association of Sl2 was 
observed most clearly when both McCb and α+thalassaemia genotypes were 




previous studies. It is possible that some of the other discrepant genetic 
associations with severe malaria (Rockett et al., 2014) might result from 
interactions between multiple loci that vary across populations and may not be 
revealed by standard analyses. Biologically, it makes sense to account for McC 
genotype when investigating associations with Sl2 and vice versa, as the two 
polymorphisms encode changes only 11 amino acids apart in the CR1 molecule 
(Figure 1-8). The possibility that the observed association might be due to a 
haplotype rather than independent effects of Sl and McC cannot be discounted.  
The interaction we describe here between Sl2 and α+thalassaemia is reminiscent of 
the epistatic interactions that have been observed between α+thalassaemia and 
other malaria-protective polymorphisms including sickle cell trait (HbAS) (Williams 
et al., 2005c) and haptoglobin (Atkinson et al., 2014). It is possible, therefore, that 
α+thalassaemia has a broad effect on multiple malaria-protective polymorphisms, 
influencing their restricted global frequencies (Penman et al., 2009), and 
contributing to the discrepant outcomes of previous association studies. Recent 
large genetic association studies on malaria do not include data on α+thalassaemia, 
because the causal deletions are not typed on automated platforms (Rockett et al., 
2014), instead requiring manual genotyping using labour-intensive PCR-based 
methods (Chong et al., 2000). Replication of the Sl2/α+thalassaemia interaction will 
be required, and we suggest that α+thalassaemia genotype should be included as an 
important confounding variable in future malaria epidemiological studies and that 
efforts should continue to discover the mechanism of protection afforded by 
α+thalassaemia, which remains controversial (Carlson et al., 1994; Fowkes et al., 
2008; Krause et al., 2012; Opi et al., 2014, 2016). 
We examined one possible biological mechanism by which the Sl2 allele might 
influence cerebral malaria by studying P. falciparum rosetting, a parasite virulence 
factor associated with severe malaria in African children (Doumbo et al., 2009). 
Previous in vitro experiments showed that CR1 is a receptor for P. falciparum 




Sl1 antigen (likely to be from donors with Sl1/Sl2 or Sl2/Sl2 genotypes) (Moulds et 
al., 2001) show reduced binding to the parasite rosetting ligand PfEMP1 (Rowe et 
al., 1997). In this study, we found a significantly lower median rosette frequency in 
P. falciparum parasite isolates from Malian patients with Sl2 genotypes compared 
to Sl1/Sl1 controls (Figure 2-6).  Therefore, similar to HbC (Fairhurst et al., 2005), 
blood group O (Rowe et al., 2007) and RBC CR1 deficiency (Cockburn et al., 2004), it 
is possible that reduced rosetting and subsequent reduced microvascular 
obstruction (Kaul et al., 1991) may in part explain the protective association of Sl2 
against cerebral malaria. However, given the protective association of Sl2 with 
uncomplicated malaria, and the possible associations of Sl2 and McCb with other 
common childhood infections, it seems likely that the Knops polymorphisms may be 
associated with broader effects, for example on the complement regulatory 
functions of CR1. Previously, we have shown that neither cofactor activity for the 
breakdown of C3b and C4b nor binding to C1q are influenced by the Sl2 and McCb 
mutations (Tetteh-Quarcoo et al., 2012). In addition, we can find no association 
between Knops genotype and CR1 clustering on erythrocytes (Paccaud et al., 1988; 
Swann et al., 2017). However, other potential effects such as altered immune 
complex binding and processing or activation of the complement lectin pathway via 
mannose-binding lectin (Ghiran et al., 2000) have not yet been investigated.  
Our studies have several limitations: McCb homozygotes are relatively infrequent in 
Kenya, which limited our power to detect associations with McCb in the 
homozygous state. Our longitudinal cohort study generated several values of 
borderline statistical significance for the McCb allele which are inconclusive. Studies 
with larger sample sizes will be needed to examine the specific associations of McCb 
on assorted childhood diseases. Another limitation is that our functional (Mali) and 
epidemiological (Kenya) studies were conducted in different populations. The 
mechanisms of rosetting and associations with malaria severity are thought to be 
similar across sub-Saharan Africa (Rowe et al., 2009), suggesting that data collected 
in either location are likely to be comparable. Furthermore, our examination of a 




association between Sl2/Sl2 genotype and cerebral malaria also occurs in this 
setting. Ideally, future epidemiological and functional studies of specific 
polymorphisms on malaria should be conducted within a single population, 
although this remains logistically challenging.  
In conclusion, we show that two high frequency CR1 polymorphisms have opposing 
associations with cerebral malaria and death in Kenyan children. While the Sl2 allele 
may have reached high frequency in African populations by conferring a protective 
advantage against cerebral malaria, our data suggest that McCb arose due to a 
survival advantage afforded against other non-malarial infections (Fitness et al., 
2004a; Noumsi et al., 2011). Sl2 may in part protect against cerebral malaria by 
reducing rosetting, but additional effects seem likely. Further work is needed to 
examine both the epidemiological effects of the Knops polymorphisms on diverse 
childhood diseases, and the biological effects of the Sl2 and McCb polymorphisms 
on CR1 function. Future epidemiological studies should account for the effect of 
α+thalassaemia on the associations between Sl2 and McCb on malaria and other 
infectious diseases. 
2.9 Additional discussion to this manuscript 
2.9.1 Potential functions of the Sl and McC polymorphisms 
This study provides epidemiological evidence of an association between the Sl and 
McC polymorphisms and the outcomes of CM and death with malaria. Although 
these non-synonymous SNPs are sufficient to alter blood group, their function 
remains undefined. Only a few studies have investigated their potential function 
using erythrocytes from individuals with the genotypes of interest (Opi, 2013; Rowe 





2.9.1.1 Sl/McC and rosetting in P. falciparum infection 
The Sl2 polymorphism has previously been associated with rosetting, with 
erythrocytes of the Sl -1,2 phenotype (i.e. likely Sl1/2 or Sl2/2 genotypes) showing 
lower binding to COS-7 cells expressing the DBL1-α portion of PfEMP1 of the R29 
rosetting parasite strain (Rowe et al., 1997), suggesting this might translate into 
reduced rosetting in vivo. A smaller unpublished study examined the rosetting 
frequency of erythrocytes collected from 55 children in Kilifi, Kenya using the R29 
strain but found no association with the Sl or McC polymorphisms (Opi, 2013). 
However, these experiments were performed using aliquots of frozen erythrocytes 
which had undergone long-term storage, a factor that may affect complement 
control proteins (Chen et al., 2007; Cockburn et al., 2002; Pascual et al., 1993). 
Experiments also used pooled serum from UK donors, which may have influenced 
findings.  
Another study produced short recombinant proteins of CR1 CCP 15-25, with 
mutations corresponding to the Sl1/McCa, Sl1/McCb, Sl2/McCa and Sl2/McCb 
haplotypes (Tetteh-Quarcoo et al., 2012). These fragments spanned CCP 15-17 
which is integral for rosetting (Rowe et al., 2000). Many functions of the proteins 
were investigated (see below), including their ability to disrupt rosettes in the R29 
strain, but no differences were seen between the four recombinant proteins.  
2.9.1.2 Sl/McC and erythrocyte invasion, PfEMP1 expression and cytoadherence in 
P. falciparum infection. 
As outlined in section 1.7.2, CR1 acts a sialic acid-independent invasion receptor for 
P. falciparum into uninfected erythrocytes (Spadafora et al., 2010; Tham et al., 
2010). The CCP 15-25 recombinant proteins containing Sl and McC mutations 
previously described were examined for their ability to inhibit erythrocyte invasion 
by P. falciparum the laboratory strain 3D7 and no differences were found between 
the variants (Tetteh-Quarcoo et al., 2012). This is perhaps unsurprising as the CCPs 
mapped for erythrocyte invasion (CCP 1-3 region, likely CCP 1 (Park et al., 2013; 




Unpublished experiments examining invasion of the 3D7 strain into erythrocytes 
from Kenyan children with various Sl/McC genotypes also found no association 
between the two (Opi, 2013). This same set of studies found Sl/McC genotypes did 
not influence PfEMP1 display (a characteristic that may be involved in reduced 
cytoadherence in HbS and α-thalassaemia (Cholera et al., 2008; Krause et al., 2012)) 
on the surface of IEs. Nor did the polymorphisms appear to affect binding to 
endothelial cytoadherence receptors CD36 or ICAM. However, it should be noted 
that these experiments used recombinant CD36 and ICAM receptors spotted on 
plastic dishes and may not be representative of cytoadherence in vivo. 
2.9.1.3 Sl/McC and erythrocyte CR1 expression level 
Another hypothesis that has been explored is whether the Sl/McC polymorphisms 
might influence CR1 expression level on erythrocytes (copy number). Whilst the 
HindIII polymorphism is associated with CR1 copy number in Caucasian and Asian 
populations, no correlation is seen in Africans (Rowe et al., 2002b). A large study 
from Kilifi, Kenya determined the erythrocyte CR1 copy numbers of 3535 children 
aged 0-13 years and related this to Sl/McC genotypes (Opi et al., 2016). Both Sl2 and 
McCb were positively associated with CR1 copy number, with the combined 
genotype Sl2/Sl2 McCb/McCb having the highest level of CR1. However, although 
statistically significant, the absolute differences seen in CR1 copy number with 
different genotypes was comparatively small (lowest group mean 250 CR1 copies 
per cell, highest group mean 347 CR1 copies). As such, the association of Sl/McC 
with CR1 copy number may not be functionally significant as this would necessitate 
a very narrow window of effect if this was the mechanism of action of these SNPs. 
2.9.1.4 Sl/McC and complement function 
The effect of the Sl and McC polymorphisms on complement function has only been 
explicitly examined by one study (Tetteh-Quarcoo et al., 2012). Using the 
recombinant proteins described above, the authors reported no difference between 
any of the four recombinant proteins in their ability to bind C1q, C3b and C4b and 




authors examined whether the Sl2 and McCb polymorphisms might influence the 
structure of CR1, allowing a “bent-back architecture that would facilitate co-
operation between key functional modules and the Knops blood group antigens.” 
However, no such structural differences were identified. It should be noted that this 
study was limited by the fact that the proteins were expressed in Pichia pastoris 
yeast and then enzymatically de-glycosylated. Correct glycosylation of CR1 appears 
to be key to its function (discussed in detail in section 5.6) and as such, it is hard to 
conclude a lack of effect of the Sl and McC polymorphisms when this study 
specifically used de-glycosylated proteins. 
2.9.2 Association of the Sl and McC polymorphisms with other diseases 
in Africa 
Another interesting finding from this chapter was the association of McCb with 
protection against infectious diseases other than malaria in the Kenyan cohort 
study. Three other studies have reported links between the Sl/McC polymorphisms 
and other infectious diseases. Two studies were conducted in parallel by the same 
team, with one study focusing on leprosy (Mycobacterium leprae) and the other on 
culture-positive tuberculosis (Mycobacterium tuberculosis) (Fitness et al., 2004a, 
2004b). Both studies were based in Karonga (northern Malawi) with controls 
matched by age, sex and location of residence. As both complement-opsonised M. 
tuberculosis and M. leprae use CR1 to gain entry into macrophages (Hirsch et al., 
1994; Schlesinger et al., 1990), five CR1 polymorphisms (including Sl and McC) were 
investigated as possible susceptibility mutations, typed by RFLP-PCR. The group 
reported that the McCb/McCb genotype was associated with reduced odds of 
leprosy (aOR 0.3, 95% CI 0.1–0.8, p=0.02), but found no significant association for Sl 
(Fitness et al., 2004a). Neither McC nor Sl were found to be associated with 
tuberculosis in Malawi (Fitness et al., 2004b). 
A later study re-examined the association between the Knops blood group 
polymorphisms and culture-positive tuberculosis in Bamako, Mali (Noumsi et al., 




tuberculosis (aOR 0.42, 95% CI 0.22-0.81, p = 0.007 and aOR 0.50, 95% CI 0.28-0.90, 
p = 0.02 respectively) whilst the Sl2/Sl2 genotype was associated with increased odd 
of tuberculosis (aOR 1.73, 95% CI 0.99-3.04, p=0.05).  
If associations for the Sl and McC polymorphisms are not limited to severe malaria, 
it may suggest that the SNPs (or a mutation in linkage disequilibrium with them) 
have broader effects on complement activity. It is possible that one SNP (e.g. Sl2 
based on Kenyan study data) might be associated with protection against severe 
malaria whilst simultaneously increasing the odds of other infectious diseases. This 
may have led to the selection of a second SNP (McCb), to abrogate the effect of Sl2.  
2.10 Directions of investigation 
The findings of this chapter suggest a strong protective association between the Sl2 
polymorphism and both CM and death. Conversely, McCb was associated with 
increased odds of CM, but protection against gastroenteritis, URTI and LRTI. Ex vivo 
rosetting assays indicated that the protection associated with Sl2 may be related to 
reduced rosetting of IEs. It was clear that further investigation was required to 
ascertain the functions of these two polymorphisms. In light of the associations 
seen with McCb and other infectious disease, it was decided not to limit further 
investigation to P. falciparum-based assays. Instead, three broader hypotheses 
were considered that were pertinent to the pathogenesis of CM, but had wider 
implications for other infectious disease. The hypotheses pursued were: 
- Sl2 and McCb may alter how CR1 clusters on the erythrocyte surface 
- CR1 may be expressed by human brain endothelial cells 
- Sl2 and McCb may influence binding of the complement components MBL, 
C1q or L-ficolin to the LHR-D region of CR1. 





3 Do the Swain Langley and McCoy polymorphisms 
influence how CR1 clusters on the erythrocyte 
membrane? 
Please note – this main body of this chapter is reproduced from the manuscript “No 
Evidence that Knops Blood Group Polymorphisms Affect Complement Receptor 1 
Clustering on Erythrocytes” published in Scientific Reports (Swann et al., 2017). In 
accordance with the University of Edinburgh guidelines for inclusion of publications 
in a thesis (Appendix 8.2), the publication is presented in this chapter with an 
additional introduction and discussion. Abstract, introduction, methods, results, 
discussion, figures tables and legends are taken directly from the publication itself. 
For this chapter, the manuscript and accompanying references have been re-
formatted to correspond to the style used in this thesis. Supplementary information 
has been placed in-line for clarity. A PDF of the manuscript is available at 
https://doi.org/10.1038/s41598-017-17664-9, with the corresponding open access 
licence in Appendix 8.4. 
3.1 Declaration 
CR1 copy number determination was performed by Emily Nyatichi. Sl, McC, HbS and 
ABO blood group and α-thalassaemia genotyping had been previously performed by 
Dominic Kwiatkowski, Kirk Rockett, Sophie Ugoya and Alex Macharia for a separate 
study. Advice on statistical analysis was provided by Ewen Harrison. Thomas 
Williams designed and oversaw recruitment of the Immunology Cohort Study in 
Kilifi, which provided the blood samples for this chapter. All other experiments, 
analyses and the writing of the manuscript were undertaken by myself. The final 






Clustering of Complement Receptor 1 (CR1) in the erythrocyte membrane is 
important for immune-complex transfer and clearance. CR1 contains the Knops 
blood group antigens, including the antithetical pairs Swain-Langley 1 and 2 (Sl1 and 
Sl2) and McCoy a and b (McCa and McCb), whose functional effects are unknown. 
We tested the hypothesis that the Sl and McC polymorphisms might influence CR1 
clustering on erythrocyte membranes. Blood samples from 125 healthy Kenyan 
children were analysed by immunofluorescence and confocal microscopy to 
determine CR1 cluster number and volume. In agreement with previous reports, 
CR1 cluster number and volume were positively associated with CR1 copy number 
(mean number of CR1 molecules per erythrocyte). Individuals with the McCb/McCb 
genotype had more clusters per cell than McCa/McCa individuals. However, this 
association was lost when the strong effect of CR1 copy number was included in the 
model. No association was observed between Sl genotype, sickle cell genotype, 
α+thalassaemia genotype, gender or age and CR1 cluster number or volume. 
Therefore, after correction for CR1 copy number, the Sl and McC polymorphisms did 
not influence erythrocyte CR1 clustering, and the effects of the Knops 
polymorphisms on CR1 function remains unknown.   
3.3 Additional introduction to this manuscript 
The analyses presented in Chapter 2 outlined a protective association between the 
Sl2/Sl2 genotype and both cerebral malaria and death while suggesting the McCb 
might increase the odds of cerebral malaria. Following this finding, a number of 
hypotheses presented themselves as discussed in section 2.10. A key property of 
CR1 molecules on the erythrocyte surface is their ability to form clusters on binding 
to a ligand (Chevalier and Kazatchkine, 1989; Ghiran et al., 2008; Paccaud et al., 
1988). Humans and other higher primates are unique in using this process for 
immune clearance (the binding and transport of opsonised immune complexes from 




et al., 1992; Schifferli and Taylor, 1989), whereas, in non-primate mammals, this 
process is performed by alternative receptors on platelets and unstimulated 
neutrophils (Henson, 1969; Taylor et al., 1985). 
I chose to examine whether the Sl and McC genotypes affected CR1 clustering as 
this provided a simple starting point to investigate a number of potential biological 
processes all relevant to cerebral malaria. These included: 
- Immune complex transfer (children with cerebral malaria may have higher 
levels of circulating immune complexes than in other forms of malaria 
(Mibei et al., 2008)). 
- Rosetting (clustering of CR1 molecules could influence the binding avidity to 
PfEMP1, influencing size or strength of rosettes formed). 
- Deformability of erythrocytes (clustering of CR1 increases deformability of 
the erythrocyte (Glodek et al., 2010) which might be important in 
maintaining cerebral blood flow in microvasculature partially obstructed by 
sequestered IEs). 
- Invasion of P. falciparum into the erythrocyte (CR1 “capping” of the 
merozoite reported (Biryukov et al., 2016) which might be influenced by the 
size or number of CR1 clusters formed). 
In light of these possibilities, if the Sl or McC genotypes influence CR1 clustering, 
they could in turn affect a number of key processes in cerebral malaria, making CR1 
clustering a useful starting point for investigation. Indeed, the possibility that the 
Sl2 polymorphism might affect CR1 clustering was raised 16 years ago but never 
investigated (Krych-Goldberg et al., 2002). 
In this chapter, CR1 clusters were imaged using confocal microscopy in preference 
to conventional fluorescence microscopy. Traditional fluorescence microscopy 
images the whole sample simultaneously, using the objective lens of the 
microscope to render parts of interest brighter and clearer. However, the 
fluorescent signal from the rest of the sample remains, producing “noise” and 




wavelength to excite the desired fluorophore) which passes through a pinhole 
aperture to eliminate scattered light (Nwaneshiudu et al., 2012). The beam is 
focused to a point within the sample and the emitted light is reflected via a dichroic 
mirror onto a separate photo detector. As a result, confocal microscopy both 
eliminates light coming from out of focus sections of the sample and permits the 
collection of serial optical sections which can be recombined into a 3D image. 
Confocal imaging was thus chosen for this study to maximise image quality and 
reduce background light that might otherwise jeopardise the identification of very 
small clusters.  
3.4 Introduction 
Complement receptor 1 (CR1) is a polymorphic transmembrane glycoprotein 
expressed in humans on erythrocytes, most leucocytes and glomerular podocytes 
(Fearon, 1985). It is encoded by the CR1 gene at the 1q32 locus, spanning 
approximately 133 kb and consisting of 39 exons (Vik and Wong, 1993). Four size 
polymorphisms of CR1 have been identified, the most common form being CR1*1 
(Dykman et al., 1985). This classical form has a molecular weight of 220 kDa under 
non-reducing conditions, with an ectodomain comprising 30 short consensus 
repeats (SCRs), the first 28 of which are arranged into four long homologous repeats 
(LHRs) A-D (Figure 3-1) (Wong, 1990). Insertion or deletion of LHRs accounts for the 
variation seen in the molecule size (Wong, 1990). Variation also occurs in 
erythrocyte CR1 copy number, with the mean number of CR1 molecules per cell 
varying between individuals from 50 to 1200 (Moulds et al., 1992). A HindIII 
restriction fragment length polymorphism in intron 27 of the CR1 gene correlates 
with high (H allele) or low (L allele) CR1 expression on erythrocytes (Wilson et al., 
1986). However, this polymorphism is not associated with CR1 copy number in 
African populations (Herrera et al., 1998; Rowe et al., 2002b). 
CR1 is a key regulator of complement cascade activation, namely through 
accelerating the decay of C3 and C5 convertases thus reducing production of 




with factor I to inactivate C3b and C4b to iC3b and iC4b (Medof and Nussenzweig, 
1984). These functions map to specific sites within the CR1 molecule, with site 1 
(SCRs 1-3 in LHR-A) displaying high decay accelerating activity (Krych-Goldberg et 
al., 1999) and binding C4b (Klickstein et al., 1988; Krych et al., 1991), and site 2 
(SCRs 8-10 in LHR B and SCRs 15-17 in LHR C) being responsible for cofactor activity 
with factor I and the binding of C3b and C4b (Figure 3-1) (Klickstein et al., 1988; 
Krych et al., 1991).  
 
 
Figure 3-1. Schematic representation of the most common CR1 size variant (CR1*1). 
Adapted from (Schmidt et al., 2015). The extracellular domain of CR1 is composed of 30 Complement 
Control Protein (CCP) domains organized into four “Long Homologous Repeats” (LHR). Two major 
functional sites are found within the CR1 molecule. Site 1 is located in LHR-A (CCP 1-3) and is a 
binding site for C3b, C4b and the P. falciparum invasion ligand PfRh4, and has decay accelerating 
activity. Site 2 is located in LHR-B (CCP 8-10) and LHR-C (CCP 15-17), and binds C3b and C4b, and 
interacts with P. falciparum infected erythrocytes to form rosettes. In addition, site 2 has factor I-
cofactor activity. SNPs determining the Sl and McC polymorphisms are localized in LHR-D (CCP 25, 
shown in red). CCP regions within Sites 1 and 2 that share high sequence identity (between 1 to 3 
amino acid changes) are represented with identical shading. TM, transmembrane region; CYT, 
cytoplasmic tail. 
 
The function of the LHR-D region of CR1 is unclear, but may include binding sites for 
C1q (Klickstein et al., 1997) and Mannose Binding Lectin (MBL) (Ghiran et al., 2000). 
SCR 25 in LHR-D also contains the Knops blood group antigens, which include the 
Swain-Langley (antithetical pairs Sl1 and Sl2) and McCoy (McCa and McCb) antigens 
(Figure 3-1) (Moulds et al., 2001). The Sl2 allele results from a single nucleotide 
polymorphism (SNP) (rs17047661), encoding an amino acid change from arginine to 
glycine (R1601G), while the McCb allele results from a SNP 33 base pairs away 




Figure 3-1) (Moulds et al., 2001). The functional effects of the Sl2 and McCb 
polymorphisms remain unknown. Recent work investigating short recombinant 
proteins bearing the Sl and McC antigens found no difference between the variant 
forms in their affinities for immobilised C3b, C4b or C1q, nor in their co-factor 
activity for cleavage of C3b and C4b in conjunction with factor I (Tetteh-Quarcoo et 
al., 2012).  
A marked geographical difference is seen in the frequency of Sl2 and McCb alleles, 
with the alleles being common in African populations and rare in Caucasians 
(Moulds, 2010). This has led to the suggestion that these polymorphisms arose due 
to selection pressure from malaria (Rowe et al., 1997), however, studies to date 
have been conflicting. An observational study from Western Kenya reported an 
association between the Sl2/Sl2 genotype and a reduced odds ratio of cerebral 
malaria (OR 0.17, p = 0.02) when compared to the Sl1/Sl1 genotype (Thathy et al., 
2005). Recently, analysis of a large case-control study from Kilifi (eastern Kenya) 
identified an association between the Sl2/Sl2 genotype and protection against 
cerebral malaria and death from malaria, but conversely found addition of the McCb 
allele to be associated with increased odds of cerebral malaria (Opi, Swann et al, 
2018). However, studies from The Gambia and Ghana did not find significant 
associations between the polymorphisms and severe malaria (Hansson et al., 2013; 
Zimmerman et al., 2003). 
In addition to complement regulation, CR1 on erythrocytes is responsible for 
immune adherence, the binding and transfer of opsonised immune complexes (ICs) 
from the circulation to resident macrophages in the liver and spleen for 
phagocytosis (Emlen et al., 1992; Schifferli and Taylor, 1989). The clustering of CR1 
in the erythrocyte membrane is thought to play a key role in its immune adherence 
function. On the resting erythrocyte membrane, CR1 is widely dispersed in small 
clusters, which coalesce into larger clusters when cross-linked by ligands or 
antibodies (Chevalier and Kazatchkine, 1989; Ghiran et al., 2008; Glodek et al., 




also been demonstrated to co-immunoprecipitate with Fas-associated binding 
protein 1 (FAP-1) in the cytoskeleton fraction, which acts as a scaffolding protein for 
cross-linked CR1 and cluster formation (Ghiran et al., 2008). It has been 
hypothesized that CR1 clustering after cross-linking by ligands could prevent 
ingestion of the erythrocyte during IC transfer to macrophages by concentrating 
opsonic stimuli in a few areas of the membrane (Ghiran et al., 2008). Ligation of CR1 
has also been demonstrated to increase erythrocyte deformability, which could 
allow IC-laden erythrocytes to traverse the hepatic and splenic capillaries and 
transfer their cargo to the resident macrophages more easily (Glodek et al., 2010).  
The number of CR1 clusters per erythrocyte increases with CR1 copy number (Cosio 
et al., 1990; Paccaud et al., 1988; Taylor et al., 1991), although CR1 copy number 
alone does not completely explain inter-individual variation in clustering, implying 
involvement of other factors (Cosio et al., 1990). The possibility that the Sl2 
polymorphism might affect CR1 clustering has been raised (Krych-Goldberg et al., 
2002), but never investigated. If the Knops blood group is indeed associated with 
malaria, there are a number of mechanistic possibilities that could include a role for 
variation in CR1 clustering. If the Sl2 or McCb polymorphisms influenced the size or 
number of CR1 clusters formed, this might influence the process of invasion of P. 
falciparum into the erythrocyte via CR1 “capping” of the merozoite (Biryukov et al., 
2016).  Alternatively, CR1 clustering could be important in the pathogenesis of 
cerebral malaria. Children with cerebral malaria may have higher circulating levels 
of immune complexes (ICs) than children with other malaria disease syndromes 
(Mibei et al., 2008). ICs deposited on the endothelial surface can activate 
complement and stimulate the release of local pro-inflammatory mediators (Jancar 
and Sánchez Crespo, 2005). ICs can also cross-link Fc-receptors on monocyte and 
macrophages, stimulating production of tumour necrosis factor (Debets et al., 
1988), a cytokine whose relationship with cerebral malaria has been previously 
reported (Kwiatkowski et al., 1990). As avidity of IC binding to erythrocytes depends 






We therefore set up a study using blood samples from healthy children in Kilifi, 
Kenya to examine the hypothesis that the Sl2 and McCb polymorphisms might 
influence erythrocyte CR1 clustering. 
3.6 Methods  
3.6.1 Study Population and Ethical Approval  
The Immunology Cohort Study in Kilifi, Kenya comprises 1041 children resident in 
the Junju or Ngerenya regions of the Kilifi Demographic Surveillance System (KDSS) 
(Scott et al., 2012; Williams et al., 2005a). The Kilifi district borders the Indian Ocean 
and the local economy depends on subsistence farming (Scott et al., 2012). It is a 
malaria endemic area with seasonal transmission after the long (April-June) and 
short (October-November) rainy seasons, although recently malaria transmission 
has fallen in the area (O’Meara et al., 2008). Ethical approval for this study was 
obtained from the KEMRI Ethical Review Committee and all methods were 
performed in accordance with the relevant guidelines and regulations. Following 
informed consent from a parent or guardian, blood samples were obtained by 
venepuncture between 2nd and 30th April 2013 (inclusive).  
3.6.2 Donor selection and genotyping 
Donors had previously been genotyped for Sl and McC polymorphisms using the 
SEQUENOM iPLEX® Gold platform (Fry et al., 2008), for sickle cell (HbS) and α+ 
thalassaemia genotype (–α3.7 deletion) by PCR (Chong et al., 2000; Waterfall and 
Cobb, 2001) and typed for ABO blood group by standard haemagglutination 
methods (Rowe et al., 2007). Our investigation was limited to the Sl and McC 
homozygote genotypes, 1a (Sl1/Sl1 McCa/McCa), 2a (Sl2/Sl2 McCa/McCa) and 2b 
(Sl2/Sl2 McCb/McCb).  The 1b genotype does not occur because the McCb 
polymorphism is only found on the background of the Sl2 variant (Moulds, 2010; 
Moulds et al., 2001).  148 children in the cohort with 1a, 2a or 2b genotypes, and 




influence CR1 copy number (Cockburn et al., 2004; Opi et al., 2016; Otenio et al., 
2013)) were eligible for inclusion. Nine children did not attend for venepuncture, 12 
were excluded because they were positive for P. falciparum on thick blood smear, 
and two were accidently discarded, giving 125 samples for analysis (29 with 
genotype 1a, 88 with genotype 2a and eight with genotype 2b).  
3.6.3 Sample collection and processing 
4.4 mls of venous blood was collected into a lithium heparin tube, centrifuged at 
400g for 10 minutes and plasma removed. The sample was then made up to 5 mls 
with R2 medium (500 ml RPMI (catalogue number R0883, Sigma-Aldrich, Missouri, 
USA) with final concentration of 0.02M HEPES (4-(2-hydroxyethyl)-piperazine-
ethanesulfonic acid, Gibco, New York, USA), 0.1mM L-glutamine (Gibco, New York, 
USA), 1% vol/vol Penicillin–Streptomycin Solution Hybri-Max (Sigma-Aldrich, 
Missouri, USA) and 2% pooled human AB serum). The cell suspension was layered 
onto 3ml of Lymphoprep (PROGEN Biotechnik, Heidelberg, Germany) and 
centrifuged at 1000g for 20 minutes at 20oC. The white cell layer was removed and 
the resulting erythrocytes washed twice in R2 medium without serum by 
centrifugation at 400g for 5 minutes. They were then adjusted to 4% haematocrit by 
adding R2 medium without serum. The clustering assay was subsequently 
performed on these unfixed cells. As storage of blood samples can affect CR1 copy 
number and function (Chen et al., 2007; Cockburn et al., 2002; Pascual et al., 1993), 
all clustering assays were performed within eight hours of venepuncture. 
3.6.4 CR1 copy number determination. 
An aliquot of washed erythrocytes from above was fixed in 5% formaldehyde 
(Sigma-Aldrich, Missouri, USA) on the day of venepuncture and CR1 copy number 
was determined within 8 weeks as previously described in detail (Cockburn et al., 
2002). Briefly, this method uses flow cytometry to quantify CR1 copy number on 
fixed erythrocytes using a standard curve derived from donors with known CR1 
copy numbers that have been fixed at the same time as the samples. Erythrocytes 




GeneTex, California, USA), followed by 5 μg/ml of Alexa Fluor 488-conjugated goat 
anti-mouse IgG (A-11001, ThermoFisher Scientific, Paisley, UK) and the mean 
fluorescence intensity determined on a FC500 flow cytometer (Beckman-Coulter 
Inc.). Examples of the gating strategy and staining of low, intermediate and high CR1 
standard donors are shown in Figure 3-2.  
 
Figure 3-2. Immunofluorescence staining and flow cytometry to determine CR1 copy number. 
. Representative flow cytometry analyses comparing unstained red blood cells (RBCs) with RBCs from 
individuals with low, intermediate and high CR1 copy numbers. Dot plots (top row) show forward 
scatter against side scatter with a gating strategy to include only intact cells. Histograms (middle 
row) show Alexa Fluor488 fluorescence from J3D3 (α-CR1) antibody staining for all intact RBCs in 
each sample. Increasing fluorescence is seen with higher CR1 copy number. The overlay (bottom row) 





3.6.5 Immunofluorescent staining of CR1 clusters 
The IgG1 mouse anti-CR1 monoclonal antibody J3D3 was used to stain CR1 clusters, 
as it does not recognise epitopes in the LHR-D region (Nickells et al., 1998), so was 
considered unlikely to influence any effect the Sl or McC polymorphisms might have 
on clustering. Two aliquots from each sample of washed, unfixed erythrocytes at 4% 
haematocrit in PBS/1% BSA were incubated with 5 μg/ml of either J3D3 or IgG1 
mouse anti-human isotype control (MCA928, AbD Serotec, Kidlington, UK) to give a 
final sample volume of 50 μl. Samples were incubated at 4oC for one hour 
(resuspended every ten mins) and washed three times in 1 ml cold PBS (Oxoid, 
Basingstoke, UK). 50 μl of 4 μg/ml Alexa Fluor 488-conjugated goat anti-mouse 
secondary antibody was added and the sample was incubated at 4oC in the dark for 
one hour (resuspended every ten mins) and subsequently washed three times in 1 
ml cold PBS. The sample was resuspended at 30-40% haematocrit, smeared on a 
glass slide, air-dried, mounted under a 22mm x 22mm glass coverslip with 10 μl of 
DABCO-glycerol (2.5 mg 1, 4-Diazabicyclo[2.2.2]octane (Sigma-Aldrich, Poole, UK), 
0.5 ml glycerol and 0.5 ml PBS) and sealed with nail varnish. All steps to this point 
were undertaken at the KEMRI-Wellcome Trust Research Unit, Kilifi and the 







Figure 3-3. Immunofluorescent staining of erythrocyte CR1 clusters and image analysis.  




A) Erythrocyte CR1 clusters were visualised by staining with 5 μg/ml of CR1 monoclonal antibody 
J3D3, followed by 4 μg/ml of Alexa Fluor 488 goat anti-mouse IgG. See methods for full details. B) For 
each donor, five confocal microscopy images were taken from the central area of the microscope 
slide as indicated by the grey shaded areas. Each image was a z-stack comprising 8-10 steps. C-F) To 
illustrate the image analysis process, a section containing 4 erythrocytes from one of the 5 images 
from a single donor is shown. Overall, at least 200 erythrocytes were examined per donor.  C) For 
each image, the bright-field view was used to identify the positions of erythrocytes. D) Non-touching 
cells were then stamped. E) The stamped region was then applied to the fluorescent image. F) Cluster 
numbers and volumes within the stamped regions were assessed by an automated protocol using 
Volocity software as described in the methods. G) An example of the clusters identified in a single 
erythrocyte. H) The same erythrocyte as shown in G, with distinct clusters being shown in different 
colours. I) A different erythrocyte with each of the 8 steps that comprise the z-stack shown separately 
(1 to 8). 
3.6.6 Confocal microscopy  
Slides were imaged with a Leica SP5 confocal microscope using the glycerol x 63 
objective, argon laser and differential interference contrast settings (now referred 
to as “bright field”). Five images per slide (Figure 3-3 A shows a representative 
image) were taken from predefined areas (Figure 3-3 B). To prevent bias for stained 
cells, each slide was navigated using the bright field image, ensuring that only 
erythrocyte outlines, rather than CR1 clusters, were visible. To minimise photo-
bleaching, a z-stack of images was taken at 0.8 μm intervals and between eight to 
ten steps were acquired per stack (an example of the 8 steps comprising a z-stack 
are shown in Figure 3-3 I. The images in the z-stack were then merged into one 3D 
image using Volocity 3D Image Analysis Software version 6.3 (PerkinElmer, 
Massachusetts, USA). Slides were imaged blind to donor information.  
3.6.7 Image Analysis 
Using the bright field image (to obscure CR1 clusters and increase objectivity) 
(Figure 3-3 C), a region of interest stamp 9 µm in diameter (area 63.6 µm2, slightly 
larger than an erythrocyte) was used to identify individual erythrocytes that were 
not touching other cells (Figure 3-3 D). Approximately 40 erythrocytes per image 
were stamped. Image analysis was then carried out within the stamped areas in the 
fluorescent channel (Figure 3-3 E-F). An automated software protocol was 




version 6.3 (Perkin Elmer), and was used to determine the number of CR1 clusters 
per erythrocyte (Figure 3-3 G-H), and to calculate the volume of each cluster. The 
protocol identified objects within the stamped area based on a minimum size 
threshold and subsequently separated touching objects using an object size guide. 
To establish the protocol settings, five cells from five separate donors (total cell 
number = 25) were reviewed. Settings over a range from 0.01 to 2.56 μm3 were 
examined for both minimum size and object size guide. A minimum size threshold 
of 0.06 μm3 and object size guide of 0.06 μm3 gave the optimal correlation with 
number of clusters identified by eye (Pearson’s correlation coefficient of 0.927 and 
r2 of 0.859), therefore these settings were used throughout. To account for 
background fluorescence, 30 maximum fluorescent intensity (MFI) readings were 
taken from areas of cells without visible CR1 clusters for each donor. The median of 
these readings was calculated for each individual to give the background MFI. The 
median of all donor medians was then calculated, giving a universal background 
correction factor (median = 554, IQR = 554-693) that was subtracted from all 
samples before running the Volocity protocol.   
In order to determine the optimal number of cells to image from each donor, 400 
erythrocytes were imaged from a single donor. The standard error of the mean 
(SEM) of the number of CR1 clusters per erythrocyte was plotted against the 
number of erythrocytes imaged (Figure 3-4). It was decided to image 200 





Figure 3-4. Determining the optimal number of erythrocytes to image. 
The plot illustrates how the standard error of the mean (SEM) of the number of CR1 clusters per 
erythrocyte alters with increasing number of erythrocytes imaged (n) from a single donor. Based on 
these data, it was decided to image 200 erythrocytes for each sample, as reductions in SEM beyond 
this point were small. 
The reproducibility of the assay was assessed by imaging a blood sample taken from 
a single donor at the same time each day for three consecutive days. Neither the 
median number of CR1 clusters per cell, nor the mean CR1 cluster volume was 
significantly different across the three days (Kruskal-Wallis test p = 0.337 and 0.054 







Figure 3-5. CR1 cluster number and volume for three samples taken over consecutive days from one 
donor. 
A)  CR1 cluster number per cell. Each data point represents one of the 200 cells imaged. The median 
and interquartile range are shown as red bars. There were no significant differences between the 
sample medians (Kruskal-Wallis test p=0.337). B) Volume per CR1 cluster. The median and 
interquartile range are shown as red bars. The difference between the median cluster volumes was of 
borderline significance (Kruskal-Wallis test p= 0.054), but the absolute difference between the 




3.6.8 Statistical analyses 
Our experiments generated data on individual CR1 clusters from at least 200 
erythrocytes per donor. These data were then summarised at three levels: 1) at the 
level of each individual cluster (to allow for detailed analysis of cluster volume); 2) 
at the level of each individual cell (to allow for detailed analyses of cluster number 
per cell) and 3) at the level of each individual donor (to provide a single data point 
for each participant which represented their median CR1 cluster number or mean 
cluster volume).  
Initial exploratory analyses used the data at the level of the individual donor to 
examine the influence of donor variables on CR1 copy number, CR1 cluster number 
and cluster volume. The donor variables explored in our analyses were basic 
demographic data (age and gender), other variables reported to influence CR1 copy 
number (α+thalassaemia genotype and sickle cell genotype (Cockburn et al., 2004; 
Opi et al., 2016; Otenio et al., 2013)), ABO blood group (repeatedly associated with 
malaria in this population) (Fry et al., 2008; Rowe et al., 2007) and Knops genotype 
(1a, 2a and 2b). Correlation between continuous variables was analysed by linear 
regression, and differences between means were analysed by one-way ANOVA or t 
tests.  
To examine factors potentially influencing CR1 cluster number, the data were then 
analysed at the level of the individual cells. To permit inclusion of all the data 
collected and account for the intra-donor individual variation in the number of 
clusters per cell, a two-level hierarchical mixed effects Poisson regression model 
was used. Donor identifier and date the experiment was performed were included 
as random effects. Each donor variable (as above) was then examined in turn as a 
fixed effect. In view of the well documented relationship between CR1 cluster 
number and CR1 copy number (Cosio et al., 1990; Paccaud et al., 1988; Taylor et al., 





Finally, to examine factors potentially influencing CR1 cluster volume and account 
for both intra-individual and intra-cell variation in volume of clusters, a three-level 
hierarchical mixed effects linear regression model was used with both donor 
identifier and cell identifier included as random effects. Each donor variable was 
then examined as a fixed effect with and without CR1 copy number in the model. 
Where t values were significant, bootstrapping with 1000 iterations was performed 
to provide an equivalent p value for ease of interpretation.  
Analyses were performed using R statistical software (R Foundation for Statistical 
Computing, Vienna, Austria) (R Development Core Team, 2010) using the packages 
“plyr”, “ggplot2”, “boot” and “lme4” (Bates et al., 2013; Wickham, 2009, 2011). 
Graphs were drawn using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, 
USA). 
3.7 Results 
Erythrocyte CR1 clustering was assessed in blood samples from 125 Kenyan children 
with the homozygous Knops genotypes Sl1/Sl1 McCa/McCa, Sl2/Sl2 McCa/McCa or 
Sl2/Sl2 McCb/McCb. These genotypes are hereafter referred to as 1a, 2a and 2b 
respectively. Only homozygous genotypes were studied in order to examine the 
associations of the “pure forms” of the polymorphisms on CR1 clustering. The 
characteristics of the children are summarised in Table 3-1; no significant 
differences were seen between the 1a, 2a or 2b genotype groups in terms of 









Table 3-1. Characteristics of individuals studied. 
#1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa genotype, 2b = Sl2/Sl2, McCb/McCb 
genotype. *Fisher’s exact test, §One-way ANOVA. ‡α+thalassaemia and sickle cell genotype were 
included in the study as both have previously been reported to influence CR1 copy number  (Cockburn 
et al., 2004; Opi et al., 2016; Otenio et al., 2013). SD, standard deviation. NA, not applicable. 
In order to examine CR1 clusters, we carried out immunofluorescent staining of 
unfixed erythrocytes with a monoclonal antibody to CR1 (Figure 3-3 A), and 
analysed confocal microscopy images with an automated protocol developed using 
Volocity Image Analysis software (version 6.3, Perkin Elmer) to determine CR1 





3.7.1 Increased CR1 copy number in individuals with the McCb/McCb 
genotype. 
CR1 copy number (mean number of CR1 molecules per erythrocyte) positively 
correlates with number of CR1 clusters (Cosio et al., 1990; Paccaud et al., 1988; 
Taylor et al., 1991) and was therefore measured in all individuals. We first examined 
the association of CR1 copy number and donor variables in univariate analyses. We 
observed that individuals with the 2b genotype had a higher CR1 copy number 
when compared to individuals with 1a and 2a genotypes (Table 3-1 and Figure 3-6 
A, p=0.098 by ANOVA).  This was driven by the McC component of the genotype, as 
individuals with the McCb/McCb genotype had a significantly higher CR1 copy 
number than McCa/McCa (mean 658 copies per cell versus 483 copies per cell, 
p=0.033, t-test, Figure 3-6 B). The Sl component of the genotype was not 
significantly associated with CR1 copy number (p=0.978, t-test, Figure 3-6 C). Age, 
gender, ABO blood group and sickle cell trait showed no significant association with 
CR1 copy number in this study. Individuals who were homozygotes for 
α+thalassaemia had a lower CR1 copy number (441) than those who were 
heterozygotes (495) or who had normal α globin (520), however this was not 












Figure 3-6. The McCb genotype is associated with CR1 copy number and cluster number. 
Preliminary exploration of the association of Swain Langley (Sl) and McCoy (McC) genotypes with CR1 
copy number (mean number of CR1 molecules per erythrocyte), median CR1 cluster number per cell 
and mean cluster volume. Panels A-C: Relationship between CR1 copy number and (A) combined Sl 
and McC genotype (1a = Sl1/Sl1 McCa/McCa, 2a = Sl2/Sl2 McCa/McCa and 2b = Sl2/Sl2 McCb/McCb), 
(B) McC genotype and (C) Sl genotype. Panels D-F: Relationship between median number of CR1 
clusters per cell and (D) combined Sl and McC genotype, (E) McC genotype and (F) Sl genotype. 
Panels G-I: Relationship between mean CR1 cluster volume per cell and (G) combined Sl and McC 
genotype, (H) McC genotype and (I) Sl genotype. Red bars indicate mean and standard deviation, 
with statistical testing by t test or ANOVA as indicated. Individuals with the McCb genotype had 








Figure 3-7. Preliminary exploration of the association of donor variables and erythrocyte CR1 copy 
number (mean number of CR1 molecules per cell). 
A) host age B) gender C) ABO blood group D) sickle cell genotype E) α+thalassaemia genotype (Norm, 
normal α globin; Het, heterozygote; Homo, homozygote). Red bars represent mean and standard 
deviation. Correlation was analysed by linear regression, and differences between means were 







3.7.2 Increased CR1 cluster number in individuals with the McCb/McCb 
genotype. 
As previously reported (Chevalier and Kazatchkine, 1989; Cosio et al., 1990; Glodek 
et al., 2010), the number of CR1 clusters per cell varied widely within each 
individual. Overall, the number of clusters per cell ranged from 0 to 43, with the 
maximum number of clusters per cell ranging from 15 to 43 amongst different 
individuals (Figure 3-8). The volume of CR1 clusters also varied within individuals, 
with the largest clusters being >3μm3 (Figure 3-9). 
Preliminary analysis of the relationship between Knops genotype and erythrocyte 
CR1 cluster number was conducted by ANOVA, with data summarised at the level of 
the individual donor (i.e. using a single data point per donor, representing the 
median cluster number for that donor). These data were suggestive of a higher 
cluster number in 2b individuals, driven by the McCb genotype, although this was 
not statistically significant (Figure 3-6 D-F). Similar analysis by ANOVA of the 
relationship between Knops genotype and mean CR1 cluster volume revealed no 
significant associations (Figure 3-6 G-I). There were also no significant associations 
between CR1 cluster number (Figure 3-7) or cluster volume (Figure 3-10) and age, 
gender, ABO blood group, sickle cell genotype and α+thalassaemia genotype. 
In agreement with previous findings (Cosio et al., 1990; Taylor et al., 1991), a strong 
positive linear correlation was observed between CR1 cluster number and CR1 copy 
number (R2 = 0.530, p < 0.001, Figure 3-11 A), and a positive correlation was also 
observed between CR1 cluster volume and CR1 copy number (R2 = 0.398, p < 0.001, 
Figure 3-11 B). Cluster number and cluster volume were also strongly positively 
correlated (R2 = 0.573, p < 0.001, Figure 3-11 C). Because of the potential 
confounding effect of CR1 copy number on the relationship between Knops 
genotype and CR1 cluster number and volume, more detailed statistical analyses 





Figure 3-8. Box plot to illustrate within individual variation in number of CR1 clusters per cell. 





Figure 3-9. Box plot to illustrate within individual variation in median cluster volume per cell. 





Figure 3-10. Preliminary exploration of the association of donor variables and mean erythrocyte 
cluster volume. 
Red bars represent mean and standard deviation. A) host age B) gender C) ABO blood group D) sickle 
cell genotype E) a+thalassaemia genotype (Norm, normal a globin; Het, heterozygote; Homo, 
homozygote). Red bars represent mean and standard deviation. Correlation was analysed by linear 







Figure 3-11. Positive correlation between CR1 copy number, cluster number and cluster volume. 
A) Scatter plot of median CR1 cluster number per cell by CR1 copy number (mean number of CR1 
molecules per cell) with linear regression. Each dot represents an individual donor. B) Scatter plot of 
median CR1 cluster volume per cell by CR1 copy number with linear regression. Each dot represents 
an individual donor. C) Scatter plot of median CR1 cluster volume per cell by CR1 cluster number with 
linear regression. Each dot represents an individual donor. There were significant positive correlations 




3.7.3 No evidence of an association between Knops genotype and CR1 
cluster number after adjustment for CR1 copy number. 
A hierarchical mixed effects Poisson regression analysis was constructed to include 
all available data at the level of the cell (using at least 200 data points per individual 
donor, representing the CR1 cluster number for each cell imaged) and to allow for 
adjustment for CR1 copy number. The analysis examined each donor variable 
(combined Sl and McC genotype, Sl genotype alone, McC genotype alone, gender, 
age, ABO blood group, α+thalassaemia genotype or sickle cell genotype) in turn. 
Each donor variable was specified as a fixed effect and donor identifier and date of 
assay were specified as random effects. The relationship between each donor 
variable and the number of CR1 clusters per cell was reviewed both before and 
after adjustment for CR1 copy number.  
Prior to inclusion of CR1 copy number in the model, the 2b genotype was associated 
with a higher number of clusters per cell than the 1a genotype (multiplicative 
increase of 1.200 (95% CI 0.997-1.443, p=0.053, Table 3-2)). When broken down by 
component genotypes, this association was driven by the McC component rather 
that the Sl component, with the McCb/McCb genotype associated with a significantly 
higher number of clusters per cell than the McCa/McCa genotype (multiplicative 
increase = 1.216, 95% CI 1.027-1.439, p=0.023, Table 3-2). No significant 
associations were seen for gender, age, ABO blood group, α+thalassaemia genotype 
or sickle cell genotype. 
The correlation between CR1 copy number and number of clusters per cell was 
strong, with each increase in CR1 copy number of 100 being associated with a 
multiplicative increase in CR1 cluster number of 1.084 (p <0.001). Adjustment for 
CR1 copy number obscured any association between cluster number and McC 
genotype (Table 3-2). This suggests that the original association was likely to be 
driven by a difference in CR1 copy number, rather than any unique effect of the 





Table 3-2. Effect of donor variables on cluster number from mixed effects Poisson regression. 
The rate ratio is the multiplicative change from the reference group. 
#1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa genotype, 2b = Sl2/Sl2, McCb/McCb. 








3.7.4 No evidence of an association between Knops genotype and 
erythrocyte CR1 cluster volume after adjustment for CR1 copy 
number. 
Similarly, a more detailed hierarchical mixed effects linear regression analysis was 
constructed to include all available data at the level of the individual clusters, and to 
allow for adjustment for CR1 copy number. Donor variables (combined Sl and McC 
genotype, Sl genotype alone, McC genotype alone, gender, age, ABO blood group, 
α+thalassaemia genotype or sickle cell genotype) were examined individually as 
fixed effects, while cell identifier and donor identifier were specified as random 
effects (Table 3-3). The relationship between each donor variable and CR1 cluster 
volume was reviewed both before and after adjustment for CR1 copy number.  
No donor variables were found to have a significant association with cluster volume 
before adjustment for CR1 copy number (i.e. t values were all <1.96 or > - 1.96). The 
correlation between CR1 copy number and cluster volume was extremely strong, 
with each increase in CR1 copy number of 100 being associated with an absolute 
increase in CR1 cluster volume of 0.039 µm3 (t value = 9.446, Table 3-3. 
Bootstrapped p value <0.001).  Adjustment for CR1 copy number had no impact on 
the non-significant relationships between cluster volume and combined Sl and McC 
genotype, Sl genotype alone, McC genotype alone, gender, age, α+thalassaemia 
genotype or sickle cell genotype (Table 3-3). However, in models adjusting for CR1 
copy number, the B blood group was associated with an absolute increase in cluster 
volume of 0.057 µm3 when compared to the reference O blood group (t value = 









Table 3-3. Effect of donor variables on cluster volume from mixed effects linear regression. 
The coefficient is the absolute change from the reference group. 
#1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa genotype, 2b = Sl2/Sl2, McCb/McCb. 












In agreement with existing literature, we report that both the number of CR1 
clusters per erythrocyte and CR1 cluster volume are highly correlated with an 
individual’s erythrocyte CR1 copy number (Cosio et al., 1990; Paccaud et al., 1988; 
Taylor et al., 1991). The strength of association between CR1 copy number and 
cluster number was such that the inclusion of CR1 copy number in the statistical 
model obscured any other associations. However, on review of individual 
explanatory variables (without CR1 copy number in the model), the McCb/McCb 
genotype was associated with significantly higher cluster number than the 
McCa/McCa genotype. Individuals of the McCb/McCb genotype were found to have a 
significantly higher CR1 copy number than McCa/McCa, which is in agreement with a 
larger analysis of Kenyan children (Opi et al., 2016). As such, it is likely that the 
association of the McCb/McCb genotype with increased CR1 cluster number was due 
to the higher CR1 copy numbers in McCb/McCb individuals, rather than being a 
distinct biological effect of the variant itself. Exactly how the McCb polymorphism 
influences erythrocyte CR1 copy number is unknown, but could be due to resistance 
to cleavage by tryptic proteases resulting from the lysine to glutamic acid (K1590E) 
mutation, as discussed previously (Opi et al., 2016).  
In contrast to existing literature (Opi et al., 2016; Waitumbi et al., 2004), we found 
no evidence of an association between age and CR1 copy number. However, the 
previous studies included children between birth and 13 years (Opi et al., 2016) or 
birth and 32 years (Waitumbi et al., 2004), with the major changes occurring during 
the first four years of life. The narrower age range of our study (5.7 years – 12.7 
years) may explain why no association between age and CR1 copy number was 
detected. We also found no significant effect of α+thalassaemia genotype on CR1 
copy number, unlike other studies which showed lower CR1 copy number in 
α+thalassaemia homozygotes compared to normal individuals in Papua New Guinea 
(Cockburn et al., 2004) and Kenya (Opi et al., 2016). Whilst we also observed a 




sample size in our study may have prevented this from reaching statistical 
significance. 
One unexpected finding from this study was that blood group B was associated with 
significantly larger CR1 clusters than the reference blood group O. There is no 
known link between ABO blood group and CR1 function, and further work will be 
required to determine if this is a reproducible finding, and if so, to determine its 
biological significance. 
Owing to the high level of within and between donor variation, this was a 
challenging assay to develop and interpret. The sample size of this study was small, 
in particular for the 2b genotype, which is a limitation of this study. However, given 
the logistics of sampling (see methods), it was not possible to recruit more 
individuals prospectively. Another consideration is that although all children 
positive for malaria on a thick film were excluded, information on other infective or 
inflammatory conditions that might influence CR1 copy number was not available. 
Therefore, it is possible that the CR1 copy number of some children may have been 
transiently altered by concurrent conditions. However, all children were sampled in 
the community and were not inpatients in health centres, therefore were in broadly 
good health. 
The use of field samples also conferred other limitations on our study. When 
carrying out the confocal imaging in Edinburgh, we used conservative imaging 
settings to avoid photo-bleaching the slides during image acquisition. This was done 
in case repeat imaging was needed, as the slides themselves could not be replaced. 
Therefore, it is possible that we may have under-sampled the immunofluorescent 
slides, resulting in missing very small clusters. As temperature has been reported to 
affect cluster size in some studies (Chen et al., 2007), the use of physiological 
temperature during the assay (rather than 4oC as used here) may have increased 
the relevance of the findings, as may the use of a physiological ligand to induce 
clustering (e.g. C3b covered beads or immune complexes). Furthermore, the J3D3 




(Nickells et al., 1998), and results could therefore be influenced by CR1 size 
polymorphisms (allotype), which was not accounted for here. An antibody with a 
single epitope on CR1 that would not be affected by CR1 allotype (Chen et al., 2007) 
could be used in future studies. Other technical aspects of the assay may have 
affected the results shown here. For example, the mounting medium used after 
staining and preparing the thin blood films can cause lysis of the erythrocytes, 
potentially bringing the top and bottom membranes closer together. This could 
cause overlap of some clusters making them appear fewer or larger than in vivo. 
Despite these limitations, our methods were consistent throughout all samples, 
thus allowing for direct comparison between the different genotypes. 
The functional effects of the Sl and McC polymorphisms remain elusive. Laboratory 
evidence suggests that Sl2 may affect rosetting (the binding of Plasmodium 
falciparum IEs to uninfected erythrocytes) (Rowe et al., 1997), a parasite virulence 
factor associated with severe malaria in African children (Rowe et al., 1995). 
Rosetting occurs when P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) 
expressed on the surface of IEs binds to uninfected erythrocyte receptors, and is 
thought to involve site 2 on CR1 (the C3b binding site) in LHR-B and LHR-C (Rowe et 
al., 2000). Erythrocytes from Sl2/Sl2 donors rosette less well than erythrocytes from 
Sl1/Sl1 donors when PfEMP1 is expressed heterologously on the surface of COS-7 
cells (Rowe et al., 1997). However, a study using short recombinant proteins of the 
Sl and McC variants found no difference in their abilities to disrupt rosettes (Tetteh-
Quarcoo et al., 2012). Further investigation of the effects of the Knops 
polymorphisms on P. falciparum rosetting is required. 
In addition to its role in rosetting, CR1 has also been identified as a sialic acid-
independent invasion receptor for P. falciparum (Spadafora et al., 2010) , via the 
reticulocyte-binding–like homolog 4 (PfRh4) (Tham et al., 2010). The binding of 
PfRh4 has been mapped to site 1 in LHR-A (Lim et al., 2015; Park et al., 2013; Tham 
et al., 2011). Immunofluorescent staining of freshly released invasive merozoites 




by the authors as “capping,” suggesting CR1 clustering may have a role in invasion 
(Spadafora et al., 2010). However, the previously cited study using short 
recombinant proteins of the Sl and McC variants also found no difference in their 
abilities to inhibit erythrocyte invasion by P. falciparum (Tetteh-Quarcoo et al., 
2012). 
Interestingly, the binding site for mannose binding lectin (MBL) has been mapped to 
CCP 24-25, in close proximity to the Sl and McC polymorphisms (Jacquet et al., 
2013). MBL may influence malaria in Ghanaian children, with alleles responsible for 
low levels of MBL associated with increased parasite load, lower blood glucose 
levels and increased odds of severe malarial anaemia (Garred et al., 2003; Holmberg 
et al., 2008). It has also been suggested that MBL may opsonize P. falciparum IEs 
(Garred et al., 2003) or merozoites (Korir et al., 2014). However, whether the Sl or 
McC polymorphisms have functional effects on MBL interactions with CR1 has not 
yet been explored. 
In summary, after accounting for the effect of CR1 copy number, there was no 
significant association between Sl or McC genotypes (separately or in combination) 
and erythrocyte CR1 cluster number or cluster volume in Kenyan children. The 







3.9 Additional discussion to this manuscript 
Whilst the investigation of whether Sl and McC polymorphisms affected CR1 
clustering appears to be a simple question, as discussed above, this assay was more 
challenging than anticipated. In addition, whilst no association was found between 
the Sl and McC polymorphisms and CR1 cluster number or volume, it is possible that 
such differences do exist, but that this assay was insufficiently sensitive to detect 
them. A previous report used scanning near-field optical microscopy to quantify CR1 
cluster number on erythrocyte ghosts which reported a far higher number of 
clusters per erythrocyte (mean = 92 clusters per erythrocyte, range = 61–124, (Lapin 
et al., 2012)) than in my investigation (mean = 9 clusters per erythrocyte, range = 0–
43). The near-field optical microscopy approach also identified many more clusters 
per erythrocyte than previous studies on CR1 clustering (8-20 clusters per 
erythrocyte reported in two donors by electron microscopy (Chevalier and 
Kazatchkine, 1989), 8 ± 4 and 15 ± 6 clusters per erythrocyte (low and high CR1 
donors respectively) by fluorescence microscopy (Ghiran et al., 2008) and between 
1 - 40 clusters per erythrocyte in three donors by fluorescence microscopy (Paccaud 
et al., 1988)). As such, it is possible that near-field optical microscopy might have 
identified more clusters than using my methodology. However near-field optical 
microscopy required wet preparations of erythrocytes labelled with α-CR1 
monoclonal antibodies (which would have prohibited shipping of the samples out of 
Kenya) and an investigator-built scanning near-field optical microscope, neither of 
which were practical for field work studies. In addition, the report only describes 
the CR1 clusters on erythrocytes from a single donor and number of erythrocytes 
imaged is not described. Thus, while using the near-field optical microscopy 
approach may have identified more clusters in my study, this may have introduced 
other problems with validity, reproducibility and artefact. 
Another possibility is that the Sl or McC polymorphisms might affect the distribution 
of the CR1 molecules in the resting (i.e. un-clustered) form rather than bound to a 




with dimethylsuberimidate in a sodium borate buffer and 0.05% glutaraldehyde and 
fewer larger clusters after incubation with an α-CR1 monoclonal antibody, 
suggesting that CR1 is un-clustered in its resting state on the erythrocyte membrane 
(Glodek et al., 2010). Although this was explored during assay development, 
attempts to recreate this fixation method were unsuccessful and the fixed timing of 
the Immunology Cohort annual venepuncture precluded using this approach. 
A further possibility is that Sl/McC might affect CR1 clustering, but on cells other 
than erythrocytes. CR1 also clusters on the membranes of polymorphonuclear 
leucocytes (PMNs) but to a lesser extent than on erythrocytes (Paccaud et al., 
1990). In addition, a separate study describes CR1 clustering on neutrophils using 
electron microscopy but also the internalisation of the receptor on stimulation with 
formyl methionyl leucy phenylanine (fMLP) (Carpentier et al., 1991). In addition, 
PMNs are able to quickly upregulate the amount of CR1 on their membranes in 
response to a number of stimuli (including temperature change and local C3b 
concentration) (Berger et al., 1989; Fearon and Collins, 1983; Porteu et al., 1987). 
These issues potentially introduce a large number of confounding variables into the 
study of CR1 clustering on PMNs and it was felt this question could not be 
addressed satisfactorily using a field study. As such, erythrocytes with stable levels 
of CR1 were investigated in the first instance.  
In summary, this chapter found no evidence to support the hypothesis that the Sl or 
McCb polymorphisms influenced CR1 cluster number or volume on erythrocytes. As 
such, this seems unlikely to be the functional mechanism behind the 
polymorphisms’ association with CM. For the next line of enquiry, the focus of 
investigation was turned back to the specificity of the polymorphisms’ relationship 





4 Do human brain endothelial cells express CR1? 
4.1 Abstract 
Expression of complement receptor 1 (CR1) by endothelial cells has been reported, 
but there are no reports on brain endothelium. It was hypothesised that the 
association between the Sl2 and McCb polymorphisms in CR1 and cerebral malaria 
could be due to human brain endothelial cells (HBECs) expressing CR1.  
The immortalised cell line HBEC-5i was investigated for expression of CR1 using 
immunofluorescence assays (IFA), flow cytometry, western blotting, functional C3b 
degradation assays, mass spectrometry, immunoprecipitation and siRNA 
knockdown experiments. 
A pool of α-CR1 monoclonal antibodies weakly stained unpermeabilised HBEC-5i 
cells. Staining was increased on permeabilisation of the cells, whereby a large 
intracellular pool of antigen was recognised. Western blotting of HBEC-5i lysate 
revealed a band recognised by the pool of α-CR1 monoclonal antibodies of a similar 
molecular weight to CR1. However, when the α-CR1 monoclonal antibodies were 
tested individually, only E11 recognised an HBEC-5i protein on western blot and IFA. 
HBEC-5i lysate was resolved by gel electrophoresis and the band of interest was 
submitted for mass spectrometry, but no CR1 was detected. HBEC-5i + factor I could 
degrade C3b to C3dg, but this was not inhibited by the α-CR1 monoclonal 3D9, 
suggesting a cofactor other than CR1. Immunoprecipitation with E11 failed to 
produce CR1 from an HBEC-5i lysate. CR1 siRNA knockdown did not alter E11 
staining of HBEC-5i, implying E11 is not specific for CR1. The E11-staining was found 
to co-localize to the Golgi apparatus in HBEC-5i. 
In conclusion, these data indicate that HBEC-5i cells do not express CR1. In addition, 
the data suggest that the widely used α-CR1 monoclonal E11 is not entirely specific 






4.2.1 The blood-brain barrier  
In the cerebral vasculature, the blood-brain barrier (BBB) is predominantly formed 
by brain endothelial cells and provides a highly selective semi-permeable 
membrane which divides the circulating blood from brain tissue. Cerebral 
microvessels are continuous and nonfenestrated allowing the movement of 
molecules, ions, and cells between the blood and the CNS to be tightly regulated 
(reviewed in (Daneman, 2012)). The endothelial cells are incompletely surrounded 
by a layer of vascular smooth muscle cells and pericytes which are involved in 
angiogenesis, vascular tone and remodelling as well as the function of the BBB 
(Armulik et al., 2011; Winkler et al., 2011). These, in turn, are enclosed by a basal 
lamina consisting of collagens, laminins and heparan sulfate proteoglycans (Tilling 
et al., 2002) which provides a structural matrix for the cells (Daneman, 2012). 
Astrocyte (glial cell) endfeet then encircle the blood vessels and can regulate the 
transport properties of the BBB (Janzer and Raff, 1987). Immune cells interacting 
with the BBB include perivascular macrophages and microglia which are involved in 
CNS innate immunity, antigen presentation and regulation of immune cell passage 
across the BBB (Hudson et al., 2005; Streit et al., 2005). Together with neurons, 
these cells comprise the neurovascular unit (Figure 4-1). 
Endothelial cells in the CNS differ from those in non-neuronal tissues as they are 
highly polarised and linked by tight junctions which regulate the paracellular 
movement of molecules and ions (reviewed by (Daneman, 2012). Transcellular 
movement of molecules and ions is limited by the lack of fenestra and low rates of 
pinocytosis of the brain endothelial cells (Brightman and Reese, 1969; Reese and 






Figure 4-1. Example of a neurovascular unit in a rat brain. 
Panel A - Electron microscopy. Panel B – schematic representation.  
The relationship between the endothelial cell, basal lamina and atsrocyte can be seen. EC = 
endothelial cell, BL = basal lamina, AEF = astrocyte end-feet, N = neurons, P = pericyte.  
 Scale bar = 0.5 µm. (Figure from (Miller et al., 2012). 
A critical function of any endothelium is to provide an antithrombotic surface to 
prevent blood clots. Heparan sulfate in the basal lamina together with the 
expression of thrombomodulin and production of tissue-type plasminogen activator 
are key for thrombostasis (Bernfield et al., 1999; Esmon, 1989; Levin et al., 1989). In 
addition, the endothelium is key in the regulation of cerebral microvascular tone 
through the release of vasodilators (including nitric oxide and prostaglandin PGI2) 
and vasoconstrictors (including endothelin-1 and platelet activating factor (Cines et 
al., 1998; Palmer et al., 1987)).  
4.2.2 Complement and the endothelium 
The endothelium plays a dynamic role in the equilibrium between complement 
activation and regulation. Constant exposure to circulating complement 
components leaves the endothelium at risk of complement activation. To minimise 
this, endothelial cells are able to locally produce many of the regulators of 
complement. Resting HUVECS are reported to express soluble complement 
regulators; C1-inhibitor, factor H and factor I (Brooimans et al., 1990; Gulati et al., 




accelerating factor (CD55), membrane inhibitor of reactive lysis (CD59) and 
membrane cofactor protein (CD46) (Collard et al., 1997; Hamilton et al., 1990).  
Damaged endothelium can activate complement, for example endothelial cells 
which have undergone hypoxia-reoxygenation can activate complement via the LP 
(Collard et al., 2000, 2001). Apoptotic endothelial cells can also activate the 
complement system via the CP, either through the globular heads of C1q 
recognising surface blebs on these apoptotic cells or by the exposure of 
phosphatidylserine on their surface (Navratil et al., 2001). The effects on the 
endothelium of activation by C1q, C5a and MAC culminate in the increased 
expression of endothelial adhesion molecules (including ICAM-1, vWF and P-selectin 
(Albrecht et al., 2004; Foreman et al., 1994)), increased production of cytokines and 
chemokines (including IL-1, Il-6 and TNF-α (Kilgore et al., 1996, 1997), as well as an 
increase in PMN adhesion to endothelial cells (Foreman et al., 1994), leucocyte 
extravasation (Casarsa et al., 2003; Dobrina et al., 2002) and the creation of a pro-
coagulopathic state (reviewed in (Roumenina et al., 2016; Wiegner et al., 2016)). 
Endothelial cells themselves are also sources of complement components. 
Quiescent HUVECs have been reported to produce the components C1r, C1s, C2, C3, 
C5, C6, C7, C8 and C9 (Gulati et al., 1993; Johnson and Hetland, 1991; Langeggen et 
al., 2000, 2001; Warren et al., 1987), with production being upregulated by pro-
inflammatory cytokines (Berge et al., 1996; Brooimans et al., 1990; Dauchel et al., 
1990; Langeggen et al., 2000).  
4.2.2.1 Complement and the human brain endothelium 
Most of the above evidence derives from HUVECs, which are cells from medium 
sized umbilical vessels. As such, parallels cannot always be drawn with 
microvascular endothelium, particularly brain microvascular endothelium. Such 
specific studies are lacking with information being particularly scarce regarding 
HBEC complement receptors and membrane regulatory proteins. However, cultured 
human brain endothelial cells have been reported to produce factor H, C1-inhibitor, 




interferon γ (Vastag et al., 1998). A separate study reported the synthesis of factor 
H, factor B and C4 synthesis by cultured human brain endothelial cells, increasing in 
response to TNF-α and IL-1α stimulation (Nagy et al., 1996). A further study 
examined complement mRNA expression in primary human brain endothelial cells 
for the CP and reported the expression of mRNAs for C1qB, C1r, C1s, C2, C3, C4, C5, 
C7, C8γ and C9 (Klegeris et al., 2000).  
Human brain endothelial cells have also been reported to express the complement 
regulatory proteins CD55 (Visser et al., 2002), CD46 (Andres et al., 2003) and CD59 
(Vedeler et al., 1994), suggesting that these proteins are important in protecting the 
brain endothelium from complement attack. Taken together, these studies present 
the brain endothelium as a dynamic player in local CP and AP activation and support 
a role for HBECs as a significant source of complement proteins and regulatory 
proteins. 
4.2.3 CR1 expression on endothelial cells  
A table summarising the evidence for CR1 expression on endothelial cells is 
presented below (Table 4-1). CR1 expression has been reported by hypoxic HUVECs, 
with expression determined by ELISA, western blotting of HUVEC lysates and RT-
PCR for human CR1 (Collard et al., 1999). The same study reported hypoxic HUVECs 
were able to bind immune complexes, which was inhibited by the addition of sCR1. 
Confocal microscopy of the cells found the majority of the CR1 was intracellular and 
colocalised with von Willebrand factor (vWF). Finally, the authors used a western 
blot-based method to illustrate that CR1 on HUVECs was functional and able to 
cleave C3b to C3dg (method detailed in 4.4.14). Human bone marrow microvascular 
endothelial cells have also been reported to express CR1 when exposed to shear 
stress and tobacco smoke extract (Yin et al., 2008). 
After these reports of CR1 on activated endothelium, expression of CR1 on 
unstimulated HUVECs was described (Langeggen et al., 2002). In contrast to the 
predominantly intracellular expression reported by Collard et al., Langeggen et al. 




experiments which was supplemented by RT-PCR for human CR1. The authors 
repeated their experiments after stimulation of the cells with TNFα, 
lipopolysaccharide (LPS) and C5a, but in contrast to earlier studies, found no 
increase in CR1 expression. The same group later reported that HUVECs were able 
to uptake opsonised zymogen particles and postulated that this may be through 
CR1, but evidence presented was not definitive (Langeggen et al., 2003). A recent 
investigation into HUVECs and microfilariae reported surface CR1 expression 
determined by flow cytometry which was not altered by stimulation with IFN-γ 
(Schroeder et al., 2017).  
However, multiple studies have been unable to demonstrate the presence of CR1 
on HUVECs. Tsuji et al. detected no CR1 expression by flow cytometry on either 
quiescent or apoptotic HUVECs (Tsuji et al., 1994). Similarly, other groups could not 
detect CR1 by flow cytometry on quiescent HUVECs (Oroszlán et al., 2007; 
Roumenina et al., 2009) or on LPS/TNFα stimulation (Oroszlán et al., 2007).  
No studies to date have closely investigated the presence of CR1 on HBECs. The 
supplementary information of one paper suggested that α-CR1 antibodies (E11, 
J3D3, H-300 and rabbit polyclonal α-CR1 antibodies) might recognise brain vessel 
endothelial cells on immunohistochemical staining of cortical and hippocampal 
sections (Fonseca et al., 2016). However, the paper presented no data to support 
this and also included the caveat these antibodies may have been recognising RBCs 
within the vasculature instead. 
CR1 is a well-defined host receptor on erythrocytes for P. falciparum, both for 
rosetting via the N-terminal domain of PfEMP1 (DBLα) and as the host receptor for 
the sialic acid-independent invasion via the ligand PfRh4 (Cockburn et al., 2004; 
Rowe et al., 1997, 2000; Spadafora et al., 2010; Tham et al., 2010) (see sections 
1.7.1 and 1.7.2). However, there have been no reports of P. falciparum interacting 





Study (date) Cells/tissue studied Methods used 
α-CR1 
antibodies used CR1 detected? Comments 
Tsuji et al. 
(1994) 
HUVECs FC 31R No 
(live or apoptotic 
HUVECs) 
No positive control 
Collard et al. 
(1999) 
HUVECs ELISA, IFA, WB,  
RT-PCR, FISH 
C3b breakdown assay 
(with factor I) 
IC binding assay 
Rabbit polyclonal + 
3C6.D11 (ELISA) 




(hypoxic HUVECs and 
after stimulation with 
LPS and TNF-α) 
CR1 predominantly intracellular 
Inappropriate isotype controls used for ELISA 
No isotype control used for IFA 
No negative control used for WB 
 





E11  Yes  
(unstimulated HUVECs, 
no change with LPS/ 
C5a/TNF-α stimulation) 
CR1 predominantly extracellular 
Data from WB described but not shown 
Oroszlán et al. 
(2007) 
HUVECs FC Rabbit polyclonal 






stimulated with LPS or 
TNF-α) 
No positive control 
Yin et al. 
(2008) 
HBMMVECs ELISA E11 Yes 
(HBMVECs stimulated 
with tobacco smoke 
and shear stress) 
No negative or positive controls 
Roumenina et al. 
(2009) 
HUVECs FC E11 No  
(unstimulated HUVECs) 
Data described  but not shown 
Schroeder et al. 
(2017) 
HUVECs FC 3D9 Yes 
(no change with IFN-γ) 
No negative or positive controls used  
 
Table 4-1. Summary of published data investigating CR1 expression by human endothelial cells. 
HUVECs= Human umbilical vein endothelial cells, HBMMVECs = human bone marrow microvascular endothelial cells, FC= flow cytometry, ELISA = enzyme-linked 






As human brain endothelial cells have been reported to express both complement 
components and complement regulatory proteins (see 4.2.2.1), I postulated that 
human brain endothelial cells might also be able to produce CR1. If true, IEs might 
therefore use CR1 as a cytoadherence receptor via PfEMP1 on their surfaces, 
contributing to sequestration of IEs in the brain. Alternatively, if HBECs expressed 
CR1, this might modulate local complement activation in the cerebral 
microenvironment and control a potentially damaging complement response to P. 
falciparum. In addition, If CR1 was present on HBECs, it might bind malarial immune 
complexes limiting their ability to activate the cerebral endothelium. Finally, if CR1 
was present on HBECs, this could explain why the protective association with 
Sl2/Sl2 is specific to cerebral malaria. In this chapter, I aim to establish whether 
HBECs can express CR1 protein using antibody-based approaches. 
4.4 Methods 
4.4.1 Antibodies used  
4.4.1.1 α-CR1 antibodies  
CR1 is a large and complex protein, thus α-CR1 antibodies have various epitopes. 
Table 4-2 and Figure 4-2 summarise the α-CR1 antibodies used in these studies.  
4.4.1.2 Other antibodies and cellular markers 
Antibodies used for isotype controls, characterisation of cell lines, colocalisation 
experiments and detection of complement components are summarised in Table 
4-3. In addition, low density lipoprotein acetylated Dil complex (Dil-AcLDL, Thermo 
Fisher Scientific, L3484) which is taken up by endocytosis by endothelial cells was 
used as a cellular marker (Voyta et al., 1984). Secondary antibodies used in these 
experiments are detailed in Table 4-4 and were made up to contain 1 μg/ml of the 





Antibody Host Clonality Class/subclass Source (Cat #) Probable CR1 CCP epitope(s) Comment 
J3D3 Mouse Monoclonal IgG1 GeneTex (44217) 5-7, 12-14, 19-21 $ 
These antibodies 
make up the 
“commercial pool”  
To5 Mouse Monoclonal IgG1 Santa Cruz (20055) 5-7, 12-14, 19-21 $ 
E11 Mouse Monoclonal IgG1 Abcam (76520) 5-7, 12-14, 19-21, 26-27 $ 
HB8592 Mouse Monoclonal IgG1 Gift – Ron Taylor 5-7, 12-14, 19-21, 26-27 $ These antibodies 
added to the 
“commercial pool” 
“extended pool”  
9H3 Mouse Monoclonal IgG1 Gift – Ron Taylor 5-7, 12-14, 19-21 $ 
57F Mouse Monoclonal IgG1 Gift – Ron Taylor  8-10, 15-17 * 
YZ-1 Mouse Monoclonal IgG1 Gift - Ionita Ghiran 5-7, 12-14, 19-21 $  
Ber-Mac-DRC Mouse Monoclonal IgG1 Santa Cruz (19662) 5-7, 12-14, 19-21 $  
3D9 Mouse Monoclonal IgG1 Gift – Ron Taylor 3, 10,17 $  
1B4 Mouse Monoclonal IgG1 Gift – Ron Taylor 3, 10,17 $  
J3B11 Mouse Monoclonal IgG1 Gift – Jacques Cohen 8,15 $  
EPR6602 Rabbit Monoclonal IgG Abcam (126737) Amino acid residues at C 
terminus ¥ 
 
H300 Rabbit Polyclonal IgG Santa Cruz (20924) Amino acids 1740-2039 at 




Rabbit Polyclonal IgG Gift - John Atkinson “Rabbits immunised with 
purified sCR1” † 
 
Table 4-2. Summary of α-CR1 antibodies used in this chapter.  
Affiliations of collaborators: Prof Jacques Cohen - Hospital Robert Debré, Reims, France, Prof Ron Taylor - University of Virginia, USA, Prof Ionita Ghiran - Beth Israel 
Deaconess Medical Center, USA,  Prof John Atkinson -Washington University, USA.  References for antibody epitopes;  $(Nickells et al. 1998),  *(Iida et al., 1982)    





Figure 4-2. Epitopes of α-CR1 mouse monoclonal antibodies used in this chapter. 




Antibody Host Clonality (Sub) Class Source (Cat #) Comment 
Isotype controls 
MOPC-21 Mouse Monoclonal IgG1  Abcam (18443)  
Rabbit polyclonal IgG Rabbit Polyclonal  IgG Rowe laboratory From non-immunised rabbits 
Goat polyclonal IgG Goat Polyclonal IgG R&D Systems (AB-108-C)  
HBEC-5i characterisation 
Intercellular adhesion molecule 1 Mouse Monoclonal IgG1 Bio-Rad (1615) Clone 15:2 
Smooth muscle actin Mouse  Monoclonal IgG1 Santa Cruz (53142) Not present on endothelial cells 
von Willebrand factor Rabbit Polyclonal IgG  Abcam (6994)  
Zona occludens 1 Rabbit Polyclonal IgG Abcam (59720) Tight junction marker 
Endothelial protein C receptor Goat Polyclonal  IgG R&D Systems (AF2245)  
Intracellular co-localisation 
Apoptosis-inducing factor Rabbit Monoclonal  IgG 
These antibodies 
comprise the Organelle 
Localization IF Antibody 
Sampler Kit (Cell 
Signalling Technology,  
8653) 
Mitochondrial marker 
Early endosome antigen 1 Rabbit Monoclonal  IgG Endosome marker 
Lysosome-associated membrane 
protein 1 
Rabbit Monoclonal  IgG Lysosome marker 
Protein disulfide isomerase Rabbit Monoclonal  IgG Endoplasmic reticulum marker 
Receptor binding cancer antigen 
expressed on SiSo cells 
Rabbit Monoclonal  IgG Golgi apparatus marker 
Complement components 
C3d Rabbit Polyclonal  IgG DAKO (0063)  





Antibody Host Target species Fluorophore Source (Cat #) 
Goat α-mouse IgG (H+L) 488 Goat Mouse IgG Green Thermo Fisher Scientific, A11029 
Goat α-mouse IgG (H+L) 594 Goat Rabbit IgG Red Thermo Fisher Scientific, A11032 
Goat α-rabbit IgG (H+L) 488 Goat Rabbit IgG Green Thermo Fisher Scientific, A11034 
Goat α-rabbit IgG (H+L) 594 Goat Rabbit IgG Red Thermo Fisher Scientific, R37117 
Goat α-rabbit IgG (H+L) 647 Goat Rabbit IgG Far red Thermo Fisher Scientific, A32733 
Donkey α-goat IgG (H+L) 488  Donkey Goat IgG Green Thermo Fisher Scientific, A11055 
Goat α-rabbit IgG (H+L) 680RD Goat Rabbit IgG Near infrared Li-cor Biosciences UK, 925-68071 
Goat α-mouse IgG (H+L) 800CW Goat Mouse IgG Infrared Li-cor Biosciences UK, 925-32210 
Rat α-mouse IgG1 phycoerythrin 
(PE) conjugated  
Rat Mouse IgG1 Red-orange BD Biosciences, 550083 
 





4.4.2 Human Brain Endothelial cell line (HBEC-5i) 
Commercially available primary HBEC cells have been found to have batch-to-batch 
differences due to multidonor origins (reviewed in (Bouïs et al., 2001)) with 
immortalised HBEC lines being more stable in their endothelial traits. The 
immortalised human brain endothelial cell line HBEC-5i was established from the 
microvessels of cortical fragments of human brains (Dorovini-Zis et al., 1991; 
Wassmer et al., 2006) and provided by Franciso Candal (Centers for Disease Control 
and Prevention, Atlanta, USA). 
Primary cell lines were established using multiple cortical fragments, with 19 from 
temporal lobe biopsies and 11 from autopsies, with patients ranging from 19 to 75 
years old (Dorovini-Zis et al., 1991). Following this, primary HBEC cells (single donor) 
in their fifth passage were transfected with a plasmid containing the large T 
transforming protein of simian virus 40 (SV40) and Rous sarcoma virus long terminal 
repeat sequences to produce an immortalised cell line (Wassmer et al., 2006). In 
culture, HBEC-5i cells form monolayers with tight junctions as seen in the blood 
brain barrier (confirmed by the ability to exclude horseradish perioxidase from 
penetrating inter-endothelial spaces), showed cytoplasmic staining for von 
Willebrand factor (vWF) antigen and have lectin binding sites for Ulex europaeus 
agglutination, properties which support the endothelial nature of these cells 
(Dorovini-Zis et al., 1991). HBEC-5i do not express the receptors CD36 or CD31 
either at rest or on stimulation (Wassmer et al., 2006). The cell line is a key tool in 
the investigation of cerebral malaria pathogenesis (Adams et al., 2014; Claessens 






4.4.3 HBEC-5i culture media 
All work using HBEC-5i cells was performed in a Class II biological safety cabinet 
under sterile conditions. All culturing solutions were sterile and pre-warmed to 37oC 
before use. 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM, Sigma-
Aldrich, D6421) was used in the culture process as either complete DMEM or 
incomplete DMEM.  
Incomplete DMEM - DMEM supplemented with 2mM L-glutamine (Thermo Fisher 
Scientific, 25030) and 100 U/ml penicillin/0.1mg/ml streptomycin (Gibco, 15140) 
with the pH adjusted to 7.4 with 1M NaOH.  
Complete DMEM - incomplete DMEM plus 10% v/v heat-inactivated foetal bovine 
serum (HI-FBS, Thermo Fisher Scientific, 10500064), 1% v/v endothelial cell growth 
supplement (ScienCell, 1052) with the pH adjusted to 7.4 with 1M NaOH. 
4.4.4 HBEC-5i thawing  
HBEC-5i cells were grown on Corning® tissue flasks (Sigma-Aldrich, CLS430639) 
coated with gelatin. In preparation for seeding cells into a 25cm2 flask, 3 ml of 0.1% 
v/v sterile gelatin (Sigma-Aldrich, G1393) in dH2O was added to the flask. This was 
lain flat for 30 minutes at 37oC before excess gelatin was aspirated, leaving an 
optimal coating for cell growth. 
HBEC-5i were maintained in liquid nitrogen for long term storage. For thawing, a 1 
ml aliquot of HBEC-5i cells was placed in a water bath at 37oC and then gently 
resuspended in 10 ml complete DMEM in a 15 ml Falcon tube. The tube was spun at 
800g for 4 minutes and the supernatant removed. The cell pellet was thoroughly 
resuspended with 10 ml of fresh complete DMEM until no clumps remained and 
seeded onto gelatin-coated 25 cm2 tissue culture flask with a filter cap and 
incubated at 37oC with 5% CO2/air. The medium was replaced with fresh complete 




4.4.5 General HBEC-5i culture and passage 
Before reaching 100% confluency, cells were passaged and diluted into a new flask. 
Cell medium was changed every 48 hours or earlier if the medium changed from 
red/orange to yellow, implying acidity and nutrient depletion. For the passage of 
cells in a 75cm2 flask (Sigma-Aldrich, CLS430641U), spent medium was aspirated 
and cells washed twice with 10 ml incomplete DMEM. Two ml of 0.25% trypsin-
EDTA (Thermo Fisher Scientific, 25200) was added and the flask was incubated at 
37oC for 2-3 minutes until the cells had detached. Nine ml of complete DMEM was 
added to terminate protease activity. Cells were resuspended, transferred to a 15 
ml tube and centrifuged at 800g for 4 minutes. The supernatant was aspirated and 
cells diluted 1 in 10 in complete DMEM into a new gelatin-coated flask.  
CR1 is extremely sensitive to cleavage by tryspin (Pascual et al., 1994b; Sugita et al., 
1986) making trypsin-based cell lifting unsuitable for downstream assays 
investigating CR1 expression. Instead, cells were lifted using lignocaine 
hydrochloride, an approach used for cells including macrophages and fibroblasts 
(Fleit et al., 1984; Rabinovitch and DeStefano, 1975). For a 75 cm2 flask, cells were 
washed twice with 10 ml of calcium and magnesium-free PBS x 1 (Sigma Aldrich, 
P4417) which had been warmed to 37oC, following which 5 ml of pre-warmed 
lignocaine hydrochloride 4 mg/ml (AppliChem, A2870) made up in calcium and 
magnesium-free PBS x 1) was added and the flask was incubated at room 
temperature for 20 minutes. The flask was tapped to release the cells and 5 ml of 
calcium and magnesium-free PBS was added to aid detachment. The cell suspension 
was then used for various CR1 assays as described below. 
4.4.6 HBEC-5i freezing 
HBEC-5i at 80 – 100% confluency were lifted using the trypsin-EDTA method and 
washed in complete DMEM. Cell density was estimated using a haemocytometer 
and cells diluted in Cell Freezing Medium (ScienCell, 0133) at ~ 1 x 106 cells / ml. 




4.4.7 CHO cell culture 
Chinese hamster ovary (CHO) cells are a commonly used epithelial cell line and are 
well adapted to culture and to protein expression. Two stably transfected CHO cell 
lines were used in these experiments; CR1-CHO (CHO cells expressing ~ 200,000 
copies of CR1 per cell, positive control) and RCHO (CHO cells transfected with CR1 
cDNA in the reverse orientation, negative control), both kind gifts from John 
Atkinson (St Louis, USA) (Gunning et al., 1987; Java et al., 2015). Untransfected CHO 
cells do not have any membrane regulatory proteins with activity for human 
complement components, thus this system allows for the investigation of CR1 alone 
(Barilla-LaBarca et al., 2002).  
CHO cells were cultured in complete Ham’s F-12 media with 10% HI-FBS, 100 U/ml 
penicillin/0.1mg/ml streptomycin, 2mM L-glutamine, geneticin 250 µg/ml (Thermo 
Fisher Scientific, 10131019), Incomplete Ham’s F-12 media was made as above 
without HI-FBS and used for washes. Cells were routinely passaged using trypsin-
EDTA and with lignocaine hydrochloride if being used for a downstream CR1 assay 
(as described in 4.4.5). Freezing and thawing techniques were as described in 4.4.4 
and 4.4.6, using Ham’s F-12 media rather than DMEM. 
4.4.8 Mycoplasma surveillance 
Mycoplasma are common bacteria that can contaminate laboratory cultures, 
affecting cell physiology and metabolism which may influence experimental findings 
(reviewed in (Rottem and Naot, 1998)). Cell cultures were regularly checked for 
mycoplasma contamination using a commercial PCR detection kit (Venor™ GeM 
Mycoplasma Detection Kit (Minerva Biolabs, 11-1025)). An aliquot (100 µl) of cell 
medium was removed and heated to 100oC for 5 minutes. In a new tube, a 25 µl 
reaction was prepared consisting of 2 µl of heat-treated medium, 15.3 µl dH2O, 2.5 
µl primer-nucleotide mix, 2.5 µl 10x buffer (100 mM Tris-HCl pH 8.5, 500 nM KCl, 30 
mM MgCl2), 2.5 µl internal control and 0.2 µl of GoTaq® G2 DNA Polymerase 




control) or 2 µl of dH2O (negative control) were run alongside the sample. The PCR 
programme is shown in Figure 4-3. 
 
Figure 4-3. PCR programme for mycoplasma surveillance. 
PCR products were run on a 1.5 % agarose gel (see section 5.4.5), with a band at 
350 bp indicating a successful PCR and a second band at 280 bp indicating 
mycoplasma contamination. Contaminated cultures were discarded. 
4.4.9 Preparation of cell lysates 
Cell lysates of HBEC-5i, CR1-CHO and RCHO cells were made for SDS-PAGE / western 
blot analysis for CR1. A cell lysis buffer was prepared containing 2mM of the 
protease inhibitor phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, P7626), 1% 
v/v Nonidet™ P-40 (Sigma-Aldrich, 18896) and 0.05% SDS in PBS. For some 
experiments, PMSF was substituted for cOmplete™ Mini EDTA-free Protease 
Inhibitor Cocktail (PIC, Sigma, 11836170001) with one tablet made up in 10 ml of 
the above cell lysis buffer.  
A 90-100% confluent flask of cells was washed twice in warm calcium and 




Ten µl of the sample was removed and cell concentration calculated using a 
haemocytometer. The remaining recovered cells were centrifuged at 800g for 5 
minutes. The supernatant was removed and the cells resuspended in ice cold lysis 
buffer to adjust the concentration to 2 x 107 cells/ml. The cell suspensions were 
incubated on ice for 20 minutes with resuspension every 5 minutes. They were then 
centrifuged at 11942g at 4oC for 10 minutes, 100 µl aliquots prepared and used 
immediately or frozen at -70oC until required. Whilst lysates were produced from 
the same number of cells, it should be remembered that HBEC-5i cells are 
considerably larger than CHO cells.  
4.4.10 Immunofluorescence assays 
To enable visualisation of immunofluorescence assays (IFAs), it was necessary to 
grow HBEC-5i on glass coverslips. This was performed using a Corning® 24-well plate 
(Sigma-Aldrich, CLS3527) with one 10 mm diameter glass coverslip (Thermo Fisher 
Scientific, 12392108) placed at the bottom of each well. The coverslips were coated 
with 0.1 % gelatin prior to the experiment (as outlined in 4.4.4). Confluent HBEC-5i 
cells were lifted with lignocaine (as described in 4.4.5) and plated onto the gelatin 
coated coverslips and cultured until they were ~ 80% confluent (with higher 
confluences resulting in the cells lifting off the glass). The media was aspirated and 
cells washed with 500 µl of pre-warmed calcium and magnesium-free PBS added to 
each well, gently swirled and aspirated off. The cells were fixed by adding 500 µl of 
1% v/v methanol-free formaldehyde (Thermo Fisher Scientific, 28906) in calcium 
and magnesium-free PBS to each well. The cells were fixed for 15 minutes at room 
temperature, following which the formaldehyde solution was removed and the cells 
washed with 500 µl of calcium and magnesium-free PBS.  
For experiments requiring permeabilised cells, an extra step was included at this 
point by adding 500 µl 0.1% v/v Triton™ X-100 (Sigma-Aldrich, T9284) in PBS to the 
wells with incubation at room temperature for 5 minutes. This was then aspirated 
and the cells washed twice with 500 µl PBS. Each well was then blocked with 500 µl 




Aldrich, G9023) in PBS for 15 minutes before this was aspirated. 120 µl of the 
primary antibody was then carefully added to each coverslip and the 24 well plate 
was incubated in a humid chamber at room temperature for 60 minutes. The wells 
were then washed twice with 500 µl PBS and then incubated with 120 µl of the 
secondary antibody and incubated in a humid chamber at room temperature for 45 
minutes. Antibody concentrations varied with experiments. The coverslips were 
then washed twice in PBS and carefully removed with curved tweezers before being 
mounted upside down on a glass slide with a drop of Fluoromount 
(SouthernBioTech 0100-01). Slides were stored at 4oC overnight before being 
imaged the next morning.  
For staining with ZO-1, HBEC-5i were grown on polylysine coated glass coverslips 
(VWR, 631-0683) which had been coated with human fibronectin (50 μg/ml,) Merck 
Millipore, FC1010) in PBS for 20 minutes prior to seeding the cells. For staining with 
vWF antibody, the marker was most clearly visualised by growing the HBEC-5i on 8 
well Nunc Lab-Tek II CC2 Chamber slides (Thermo Fisher Scientific, 154941) as 
described in (Dmitrieva and Burg, 2014). 
On occasion, staining with two primary antibodies was necessary. When this was 
the case, primary antibodies produced in different species were used (i.e. mouse 
and rabbit) and secondary antibodies with different excitation wavelengths were 
used for detection to allow discrimination between the staining. 
To assess the ability of HBEC-5i to take up Dil-Ac-LDL, HBEC-5i grown on glass 
coverslips were incubated with 25 μg/ml of Dil-Ac-LDL in complete DMEM and 
incubated at 37oC in 5% CO2/air for 4 hours. After this they were washed three 
times in PBS and fixed with 1% v/v formaldehyde in PBS, blocked for 15 minutes 
with 1% BSA in PBS and the nuclei stained with 1 μg/ml DAPI before visualisation.  
The stained HBEC-5i were imaged using standard fluorescent microscopy or 
confocal fluorescent microscopy. For fluorescent microscopy, a Leica DMLB2 
microscope was used with x20, x40 or x100 objective. Pictures were taken using a 




positive controls and samples. Separate images were obtained for nuclear and 
cytoplasmic/membrane staining, which were overlain to produce a composite using 
the open source imaging processing software, ImageJ (version 1.51j8, National 
Institutes of Health, USA, https://imagej.nih.gov/ij/index.html). For confocal images, 
slides were imaged with a Leica SP5 confocal microscope using the glycerol x 63 
objective. A z-stack of images was taken at 0.8 μm intervals, with number of images 
taken depending on the thickness of the slide. A composite image was created using 
Volocity 3D Image Analysis Software version 6.3 (PerkinElmer, Massachusetts, USA). 
4.4.11 Flow cytometry  
HBEC-5i at 80 – 100% confluency were lifted using lignocaine hydrochloride as 
described in 4.4.5, placed in a polypropylene tube (Greiner Bio-One International, 
115201) and centrifuged at 400g for 5 minutes at 4oC. Most experiments were 
performed on live (unfixed) cells, however some experiments required a fixation +/- 
permeabilisation step, which was performed at this point. (NB – subsequent steps 
were performed at 4oC for live cells or at room temperature for fixed cells). For 
fixation, the supernatant was removed and 1 ml of 1% v/v formaldehyde in PBS was 
added to each sample tube, resuspended with a pipette and incubated at room 
temperature for 10 minutes. Following this, 2 ml of FACS buffer (0.1% v/v BSA and 
0.1% v/v azide in PBS was added to the sample which was centrifuged at 400g for 5 
minutes at room temperature. The supernatant was removed and 1 ml 0.1% v/v 
Triton™ X-100 in PBS was added and incubated for 5 minutes at room temperature. 
Following this, 2 ml of fluorescent activated cell sorting (FACS) buffer was added 
and the sample centrifuged at 400g for 5 minutes at room temperature.  
The supernatant was removed and 100 µl of 100 µg/ml α-CR1 monoclonal antibody 
pool (commercial or extended) made up in PBS/1% BSA containing 1.25 µg/ml 
Hoechst (Thermo Fisher Scientific: H3570) was added. The commercial pool 
contained the antibodies J3D3, To5 and E11, each at a concentration of 33.3 µg/ml. 
The extended pool contained the antibodies J3D3, To5, E11, HB8592, 9H3 and 57F, 




The sample was incubated at 4oC for one hour with resuspension every 10 minutes. 
Three ml of ice cold FACS buffer was added and the tube was centrifuged at 400g 
for 5 minutes at 4oC. The supernatant was removed and 100 µl of 0.07 µg/ml 
phycoerythrin (PE)-conjugated rat α-mouse IgG1 (BD Biosciences, 550083) made up 
in 1% BSA in PBS containing 1.25 µg/ml Hoechst.  
Samples were protected from light and incubated at 4oC for 30 minutes with 
resuspension every 10 minutes. Three ml of ice cold FACS buffer was added and the 
tube was centrifuged at 400g for 5 minutes at 4oC. The supernatant was removed 
and the sample resuspended in 250 µl of ice cold FACS buffer and analysed 
immediately. Approximately 60,000 events per sample were analysed on an LSR II 
flow cytometer (Beckton Dickinson Biosciences). Flow cytometry data were 
analysed using FlowJo v10 software (Tree Star Inc., Ashland USA). 
4.4.12 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels were 
cast to run samples prior to western blotting and for mass spectrometry. Separating 
gels generally contained 10% polyacrylamide. The separating solution was prepared 
by combining 7.9 ml dH2O, 6.7 ml 30% w/v bis-acrylamide (Sigma-Aldrich, L3771), 
5.0 ml 1.5M Tris (ThermoFisher Scientific, 17926) (pH 8.8), 0.2 ml 10% w/v SDS 
(Sigma-Aldrich, L3771), 0.2 ml 10% w/v ammonium persulfate (APS, Sigma-Aldrich, 
A3678) and 8 µl N,N,N’,N’-tetramethylethylenediamine (TEMED, Sigma-Aldrich, 
T9821) and swirling gently. The separating solution was pipetted between two glass 
plates in the casting frame and allowed to gelate for 30 minutes. A small amount of 
isopropanol (ThermoFisher Scientific, 10315720) was pipetted over the separating 
gel to remove bubbles and protect from oxidation. Once set, the isopropanol was 
poured off. Five ml of stacking solution was made by combining 3.4 ml dH2O, 0.83 
ml 30% w/v bis-acrylamide, 0.63 ml 1.0 M Tris (pH 6.8), 50 µl 10% w/v SDS, 50 µl 
10% w/v APS and 5 µl TEMED which was swirled gently. The stacking solution was 




inserted ensuring no air was trapped beneath the teeth. The solution was allowed 
to gelate for at least 30 minutes before the gel was loaded.  
The samples to be run were mixed with loading buffer (0.375 M Tris pH 6.8, 12% 
w/v SDS, 60% v/v glycerol and 0.06 % w/v bromophenol blue (Electra, 44305) for 
non-reducing loading buffer (or the same buffer with the addition of 30% 2-
mercaptoethanol (Sigma-Aldrich, M3148) for reducing loading buffer) in a ratio of 5 
parts sample, 1 part loading buffer. The comb was removed from the SDS gel and it 
was clipped into the electrophoresis apparatus. SDS PAGE running buffer (25 mM 
Tris-HCl, pH 8.3, 192 mM Glycine, 0.1% SDS) was poured into the inner chamber 
until it overflowed. Eight µl of Novex Sharp pre-stained protein standard (Thermo 
Fisher Scientific, LC5800) were loaded into the first well of the gel and ~ 15 µl of 
sample (depending on the experiment) loaded into the subsequent wells. The gel 
was run at 125V until the protein marker was seen at the foot of the glass plate. 
4.4.13 Western blotting 
Western blotting was used to probe cell lysates with α-CR1 monoclonal antibodies, 
as part of immunoprecipitation process (see 4.4.16) and to visualise C3b breakdown 
products (see 4.4.14). SDS-PAGE gels were transferred to a polyvinylidene fluoride 
(PVDF, Merk Millipore, IPVH00010) or nitrocellulose membrane (Sigma-Aldrich, 
GE10600003). PVDF was activated with methanol for 1 minute before use. Filter 
paper and sponges were soaked in transfer buffer (25 mM Tris, 192 mM glycine, 
20% v/v methanol) for 10 minutes prior to the assembling the transfer stack. The 
blotting stack was prepared as shown in Figure 4-4.  
 




An ice block was placed in the tank which was then filled with transfer buffer and 
run at 15V overnight at 4oC (or 80 V for 1 hour for the C3b degradation assay). The 
next morning the membrane was incubated with Ponceau S (Sigma-Aldrich, P7170) 
for 2 mins to allow visualisation of the transferred proteins and removal of 
extraneous membrane. The membrane was washed in 0.1% Tween®20 in PBS 
(Sigma-Aldrich, P9416) and blocked in in 5% non-fat milk (instant dried skimmed 
milk, Tesco) in 0.1% Tween®20 in PBS for two hours on a rocker. The membrane 
was washed three times in 0.1% Tween®20 in PBS for 10 minutes and incubated 
with the primary antibody (made up in 1% v/v IgG-free BSA and 0.05% v/v 
Tween®20 in PBS) overnight at 4oC.  
The membrane was washed three times in 0.1% Tween®20 in PBS for 10 minutes 
and secondary antibody added (Goat anti-Rabbit IgG (H + L), IRDye® 680RD, Li-Cor 
Biosciences UK, 925-68071 or IRDye® 800CW Goat anti-Mouse IgG (H + L) Li-Cor 
Biosciences UK, 925-32210) at a dilution of 1:5000 – 1:8000 (made up in 0.05% v/v 
Tween®20 and 50% v/v Odyssey Blocking Buffer (Li-Cor Biosciences UK, 927-40010) 
in PBS) and incubated in the dark at room temperature for an hour and washed a 
final three times in 0.1% Tween®20 in PBS for 10 minutes. Stained membranes were 
imaged directly on a Li-COR Odyssey® scanner using the 700 nm and 800 nm 
channels. Images were imported using Image Studio Lite software v5.2 and contrast 
adjusted to allow visualisation of the bands without changing the raw data. 
(https://www.licor.com/bio/products/software/image_studio_lite/). 
4.4.14 C3b degradation assay 
4.4.14.1 Role of CR1 in C3b breakdown 
C3 is an essential component of the complement system consisting of an α-chain 
(~110 kDa) and a β-chain (~75 kDa) connected by cysteine bridges. In its native 
form, C3 is inactive, requiring activation through cleavage by one of three forms of 
C3 convertase; C3(H2O)Bb and C3bBb in the alternative pathway (Fearon et al., 
1973; Nilsson and Nilsson Ekdahl, 2012), and C4b2a in the classical and lectin 




these C3-convertases produce C3a and C3b. On host cells, C3b subsequently 
undergoes successive proteolytic cleavages which produce inactive C3 products, 
thus protecting the cell from opsonisation and complement attack.  The first 
cleavage of C3b to iC3b (+ C3f) is performed by factor I, together with another 
cofactor which can be factor H, MCP or CR1 (reviewed in (Foley et al., 2015)) and is 
thus not CR1-dependent. The degradation of iC3b to C3dg (+ C3c) is performed by 
factor I with CR1 as a cofactor. The presence of C3dg thus suggests that CR1 is 
present and acting as a cofactor for iC3b breakdown (Ross et al., 1982). 
Identification of C3dg in this instance has been used as a method to determine 
whether functional CR1 is present (Collard et al., 1997). CR1 has the capacity to bind 
C3b, iC3b, and C3c but not to C3d (Becherer and Lambris 1988).  
The C3b breakdown pathway is detailed in Figure 4-5. 
 
Figure 4-5. The C3 degradation pathway.  
Degradation of C3b to iC3b requires factor I and a cofactor (either factor H, MCP or CR1).  
The C3d domain present within the C3, C3b and iC3b molecules is shown by a hashed area.  




4.4.14.2 Western blot to detect C3dg in supernatant 
A modified version of the assay described by Collard et al. was used (Collard et al., 
1999). As complement components C3b, iC3b, C3dg and C3d all contain the C3d 
region (see Figure 4-5), an α-C3d antibody would be anticipated to detect all 
complement components which include this region, (depending on conformational 
changes of the C3d epitope during cleavage). An assay was therefore designed to 
detect the presence of C3dg after incubation of confluent cells (HBEC-5i, CR1-CHO 
or RCHO) with C3b and factor I as an indicator of the presence of functional CR1. 
The α-CR1 monoclonal antibody 3D9 (which abrogates the binding of C3b to CR1 
was used to inhibit C3b binding and breakdown (Madi et al., 1991; Nickells et al., 
1998; O’Shea et al., 1985)) was used to determine specificity of the process to CR1. 
Approximately 2 x 104 HBEC-5i, CR1-CHO or RCHO cells were added to each well of a 
flat bottomed 96-well plate (Sigma-Aldrich, CLS3799, which had been coated with 
gelatin) and grown to a confluent monolayer. The spent media was removed and 
cells were washed twice with incomplete DMEM. Fifty μl of incomplete DMEM 
(non-permeabilised experiments) or 50 μl of incomplete DMEM with 0.1% v/v 
Triton® X-100 (permeabilised experiments) was added to each well. To examine 
each cell line’s ability to cleave C3b, wells were incubated with either: 
• C3b alone  
• Factor I alone  
• C3b + factor I 
• C3b + factor I + mouse IgG1 isotype control antibody MOPC-21  
• C3b + factor I + α-CR1 monoclonal antibody 3D9 
C3b was sourced from Merk Milipore (204860), factor I from Sigma (C5938) and 
recombinant CR1 from R and D systems (5748). Antibody sources for this section 
are detailed in Table 4-3. C3b was used at 27.5 μg/ml, factor I at 22 μg/ml, mouse 
IgG1 isotype antibody at 10 μg/ml and 3D9 at 10 μg/ml.  
Cells were incubated in incomplete DMEM with the complement 
components/antibodies as described for 7 hours at 37oC in 5% CO2. The 




reducing loading buffer and heated for 7 minutes at 95oC. The samples were then 
resolved by SDS-PAGE on a 10% SDS gel run at 125 V for 60 minutes. The gel was 
transferred to an activated PVDF membrane by western blotting at 80 V for 60 
minutes. The membrane was blocked with 0.1% Tween®20 in PBS with 5% milk for 
two hours, then probed with α-C3d rabbit polyclonal antibody (Dako, A0063) at 15.5 
μg/μl (made up in 1% v/v IgG-free BSA and 0.05% v/v Tween®20 in PBS). The 
reaction was left overnight at 4oC on a rocker. The membrane was then washed 
three times in 0.1% Tween®20 in PBS and incubated with 1:8000 goat α-rabbit IgG 
(H + L), IRDye® 680RD (made up in 0.05% Tween®20 in PBS and 50% v/v Odyssey 
Blocking Buffer) and developed as described in 4.4.13.  
4.4.15 Transfection of HBEC-5i with CR1 siRNA  
α-CR1 antibody staining of HBEC-5i after treatment with CR1 siRNA (Santa Cruz, sc-
29994) was investigated. Transfection with EPCR siRNA (Santa Cruz, sc-39932) was 
used as a positive control for transfection, and two negative controls were included; 
transfection with control A siRNA (“control KD”, scrambled sequence with no known 
target, Santa Cruz, sc-37007) and incubation with transfection agent alone (“vehicle 
only”).  
CR1 siRNA, EPCR siRNA or control A siRNA (10 µM) was diluted in Opti-MEM reduced 
serum medium (Thermo Fisher Scientific, 31985062) at a ratio of 3:50. Separately, 
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, 13778030) was 
diluted in Opti-MEM reduced serum medium at a ratio of 3:30. Following this, an equal 
volume of the diluted CR1 siRNA, EPCR siRNA or control A siRNA was added to the 
diluted Lipofectamine RNAiMAX and incubated at room temperature for 5 minutes to 
allow the formation of each respective siRNA-lipid complex. For “vehicle only” 
experiments, one-part Lipofectamine/Opti-MEM solution was diluted with one part 
Opti-MEM (i.e. no siRNA).  
HBEC-5i were seeded onto gelatin-coated coverslips in 24 well plates on the day 
before the experiment to allow them to reach 60-80% confluency. Old medium was 




siRNA-lipid complex of interest was them added to each relevant well. CR1 siRNA, EPCR 
siRNA or control A wells each contained a final amount of 30 pmol siRNA.  
The cells were incubated at 37oC for 24 or 48 hours in 5% CO2 in air. Following this, an 
IFA was performed as per 4.4.10 to determine the effect of the transfection process. 
E11, and its respective mouse IgG1 isotype control MOPC-21, were used at 15 μg/ml 
and polyclonal α-EPCR (R&D Systems, AF2245), and its respective goat IgG isotype 
control (R&D Systems, AB-108-C) were used at 10 μg/ml. As EPCR is a surface 
receptor, cells stained with α-EPCR and goat isotype control were not 
permeabilised, whereas cells stained for E11 and mouse isotype control were 
permeabilised with 0.1% Triton® X-100. 
4.4.16 Immunoprecipitation  
Immunoprecipitation with the α-CR1 monoclonal antibody E11 was performed to 
determine whether CR1 could be isolated from the lysates of HBEC-5i, CR1-CHO and 
RCHO cells. For each cell line to be examined, 100 μl of protein G coated Dynabeads 
(Novex, 10003D) were washed in tissue-grade pre-prepared PBS (Sigma, D8537), for 
one minute, after which the beads were separated using a magnet and the 
supernatant discarded (“magnetic wash”). The bead pellet was made up to 100 μl 
with PBS and divided into two aliquots. Fifty μl of beads was incubated with 5 μg of 
E11 antibody in 200 μl of PBS while the other 50 μl of beads was incubated with 5 
μg of mouse IgG1 isotype control MOPC-21. The antibody-bead mixtures were 
incubated for 30 minutes at room temperature with resuspension. Three magnetic 
washes in 1 ml PBS were performed and beads made up to 50 μl volume with PBS.  
Lysates from the three cell lines; HBEC-5i, CR1-CHO and RCHO had previously been 
prepared as described in 4.4.9, at a cell density of 2 x 107 cells /ml. 100 μl of each 
lysate was added to the E11 or isotype control bead mixture and made up to 1 ml 
with ice cold tissue grade PBS. The lysate-bead mixture was incubated overnight at 
4oC with continuous agitation on a rotating mixer. The next day, the mixtures 
underwent 3 magnetic washes in 0.05% Tween®20 in PBS followed by 2 magnetic 




of 50 μl 0.1 M glycine (ThermoFisher Scientific, BP381-500) pH 2.7 to the bead 
pellet with gentle agitation by hand for 5 minutes at room temperature. The beads 
were then pelleted using a magnet and the supernatant removed. The mixture was 
neutralised with 5 μl of 1M Tris pH9 to prevent hydrolysation of the protein.  
The immunoprecipitants were immediately run on a non-reducing 8% 
polyacrylamide gel. Duplicate gels were run for each experiment at 125 V for 80 
minutes. One gel was stained with InstantBlue Protein Stain (Expedeon, UK, ISB1L) 
for one hour on a rocker while the other was transferred onto a nitrocellulose 
membrane overnight at 15 V at 4oC.  
While the proteins were transferring, the detection antibody was prepared. It was 
necessary to use E11 as both the capture and detection antibody in this experiment. 
As such, the E11 to be used for detection on the western blot was conjugated to a 
fluorescent dye to differentiate it from the capture E11. The Lightning-Link Rapid 
Dylight 800 antibody and protein labelling kit (Innova Biosciences, 329-0030) was 
used to label E11 at 1 μg/μl as per the kit instructions.  
After transfer, the nitrocellulose membrane was blocked in 0.1% Tween®20 and 5% 
milk in PBS for 2 hours, then washed with 0.1% Tween®20 in PBS and then 
incubated with 1:10,000 conjugated-E11 (made up in 0.05% Tween®20 and 50% v/v 
Odyssey Blocking Buffer in PBS) in the dark at 4oC for 24 hours. The membrane was 
washed 3 times in 0.1% Tween®20 in PBS and imaged using the Li-COR Odyssey® 
scanner and Image Studio Lite software as described in section 4.4.13. 
4.4.17 Mass Spectrometry 
Cell lysates were prepared for HBEC-5i and CR1-CHO (positive control) as outlined in 
4.4.9. Twenty μl of lysate was mixed with 4 μl of non-reducing loading buffer and 
resolved by SDS-PAGE on a non-reducing 8% polyacrylamide gel at 80 V for 100 
minutes. Duplicate gels were run to allow one to be stained for protein detection 
and one for western blotting and probing with the α-CR1 antibody pool. The first gel 




temperature and then stored at 4oC until ready to be cut. The second gel was 
transferred onto a nitrocellulose membrane over night at 15 V at 4oC. The 
membrane was then blocked with 5% milk and 0.1% Tween®20 in PBS for one hour 
and incubated with E11, J3D3 and To5 α-CR1 antibodies. Each antibody was used at 
0.33 μg/μl concentration with a final concentration of 1 μg/μl. The membrane was 
incubated overnight on a rocker at 4oC then washed 3 times in 0.1% Tween®20 in 
PBS before incubation with 1:8000 IRDye® 800CW Goat anti-Mouse IgG (H + L) 
antibody (made up in made up in 0.05% Tween®20 and 50% v/v Odyssey Blocking 
Buffer in PBS) for 1 hour on a rocker. The membrane was washed three times in 
0.1% Tween®20 in PBS and imaged using the Li-COR Odyssey® scanner and Image 
Studio Lite software as described in section 4.4.13. 
The western blot was used to determine the position of the band of interest on the 
corresponding stained gel. A scalpel was used to cut gel bands from the HBEC-5i 
lysate and the CR1-CHO lysate lanes, which were destained in 40 % v/v methanol 
(ThermoFisher Scientific, 10284580) and 10 % v/v acetic acid (ThermoFisher 
Scientific, 10394970) in dH20 for 20 minutes at room temperature followed by a 
wash with dH2O.  
Samples were sent for processing to the Mass Spectrometry and Proteomics Facility 
at the University of St Andrews (http://mass-spec.wp.st-andrews.ac.uk/) which 
performs nano-scale liquid chromatographic electrospray ionisation tandem mass 
spectrometry (nLC-ESI-MS/MS). Downstream reduction, alkylation and trypsin 
digestion of the gel bands was performed by the facility. Tryspin cleaves the 
proteins at arginine and lysine residues into peptides, which are acid-extracted and 
injected into the liquid chromatography mass spectrometer. The resultant spectra 
are searched against NCBI, Swissprot and the facility’s internal database, Mascot 
(https://bsrcmascot.st-andrews.ac.uk/mascot/) for potential peptide matches. The 





4.5.1 HBEC-5i cell line expresses expected cellular markers 
HBEC-5i cells were grown to ~ 80% confluence on glass coverslips and IFAs carried 
out as detailed in 4.4.10. Non-permeabilised HBEC-5i were stained for ICAM-1 
(intercellular adhesion molecule 1, 50 μg/ml), zona-occludens-1 (ZO-1, 50 μg/ml) 
and α-SMA (20 μg/ml) and permeabilised cells were stained for intracellular von 
Willebrand factor (vWF, 62 μg/ml).   
HBEC-5i were found to take up Dil-Ac-LDL (Figure 4-6) and expressed ICAM-1 and 
ZO-1 (tight junction marker) on the membrane as anticipated (Figure 4-7). 
Permeabilised HBEC-5i were confirmed to contain intracellular stores of the 
endothelial marker vWF as well as having ultra-long fibres of vWF coating their 
surfaces (Figure 4-8). As anticipated, HBEC-5i did not express the fibroblast marker 
α-SMA (Figure 4-8). 
 
Figure 4-6. HBEC-5i can take up Dil-Ac-LDL. 
 Blue = DAPI nuclear staining. Red = Dil-Ac-LDL.  x63 magnification.  





Figure 4-7. HBEC-5i form tight junctions and express intercellular adhesion molecule 1 (ICAM-1). 
Panel A: Green = Mouse IgG1 isotype control (50 µg/ml). Blue = DAPI nuclear staining. Panels B and C: Green = Zona occludens-1 (50 µg/ml). Blue = DAPI nuclear 
staining. 
Panels D and E: Green = ICAM-1 (50 µg/ml). Blue = DAPI nuclear staining. 





Figure 4-8. HBEC-5i contain intracellular von Willebrand factor (vWF) and do not express α-smooth muscle actin (α-SMA). 
Panel A: Green = Rabbit IgG isotype control (62 µg/ml). Blue = DAPI nuclear staining. Panels B and C: Green = vWF (62 µg/ml). Blue = DAPI nuclear staining. 
Panel D: Green = Mouse IgG1 isotype control (20 µg/ml). Blue = DAPI nuclear staining. Panel E: Green = α-SMA (20 µg/ml). Blue = DAPI nuclear staining. 




4.5.2 α-CR1 monoclonal antibodies recognise an epitope on HBEC-5i 
After characterising the HBEC-5i line, IFAs using a pool of α-CR1 monoclonal 
antibodies were performed. Two pools of IgG1 mouse monoclonal antibodies were 
used; the “commercial α-CR1 pool,” which included three commercially available 
antibodies J3D3, To5 and E11 and the “extended α-CR1 pool” containing the 
commercial antibodies plus 57F, 9H3 and HB95G2 (kind gifts detailed in Table 4-2). 
IFAs were performed on unpermeabilised HBEC-5i with the extended α-CR1 pool 
suggested low levels of staining on the surface of some HBEC-5i (representative 
images in Figure 4-9). It had previously been reported that the expression of CR1 by 
HUVEC was increased under hypoxic conditions (Collard et al., 1999). As such, the 
experiment was repeated comparing the antibody staining of HBEC-5i cultured in 
normal growing conditions of 5% CO2/air (“normoxic”) with those grown in 1% O2, 
3% CO2 and 96% N2 (“hypoxic”) for 48 hours. HBEC-5i grown under hypoxic 
conditions were seen to stain more brightly and more uniformly with the extended 
α-CR1 pool than those grown under normal culture conditions (representative 
images in Figure 4-10). Fewer hypoxic cells were available for staining as they 
detached from the glass coverslip under these conditions. 
Collard et al. also reported the majority of CR1 identified in HUVECs was 
intracellular (Collard et al., 1999). The IFA was repeated using permeabilised HBEC-
5i and the commercial α-CR1 pool. Large intracellular stores of the antigen were 
seen in all cells with prominent peri-nuclear vesicles (Figure 4-11). Staining was 








Figure 4-9. Extended pool of α-CR1 monoclonal antibodies recognises an antigen on the surface of 
HBEC-5i cells. 
Panels A+B: Green = Mouse IgG1 isotype control (100 µg/ml). Blue = DAPI nuclear staining. 
Panels C+D: Green = Extended α-CR1 monoclonal pool (100 µg/ml). Blue = DAPI nuclear staining. 






Figure 4-10. Staining of HBEC-5i by extended pool of α-CR1 antibodies is increased under hypoxic 
conditions.  
Green = extended α-CR1 monoclonal pool (100 µg/ml) or mouse isotype control (100 µg/ml) 
respectively.  
Blue = DAPI nuclear staining. HBEC-5i fixed and not permeabilised. 





Figure 4-11. α-CR1 monoclonal pool detects intracellular pool of antigen in  permeabilised HBEC-5i. 
Panels A+B: Green = Mouse IgG1 isotype control (100 µg/ml). Blue = DAPI nuclear staining. 
Panels C+D: Green = Commercial α-CR1 monoclonal pool (100 µg/ml). Blue = DAPI nuclear staining. 
Fixed permeabilised HBEC-5i. Panels A+C x20 magnification. Panels B+D x 40 magnification. 
 
Figure 4-12. α-CR1 monoclonal pool stains dividing HBEC-5i. 
Green = commercial α-CR1 monoclonal pool (100 µg/ml). Blue = DAPI nuclear staining.  
Panel A = α-CR1 monoclonal pool staining. Panel B =DAPI DNA staining identifies dividing cell.  




To quantify the staining of HBEC-5i by α-CR1 monoclonal antibodies, flow cytometry 
was performed using live HBEC-5i cells as outlined in 4.4.11.  
The gating was performed as follows. Firstly, cells that lay at the boundaries of 
visualisation were excluded using the gate “Visible.” The amount of Hoechst 
detected in these visible cells was then used to assign them to where they were in 
the cell cycle (G0-G1, S and G2-M phases) allowing exclusion of apoptotic cells and 
debris. Cells in cycle were then gated on PE fluorescence to categorise them into 
“CR1 positive” or “CR1 negative.” Figure 4-13 shows an example of the gating 
strategy used.  
Lignocaine-lifted non-permeabilised HBEC-5i stained with the α-CR1 monoclonal 
pool showed a modest increase in MFI over those stained with an isotype control 
(Figure 4-14 Panel A), which was greatly increased by permeabilisation with Triton™ 
X-100 (Figure 4-14 Panel B). MFI was also increased when HBEC-5i were lifted, 
cooled and then rewarmed to 37oC (Figure 4-14 Panel C). However, MFI was 
reduced when cells were lifted with trypsin rather than lignocaine, suggesting that 






Figure 4-13. Example of gating strategy used for HBEC-5i flow cytometry experiments.  
Unpermeabilised HBEC-5i stained with 100 µg/ml isotype control (top row) or α-CR1 antibody pool (bottom row) with 0.07 µg/ml PE-conjugated rat α-mouse IgG as 





Figure 4-14. Staining of HBEC-5i by an α-CR1 antibody pool is increased with permeabilisation and 
heat treatment but decreased by treatment with trypsin. 
Red histograms - α-CR1 antibody pool (J3D3, To5, E11, 57F, 9H3, HB85G2), 100 µg/ml. 
Blue histograms – mouse IgG1 isotype control (MOPC-21, 100 µg/ml. 
Panel A – Unpermeabilised HBEC-5i. Panel B – HBEC-5i cells permeabilised with Triton™ X-100. 
Panel C – Unpermeabilised HBEC-5i cooled to 4oC then heated to 37oC for 5 minutes 
Panel D – Unpermeabilised HBEC-5i cells treated with trypsin EDTA for 5 minutes. 





4.5.2.1 Epitope on HBEC-5i recognised by α-CR1 monoclonal antibodies is the same 
molecular weight as CR1 
Western blotting was then undertaken to ascertain the molecular weight of the 
antigen being detected by the pool of α-CR1 monoclonal antibodies. Twenty μl of 
HBEC-5i lysate, RCHO lysate (negative control), CR1-CHO lysate (positive control) 
and 100 ng of recombinant CR1 were resolved by SDS-PAGE on a non-reducing 8% 
polyacrylamide gel at 125 V for 100 minutes followed by overnight transfer to a 
nitrocellulose membrane at 15 V at 4oC. The membrane was stained with the 
commercial α-CR1 monoclonal antibody pool (J3D3, To5 and E11), each used at a 
concentration of 0.1 μg/ml with a final concentration of 0.3 μg/ml. The membrane 
was incubated overnight at 4oC, followed by detection with 1:8000 IRDye 800CW 
(green) goat anti-Mouse IgG (H + L) antibody and developed using the Odyssey 
imaging system (see 4.4.13).  
A specific band was seen in the positive control (CR1-CHO lysate) at ~250 kDa. A 
band migrating at a slightly lower apparent molecular weight was also seen in the 
HBEC-5i lysate lane, suggesting that the presence of CR1. CR1 is known to vary 
slightly in molecular weight in different cell types as a result of glycosylation 
differences (Dykman et al., 1983a; Lublin et al., 1986). In addition, a strong lower 
band was seen in the HBEC-5i lysate lane at ~ 170 kDa at a similar molecular weight 
to a band in both the CR1-CHO and RCHO lysate lanes. Variations on this 








Figure 4-15. Western blot of HBEC-5i lysate reveals a band of the same molecular weight as CR1. 
Western blot probed with commercial α-CR1 pool (E11, J3D3 and To5) concentration 1 μg/ml 16 
hours at 4oC. Blue arrows indicate bands of interest (see text).  
Non-reducing 8% polyacrylamide gel. 
Lane 1 = HBEC-5i lysate. 
 Lane 2= negative control (RCHO lysate).  
Lane 3 = positive control (CR1-CHO lysate).  










4.5.3 HBEC-5i together with factor I can cleave C3b to C3dg, but this is 
not inhibited by the α-CR1 monoclonal antibody 3D9 
The next step of the investigation was to determine whether the putative CR1 
expressed by HBEC-5i was functional. One of the functions of CR1 is to act as a co-
factor with factor I in the breakdown of iC3b (reviewed in section 4.4.14.1). In the 
presence of CR1, factor I will act as a cofactor with it to breakdown iC3b to C3dg. 
Therefore, the detection of C3dg in such an assay acts as a proxy for the presence of 
functional CR1.  
An assay to assess C3b degradation was performed as described in 4.4.14.2. To 
investigate the possibility of membrane-bound or intracellular CR1 in HBEC-5i cells 
having different cofactor abilities, the experiment was performed in parallel with 
both permeabilised and unpermeabilised cells. To further examine whether the 
breakdown of C3b was CR1-specific, experiments were also performed with HBEC-5i 
incubated with α-CR1 monoclonal antibody 3D9 (which blocks the C3b binding site 
on CR1) or relevant mouse IgG1 isotype control (final concentration 10 μg/ml). CR1-
CHO cells were used as a positive control and RCHO as a negative control. Variations 
on this experiment were performed four times and representative western blots are 
shown in Figure 4-16. 
CR1-CHO cells were able to breakdown C3b to C3dg when coincubated with factor I 
positive control). The 3D9 antibody inhibited this breakdown (green circled bands), 
but the isotype control had no blocking effect, implying the breakdown of iC3b to 
C3dg by CR1-CHO cells was specifically performed by CR1. In contrast, HBEC-5i cells 
were able to breakdown C3b to C3dg in the presence of factor I, but this was not 
affected by the presence of 3D9 antibody (blue circled bands), suggesting this 
process may not be CR1 specific on HBEC-5i cells. Negative control RCHO cells were 






Figure 4-16. HBEC-5i can breakdown C3b to C3dg with factor I, but this is not inhibited by the α-CR1 monoclonal antibody 3D9.  
CR1-CHO (positive control) and HBEC-5i cells are both able to cleave C3b to C3dg but 3D9 only inhibits this process in CR1-CHO cells (green circles), not in HBEC-5i 
(blue circles). As expected, RCHO cells (negative control) are unable to cleave C3b to C3dg . Concentrations: C3b - 27.5 μg/ml, factor I - 22 μg/ml, mouse IgG1 isotype - 
10 μg/ml and 3D9 α-CR1 monoclonal antibody 10 μg/ml. Components/antibodies incubated with cells for 7 hours at 37oC.  




One possibility for the inability of 3D9 to block iC3b breakdown by HBEC-5i together 
with factor I is the presence of an alternative cofactor for this degradation process. 
Factor H has been reported to act as a cofactor with factor I to breakdown iC3b to 
C3dg, but only in low ionic strength conditions (Ross et al., 1982), which were not 
used in this assay. More recent work has also identified von Willebrand factor (vWF) 
as a cofactor with Factor I to degrade iC3b to C3dg (Feng et al., 2015). HBEC-5i cells 
produce vWF (see Figure 4-8) making this a potential alternative to CR1 in the 
cleavage process.  
An extension to the C3b degradation assay was performed to block vWF cofactor 
activity by incubating cells with α-vWF antibody. As the portion of the vWF 
molecule involved in cofactor activity has not been identified, a polyclonal α-vWF 
antibody was chosen to block as many sites as possible. Recombinant CR1 was used 
as a positive control at 1 μg/ml with C3b and FI concentrations unaltered. The 
effects of 3D9 and its isotype control were compared to that of the polyclonal α-
vWF antibody and its rabbit IgG control. All antibodies were used at 100 μg/ml.  
Western blots are shown in Figure 4-17.  As anticipated, the 3D9 antibody was able 
to block C3dg production when recombinant CR1 was used as a cofactor (green 
circled bands) but no effect was seen on C3dg production when the reaction was 
incubation with α-vWF (red circled band). The 3D9 antibody (even at a higher 
concentration than previously) had no effect on C3dg production by non-
permeabilised HBEC-5i (blue circled bands). No effect on C3dg production was seen 
in non-permeabilised HBEC-5i incubated with α-vWF antibody (yellow circled band), 
implying that vWF is unlikely to be acting as a cofactor for factor I for HBEC-5i, 
leaving this cofactor unidentified. (NB - Results for permeabilised HBEC-5i mirror 





Figure 4-17. Polyclonal α-vWF antibody is unable to inhibit the breakdown of C3b  C3dg by HBEC-5i.  
No effect on C3dg production was seen when α-vWF polyclonal antibody  was incubated with recombinant CR1 (red circle) or HBEC-5i (yellow circle).  
α-CR1 monoclonal antibody 3D9 was able to inhibit the breakdown of C3b  C3dg for recombinant CR1 (green circles) but not for HBEC-5i cells (blue circles). 
Concentrations: C3b - 27.5 μg/ml, factor I - 22 μg/ml, 3D9 α-CR1 monoclonal antibody, α-vWF polyclonal antibody, mouse IgG1 isotype and rabbit IgG isotype, all 
used at 100 μg/ml. Components/antibodies incubated with cells for 7 hours at 37oC. Reducing 10% polyacrylamide gels. 




4.5.4 Mass spectrometry of HBEC-5i lysate fails to detect CR1 
Mass spectrometry was performed to identify the HBEC-5i antigen being detected 
by the commercial pool of α-CR1 antibodies. Hypoxic lignocaine-lifted HBEC-5i 
lysates were resolved in duplicate on non-reducing 8% polyacrylamide gels, with 
one gel subsequently transferred onto nitrocellulose and probed with the 
commercial α-CR1 pool (1 μg/ml for 18 hours) and the other gel stained with 
InstantBlue (as detailed in 4.4.17). CR1-CHO cell and RCHO cell lysates served as 
positive and negative controls respectively. The western blot and the stained gel 
were compared and gel sections corresponding to the bands were excised and sent 
for mass spectrometry analysis.  
Figure 4-18 shows the corresponding western blot of the cell lysates and the gel 
slices excised. Three slices were taken from the HBEC-5i lane gel; one spanning 
~220-260kDa (slice A, corresponding to the upper band recognised by α-CR1 
antibodies at ~250 kDa), one spanning ~160-190 kDa (slice C, corresponding to the 
lower band detected by α-CR1 antibodies at ~170 kDa) and the gel slice in between 
these spanning ~ 190-220 kDa (slice B). As a positive control, the gel slice 
corresponding to the upper band on the CR1-CHO lane was also sent (slice D, 







Figure 4-18. Western blot of HBEC-5i and CR1-CHO lysates illustrating gel slices sent for mass 
spectrometry 
Lane 1 = HBEC-5i lysate, Lane 2 = RCHO lysate (negative control),  
Lane 3 = CR1-CHO lysate (positive control). 
 Duplicate SDS gels of cell lysates were run. One gel subsequently underwent western blotting and 
staining with E11, J3D3 and To5 α-CR1 antibodies 1 μg/μl overnight.  
The corresponding gel bands of interest (bands A, B and C) were then excised from the HBEC-5i lane 
of the untransferred gel and sent for mass spectrometry. The upper band in the CR1-CHO lane (band 
D) was sent as a positive control. Non-reducing 8% polyacrylamide gel. 
Primary mass spectrometry analysis revealed a very complex, high molecular weight 
mixture in all four slices. The peptide fragment masses were searched against all 
human proteins in the NCBIprot database. CR1 was not detected in any of the three 
HBEC-5i samples. However, CR1 was also not detected in the positive control CR1-
CHO sample by this approach. Tables of human protein matches for each of the gel 
slices are detailed in Appendix 8.1. 
In a complex, high molecular weight mixture, the detection of a protein with 
relatively low abundance can be challenging. To increase the chance of detection, 
the CR1 amino acid sequence from NCBI 
(http://www.ncbi.nlm.nih.gov/nucleotide/767908442) was added to an internal 
database of ~ 4800 human peptides curated by the BSRC Mass Spectrometry Facility 




peptides against this smaller database is reserved for the detection of low 
quantities of protein in a sample, as database size will affect probability scoring. 
This method resulted in the detection of CR1 in the CR1-CHO positive control 
sample, ranking 12th in this smaller database. Four peptides corresponding to CR1 
were identified, as shown below Table 4-5. However, scores for these peptides 
were extremely low. The location of these peptides in the CR1 amino acid sequence 
is shown in Figure 4-19. Even using this more restrictive analysis, no peptides 
matching CR1 were identified in any of the HBEC-5i samples. Matched proteins for 
this reanalysis are detailed in Appendix 8.1. 
Observed m/z Mr (expt) Mr (calc) Score Peptide 
608.2754 1214.5362 1214.5390 41 K.VSFVCDEGFR.L 
639.9083 1277.8020 1277.8071 72 R.VLLPLNLQLGAK.V 
656.9000 1311.7854 1311.7914 48 R.VLFPLNLQLGAK.V 
720.3756 1438.7367 1438.7456 97 R.SLFSLNEVVEFR.C 
Table 4-5. CR1 peptides detected in the CR1-CHO positive control by mass spectrometry.  
m/z = mass to charge ratio. Mr (expt) = expected molecular weight, Mr (calc) = calculated molecular 
weight. 
As a final approach, the HBEC-5i samples were reanalysed using a product ion scan. 
This method restricted the apparatus to only fragment peptides of the same mass 
as those four previously identified in the CR1-CHO control. The anticipated 
fragmentation pattern for each of the peptides was retrieved from the Mascot 
server. Peptide elution times were determined by running a product ion scan on the 
CR1-CHO positive control and noting when each peptide eluted. The same restricted 
product ion scan was run on the HBEC-5i samples and ion chromatograms were 
examined from the elution times of interest and compared against the expected 
Mascot predicted fragmentation. None of the 4 CR1 peptides were identified in any 
of the HBEC-5i samples. As such, despite extensive efforts, no CR1 peptides could be 
detected by mass spectrometry of HBEC-5i lysates. An example peptide ion scan 






Figure 4-19. Peptides matching the CR1 amino acid sequence identified in the positive control by 
mass spectrometry.  





Figure 4-20. CR1 peptide fragments can be identified in CR1-CHO sample but not in HBEC-5i. 
Peptide ion scans of CR1-CHO and HBEC-5i sample A for peptide fragment 608 m/z (see Table 4-5). 
Panel A – Peptide ion scan shows peptide 608 m/z eluting at 24 minutes for CR1-CHO positive control (dotted rectangle). Panel B – Tandem mass spectrometry 
fragmentation pattern from 24 minutes for CR1-CHO. Panel C – Peptide ion scan for HBEC-5i sample A, 24 minutes marked by blue shaded area. Panel D – Tandem 
mass spectrometry fragmentation pattern for 24 minutes for HBEC-5i sample A. Panel E – Expected tandem mass spectrometry fragmentation pattern for 680 m/z 
peptide (from Mascot). Panel B matches Panel E, (i.e. detection of a CR1 peptide in the CR1-CHO sample). Panel D does not match Panel E (i.e. this CR1 peptide 




4.5.5 E11 is the only α-CR1 monoclonal antibody to recognise an HBEC-
5i antigen 
Given the failure to detect CR1 in functional assays and mass spectrometry, I 
returned to the antibody-based assays to investigate the possibility that artefactual 
results had been obtained. To investigate whether all three of the α-CR1 
monoclonal antibodies within the commercial pool were able to recognise HBEC-5i, 
staining was carried out with individual antibodies (J3D3, To5 and E11). The α-CR1 
antibody 3D9 was also examined. In addition to the separate antibodies, the pooled 
α-CR1 monoclonal antibody staining pattern was compared to the staining of a pool 
of isotype controls, to ascertain whether the use of multiple antibodies might 
contribute to the staining pattern of the α-CR1 pool. Two mouse IgG1 monoclonal 
antibodies to PfEMP1 epitopes (KE6 and TC7, which would not be expected to 
recognise human antigens) were included in this pool of isotype controls.  
HBEC-5i on coverslips were separately stained with J3D3, To5, E11, 3D9 and MOPC-
21 mouse IgG1 isotype control at 16.7 μg/ml. In parallel, HBEC-5i were stained with 
either the α-CR1 monoclonal pool (J3D3, To5 and E11) at a final concentration of 50 
μg/ml, MOPC-21 mouse IgG1 isotype control at 50 μg/ml, or an isotype control pool 
(consisting of MOPC-21 mouse IgG1 isotype control, KE6 and TC7) at a final 
concentration of 50 μg/ml. Representative images are shown in Figure 4-21. 
Of the three α-CR1 antibodies comprising the pool, only E11 recognised an antigen 
on permeabilised HBEC-5i cells (Figure 4-21). J3D3, To5 and 3D9 did not stain above 
the level of the isotype control. The E11 staining pattern was identical to that of the 
α-CR1 pool, suggesting that all the signal from experiments using this pool may be 
coming from a single antibody. The pooled isotype control did give higher 
background staining that the MOPC-21 isotype control alone (Figure 4-22), 
suggesting the use of a single isotype control may have underestimated the 





Figure 4-21. Only E11 recognises an antigen on HBEC-5i when staining is performed with individual α-CR1 monoclonal antibodies. 
Mouse IgG1 isotype control, J3D3, To5, 3D9 and E11 all used at 16.7 μg/ml. 









Figure 4-22. A pool of isotype control antibodies increases background staining of HBEC-5i compared to a single isotype control antibody. 
Single isotype control = MOPC-21 mouse IgG1 isotype control. Pooled isotype control contains MOPC-21 plus KE6 and TC7 mouse IgG1 monoclonal antibodies against 
PfEMP1 epitopes (should not recognise human antigens). α-CR1 monoclonal pool contains J3D3, To5 and E11 monoclonal antibodies. Final concentrations for each 





IFA data suggested that only E11 was recognising an epitope on HBEC-5i cells. To 
investigate the possibility that the fixation process was influencing HBEC-5i epitopes 
(or changing their availability to antibodies), a series of western blots was 
performed using HBEC-5i lysates probed with individual antibodies.   
As initial experiments had suggested that α-CR1 antibodies stained hypoxic HBEC-5i 
more strongly (Figure 4-10) lysates were made from HBEC-5i as described in 4.4.9) 
which had been cultured for 24 hours in hypoxic conditions (1% O2, 3% CO2 and 96% 
N2). Hypoxic HBEC-5i lysates that had been lifted with lignocaine or with tryspin 
were compared. RCHO lysate was used as a negative control and CR1-CHO lysate as 
a positive control. Lysates were resolved by SDS-PAGE on non-reducing 10% 
polyacrylamide gels, transferred overnight onto a nitrocellulose membrane and 
probed with individual α-CR1 antibodies (as described in 4.4.13). Antibodies were 
used at concentrations between 0.3 and 1.9 μg/ml and the membrane incubated 18 
to 48 hours depending on the experiment. Some experiments examined whether 
the composition of the cell lysis buffer (PMSF or PIC) affected antibody binding. 
Cell lifting conditions, lysis buffers, antibody concentrations and incubation times 






Figure 4-23. Only E11 recognises an antigen in HBEC-5i lysates when western blotting is performed with individual α-CR1 monoclonal antibodies. 
 HBEC-5i lysates probed with monoclonal α-CR1 antibodies E11, To5, J3D3 and 3D9. 
Lane 1 Hypoxic HBEC-5i lysate (lignocaine lifted) 
Lane 2 Hypoxic HBEC-5i lysate (trypsin lifted) 
Lane 3 RCHO lysate (negative control) 
Lane 4 CR1-CHO lysate (positive control) 
Lane 5 Recombinant CR1 - 10 ng (positive control) 








Figure 4-24. Only E11 recognises an antigen in HBEC-5i lysates when western blotting is performed with individual α-CR1 monoclonal antibodies 
 HBEC-5i lysates probed with monoclonal α-CR1 antibodies E11, YZ-1, Ber-Mac-DRC, IB4, 57F, HB8592 and J3B11. 
All cells lifted with lignocaine. Non-reducing 10% polyacrylamide gels. Antibodies used at 1 μg/ml with 48 hour incubation. Please note, the top four panels were 
developed using enhanced chemiluminescent method (ECL) prior to being developed using the Odyssey system which has increased background staining.  





Figure 4-25. Rabbit α-CR1 antibodies do not recognise antigens of a similar molecular weight to CR1 in HBEC-5i lysate. 
Lane 1 Hypoxic HBEC-5i lysate 
Lane 2 RCHO lysate (negative control) 
Lane 3 CR1-CHO lysate (positive control) 
All cells lifted with lignocaine. Non-reducing 10% polyacrylamide gels. 
 Non-immunised rabbit IgG was used as an isotype control. All antibodies were used at a concentration of 1.9 μg/ml with 18 hour incubation. 





E11 was the only mouse monoclonal α-CR1 antibody to recognise a band at ~250 
kDa in lignocaine-lifted hypoxic HBEC-5i lysate of a similar molecule weight to that 
in the CR1-CHO positive control (Figure 4-23 and Figure 4-24). E11 did not recognise 
this band in the trypsin-lifted hypoxic HBEC-5i lysate, suggesting that the antigen is 
trypsin sensitive. However, no other mouse monoclonal α-CR1 antibodies (To5, 
J3D3, 3D9, YZ-1, Ber-Mac-DRC, IB4, 57F, HB8592 or J3B11) identified any proteins of 
a similar molecular weight to CR1 (Figure 4-23 and Figure 4-24). It appears that, as 
with the IFAs, all the signal from the α-CR1 commercial pool of antibodies is coming 
from monoclonal antibody E11.  
Hypoxic HBEC-5i lysate probed with monoclonal rabbit α-CR1 antibody showed no 
difference to the isotype control (Figure 4-25). Probing with polyclonal rabbit α-CR1 
antibody identified a band just below 260 kDa, but a band at this molecular weight 
was also seen in a fainter form on the isotype control membrane.  
To further explore whether the antigen recognised by E11 was the same on HBEC-5i 
cells as on CR1-CHO cells, the effect of heat on the sample was examined. 
Lignocaine-lifted HBEC-5i, CR1-CHO and RCHO lysates were either heated at 95oC 
for 7 minutes (in non-reducing loading buffer) or not heated prior to resolution on 
by SDS-PAGE on a non-reducing 8% polyacrylamide gel. Samples were transferred 
overnight and then stained for 48 hours with E11 or mouse IgG1 isotype control at   
1 μg/ml.  
E11 could not recognise an antigen in hypoxic lignocaine-lifted HBEC-5i lysates after 
they had been heat-treated, but continued to recognise the CR1 antigen in heat-
treated CR1-CHO cell lysate, suggesting the antigens on the two cell lines recognised 











Figure 4-26. E11 does not recognise HBEC-5i antigen after heat treatment.  
Lane 1 Hypoxic HBEC-5i lysate - not boiled. Lane 2 Hypoxic HBEC-5i lysate – boiled.  
Lane 3 RCHO lysate (negative control) – not boiled. Lane 4 RCHO lysate (negative control) –boiled.  
Lane 5 CR1-CHO lysate (positive control) – not boiled. Lane 6 CR1-CHO lysate (positive control) –
boiled.  
Boiled samples = 7 minutes at 95oC in non-reducing loading buffer.  
Non-reducing 10% polyacrylamide gels. 
E11 and mouse isotype control used at 1 μg/ml with 48-hour incubation. 








4.5.6 CR1 siRNA knockdown does not alter E11 staining of HBEC-5i 
To further examine the specificity of E11 for CR1, an experiment to silence any 
expression of CR1 by HBEC-5i with CR1 siRNA was performed. EPCR was chosen as a 
positive control, as previous successful knockdowns using EPCR siRNA have been 
performed in this cell line with the same method (Azasi et al., 2018). In addition to 
incubation of the cells with CR1/EPCR siRNA, two negative transfection controls 
were performed: incubation with Lipofectamine RNAiMAX transfection agent 
without any siRNA (to examine the effect this reagent on protein expression 
(“vehicle only”)) and incubation of the cells with the Lipofectamine RNAiMAX plus 
control A siRNA (scrambled sequence, control for the transfection process). 
Transfections were performed as described in 4.4.15.  
IFAs were performed at 24 and 48 hours post-transfection, with cells stained with 
E11 (and mouse IgG1 isotype control) and α-EPCR (and goat IgG isotype control). 
The experiment was performed twice. Representative immunofluorescent images 
from 48 hours after transfection are shown in Figure 4-27 (at x 40 magnification) 
and in Figure 4-28 (at x100 magnification). 
Incubation with the vehicle only had no effect on the subsequent staining patterns 
of E11 or α-EPCR on their respective knockdowns. Incubation with control A siRNA 
resulted in a moderate reduction of the α-EPCR staining (suggesting potential 
broader effects on protein expression by the transfection method), but α-EPCR 
staining was greatly reduced by incubation with EPCR siRNA. In contrast, incubation 
with control A siRNA had little effect on E11 staining and incubation with CR1 siRNA 
had no effect on subsequent staining with E11, supporting the conclusion that E11 





Figure 4-27. CR1 siRNA knockdown of HBEC-5i does not alter E11 staining (lower magnification). 
EPCR KD = positive control. Vehicle only = no siRNA. Control KD = control A (scrambled) siRNA. α-EPCR and goat isotype control = 10 μg/ml. E11 and mouse isotype 
control = 15 μg/ml. Cells stained with α-EPCR and goat isotype control are fixed but not permeabilised.  





Figure 4-28. CR1 siRNA knockdown of HBEC-5i does not alter E11 staining (higher magnification). 
EPCR KD = positive control. Vehicle only = no siRNA. Control KD = control A (scrambled) siRNA. α-EPCR and goat isotype control = 10 μg/ml. E11 and mouse isotype 
control = 15 μg/ml. Cells stained with α-EPCR and goat isotype control are fixed but not permeabilised.  




4.5.7 Immunoprecipitation of HBEC-5i lysate fails to produce CR1 
Immunoprecipitation with E11 or mouse IgG1 isotype control of hypoxic lignocaine-
lifted HBEC-5i lysates was performed, with CR1-CHO cell lysate as a positive control 
and RCHO lysate and PBS as negative controls (as detailed in 4.4.16). 
As E11 was the only antibody to recognise the HBEC-5i antigen, it was necessary to 
use this both as the capture and the detection antibody for this assay. To 
differentiate these roles, after “capture” E11 had bound the antigen and the lysates 
were resolved on SDS-PAGE (non-reducing 8% polyacrylamide gel) and transferred 
to nitrocellulose membrane, “detection” E11 was conjugated to a fluorescent 
marker (DyLight 680 fluorophore) before incubation with the membrane (antibody 
concentration for 24 hours). As such, only “detection” E11 was seen when the 
membrane was developed using the Li-Cor system.  
The assay successfully immunoprecipitated CR1 from the CR1-CHO cell lysate, but 
no signal was detected in the HBEC-5i lane (Figure 4-29). It was considered possible 
that all E11 binding sites on the HBEC-5i antigen were saturated with “capture” E11, 
preventing the “detection” E11 from binding to them. Rabbit polyclonal α-CR1 
antibody had previously detected a possible faint band on HBEC-5i lysate of similar 
size to CR1 (Figure 4-25). The membrane was washed three times in 0.1 % 
Tween®20 in PBS for 10 minutes and re-probed with polyclonal rabbit α-CR1 










Figure 4-29. E11 can immunopreciptate CR1 from CR1-CHO lysate but not from HBEC-5i lysate.  
Immunoprecipitates (IP) of E11 or isotype control antibody from HBEC-5i, CR1-CHO and RCHO lysates. 
Lane 1 – E11 IP of HBEC-5i. Lane 2 – Isotype control IP of HBEC-5i. 
Lane 3 – E11 IP of RCHO. Lane 4 – Isotype control IP of RCHO. 
Lane 5 – E11 IP of CR1-CHO. Lane 6 – Isotype control IP of CR1-CHO isotype control. 
Lane 7 - E11 IP of PBS. Lane 8 – Isotype control IP of PBS. 
Non-reducing 8% polyacrylamide gel. 





4.5.8 Intracellular HBEC-5i antigen recognised by E11 α-CR1 monoclonal 
antibody colocalises to the Golgi apparatus. 
(Please note – the experiments in this section were designed, supervised and 
analysed by myself but performed by Mr Alexandros Constaninou whilst a summer 
student in the Rowe laboratory.) 
To ascertain which intracellular compartment the epitope recognised by E11 was 
located in, a series of colocalisation experiments were carried out by dual-staining 
HBEC-5i with E11 antibody (20 μg/ml) together with markers for mitochondria 
(apoptosis-inducing factor, AIF, 0.5 μg/ml), endosomes (early endosome antigen 1, 
EEA-1, 0.5 μg/ml), lysosomes (lysosome-associated membrane protein 1, LAMP-1, 1 
μg/ml), endoplasmic reticulum (protein disulphide isomerase, PDI, 1 μg/ml) and the 
Golgi apparatus (receptor binding cancer antigen expressed on SiSo cells, RCAS, 1 
μg/ml). Mouse monoclonal IgG1 MOPC-21 (20 μg/ml) was used as an isotype 
control for E11 and non-immunised rabbit IgG (7 μg/ml) was used as an isotype 
control for the intracellular markers.  
E11 was found to colocalise with RCAS, a marker for the Golgi apparatus, but not 





Figure 4-30. E11 staining of HBEC-5i cells colocalises with staining for the Golgi marker RCAS (part 1). 
EEA-1 - endosomal marker (0.5 μg / ml), AIF - mitochondrial marker (0.5 μg / ml), LAMP-1 – lysosomal marker (1 μg / ml), PDI – endoplasmic reticulum marker (1 μg / 





Figure 4-31. E11 staining of HBEC-5i cells colocalises with staining for the Golgi marker RCAS (part 2).  
Further examples of RCAS (1 μg/ml) / E11 (20 μg/ml) colocalisation. 





Figure 4-32. Isotype controls for colocalisation experiment. 
Right hand panels: Non-immunised rabbit IgG (7 µg/ml) –isotype control for intracellular organelle 
staining. 
Left hand panels:  MOPC-21 mouse IgG1 isotype control (20 µg/ml) – isotype control for E11 staining. 






In light of the finding that E11 colocalises with a marker for the Golgi apparatus, the 
original mass spectrometry data was revisited to see if any Golgi-specific proteins 
had been detected in the upper and lower gel bands of HBEC-5i lysate. Several 
candidate Golgi proteins with mass spectrometry scores over 300 were identified 
(Table 4-6).  
Golgi protein Mass spectrometry score Molecular weight Comments 




factor 1 isoform 1 
2955 206 kDa 
Similar IFA staining 
pattern to E11 in HBEC-
5i when used to stain 
HeLa cells (Quilty et al., 
2018)  
Golgi alpha-
mannosidase II 1284 132 kDa 
 
Golgin subfamily A 
member 4 629 261 kDa 
Similar IFA staining 
pattern to E11 in HBEC-
5i when used to stain 





438 228 kDa 
 
Golgi membrane 
protein GP73 240 45 kDa 
 
Lower band 
Golgin subfamily A 
member 3 1771 168 kDa 
Similar IFA staining 
pattern to E11 in HBEC-
5i when used to stain 
HeLa cells (Maag et al., 
2005) 
Table 4-6. Golgi proteins identified by mass spectrometry of HBEC-5i lysate 
The Golgin subfamily A member 3 protein was considered to be a potential match 
for the lower band seen on E11 staining of HBEC-5i lysate and is of a similar 
molecular weight to that seen. However, there appear to be multiple Golgi-specific 
possibilities for the upper band. A preliminary exploration of the protein sequence 
homology between CR1, Golgin subfamily A member 3 and each of the five 






Center for Biotechnology Information, USA). A small area of low homology was 
identified between CR1, Golgin subfamily A member 3 and Golgi-specific brefeldin 
A-resistance guanine nucleotide exchange factor 1 isoform 1 (Figure 4-33), which 
might represent an overlapping epitope between the three proteins. 
 
Figure 4-33. Small area of homology between CR1 and two Golgi-specific proteins sequences. 
Ref sequence (green) = CR1, middle protein sequence = Golgin subfamily A member 3, lower protein 
sequence = Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 isoform 1. 
4.6 Discussion 
4.6.1 Summary and interpretation of results 
The finding that Sl and Mc polymorphisms in CR1 are specifically associated with 
cerebral malaria but not with other clinical sub-phenotypes of the disease (Chapter 
2) raised the hypothesis that this association might be due to the expression of CR1 
by brain endothelial cells. This chapter examined whether CR1 protein was 
expressed by the immortalised brain endothelial cell line HBEC-5i. The overall 
experimental design included antibody-based assays (IFA, flow cytometry, western 
blotting and immunoprecipitation) complimented by siRNA knock down 
experiments, functional complement assays and mass spectrometry studies to 
ensure the question was investigated by a variety of approaches.  
Initial experiments found that a pool of α-CR1 monoclonal antibodies (including 
J3D3, To5 and E11) detected low levels of an antigen on the surface of 
unpermeabilised HBEC-5i cells (IFA and flow cytometry data). Commensurate with 
the antigen being CR1, treatment with tryspin reduced the signal seen in 




permeabilised, the pool of α-CR1 monoclonal antibodies recognised intracellular 
antigen in all cells (IFA and flow cytometry data). An intracellular pool of CR1 has 
been described in neutrophils (Berger et al., 1988; Kumar et al., 1997; O’Shea et al., 
1985) with surface CR1 expression stimulated by cooling and reheating neutrophils 
to 37oC (Fearon and Collins, 1983). A similar increase in signal was seen when HBEC-
5i cells were cooled to room temperature and reheated to 37oC (flow cytometry 
data). Western blot experiments using HBEC-5i lysate probed with a pool of α-CR1 
monoclonal antibodies identified a band of a similar molecular weight to that seen 
in CR1-CHO lysate (positive control). Together with factor I, HBEC-5i were capable of 
cleaving C3b to C3dg, with the final step of this process classically performed by 
CR1. Findings to this point supported the presence of functional CR1 on HBEC-5i.  
However, an extension of the functional iC3b breakdown assay found that the 
breakdown of iC3b to C3dg in the presence of factor I and HBEC-5i cells was not 
inhibited by the α-CR1 monoclonal 3D9 (which blocks the C3b binding site (Madi et 
al., 1991; Nickells et al., 1998; O’Shea et al., 1985)). This suggested a cofactor other 
than CR1 was responsible for this breakdown on HBEC-5i cells. HBECs can produce 
factor H (Vastag et al., 1998) which has been reported to act as a cofactor with 
factor I to breakdown iC3b to C3dg (Ross et al., 1982). However, this was only 
reported under low ionic strength conditions, which were not used in this assay. 
Another cofactor (vWF (Feng et al., 2015)) was explored, but polyclonal α-vWF 
antibody was also unable to block iC3b breakdown. However, as the vWF epitope 
involved in iC3b to C3dg breakdown is unknown, it may not have been covered by 
the polyclonal antibody. In addition, the cofactor activity of vWF was only reported 
in experiments using a non-physiological pH of 8.5. 
Another alternative degrading enzyme is plasmin (Foley et al., 2015; Lachmann et 
al., 1982). It has been reported that “Plasmin cleavage of iC3b provides a 
complement regulatory pathway that is as efficient as FI/CR1 but does not require a 
cellular cofactor” (Foley et al., 2015). A potential source of plasmin in the HBEC-5i 




plasmin, however HBEC-5i were grown in complete DMEM containing foetal bovine 
serum (potentially containing plasmin) before being washed with incomplete 
DMEM for the C3b degradation assay. However, the foetal bovine serum had been 
heat treated at 56oC for 30 minutes inactivating any residual plasmin (Metwalli et 
al., 1998). As such, it appears that the iC3b to C3dg breakdown is being performed 
by an as yet unidentified cofactor on HBEC-5i cells.   
Following the inability of 3D9 to block C3dg production, the identity of the antigen 
recognised by α-CR1 antibodies was brought into doubt. The next step was to 
establish whether CR1 could be identified in HBEC-5i lysate by mass spectrometry. 
The high molecular weight and complexity of the cell lysate made this very difficult, 
as shown by the inability to detect CR1 in the CR1-CHO cell lysate (positive control) 
on the first analysis. Only once the spectra were compared directly against a smaller 
dataset containing the CR1 amino acid sequence were four CR1 peptides detected 
in the positive control. Proton ion scanning based on the elution times of these four 
peptides in the positive control was unable to detect them in the HBEC-5i sample. 
Thus, there was no evidence from mass spectrometry that HBEC-5i express CR1. An 
attempt to reduce the complexity of the sample by immunoprecipitation was 
unsuccessful. It should be noted that the detection of a high molecular weight 
protein in a complex mixture by mass spectrometry can be challenging (Angel et al., 
2012). As an example of this, despite many attempts, another group was recently 
unable to detect CR1 in erythrocyte lysates by mass spectrometry (personal 
communication, Prof Tom Williams, Kilifi, Kenya).  
The question was then raised as to the specificity of the α-CR1 monoclonal antibody 
pool used, namely J3D3, To5 and E11. The antibodies were examined individually by 
IFA of fixed HBEC-5i cells and western blotting of HBEC-5i lysates. It transpired that 
the IFA signal was coming from only one of the three antibodies (E11) and that the 
other two (J3D3 and To5) did not stain above the level of the isotype control. E11 
was also the only antibody to recognise a trypsin-sensitive antigen in HBEC-5i lysate 




antibodies (3D9, YZ-1, Ber-Mac-DRC, IB4, 57F, HB8592 or J3B11) failed to detect a 
band of similar molecular weight to CR1 on western blotting.  
The molecular weight of CR1 is variable with four allotypes of 160 kDa (CR1*3/CR1-
C), 190 kDa (CR1*1/CR1-A), 220 kDa (CR1*2/CR1-B) and 250 kDa (CR1*4/CR1-D) 
under non-reducing conditions (Dykman et al., 1983b, 1984, 1985). The 30 kDa size 
differences between these variants corresponds to the deletion or duplication of a 
LHR (Wong and Farrell, 1991; Wong et al., 1989). The relative molecular weights of 
these alleles are further altered under reducing conditions, whereby they increase 
by ~ 30 kDa (Birmingham and Hebert, 2001). Experimental conditions have also 
been found to influence the molecular weight of CR1 reported (Dykman et al., 1985; 
Wong et al., 1983, 1986). sCR1 was used as a positive control for some western 
blots, with the manufacturers (R&D Systems) stating it produces a band of 200-220 
kDa on SDS-PAGE under reducing conditions (R&D Systems, 2018). Western blotting 
experiments in this chapter were performed under non-reducing conditions so the 
sCR1 would be expected to produce a band at ~190 kDa. However, a band was seen 
at ~250 kDa for sCR1, regardless of which α-CR1 antibody was used. This was seen 
across three different batches of recombinant sCR1 protein. A band of the same size 
was also seen for the CR1-CHO lysates throughout the experiments. As such, it is 
likely that the experimental conditions or the protein ladder used may have 
influenced apparent size of the CR1 protein detected. It thus seems likely that the 
sCR1 and CR1-CHO CR1 are CR1*1 variants. The band recognised by E11 in HBEC-5i 
lysate was slightly lower than this, but not 30 kDa lower (i.e. not the size of a whole 
LHR). It has been reported that CR1 from different cells varies slightly in size – for 
example CR1 isolated from urinary vesicles (from glomerular podocytes) was 
reported to be 15 kDa larger than CR1 isolated from erythrocytes (Pascual et al., 
1994a). However, if HBEC-5i were truly producing a cell-specific form of CR1, it is 
extremely hard to explain why this was not detected by any of the other α-CR1 
monoclonal antibodies. The antibody with the most similarity to E11 is HB8592, 
which was reported to have the same reactivity pattern to sCR1 and its truncated 




and 22-30 (LHR D+) (Nickells et al., 1998). In the current experiments, HB8592 did 
not show the same pattern as E11 on western blotting of HBEC-5i lysates.  
The next set of experiments examined whether siRNA CR1 knockdown altered the 
E11 intracellular staining HBEC-5i. The siRNA knockdown worked well for the 
positive control (EPCR) but had no effect on the E11 signal from permeabilised 
HBEC-5i. It is plausible that the length of the experiment (48 hours) was insufficient 
to deplete the cells of their intracellular stores of CR1, but this seems unlikely. This 
appears to be strong evidence that the antigen recognised by E11 is not CR1.  
Following this, an attempt was made to immunoprecipitate the HBEC-5i antigen 
recognised by E11 prior to further mass spectrometry. As only one antibody 
recognised an HBEC-5i antigen, it was necessary to use E11 as both “capture” and 
“detection” antibody. E11 has been used in multiple reports to immunoprecipitate 
CR1 (Fonseca et al., 2016; Hogg et al., 1984; Mathew et al., 1995) and the protocol 
used in this chapter successfully immunoprecipitated CR1 from CR1-CHO lysate. 
However, no band was seen for the HBEC-5i lysate. It is possible that the level of 
antigen was too low for immunoprecipitation, but also possible that all available 
E11 binding sites on the antigen were occupied with “capture” E11, preventing 
“detection” E11 from binding. To see if this was the case the western blot 
membrane was reprobed with polyclonal rabbit anti-CR1 (which had weakly 
recognised a band of the anticipated size on HBEC-5i lysate), but no signal was seen. 
These experiments further suggest the antigen recognised by E11 was not CR1.  
4.6.2 E11 and the Golgi apparatus 
The question of what E11 was recognising was examined from another direction by 
performing colocalisation IFAs alongside organelle markers. Using this approach, 
E11 was found to be recognising an antigen that colocalised with receptor binding 
cancer antigen expressed on SiSo cells, (RCAS) which is used as a marker to identify 
the Golgi apparatus. CR1 is first synthesised as pro-CR1, a pre-Golgi precursor 
molecule, ~ 23 kDa smaller than mature CR1 (Atkinson and Jones, 1984; Lublin et 




which are thought to be trimmed in the cis and medial-Golgi cisternae before 
entering vesicles for incorporation into the cell membrane (Danielsson et al., 1994; 
Hamer et al., 1998). In some circumstances, CR1 is cleaved (from cell membrane or 
secretory vesicles) at a site within the transmembrane domain, releasing soluble 
CR1 (sCR1) (Hamer et al., 1998). As such, it is possible that CR1 could be detected in 
the Golgi apparatus of a permeabilised cell. However, evidence from mass 
spectrometry, C3b breakdown assay and siRNA knockdown of CR1 already strongly 
suggested that E11 was recognising an antigen other than CR1. 
Interrogation of the mass spectrometry data from HBEC-5i lysate revealed potential 
matches for Golgi-specific proteins in both the upper and lower bands recognised 
by E11. Protein sequence alignment suggested a small area of sequence homology 
between CR1, Golgin subfamily A member 3 (168 kDa) and Golgi-specific brefeldin 
A-resistance guanine nucleotide exchange factor 1 isoform 1 (206 kDa), which might 
represent an overlapping epitope between these proteins. Further experiments are 
planned to determine whether these Golgi antigens are being detected by E11. 
Experiments will include dual staining IFA of HBEC-5i using E11 and antibodies 
against each Golgi protein in turn to see if there is colocalisation. If successful, a 
western blot of HBEC-5i lysate will be undertaken using E11 and Golgi protein 
antibodies conjugated to different fluorophores to see what size bands are being 
detected. Finally, an siRNA knockdown of the Golgi proteins in question and IFA 
with E11 would confirm whether they are responsible for the cross reactivity. 
E11 is a widely used α-CR1 antibody and it will be essential to communicate to the 
scientific community that it may give false positive results in some situations. The 
likelihood of E11 not being specific for CR1 also calls into question some previous 
reports. For example, Langeggen et al.’s report of CR1 on HUVEC used E11 as the 
only antibody for flow cytometry and western blotting (confirmed by personal 
communication with Sanquin, formerly CLB, Amsterdam, Netherlands who supplied 
the antibody) (Langeggen et al., 2002). In addition, the study by Yin et al. where the 




appears to have relied entirely on data from ELISAs using E11 (methods section 
states “Murine monoclonal anti-CD35 (…) obtained from Ancell Corporation 
(Bayport, MN).” E11 is the only α-CR1 clone supplied by this company) (Yin et al., 
2008). As such, the antibody-based evidence for CR1 protein in HUVECs is limited to 
two papers; Collard et al., who used the monoclonal antibody 3C6.D11 and rabbit 
polyclonal antibodies for detection of CR1 by ELISA, and used YZ-1 for IFAs and 
western blots of the cell lysates (Collard et al., 1999) and Schroeder et al. who used 
3D9 to detect CR1 on HUVECs during an experiment to examine microfilariae 
binding (Schroeder et al., 2017). Collard et al. also used inappropriate isotype 
controls for their ELISAs (i.e. an IgG2a isotype control used for 3C6.D11, which is an 
IgG1 antibody and the use of a polyclonal rabbit α-horse antibody as an isotype for 
a polyclonal rabbit α-CR1 antibody, which is human) and did not use isotype 
controls for their IFA experiments, making interpretation more difficult. The 
evidence from Schroeder et al. also did not include any negative or positive controls 
when reporting for CR1 expression by flow cytometry in that study. 
It is important to remember that HBEC-5i is an immortalised cell line and may not 
perfectly reflect primary HBEC. For example, comparison of the transcriptional 
profiles of primary HBEC and the immortalised cell line hCMEC/D3 revealed 
differences in immune response genes which were related to the immortalisation 
procedure (Urich et al., 2012). As such, it is possible that primary HBEC might 
express CR1, the ability of which has been lost as a quirk of the immortalisation 
process. Parallel investigation of primary HBECs was initially attempted in this 
chapter, but abandoned over concerns that the cells were not exhibiting the usual 
growth characteristics of primary cells (extremely fast growth) and did not show a 
classic cobblestone appearance with the majority staining positive for the fibroblast 
marker SMA (data not shown). It will be important to repeat some of these 





4.6.3 Findings in context 
The data presented in this chapter do not support the expression of CR1 by HBEC-5i 
cells. As previously discussed, the expression of CR1 on HUVECs remains 
controversial and there are no detailed reports investigating CR1 protein expression 
on HBECs. However, a study of the proteome of primary HBEC under oxidative 
stress did not identify CR1 amongst the proteins reported (Ning et al., 2011). 
Although transcription does not always equate with the expression of a protein, 
recent transcriptomic studies have not provided evidence for CR1 transcription by 
HBECs. Two microarray-based studies, the first examining the transcriptional 
profiles of primary HBEC and the immortalised HBEC line hCMEC/D3 with and 
without co-culture with astrocytes and the second study of unstimulated 
commercially available primary HBEC found no evidence of CR1 transcription (Aung 
et al., 2014; Urich et al., 2012).  
In conclusion, the data from this chapter does not provide clear evidence for the 
expression of functional CR1 protein by HBEC-5i cells, which corresponds to the 
transcriptional data available from other studies. This finding cannot be directly 
extrapolated to primary HBECs and experiments will be necessary in these cells too. 
In addition, the α-CR1 monoclonal antibody E11 does not appear to be specific for 
CR1 and further experiments will be necessary to elucidate the antigen it is 
recognising. These investigations suggest that the production of CR1 by HBECs is 
unlikely to help explain the association between Sl2/McCb and CM. As such, 
attention was turned back to the polymorphisms themselves with the aim of 
producing recombinant proteins containing the mutations to directly characterise 







5 Do the Sl and McC polymorphisms affect the binding 
of complement components to CR1? 
5.1 Abstract  
The work from this thesis has suggested that the Sl2 and McCb polymorphisms in 
CR1 have opposing associations with cerebral malaria. These associations do not 
appear to be due to the polymorphisms influencing CR1 clustering on erythrocyte 
membranes, or to human brain endothelium expressing CR1. The LHR-D region 
containing these polymorphisms has been reported as the binding site for the 
complement components mannose binding lectin (MBL), C1q and L-ficolin, all 
associated with malaria to varying degrees. This chapter aimed to generate the 
reagents needed to test the hypothesis that the Sl2 and McCb polymorphisms affect 
the binding of these complement components to the LHR-D region.  
A region of CR1 cDNA corresponding to LHR-D plus CCP 29-30 (i.e. CCP 22-30) was 
amplified and cloned into pCRII vector. Site-directed mutagenesis was undertaken 
on the insert to create three mutant plasmids; pCRII CCP 22-30 Sl2, pCRII CCP 22-30 
McCb and pCRII CCP 22-30 Sl2/McCb. The successful mutations were confirmed by 
sequencing. An AgeI restriction site was introduced at the 3’ end of these mutant 
amplicons in preparation for sub-cloning. 
The expression plasmid pcDNA3.1 (-) CCP 22-30 His was obtained, which contains 
the unmutated CCP 22-30 region of CR1 with an additional 5’ CR1 signal peptide and 
3’ His tag. The restriction enzymes AgeI and PasI were used to digest the expression 
plasmid and remove the region containing the Sl and McC sites but preserve the 
signal peptide and His tag. The Sl2, McCb and Sl2/McCb mutant amplicons were also 
digested using AgeI and PasI to produce corresponding ends. Unfortunately, due to 
problems with restriction digestion, subcloning of the mutant amplicons into the 




5.2 Introduction  
The association between the Sl/McC polymorphisms and cerebral malaria does not 
appear to be due to differences in the clustering of CR1 on erythrocyte membranes 
(Chapter 3) or to an ability of human brain endothelial cells to express CR1 (Chapter 
4). Another possibility is that the polymorphisms might alter CR1 binding to 
complement components and hence influence complement activation or 
regulation. 
5.2.1 Function of the LHR-D region and relevance to malaria.  
The Sl and McC polymorphisms are located in CCP 25 of LHR-D on the CR1 molecule 
(Moulds et al., 2001). Unlike the rest of the CR1 molecule, the function of the LHR-D 
region is unclear, but has been reported as a binding site for the complement 
components mannose binding lectin (MBL), C1q and ficolins.  
5.2.1.1 LHR-D as a binding site for mannose binding lectin 
Mannose binding lectin (MBL) is a C-type lectin belonging to the collectin protein 
family. MBL consists of a collagen-like domain and carbohydrate-recognition 
domain with high affinity for N-acetylglucosamine and mannose (prominent in 
many micro-organisms) but does not recognise galactose or sialic acid (prominent in 
mammalian glycoproteins) (Drickamer, 1992). A review of MBL in the lectin 
pathway is provided in section 1.4.1 and Figure 1-7. MBL was first reported to bind 
to immobilised whole length sCR1 and was inhibited by C1q (Ghiran et al., 2000). As 
C1q had been reported to bind to LHR-D (Klickstein et al., 1997), MBL was deduced 
to bind in the same site. A later study used recombinant CR1 proteins spanning CCP 
22-30 (i.e. LHR-D plus CCP 29-30) and found a binding site for MBL in CCP 24/25 
using SPR (Jacquet et al., 2013). By aligning the amino acid sequences of the 30 CCP 
modules, Glu1555 was suggested as a potential MBL-binding site. This residue is 
surrounded by a patch of negative charge, with two acidic residues in CCP 24 
(Asp1553 and Glu1559) and two glutamic acid residues in CCP 25 (Glu1595 and Glu1597). 






Figure 5-1. Putative binding site for MBL on CR1. 
Amino acid sequences of the 30 CCPs comprising CR1 are aligned and CCP 24 and 25 are highlighted in grey. Conserved Cys residues are shown in red. The putative 
binding residue for MBL is shown in white lettering in a blue box (Glu1555). Negatively charged residues surrounding this are highlighted in blue.  




5.2.1.2 The role of MBL in malaria 
The role of MBL in malaria is unclear. Alleles responsible for low levels of functional 
MBL are common in sub-Saharan Africa (Garred et al., 2003; Holmberg et al., 2008; 
Lipscombe et al., 1992) and have been associated with increased parasite load, 
lower blood glucose levels and increased odds of severe malarial anaemia in 
Ghanaian children (Garred et al., 2003; Holmberg et al., 2008). A small study of 
Gabonese children also reported lower MBL levels on admission with severe malaria 
than with UM (Luty et al., 1998).  
It has also been suggested that MBL may opsonize P. falciparum IEs (Garred et al., 
2003; Klabunde et al., 2002) and merozoites (Korir et al., 2014). Downstream MBL-
mediated phagocytosis may be important as it attenuates the inflammatory 
response resulting in decreased production of IL-6, IL-1β, and TNF-α by monocytes 
(Bajtay et al., 2000; Jack et al., 2001). Indeed, a Gabonese study found malaria 
patients who had high MBL levels had lower levels of IL-1β, TNF-α and other pro-
inflammatory cytokines than those with low MBL levels (Boldt et al., 2006).  
Whether the Sl or McC polymorphisms have functional effects on MBL interactions 
with CR1 has not yet been explored. As both Sl and McC have been associated with 
infectious diseases other than malaria (Fitness et al., 2004a; Noumsi et al., 2011), 
any impact they may have on CR1 function is likely to be broad and not malaria-
specific. As such, the hypothesis that they might affect MBL binding to CR1 and the 
subsequent opsonisation or phagocytosis of malarial matter is plausible. 
5.2.1.3 LHR-D as a binding site for C1q  
C1q is the recognition molecule of the classical pathway and is composed of 
collagen-like stalks and globular heads, with the latter able to recognise and 
opsonise over 100 foreign and modified self-antigens (reviewed in (Kishore and 
Reid, 2000)). C1q also binds avidly to IgG and IgM-containing immune complexes, 
enabling the complement pathway to be activated in both an immune complex-
dependant and independent manner (reviewed in section 1.4.1 and Figure 1-7). The 




recombinant LHR-D and full length CR1 (Klickstein et al., 1997). However, this study 
did not examine the binding of C1q to LHR-A, B or C separately and used low ionic 
strength buffers, potentially affecting the relevance of the finding. The same group 
later reported that C1q and C4b bound to different sites on recombinant sCR1, but 
offered no further data to support LHR-D as the C1q binding site (Tas et al., 1999). 
There is some evidence that the C1q binding site may not be localised in LHR-D. In a 
experiments using short recombinant proteins, Tetteh-Quarcoo et al. reported C1q 
to bind most efficiently to CCP 15-17 (Tetteh-Quarcoo et al., 2012). However, these 
proteins were deglycosylated and the authors did not examine CCPs 26-28, and as 
such could have missed a C1q binding site there. In summary, the binding of C1q to 
the LHR-D region of CR1, whilst an oft accepted fact in textbooks, is actually based 
on a single paper (Klickstein et al., 1997). 
5.2.1.4 The role of C1q in malaria 
The role of C1q in malaria is unclear, but may interact with malaria-specific 
antibodies. A recent study examining malaria-exposed individuals from Papua New 
Guinea reported that their IgG was able to inhibit the invasion of erythrocytes by P. 
falciparum only when the assay was supplemented with C1q, but not when it was 
depleted of C1q (Boyle et al., 2015). The authors also reported that the antibodies 
of older children had higher C1q-fixing ability than younger children. Children with 
high C1q fixation ability were subsequently found to be less likely to develop clinical 
malaria and high density parasitaemia. The antigens underlying this antibody-
mediated complement-dependant protection included the merozoite surface 
proteins MSP-1 and MSP-2. The authors postulated that C1q-fixation may be 
inhibiting invasion through steric hindrance by blocking parasite proteins binding to 
cellular receptors. IgM is also a potent activator of C1q, with antibody pentamer 
binding to the cell surface, leaving the C1q binding sites on the Fc component 
accessible (Czajkowsky and Shao, 2009). PfEMP1 binds to natural IgM and may 
block its C1q binding sites, thus evading complement-mediated lysis of the 




5.2.1.5 LHR-D as a binding site for L-ficolin 
The ficolins are a group of lectins containing collagen-like and fibrinogen-like 
domains, which have structural and functional similarities to MBL. Three ficolins 
have been identified in humans; L-ficolin, H-ficolin and M-ficolin, each with different 
tissue distributions which act as pattern recognition molecules to recognise 
pathogens and activate complement via the LP. L-ficolin has been reported to bind 
to CCP 24/25, but CCP 27-30 may also be involved (Jacquet et al., 2013). 
5.2.1.6 The role of ficolins in malaria 
Data for an association between ficolins and malaria is scarce. A small study 
conducted in Gabon reported that levels of L-ficolin (also known as ficolin-2, FCN-2) 
were significantly raised in severe malaria when compared to mild malaria but 
found no association between any of three promoter SNPs in the FCN-2 gene and 
severe malaria (Faik et al., 2011). The same study reported “(…) we were unable to 
show a direct binding of ficolin-2 to parasitized erythrocytes, although suitable 
sugar moieties are found in plasmodial proteins (…).”  
5.2.2 Previous investigations into Sl/McC polymorphisms and 
complement function 
Considering the above evidence, it is plausible that the Sl/McC polymorphisms 
might affect the nearby binding of MBL, C1q or L-ficolin to LHR-D, with a 
subsequent influence on malarial infection and clinical outcome. The first step in 
testing any of these hypotheses is to examine the binding of MBL, C1q and L-ficolin 
to CR1 bearing the Sl2 and/or McCb mutations.  
One previous study has tried to elucidate the function of the Sl2 and McCb 
polymorphisms using four short recombinant proteins spanning CCP 15-25 which 
corresponded to the Sl1/McCa, Sl1/McCb, Sl2/McCa and Sl2/McCb haplotypes 
(Tetteh-Quarcoo et al., 2012). Recombinant proteins were expressed in Pichia 
pastoris yeast and underwent enzymatic deglycosylation. Binding of the four 
variants to C1q, C3b and C4b was determined using surface plasmon resonance and 




C4b cleavage with factor I was investigated using a fluid-phase assay and western 
blotting.  In addition, the ability of the four variants to disrupt P. falciparum rosettes 
and block RBC invasion was examined. No differences were found in the proteins’ 
ability to bind C1q, C3b and C4b, or act as cofactors (with factor I) for the 
breakdown of C3b and C4b. The mutations were not found to affect inhibition of 
erythrocyte invasion by P. falciparum (3D7 parasite strain) or disruption of rosettes 
(R29 parasite strain). The authors concluded that “Neither differences in 
complement-regulatory functionality, nor interactions with P. falciparum proteins 
tested here, appear to have driven the non-uniform geographic distribution of these 
alleles (Tetteh-Quarcoo et al., 2012).” 
5.2.3 Choice of protein expression system and CR1 glycosylation  
The four potential protein expression systems (bacterial, yeast, insect and 
mammalian) differ in their ability to fold and glycosylate proteins. The glycosylation 
repertoire of mammalian expression systems most closely resembles that seen in 
human cells (particularly N-glycosylation, reviewed in (Brooks, 2004)). It has been 
predicted that sCR1 has 25 N-linked glycosylation sites (Klickstein et al., 1988), of 
which 14 are occupied (Furtado et al., 2008). Eight of the glycosylation sites are 
located in CCP 22-30 (Figure 5-2 and (Morley and Walport, 2000)). N-linked 
glycosylation comprises ~25,000 Da of the mature form of CR1 and also accounts 
for the ~5,000 Da difference seen between PMN and erythrocyte CR1 (Dykman et 
al., 1983a; Lublin et al., 1986). High-mannose N-linked oligosaccharide chains in pro-
CR1 are converted to complex-type chains in mature CR1 (Atkinson and Jones, 
1984). N-linked glycosylation also appears to be key to CR1 function, with 
deglycosylated CR1 having ~50% half-life and 41% of the iC3 binding efficiency of 





Figure 5-2. Glycosylation sites in CR1.  
Insert shows the potential glycosylation sites in LHR-D in relation to Sl and McC mutation sites.   
Image adapted from (Furtado et al., 2008), with additional information from (Klickstein et al., 1988). 
Previous investigation into the functional effects of the Sl2 and McCb mutations 
used a yeast-based protein expression system (Pichia pastoris) and then 
deglycosylated using the endoglycosidase EndoHf (Tetteh-Quarcoo et al., 2012). 
Indeed, the first author’s thesis states: “… a limitation of the present work is that it 
effectively ignores any effects of glycosylation on structure and function of CR1 
(Tetteh-Quarcoo, 2011).” As such, the study’s findings may not represent naturally 
glycosylated CR1. Another study reported the LHR-D region as the binding site for 
MBL and the ficolins using proteins expressed using a baculovirus-insect cell 
expression system (Jacquet et al., 2013).1 This system produces more simple N-
glycans in comparison to mammalian cells (Harrison and Jarvis, 2006). 
Given the importance of N-glycosylation in CR1, it is possible the reliance of these 
two studies on yeast and baculovirus-insect systems may have affected the 
conclusions drawn. As four of the eight potential N-glycosylation sites in CCP 22-30 
are very close to the Sl and McC polymorphism sites (Figure 5-2), I decided to 
produce constructs for the Sl2, McCb and Sl2/McCb recombinant proteins for 
expression in mammalian cells in order to maximise the natural N-glycosylation 
pattern.  
                                                     
1  It should be clarified that the expression plasmid pcDNA 3.1 (-) CCP 22-30 His used in this chapter 





The aim of this chapter was to generate constructs in order to express recombinant, 
His-tagged proteins representing the LHR-D region of CR1 containing the Sl2, McCb 
and the Sl2/McCb double mutation, to enable future work examining their 
interactions with MBL, C1q and L-ficolin. 
5.4 Methods 
5.4.1 Overview of cloning strategy 
A section of CR1 cDNA spanning CCP 22-30 was amplified by PCR and ligated into 
the cloning vector pCRII. The resultant plasmid was transformed into Escherichia 
coli and selected on antibiotic-containing agar using blue/white screening. Colonies 
were subsequently screened by PCR to determine whether they contained an insert 
of the anticipated size. Promising colonies were picked and grown in broth 
containing ampicillin, following which the plasmid DNA was purified and sequenced.  
The Sl2, McCb and Sl2/McCb mutations were introduced by site-directed 
mutagenesis and confirmed by sequencing. Restriction enzyme sites were then 
added to the ends of the mutant inserts. The resulting PCR amplicon was double-
digested by the appropriate restriction enzymes. The digested insert was ligated 
into a (previously double-digested) expression vector (pcDNA3.1 (-)) bearing a CR1 
signal peptide and a His-tag. The final plasmid was transformed into E. coli, 
expanded and the insert confirmed by sequencing. 
5.4.2 Primer sequences 
Amplifying, sequencing and restriction enzyme site primers were designed using 
SnapGene molecular biology software version 4.1 (GSL Biotech). Site-directed 
mutagenesis primers were designed using PrimerX 
(http://www.bioinformatics.org/primerx/).  Primers were supplied by Sigma (Sigma-
Aldrich, St. Louis, MO, USA) desalted and in solution at 100 µM concentration.  




Primer name Sequence (5’-3’) Tm (oC) 
Amplifying primers 
LHRD_F CACTGTAAAACCCCAGAGCAGTT 67.5 
LHRD_R ATGTGCACGAGAGGTACATTTGG 69.9 
Site-directed mutagenesis primers 
SL2_F AGTTGAAAATGCAATTGGAGTACCAGGAAACAGG 75.3 
SL2_R CCTGTTTCCTGGTACTCCAATTGCATTTTCAACT 75.3 
MCCB_F GGTGTATTTCTACTAATGAATGCACAGCTCCAGA 72.3 
MCCB_R TCTGGAGCTGTGCATTCATTAGTAGAAATACACC 72.3 
Sequencing primers 
LHRD_SP1_F AACTTACCAGTGCCACACTG 60.3 
LHRD_SP2_R CTTGTGCAGCGGATGGAG 65.9 
LHRD_SP4_R CAGGATTTCTGGAGGCGG 65.8 
SP6_PROM ATTTAGGTGACACTATAGAA 50.9 
T7_PROM TAATACGACTCACTATAGGG 47.7 
Restriction enzyme site primers 
AGE1_PRIMER CAGCTGACCGGTCACTGTAAAACCCCAGAGCAG 80.7 
PAS1_PRIMER AGTCTCCTGGGGCGTG 66.7 
 
Table 5-1: Primer sequences. 
For site-directed mutagenesis primers, the mutated nucleotide is indicated in red. For restriction 
enzyme site primers, restriction sites are indicated in green letters. SP6_PROM and T7_PROM were 
kind gifts from Dr Mathieu Cayla. 
Tm = melting temperature. 
5.4.3 PCR amplification of CR1 CCP 22-30 
The nucleotide sequence of human mRNA for CR1 was sourced from GenBank 
(https://www.ncbi.nlm.nih.gov/nuccore/Y00816) and imported into SnapGene. The 
mature peptide sequence corresponding to CCP 22-30 was identified (nucleotides 
4210-5937, amino acids 1404-1979). This sequence encompasses LHR-D (CCP 22-28) 
and CCP 29-30. Primers were designed to amplify this segment of cDNA (termed 
LHRD_F and LHRD_R, see Table 5-1). Full length CR1 cDNA was a kind gift from Lloyd 
Klickstein (Boston, USA). To minimise introduction of unwanted errors, the CCP 22-




(Thermo Fisher Scientific 11304011) using the PCR buffer and MgSO4 supplied with 
this enzyme. Deoxynucleotide triphosphate (DNTP) mix was sourced from Takara 
(4030). The reaction was made up as follows: 
50 ng/µl CR1 template cDNA     1 µl  
10x High fidelity PCR buffer      2.5 µl 
50 mM MgSO4         1 µl 
10 µM DNTP mix        0.5 µl 
10 µM LHRD_F primer     0.5 µl 
10 µM LHRD_R primer     0.5 µl 
Sterilised dH2O      18.9 µl 
Platinum™ Taq DNA Polymerase High Fidelity (5 units/µl) 0.1 µl 
The reaction was run on the PCR cycle parameters in Figure 5-3. Melting 
temperature was calculated using the New England Biolabs tool 
(https://tmcalculator.neb.com/). Extension time was adjusted to allow 
approximately one minute per thousand base pairs of DNA as per the Platinum™ 






Figure 5-3: PCR programme for amplification of CCP 22-30 from CR1 cDNA. 
5.4.4 Adding 3’ adenine overhangs 
As a highfidelity enzyme had been used to amplify the cDNA, the purified PCR 
product did not possess adenine (A) overhangs, which are necessary for TA cloning. 
As such, an extra step was included to replace these A overhangs prior to ligation. 
The following products were sourced from Promega; dATP (U120A), GoTaq G2 DNA 
Polymerase (M7841) and 5x Green GoTaq Reaction Buffer (M791A). 
The reaction was set up as follows: 
 Purified PCR product     20 µl 
 dATP (100 mM)    0.1 µl 
 5x Green GoTaq Reaction Buffer  10 µl 
 Sterilised dH2O    19.7 µl 
GoTaq G2 DNA Polymerase   0.2 µl 
The reaction was incubated at 72oC for 20 minutes and then purified using the 
Nucleospin® Gel and PCR Clean-up kit (Macherey-Nagel, 74060950) according to the 
manufacturer’s instructions. DNA quantity was determined by spectrophotometry. 
5.4.5 Agarose gels 
100 ml of 1x tris-acetate EDTA (TAE) buffer was made by diluting 50x tris acetate 
EDTA (TAE, ThermoFisher Scientific, BP1332-1) in dH2O. To cast 1% agarose gels, 
0.5g UltraPure™ agarose (ThermoFisher Scientific, 16500500) was dissolved in 50 ml 
of 1x TAE and heated at 800W in a microwave for 90 seconds with agitation until 
completely dissolved (for 0.75% gels 0.375 g of agarose was used). The melted 
agarose was poured into a cast, a well-comb inserted and set for 30 minutes. The 
comb was removed and the remaining 50 ml of 1x TAE buffer poured over the gel.  
5 µl of the molecular marker Quick-Load® 1 kb DNA Ladder (New England Biolabs, 
N0468S) was added to estimate the molecular weight of the DNA samples. To allow 




(New England Biolabs, B7420S) at a ratio of five parts sample to one-part loading 
dye. The gel was run at 80V for 40-60 minutes. The gel was protected from light and 
incubated on a rocker with either 0.5 μg/ml ethidium bromide (Sigma-Aldrich, 
46067) in 1x TAE for 15 minutes or 1:10,000 SYBR Safe ® DNA Gel Stain (Thermo 
Fisher Scientific, S33102) in 1x TAE for 30 minutes. DNA was visualised under ultra-
violet (UV) light using a G:Box gel system and GeneSnap software (Syngene, India).  
5.4.6 Gel fragment isolation and purification 
Gel extraction was used to purify the amplified portion of CR1, and was also used 
following restriction digests when more than one gel band was generated. In 
addition to the sample to be purified, a guide sample was also run on an agarose gel 
and stained with ethidium bromide. The gel was divided and the guide sample 
visualised under UV light. The band of interest was then excised under direct vision. 
The gel was reassembled away from the UV source and the cut band used as a guide 
for excision of the sample band whilst avoiding exposure to mutagenic UV radiation. 
The final cut band was purified using the Nucleospin® Gel and PCR Clean-up kit 
(Macherey-Nagel, 74060950) according to the manufacturer’s instructions. The 









5.4.7 Preparation of growth media 
In preparation for ligation and transformation, antibiotic-supplemented growth 
medium was prepared. Luria-Bertani (LB) agar plates were prepared by adding  
17.5 g LB broth with agar (Lennox, Sigma L2897) to 500 of dH20 (final concentration 
15 g/L agar, 10 g/L, tryptone, 5 g/L yeast extract and 5 g/L NaCl). The solution was 
autoclaved for 15 minutes at 121 oC and left until cool to touch. 0.5ml of 100 mg/ml 
ampicillin was added to give a final concentration of 100 µg/ml. While still molten, 
the sterile LB agar was poured into 100 mm x 15 mm petri dishes next to a Bunsen 
burner on a blue flame. 25 ml of LB agar was added to each dish and left to cool for 
30 minutes at room temperature. Agar plates were stored at 4oC for up to five 
weeks and checked for contamination before use.  
For work with plasmids containing a multiple cloning site (MCS) within a lacZα 
sequence, isopropyl-β-d-thiogalactopyranoside (IPTG) and X-gal were added to the 
plate. 40 µl each of 20 mg/ml X-gal (Melford, B71800) and 100 mM IPTG (Promega, 
V3951) were spread onto the plate and incubated at 37oC for 30 minutes prior to 
plating out the transformed E. coli. LB broth was prepared by adding 20 g of LB-
broth powder (Sigma-Aldrich, L3022) to 1L dH2O and autoclaving for 15 minutes at 
121 oC. LB-broth was kept at 4oC and ampicillin added to small aliquots as necessary 
(to minimise antibiotic degradation) to give a final concentration of 100 µg/ml. 
5.4.8 Ligation into the pCRII cloning vector 
The purified PCR product with A overhangs was ligated into the cloning vector pCRII 
using the TA Cloning® Dual Promoter pCRII kit (which contains the ExpressLink™ T4 
DNA ligase and buffer, Thermo Fisher Scientific, K2070). The linearised pCRII vector 
has single thymidine (T) residues at the 3' ends which are complimentary to the 
single A added to the 3' ends of PCR products by the Taq polymerase step 






Figure 5-5: Cartoon of TA cloning. 
“T” ends of pCRII vector and “A” ends of the PCR product (insert) are complimentary, allowing 
efficient ligation.  
Image adapted from TA Cloning® Dual Promoter pCRII kit manual, Thermo Fisher Scientific. 
Fresh PCR products were used for ligation to ensure A-overhangs were maintained. 
Ratios of the cDNA inserts and linearised vector were calculated using New England 
Biolabs Ligation Calculator (http://nebiocalculator.neb.com/#!/ligation), with an 
insert DNA length of 1.79 kb, vector DNA length of 3.9 kb and vector mass of 50 ng. 
A ratio of 3 (insert): 1 (vector) was used, which resulted in using 68.85 ng of insert 
and 50 ng of pCRII vector. The reaction was set up as follows: 
Purified PCR product with A overhangs (48.6 ng/µl)  1.42 µl 
5x ExpressLink™ T4 DNA ligase buffer   2 µl 
pCRII vector (25 ng/µl)     2 µl 
Sterilised dH2O      3.6 µl 
ExpressLink™ T4 DNA ligase (5 units/µl)   1 µl 
The ligation reaction was mixed and incubated at room temperature for one hour.  
5.4.9 Transformation into E. coli 
Four µl of the ligation reaction was added to 50 µl of One Shot™ TOP10F’ chemically 
competent E. coli cells (Thermo Fisher Scientific, C303003) and swirled gently. The 
reaction was placed on ice for 30 minutes following which cells were heat shocked 
in a water bath at 42oC for 30 seconds then returned immediately to ice for a 
further two minutes. 250 µl of room temperature Super Optimal broth with 
Catabolite repression (SOC medium, Thermo Fisher Scientific, 15544034) was added 




100 µl of the reaction was spread evenly onto a 100 mm LB agar plate containing 
ampicillin, IPTG and X-gal and incubated overnight at 37oC. Plates were inspected 
the following morning and colonies selected for expansion either by blue/white 
screening or colony PCR (see below). If colony PCR was not being performed, 
isolated colonies were selected for expansion and added to 3 ml of LB broth (with 
100 µg/ml of ampicillin) in a 14 ml vented round-bottom polypropylene tube 
(Falcon 352059). These “mini-broths” were incubated at 37oC at 225 rpm on an 
orbital shaker overnight.   
5.4.10 Colony PCR 
To minimise the number of colonies expanded and sequenced, colony PCR was 
performed to screen colonies and determine whether they contained an insert of 
the anticipated size. Primers spanning the MCS of the pCRII vector were used to 
amplify any inserted DNA sequence (T7_PROM SP6_PROM primer pair, see Table 
5-1). For each colony to be screened, a PCR tube was made up containing: 
Sterilised dH2O     33.75 µl   
5 x GoTaq green buffer    10 µl    
T7_PROM (10 µM)     2.5 µl    
SP6_PROM (10 µM)     2.5 µl  
DNTP (10 µM)      1 µl 
Single isolated white colonies were lightly touched with a sterile 200 µl pipette tip 
and the tip then swirled in the respective PCR tube. The rest of the colony was then 
picked and placed into 3 ml of LB broth with 100 µg/ml of ampicillin in a labelled 14 
ml polypropylene tube with snap cap (Falcon 352059). These cultures were stored 
at 4oC until the screening PCR was complete. As the final step, 0.25 µl of GoTaq DNA 







Figure 5-6. PCR programme for screening of colonies. 
The PCR products were then run on a 1% agarose gel in 1 x TAE buffer at 80 V for 40 
minutes followed by staining in 0.5 μg/ml ethidium bromide for 15 minutes. 
Colonies containing inserts of the expected molecular weight were selected for 
expansion +/- sequencing. These promising colonies were expanded in 3 ml of LB 
broth with 100 µg/ml ampicillin and the “mini-broth” culture was incubated 
overnight at 37oC on an orbital shaker at 225 rpm. 
5.4.11 Miniprep 
Plasmids were extracted from the “mini-broth” culture using the GeneJET Plasmid 
Miniprep Kit (Thermo Fisher Scientific, K0502) as per the manufacturer’s 
instructions. DNA quantity and purity was determined using a spectrophotometer. 
5.4.12 Diagnostic restriction digestion 
To confirm that the plasmids contained inserts of the expected size, a diagnostic 
digest was undertaken using the restriction enzyme EcoRI – High Fidelity (New 
England Biolabs, R3101S) which has restriction sites flanking the TA cloning site in 





Miniprep elute    3 µl 
CutSmart buffer x 10   2.5 µl 
Sterilised dH2O   19.5 µl 
EcoRI – HF    1 µl 
The reaction was incubated at 37oC for one hour followed by an inactivation step at 
65oC for 20 minutes. The digestion products were visualised on a 1% agarose gel.  
5.4.13  Sequencing 
Three unique sequencing primers were designed for the CCP 22-30 insert (SP1, SP2 
and SP4, see Table 5-1). Two further sequencing primers (T7_PROM and 
SP6_PROM) flanking the TA cloning site were also used. Following colony PCR 
screening and diagnostic restriction digestion, clones were selected for Sanger 
sequencing. One reaction was prepared per primer as follows: 
Miniprep eluate (~ 500 ng/µl)  1 µl     
Sequencing primer (6.4 µM)   1 µl 
Sterilised dH2O    4 µl 
Samples were submitted for BigDye reaction and Sanger sequencing using an ABI 
3730XL capillary sequencing instrument (Edinburgh Genomics, The University of 
Edinburgh, http://genomics.ed.ac.uk/). Sequences were aligned using SnapGene 
molecular biology software version 4.1 (GSL Biotech). Where mismatches occurred, 
the quality of the base calls was visually inspected and calls updated as necessary.  
5.4.14 Glycerol stocks 
After sequencing had confirmed that a plasmid contained the desired insert without 
unwanted mutations, glycerol stocks of the respective transformed E. coli were 
made. 10 µl of the original mini-broth was used to inoculate 3ml of LB broth 
containing 100 µg/ml of ampicillin. The mixture was incubated at 37oC on an orbital 




growth phase. Next to a Bunsen burner, the 3 ml culture was divided into 500 µl 
aliquots in Nunc™ cryogenic tubes (ThermoFisher Scientific, 366656) to which       
500 µl of 50% sterile glycerol (Applied Biosystems, 4392215) was added and the 
tube inverted until no layers could be seen. Glycerol stocks were stored at -70oC.  
When new colonies were required, the tube was placed on dry ice and the surface 
of the glycerol stock was scratched with a colony picker, streaked onto a new LB 
agar plate (with ampicillin) and incubated overnight at 37oC. 
5.4.15  Site-directed mutagenesis 
Once the expected CR1 CCP 22-30 DNA sequence was confirmed without unwanted 
errors, site-directed mutagenesis was performed to introduce the Sl2 and McCb 
mutations. Coordinates are given as per the human mRNA sequence for CR1 
(GenBank, https://www.ncbi.nlm.nih.gov/nuccore/Y00816). 
Sl1  Sl2 
• Nucleotide change A4828G  
• Amino acid change R1610G 
• Primers used SL2_F and SL2_R 
McCa  McCb 
• Nucleotide change A4795G 
• Amino acid change K1595E 
• Primers used MCCB_F and MCCB_R 
The McCb mutation has not been reported as a single mutation and only occurs on 
the background of Sl2. However, the decision was taken to also produce the McCb 
mutation on its own (i.e. on an Sl1 background) in order to allow detailed 
examination of any influence the McCb mutation might have on CR1 function.  
The following three mutants were made using site-directed mutagenesis.  






In the case of the double mutant Sl2/McCb, mutations were introduced one at a 
time. CloneAmp HiFi PCR Premix (Takara, 639298) which contains the enzyme 
CloneAmp HiFi Polymerase was used for site-directed mutagenesis. For each 
mutation, the following reaction was set up: 
SL2_F or MCCB_F (10 µM)  0.5 µl 
SL2_R or MCCB_R (10 µ)  0.5 µl 
Plasmid template (100 ng/µl)  1 µl 
Sterilised dH2O   11.5 µl 
CloneAmp HiFi PCR Premix  12.5 µl 
Extension time was adjusted to 5 seconds per thousand base pairs of DNA as per 
CloneAmp HiFi Polymerase protocol. As the plasmid was ~ 6 kb, this was set to 30 
seconds. To reduce the risk of unwanted mutations in the process, number of cycles 
performed was kept to a minimum (18 cycles). The site-directed mutagenesis 
reaction was run on the following programme: 
 
Figure 5-7: PCR programme for site-directed mutagenesis 
Five µl of the reaction was removed to visualise on an agarose gel. The remaining 




of the template plasmid. The mutation product was added to 5 µl of 10x CutSmart 
buffer (New England Biolabs, B7204S) with 0.5 µl DpnI (New England Biolabs, 
R0176S). The reaction was incubated at 37oC for one hour followed by an 
inactivation step of 80oC for 20 minutes.  
After DpnI treatment, the mutated plasmid was purified (described in 5.4.6) and 
eluted with a final volume of 15 µl to concentrate the DNA. Five µl of the eluate was 
transformed into One Shot™ TOP10F’ E. coli (outlined in 5.4.9). As this step only 
involved mutation, not ligation, blue/white screening was not necessary. The 
transformed E. coli were plated onto LB agar with ampicillin and incubated over 
night at 37oC. Colonies were selected, plasmids purified by miniprep and sequenced 
as previously described. Glycerol stocks were made of successful mutants.  
After the single Sl2 and McCb clones were made, the Sl2/McCb double mutant was 
produced. The McCb mutation was introduced onto the back of the Sl2 clone using 
the primers MCCB_F and MCCB_R and the procedure described above.  
5.4.16  Expression plasmid 
The expression plasmid pcDNA 3.1 (-) CCP22-30 His was a kind gift from Dr Nicole 
Thielens, Grenoble, France. The group had previously produced the plasmid which 
contains the mammalian expression vector pcDNA 3.1 (-) with a 1804 bp insert 
corresponding to the CCP 22-30 fragment (nucleotides 4210-5926, amino acids 
1404-1976, with no Sl/McC mutations) (Jacquet et al., 2013). CCP 22-30 is in frame 
with part of the native CR1 signal peptide (nucleotides 100-147, amino acids 34-49, 
inserted using site-directed mutagenesis) cloned into the BamHI – KpnI sites of the 
pcDNA 3.1 (-) vector. The plasmid also has a fusion 6x His-tag at the C-terminal end 
of CCP 22-30 (introduced using site-directed mutagenesis) (Jacquet et al., 2013). 
Like the pCRII vector, the pcDNA 3.1 vector also contains an ampicillin resistance 
gene. The effect of the His tag has previously been examined and found not to 
influence the binding of MBL or L-ficolin to the CCP 22-30 recombinant fragment 





Figure 5-8: Original expression plasmid pcDNA3.1 (-) CCP 22-30 His. 
CR1 signal peptide, LHR-D region, His-tag and AgeI, PasI, BamHI, KpnI and HindIII restriction sites are 
shown. 
To allow cloning in of the mutant sequences, unique restriction enzyme sites within 
the expression plasmid’s insert were explored and AgeI and PasI were selected. 
Digestion at these points preserves the CR1 signal peptide and the His-tag, allowing 
insertion of the mutant insert. 
5.4.17  Maxi prep 
In preparation for digestion of the pcDNA3.1 (-) CCP 22-30 His plasmid, 
transformation, expansion and purification of the plasmid was performed by Maxi-





5.4.18  Adding restriction sites to mutant inserts 
To facilitate sub-cloning, the Sl2, McCb and Sl2/McCb mutant inserts were amplified 
by PCR with an AgeI added to the 5’ primer and the PasI site included in the 3’ 
primer (Table 5-1). A separate reaction was set up of for each of the mutants as 
follows: 
10x High fidelity PCR buffer      2.5 µl 
50 mM MgSO4         1 µl 
10 µM DNTP mix      0.5 µl  
10 µM AgeI primer      0.5 µl 
10 µM PasI primer      0.5 µl 
50 ng/µl Mutant plasmid      1 µl 
Sterilised dH2O      18.9 µl 
Platinum™ Taq DNA Polymerase High Fidelity (5 units/µl)  0.1 µl  
The PCR reaction was run on the following programme.  
 
Figure 5-9: PCR programme to add AgeI and PasI restriction sites to mutant inserts 




5.4.19  Double digestion 
Digestion of mutant inserts 
The Sl2, McCb and Sl2/McCb PCR products from above were digested with AgeI 
(Thermo Fisher Scientific, ER1461) and PasI (Thermo Fisher Scientific, ER1861) to 
produce “sticky ends.” Sequential digests were performed, both using the PasI 
buffer due to incompatibility of this enzyme in other buffers. The following reaction 
was set up: 
Mutant PCR products with restriction enzyme sites  20 µl  
 Sterilised dH2O      36 µl 
 10x PasI buffer        4 µl 
 PasI (10 units/µl)      2.5 µl 
 AgeI (10 units/µl)      2.5 µl  
The reaction was incubated at 37oC for 3 hours followed by 55oC for a further 3 
hours. The products were run on a 1% agarose gel and the expected band gel-
purified as previously outlined. 
Expression vector digestion 
Double digestion of the expression plasmid pcDNA3.1 (-) CCP 22-30 His using the 
above did not yield the expected band sizes, hence an alternative method was used. 
Alternative sources of PasI (PasI Optizyme™, Thermo Fisher Scientific, BP8073-1) 
and AgeI (AgeI-HF New England Biolabs, R3552S) were used and digestions 
performed sequentially. Ten parallel reactions were set up: 
Expression plasmid (250 ng/µl)    2 µl  
 Sterilised dH2O      15.9 µl 
 10x PasI buffer        2 µl 
 PasI (10 units/µl)      0.15 µl 
The reaction was incubated at 55oC for 2 hours followed by 20 minutes at 80oC to 
heat inactivate PasI. The resultant digest was purified using a Nucleospin column 




and eluted into 30 µl of elution buffer. Twelve reactions were then set up in parallel 
each containing: 
PasI digest product      2 µl  
 Sterilised dH2O      19.5 µl 
 CutSmart buffer x10      2.5 µl 
 AgeI-HF (20 units/µl)      1 µl 
The digestion reaction was incubated for 15 minutes at 37oC. The size of digestion 
products was subsequently confirmed using agarose gel electrophoresis. The gel 
band of the expected size was excised and purified as detailed in 5.4.6.  
5.4.20  Ligation into expression vector  
Following digestion, the inserts and the expression vector had compatible ends. 
Three separate reactions were set up; Sl2 mutant insert + expression vector, McCb 
mutant insert + expression vector and Sl2/McCb mutant insert + expression vector. 
A 3 (insert): 1 (vector) molar ratio was calculated using New England Biolabs 
Ligation Calculator (http://nebiocalculator.neb.com/#!/ligation), with an insert DNA 
length of 906 bp, vector DNA length of 6391 bp and a vector mass of 50 ng, which 
resulted in using 21.26 ng of insert.  The concentration of the three purified inserts 
ranged from 44.4-60.7 ng/µl). The reaction was set up as follows: 
Gel purified insert (44.4-60.7 ng/µl)    0.35-0.48 µl 
5x ExpressLink™ T4 DNA ligase buffer    2 µl 
Gel purified expression vector (30 ng/µl)   1.67 µl 
Sterilised dH2O      4.85-4.98 µl 
ExpressLink™ T4 DNA ligase (5 units/µl)    1 µl 
As a negative control, a further reaction was set up which contained the digested 
expression vector only without an insert. The volume of sterilised dH2O was 
increased accordingly. 
The four ligation reactions were incubated at room temperature for 15 minutes 




transformed into 50 µl of One Shot™ TOP10F’ chemically competent E. coli cells 
(Thermo Fisher Scientific, C303003) as described in section 5.4.9. Blue/white 
screening was not possible as the expression vector did not contain a lacZα 
sequence.  
The next morning, four colonies were selected from each plate and expanded in LB 
broth with ampicillin as described in 5.4.9. Plasmid DNA was isolated by miniprep as 
described in 5.4.11. A diagnostic restriction digestion was performed using the 
restriction enzymes BamHI-HF (New England Biolabs, R3136S) and HindIII-HF (New 
England Biolabs, R3104S), which cleave either side of the full insert (CR1 signal 
peptide + CCP 22-30 + His tag), as shown in Figure 5-8. The reaction was set up as 
follows: 
Miniprep eluate (approx. 350 ng/µl)   1 µl 
10x CutSmart buffer     2.5 µl 
BamHI-HF (20 units/µl)     1 µl 
HindIII-HF 20 (units/µl)     1 µl 
Sterilised dH2O      19.5 µl 
As a positive control, 250 ng of original expression plasmid DNA (prior to digestion 
or ligation) was used as this contains an insert of the identical size, but without any 
mutations. The samples were incubated at 37oC for 15 minutes, run on a 1% 







5.5.1 Creation of the pCRII plasmid with CCP 22-30 insert 
A delay in the arrival of the expression plasmid meant it was necessary to produce a 
pCRII plasmid containing the CCP 22-30 insert, perform site-directed mutagenesis 
and then ligate the mutated insert into the expression plasmid. 
Full length human CR1 cDNA was used as a template for amplification of the region 
of interest. The sequence corresponding to CCP 22-30 was selected (nucleotides 
4210-5937, amino acids 1404-1979), which encompasses LHR-D (CCP 22-28) and 
CCP 29-30. The intended amplicon was 1729 bp and is shown in Figure 5-10. 
 
Figure 5-10: Amplified region of CR1 cDNA 
CR1 cDNA sequence (double black line) is shown with the region corresponding to the mature CR1 
peptide (below in grey). CR1 signal peptide is shown in pink and the functional regions of CR1 are 
outlined (annotated colour blocks). The CCP 22-30 amplified is shown at the top of the figure (red 
arrow). 
The primer pair LHRD_F and LHRD_R were used to amplify the region of interest by 
PCR. To permit TA cloning, the PCR product was incubated with dATP and GoTaq G2 
DNA polymerase to add adenine overhangs to the 3’ ends of the amplicon. The 
resultant product was run on a 1% agarose gel at 80V for 40 minutes and stained 
with ethidium bromide for 15 minutes. The expected band at ~1.7 kb was excised 
while protecting it from UV light (Figure 5-11, Gel A). DNA was purified from the gel 
slice, eluted with 30 µl of elution buffer and quantified as 168.9 ng/µl on 
spectrophotometry. The purified amplicon was ligated into the commercial vector 
pCRII at a ratio of 3:1 (amplicon:vector) and transformed into One Shot™ TOP10F’ E. 
coli chemically competent cells. 100 µl of the reaction was spread on an LB agar 




Thirteen white colonies were selected from the LB agar plate and screened for the 
presence of the desired insert using colony PCR with the primer pair T7_PROM (T7 
promoter region) and SP6_PROM (SP6 promoter region). These regions flank the 
MCS of the cloning vector, therefore amplifying any insert contained. PCR products 
were visualised on a 1 % agarose gel (Figure 5-11, Gel B). 
 
Figure 5-11: Amplification and cloning of CCP 22-30 fragment. 
Gel A: Amplification of CCP 22-30 from CR1 cDNA using primer pair LHRD_F and LHRD_R produces a 
PCR product of expected molecular weight (~1.7kb). Lanes X and Y are both samples of the same PCR 
reaction. 
Gel B: Following ligation and transformation of above amplicon, colonies were screened by colony 
PCR.  
Primers spanning the multiple cloning site (MCS) were used. Each lane represents a unique colony. 
 Lanes 1, 2, and 6-13 show bands at the expected molecular weight (~1.7 kb) 
PCR products were run on 1% agarose gels with 5 µl Quick-Load® 1 kb DNA ladder and stained with 
ethidium bromide. 
Ten colonies produced bands at the expected molecular weight (~ 1.7 kb) when 
amplified with T7_PROM and SP6_PROM primers. Eight “positive” colonies (1, 2 and 
7-12) and two “negative” colonies (3 and 4), serving as negative controls, were 
expanded overnight in LB broth with ampicillin. Minipreps were performed the next 
morning to purify the plasmid. A diagnostic restriction digest was performed using 
EcoRI to digest the insert from the vector. The digested plasmids were then run on 






Figure 5-12: EcoRI restriction digestion of miniprep eluates. 
Lanes 1, 2 and 5-10 contain the two expected bands; vector at ~ 4kb and insert at ~1.7 kb. Lanes 3 
and 4 are negative controls identified through colony PCR (see above), which did not contain the 
insert.  
NB - Lanes correspond with those samples in Figure 5-11. 
PCR products were run on a 1% agarose gel with 5 µl Quick-Load® 1 kb DNA ladder and stained with 
ethidium bromide. 
5.5.2 Sequencing of the inserts 
Clone 1 was selected for Sanger sequencing of the CCP 22-30 insert. Spacing and 
direction of the sequencing primers is shown below: 
 
Figure 5-13: Spacing and direction of primers for sequencing of the insert. 
The region of the cloning vector (pCRII) immediately surrounding the insert is also shown to illustrate 
where the SP6_PROM and T7_PROM primers bind. 
Sequences were aligned against the nucleotide sequence of human mRNA for CR1 





Figure 5-14: Sanger sequencing of CCP 22-30 insert (Clone 1) 
Reads from insert-specific sequencing primers SP1 and SP4 (NB – sequencing with SP2 failed in this experiment) and vector-specific sequencing primers (T7_PROM 
and SP6_PROM) are shown. Filled red arrows indicate perfect alignment with the reference sequence. White bars within the red arrows indicate a mismatch 
(highlighted by blue circle). The insert shows the section of the chromatogram from SP1 corresponding to the mismatch at position 5416 on the plasmid with the 





Although the sequencing primer SP2 failed to provide a read, overall sequencing 
coverage was adequate. All regions of the insert aligned with the CR1 reference 
sequence (https://www.ncbi.nlm.nih.gov/nuccore/Y00816), but a CT mismatch 
was detected at plasmid nucleotide position 5416 by the SP1 and T7_PROM primer. 
This mutation on the insert corresponds to nucleotide 5654 and amino acid 1885 on 
the CR1 reference sequence, resulting in a non-synonymous codon change from 
ACT  ATT which represents an amino acid change of threonine (T) to isoleucine (I). 
Six further clones were selected to investigate this potential mismatch further to 
undergo targeted sequencing using just the T7_PROM sequencing primer (which 
provided the best coverage of the region in question). All six clones showed the 
same mutation, suggesting this was either in the template cDNA or introduced very 
early in the amplification PCR process (data not shown). 
Alternative online reference sequences of mRNA from this region of the CR1 gene 
were interrogated to ascertain whether the accepted amino acid in the human 
genome sequence at this codon represents a threonine or an isoleucine.  
Alternative sequences were retrieved from the National Center for Biotechnology 
Information (NCBI) GenBank and dbSNP databases were used.  Gorilla (Gorilla 
gorilla) and chimpanzee (Pan troglodytes) sequences were also reviewed to 





Source Sequence ID Species 
Reported amino 
acid 
NCBI GenBank Y00816.1 Homo sapiens T 
NCBI GenBank X05309.1 Homo sapiens T 
NCBI GenBank XM_011509205.1 Homo sapiens I 
NCBI GenBank XM_006711166.2 Homo sapiens I 
NCBI GenBank NM_000651.4 Homo sapiens I 
NCBI GenBank NM_000573.3 Homo sapiens I 
NCBI dbSNP rs=200990657 Homo sapiens I 
NCBI GenBank XM_019035938.1 Gorilla gorilla I 
NCBI GenBank XM_016949043.1 Pan troglodytes I 
Table 5-2: Comparison of published amino acids at the site of interest. 
T = threonine, I = isoleucine. Gorilla gorilla = Gorilla. Pan troglodytes = chimpanzee. 
 
Five of the seven human mRNA sources reported an isoleucine at this site. On 
further examination, both of the sequences reporting a threonine at this site were 
published by the same group (Klickstein et al., 1987, 1988). Both gorilla and 
chimpanzee mRNA also contained an isoleucine at this site, suggesting that this was 
the ancestral amino acid. As such, it was determined that the C nucleotide at 
position 5416 change in our plasmid was unlikely to be a mutation and the observed 
mismatch was more likely to be due to a SNP or by a sequencing error in the 
reference sequence used. 
As such, Clone 1 was selected for further work and glycerol stocks made of the 
plasmid prior to site-directed mutagenesis. 
Of note, the expression plasmid pcDNA3.1 (-) CCP 22-30 His was sequenced and also 
found to contain an isoleucine instead of a threonine at the corresponding CR1 





5.5.3 Creation of Sl2 and McCb mutations 
The CCP 22-30 insert successfully ligated into the Clone 1 plasmid contains an LHR-D 
region corresponding to the Caucasian or “wild type” genotype of Swain-Langley 
and McCoy polymorphisms, i.e. bearing the Sl1 and McCa alleles. Table 5-3 
summarises the nucleotide, amino acid and charge changes of the wild type and 
planned mutant inserts. Coordinates are given as per the human mRNA sequence 







1595 and charge 
(McC) 
Amino acid 
1610 and charge 
(Sl) 
Wild type A A K (+) R (+) 
Sl2/McCa A G K (+) G (-) 
Sl2/McCb G G E (neutral) G (-) 
Sl1/McCb G A E (neutral) R (+) 
Table 5-3 Mutations and their respective nucleotide, amino acid and charge.  
Co-ordinates are given as per the complete ligated plasmid. 
Site-directed mutagenesis was performed using the enzyme CloneAmp HiFi 
Polymerase as detailed in section 5.4.15 . The primer pairs SL2_F/SL2_R and 
MCCB_F/MCCB_R (see Table 5-1) were used to introduce the Sl2 and McCb 
mutations respectively in separate PCR reactions. To reduce the chance of 
introducing unwanted mutations, PCR cycles were kept to a minimum (18 in total).  
Five µl of the resultant PCR product was run on a 1% agarose gel at 80V for 40 
minutes and stained with ethidium bromide to visualise the size of the product. This 
revealed a strong band at the expected size of ~6 kb (plasmid = 5699 bp) for both 





Figure 5-15. Site-directed mutagenesis PCR products for Sl2 and McCb mutants  
A band at ~6 kb is seen as expected. PCR products were run on a 1% agarose gel with 5 µl Quick-
Load® 1 kb DNA ladder and stained with ethidium bromide. 
The PCR product was treated with Dpn1 to remove the methylated DNA of the 
original template plasmid and purified. As only 18 PCR cycles had been performed, 
it was anticipated that a small amount of DNA would have been produced. As such, 
the sample was eluted twice using 15 µl of elution buffer to concentrate the DNA 
prior to ligation and transformation. The Sl2 and McCb PCR products had 
concentrations of 115 ng/µl and 67.7 ng/µl respectively. Five µl of each were 
transformed into E. coli as per section 5.4.9. 100µl of each transformation reaction 
was plated onto LB agar plates and incubated at 37oC overnight. Six colonies from 
each plate were expanded into “mini-broths” and plasmid DNA extracted by 
miniprep. One µl of each miniprep eluate was sent for Sanger sequencing using the 
sequencing primer SP1 (which provided the best coverage of the Sl2/McCb mutation 
site region; Table 5-1, Figure 5-13 and section 5.4.13). 
Clones were numbered sequentially and originated from Clone 1. Clones 1-1 to 1-6 
were from the experiment to introduce the Sl2 mutation (sequencing results Figure 
5-16) and Clones 1-7 to 1-12 from the McCb experiment (sequencing results Figure 
5-17). Clones 1-5 (Sl2) and 1-9 (McCb) were taken forward for full sequencing, which 





Figure 5-16. Preliminary sequencing of Sl2 mutation site-directed mutagenesis. 
Clones were sequenced with the SP1 sequencing primer. The Sl2 mutation region is circled in red. The chromatogram insert shows the Sl2 mutation region from Clone 





Figure 5-17. Preliminary sequencing of McCb mutation site-directed mutagenesis. 
Clones were sequenced with the SP1 sequencing primer. The McCb mutation region is circled in red. The chromatogram insert shows the McCb mutation region from 
Clone 1-9, with the clone sequence on the bottom and the reference sequence along the top in bold. The C5416T “mutation” is circled in green. Sequencing failed for 







Figure 5-18. Full sequencing of Sl2 and McCb mutant constructs. 
Panel A = Sl2 experiment. Panel B = McCb experiment. Sequencing primers used are adjacent to the read given. The mutation regions are circled in red. The C5416T 




5.5.4 Creation of the double mutant Sl2/McCb  
To produce the double mutant, Sl2/McCb, the plasmid containing the Sl2 mutation 
(Clone 1-5) was selected, the primer pair MCCB_F/MCCB_R (Table 5-1) were used to 
introduce the McCb mutation (section 5.4.15) and the PCR product was run on a 1% 
agarose gel at 80V for 40 minutes. 
 
Figure 5-19. PCR product of McCb mutant on background of Sl2 shows a band of expected size (~6 kb).  
PCR products were run on a 1% agarose gel with 5 µl Quick-Load® 1 kb DNA ladder and stained with 
ethidium bromide. 
A clear band was seen at the expected size (~6 kb). The PCR product was treated 
with Dpn1 and purified (detailed in 5.4.6) and eluted into 15 µl of elution buffer. 
The eluate concentration was determined by Nanodrop to be 82.5 ng/µl. Five µl of 
this was subsequently transformed into One Shot™ TOP10F’ E. coli chemically 
competent cells (described in 5.4.9). 100 µl of the transformation reaction was 
plated onto an LB agar plate containing ampicillin and incubated overnight at 37oC. 
Six colonies were selected for expansion and miniprep (5.4.11). Preliminary 
sequencing was performed using the SP1 primer only (Figure 5-20). Clone 1-5-3 
contained the double Sl2/McCb mutation and was selected for complete 






Figure 5-20. Preliminary sequencing of McCb mutation on back of Sl2. 
Clones were sequenced with the SP1 sequencing primer. The Sl2/McCb mutation region is circled in red.  
The chromatogram insert shows the Sl2/McCb mutation region fromClone 1-5-3,  





Figure 5-21. Full sequencing of the McCb mutation on back of Sl2.  
Sequencing primers used are adjacent to the read given. The mutation region is circled in red.  
The chromatogram insert shows the Sl2/McCb mutation region from the SP4 read, 




Please note, clone 1-5-3 was made before it was determined that the T seen at 
position 5416 was the ancestral allele and not a mutation (Table 5-2). An extra site-
directed mutagenesis step had previously been undertaken to change this 
nucleotide to a C using primer pair CAATCAGCTACACTTGTGACCCCGGC and 
GCCGGGGTCACAAGTGTAGCTGATTG. As such, the sequencing results for the 
Sl2/McCb double mutant in Figure 5-20 and Figure 5-21 show no deviation from the 
CR1 reference sequence at position 5416 on the plasmid. As the PasI restriction site 
was chosen for ligation into the expression plasmid (Figure 5-22), the 5416 area of 
the insert was not included in the final construct, rendering this extra site-directed 
mutagenesis step irrelevant to subsequent experiments. 
5.5.5 Sub-cloning of the CCP 22-30 mutants into the expression plasmid 
The AgeI and PasI restriction sites on the expression plasmid were chosen for sub-
cloning (shown on Figure 5-8). On the expression plasmid, the AgeI site is 
immediately prior to the CR1 signal peptide and the PasI restriction site is midway 
along the CCP-22-30 insert. This strategy therefore preserves the signal peptide and 
the His tag on the expression plasmid, but allows for the removal of the most of the 
existing CCP 22-30 region to allow replacement with the new mutant inserts, which 
already contain a PasI restriction site as shown below.  
 
Figure 5-22. PasI restriction site in CCP 22-30 insert. 
The position of the restriction site is shown with respect to the Sl2 and McCb sites.  
The grey box represents the mature CR1 protein and the blue box the LHR-D region of CR1. 
The AgeI restriction site was added to the 5’ end of the Sl2, McCb and Sl2/McCb 
mutant inserts using the AGEI_primer as described in 5.4.18 and was combined with 
the PASI_primer (see Table 5-1). This was expected to produce a DNA sequence  




and Sl2/McCb mutant inserts. 2.5 µl of the product from each PCR reaction was then 
run on a 1% agarose gel at 80V for 40 minutes and stained with Syber Safe. Clear 
bands were seen at ~1 kb. 
 
Figure 5-23. Mutant inserts after amplification using AGEI_PRIMER and PASI_PRIMER. 
 Bands seen of the expected size (~ 1 kb). PCR products were run on a 1% agarose gel with 5 µl Quick-
Load® 1 kb DNA ladder and stained with Syber Safe. 
A double digest of the mutant inserts was subsequently undertaken using the 
restriction enzymes AgeI and PasI. Owing to the specificity of the PasI enzyme, both 
steps were performed in the PasI buffer as described in 5.4.19. The digestion 
products were then run on a 1% agarose gel and the digested DNA purified by gel 
extraction of the ~ 1 kb band. 
High quality maxiprep DNA of the expression vector pcDNA 3.1 (-) CCP 22-30 His 
was digested separately (detailed in 5.4.17). The double digestion of the expression 
vector was simulated using the SnapGene software and predicted to create two 
fragments of 908 bp and 6361 bp, with the larger fragment representing the desired 
vector for further subcloning. Unfortunately, double digestion of the vector using 
the same approach as for the mutant inserts did not yield bands of the anticipated 




PasI enzyme, a lower concentration of PasI (in PasI buffer) and a shorter incubation 
time with PasI. A method was found (5.4.19) which produced a band of the 
expected size (~7.3 kb) on an 0.75% agarose gel. (Figure 5-24). Five µg of the 
expression vector was subsequently digested with PasI using this approach.   
 
Figure 5-24. Expression vector pcDNA 3.1 (-) CCP 22-30 His before and after digestion with PasI.   
Cut (uncoiled) and uncut (supercoiled) vector are seen to run at different sizes as expected. PCR 
products were run on a 0.75% agarose gel with 5 µl Quick-Load® 1 kb DNA ladder and stained with 
Syber Safe. 
The resultant PasI digest was purified using a Nucleospin® column (see section 
5.4.4) and the eluate further digested with AgeI-HF in CutSmart buffer (5.4.19). This 
double digest was run on a 0.75% agarose gel and the gel band corresponding to 
the expected size of the cut vector was excised and purified as detailed in 5.4.6. This 
process is shown in Figure 5-25. The double digestion produced a band of the 
expected size (~6.9 kb) representing the cut vector (lane 3). As the samples were 
run on a 0.75% gel, smaller bands were harder to visualise. A very faint band was 
seen at ~ 900 bp (seen as a diffuse haze in lane 3) representing the excised insert 





Figure 5-25. Double digest of expression vector with PasI and AgeI. 
 Lane 1 = uncut vector. Lane 2 = vector digested with PasI only.  Lane 3 = vector digested with PasI 
and AgeI produces a band at ~6.9 kb as expected.  
PCR products run on a 0.75% agarose gel with 5 µl Quick-Load® 1 kb DNA ladder and stained with 
Syber Safe.  
With the inserts and the vector now having compatible ends, ligation was 
performed. A 3:1 insert:vector ratio was set up of each of the three ligation 
reactions (Sl2 mutant insert + expression vector, McCb mutant insert + expression 
vector and Sl2/McCb + expression vector) and a negative control comprising the 
vector without an insert. Ligations were set up as detailed in 5.4.20 and incubated 
at room temperature for 15 minutes followed by 2 hours at 4oC. Five µl of each 
ligation reaction was then transformed into a separate vial One Shot™ TOP10F’ E. 
coli cells and subsequently plated onto LB agar plates containing ampicillin. Blue / 
white screening was not possible with this plasmid. Plates were incubated overnight 
at 37oC. The plates from the Sl2, McCb and Sl2/McCb reactions showed good growth 
(35 colonies, >200 colonies and >200 colonies respectively) in comparison to the 
plate from the vector only reaction (12 colonies).  
Four colonies were selected from each plate, expanded in LB broth with ampicillin 




performed using restriction enzymes BamHI-HF and HindIII-HF, which cleave either 
side of the full insert, (i.e. section containing the CR1 signal peptide + CCP 22-30 + His 
tag). These restriction sites are shown in Figure 5-8. The undigested expression 
plasmid (containing the CR1 signal peptide + CCP 22-30 + His tag) was used as a positive 
control.  
 
Figure 5-26. Diagnostic restriction digest of final mutant constructs using BamHI-HF and HindIII-HF.  
The first two lanes (positive control, labelled with “+”) are the original undigested expression plasmid 
which contains the CR1 signal peptide, CCP 22-30 and His tag but no mutations. Lanes 1-4 are from 
the ligation of the Sl2 insert + digested expression vector, lanes 5-8 from McCb + digested expression 
vector and lanes 9-12 from Sl2/McCb double mutant insert + digested expression vector. No 
constructs contain inserts of the expected size. PCR products were run on a 1% agarose gel with 5 µl 
Quick-Load® 1 kb DNA ladder and stained with ethidium bromide. 
As expected, digestion of the positive control provided a band representing the vector 
at ~ 6 kb and one representing the insert at ~ 1.7 kb. However, the pattern of the other 
restriction digests suggested none of the constructs contained inserts of the expected 
size. To try and understand where the process had failed, the minipreps corresponding 
to lanes 1 + 2 (Sl2), 5 + 6 (McCb) and 9 and 10 (Sl2/McCb) were sequenced using the SP1, 
SP2, SP4 and T7_PROM primers. None of the plasmids contained CR1 inserts. 
Unfortunately, time did not permit the continuation of this project. I intend to 






5.6.1 Generation of Knops blood group mutant inserts 
The aim of this chapter was to generate expression constructs of three short 
proteins containing the Knops blood group mutations Sl2, McCb and the double 
mutant Sl2/McCb, in order to examine whether these mutations might influence 
MBL and C1q binding to the region. Time constraints did not permit this. However, 
amplification of the relevant CCP 22-30 region of CR1 cDNA and ligation into the 
cloning vector pCRII with subsequent site-directed mutagenesis to introduce the 
nucleotide changes for the Sl2, McCb and Sl2/McCb polymorphisms were successful.  
5.6.2 Inability to ligate mutant inserts into digested expression vector 
Attempts to subclone the mutant inserts into the expression vector pcDNA 3.1 (-) 
CCP 22-30 His were unsuccessful. Double digestion of the vector was challenging 
and it is possible that neither the inserts nor the vector were correctly digested. The 
unique restriction sites AgeI and PasI were chosen for subcloning as they would 
allow for insertion of the CR1 mutants whilst preserving the CR1 signal peptide and 
His tag. The AgeI restriction site was added to the mutant inserts using a specifically 
designed primer and amplified by PCR. The PasI site was naturally occurring in the 
CCP 22-30 insert (see Figure 5-22). Following introduction of the AgeI site, the 
expected PCR product size was verified by gel electrophoresis, but sequencing was 
not performed. Gel electrophoresis would not have been sufficiently sensitive to 
confirm whether the AgeI site had been incorporated as planned. As such, it may be 
that the inserts did not have AgeI sites.  
It is also possible that the use of the PasI enzyme contributed to the failure of 
ligation. Whilst commercially available, this is not a common restriction enzyme and 
only two suppliers provide it. This enzyme is only functional in its own specific 
buffer and is acknowledged to be prone to star activity (Restriction Enzymes Buffer 
Activity Chart, Thermo Scientific, 2014). For future work, an alternative subcloning 




5.6.3 Troubleshooting for future experiments 
PasI was selected as it represented a unique cutter in the expression vector which 
allowed the preservation of the CR1 cDNA sequence beyond it and the His tag. 
However, it is clear from the data presented that the enzyme has been suboptimal 
for this task. There are no other unique cutters within the original insert of the 
expression vector pcDNA 3.1 (-) CCP 22-30 His that would preserve the His tag. 
Alternative subcloning strategies were considered using the “dual cutters” function 
on SnapGene. This identified BsmBI as a possible candidate (Figure 5-27).  
 
Figure 5-27. New cloning strategy using BsmBI restriction sites on the cloning and expression 
plasmids. 
BsmBI should excise a 569 bp region containing the desired mutations when 
digesting the pCRII-based plasmid and also preserve the CR1 signal peptide and His 
tag when digesting the pcDNA 3.1 (-) CCP 22-30 His expression plasmid (Figure 
5-27). Potential colonies will be sequenced to select those with the desired 
orientation of the insert. This approach will be explored as soon as time permits.  
5.6.4 The Thr1885Ile substitution 
cDNA for this project was kindly supplied by Lloyd Klickstein (Boston, USA) with the 
CR1 mRNA sequence which was used for reference 
(https://www.ncbi.nlm.nih.gov/nuccore/Y00816) also published by the Klickstein 




between the reference sequence and that obtained by Sanger sequencing. This 
corresponded to a C5654T nucleotide substitution and Thr1885Ile amino acid 
substitution (or C5416T if using the cloning plasmid coordinates). The substitution 
results in the neutral, nonpolar amino acid isoleucine instead of the polar amino 
acid threonine.  
Interestingly, this substitution was also present in the expression plasmid pcDNA 3.1 
(-) CCP 22-30 His, which cited a different source of CR1 cDNA (Prof. J. Cohen 
Université de Reims Champagne-Ardennes, Reims, France) (Jacquet et al., 2013). 
After reviewing published CR1 cDNA sequences, it was determined that instead of 
being a substitution, the isoleucine was likely to represent the ancestral amino acid 
(Table 5-2) and experiments were continued. Two previous reports have also noted 
this substitution and concluded that it is unlikely to affect CR1 function (Furtado et 
al., 2008; Vik and Wong, 1993).  
5.6.5 Future intended experiments 
Once the mutant inserts have been efficiently ligated into the expression vector, the 
aim will be to produce the wild-type and mutant CCP 22-30 proteins using the 
Freestyle™ 293 expression system (Thermo Fisher Scientific, K900001). The final 
plasmid (pcDNA 3.1 (-) CCP 22-30 *mutant* His) containing the mutant inserts Sl2, 
McCb or Sl2/McCb, the CR1 signal protein and His tag will be transiently transfected 
into the HEK 293-F cells, and after 72 hours the his-tagged recombinant protein in 
the culture supernatant will be purified on a nickel-nitrilotriacetic acid (Ni-NTA) 
column. The intended method is as described by the authors of the original plasmid 
(Jacquet et al., 2013). Surface plasmon resonance (SPR) will then be used to 
examine whether the mutations alter how the CR1 fragments bind to MBL, C1q and 
L-ficolin as described in (Jacquet et al., 2013). Results from these experiments will 
help to shape the future direction of this research project. Potential directions are 





6 General Discussion and Conclusion 
6.1 Summary of findings 
The aim of this thesis was to investigate the relationship between malaria and the Sl 
and McC polymorphisms in CR1 and examine potential hypotheses for the results 
found. In Chapter 2 using the power of a large case-control study in Kenya, I 
identified a protective association between Sl2 homozygosity and both cerebral 
malaria (CM) and death from malaria. The associations were most clearly seen in 
children who had normal α-globin, suggesting that previous studies which did not 
include α+thalassaemia in their models may have obfuscated this important 
association. In contrast, the McCb polymorphism was associated with increased 
odds of cerebral malaria and may be under selection pressure from diseases other 
than malaria.  
The specificity of these associations to cerebral malaria alone, and not other sub-
phenotypes of the disease, lead to investigation of the potential functions of these 
polymorphisms. In Chapter 3, using an IFA with confocal microscopy and fresh 
blood samples from children prospectively genotyped for the polymorphisms, I 
found no evidence that Sl2 or McCb influenced the number or volume of CR1 
clusters formed on erythrocyte membranes. Subsequently in Chapter 4, using a 
variety of methods I could find no compelling evidence that an immortalised human 
brain endothelial cell line (HBEC-5i) expressed CR1. Finally, whilst the work in 
Chapter 5 made significant headway towards expressing the LHR-D regions 
containing the Sl and McC mutations for examining their binding affinities with the 
complement components MBL, C1q and L-ficolin, there was insufficient time to 
complete this project.  
My hope is that this thesis will reignite discussion into the role of the Sl and McC 
polymorphisms in malaria and provide a firm foundation for future research into 
their function. I hope also that my work will prompt other groups to reanalyse their 




6.2 Limitations of these findings 
6.2.1 Limitations of genetic association study 
No scientific work is without its limitations. One potential weakness in this work is 
in the hypothesis that the Sl and McC polymorphisms are the drivers behind the 
altered odds of cerebral malaria and death. Association is not causation and the 
possibility persists that these polymorphisms are not causal but actually signposts 
for another as yet unidentified mutation. As discussed in 2.7, we cannot be sure of 
this, but GWAS studies have not identified other potential SNPs associated with 
severe malaria in this region (Jallow et al., 2009; Malaria Genomic Epidemiology 
Network, 2015). In addition, there is strong biological plausibility to these blood 
group antigens being causative, as malaria has strongly influenced the frequencies 
of other blood groups. The best characterised of these is the Duffy blood group 
antigen (reviewed in (Langhi and Bordin, 2006)), which plays an essential role as the 
invasion receptor for P. vivax on reticulocytes (Chitnis and Miller, 1994; Miller et al., 
1976). Individuals with the Fy(a−b−) mutation in the promoter region of the DARC 
gene do not express Duffy antigen on erythrocytes (Tournamille et al., 1995) and 
the polymorphism has reached fixation in much of west and central Africa, areas 
where P. vivax is now rare (Culleton et al., 2008; Miller et al., 1976). Another 
example is the ABO blood group which has been repeatedly associated with severe 
malaria in epidemiological studies (Fry et al., 2008; Jallow et al., 2009; Rowe et al., 
2007; Timmann et al., 2012; Toure et al., 2012). Laboratory studies have 
demonstrated that P. falciparum strains cultured in blood group O form fewer 
weaker rosettes than those in A, B or AB blood (Carlson and Wahlgren, 1992; Rowe 
et al., 2007; Udomsangpetch et al., 1993). A further example is the Gerbich-negative 
blood group (Ge-) which occurs at high frequency in malaria-endemic regions of 
Papua New Guinea (Booth and McLoughlin, 1972) and results from the deletion of 
exon 3 in the Glycophorin C gene (Maier et al., 2003). Glycophorin C is an invasion 
receptor on erythrocytes for P. falciparum (Maier et al., 2003; Mayer et al., 2006). 




reasonable to pursue the hypothesis that the Sl and McC polymorphisms of the 
Knops blood group are causative in the respective protection against/susceptibility 
to against CM and death. However, as in all research, we must be mindful of 
alternative possibilities and be prepared to re-examine this if new evidence 
becomes available.  
Another limitation of this work may be in the construction of the genetic model. 
When developing models for genetic association studies, there is always a balance 
to be struck between ensuring important confounders are not excluded and taking 
care that the model is not over-fitted to the data (i.e., producing an analysis that 
corresponds too closely to the idiosyncrasies in a particular dataset, which is not 
able to fit subsequent datasets). The latter is a possibility in the analysis presented 
in Chapter 2 as the final model used in the case control study is quite complex. In 
particular, the novel finding of the Sl/α+thalassaemia interaction will require 
replication before it can be substantiated. Whilst the interaction was seen in both 
the case control and cohort studies, these were both performed on children 
residing in the same area of Kenya. Investigating this interaction in a separate 
population will therefore be paramount. This could be performed through 
collaboration with another of the large severe malaria case control studies 
comprising the MalariaGEN consortium (Achidi et al., 2008). Existing samples could 
be genotyped for α+thalassaemia by PCR (Chong et al., 2000) although this method 
is labour-intensive and may be off-putting for potential collaborators. An alternative 
might be the development of an algorithm to impute the α+thalassaemia genotype; 
as the α+thalassaemia polymorphism results in a 3.7 kb deletion in the α-globin 
gene it may be possible to identify a pattern of “missing” SNP calls beyond the start 
of the mutation. However, this to date, this approach has not been successful 
(personal communication with Dr Gavin Band, Wellcome Trust Centre for Human 
Genetics, Oxford, UK). 
However, it should be recalled that the Sl/α+thalassaemia interaction is also 




malaria protective polymorphisms. Of these, α+thalassaemia features prominently, 
with evidence of an epistatic interaction between α+thalassaemia and both and 
sickle cell (Williams et al., 2005c) and haptoglobin (Atkinson et al., 2014). It is likely 
such interactions may not only explain the complex global distribution of 
haemaglobinopathies (Penman et al., 2009) but also underpin why the same 
polymorphisms have different impacts on susceptibility to malaria when examined 
in different populations (Taylor et al., 2012).  As noted by Williams; “Interactions of 
this sort are unpredictable and, if common, could make the hunt for both protective 
alleles and their mechanisms even more difficult (Williams, 2006).” This is an 
important point when considering the findings of multi-centre case control studies 
of severe malaria; whilst it might be presumed their size would increase their power 
to detect new susceptibility loci, in truth it may obfuscate them if population-
specific interactions are not considered. This might explain why the Sl 
polymorphism was not identified in the recent multi-centre MalariaGEN study 
(Rockett et al., 2014), even though the study included the same Kilifi data that I 
analysed in Chapter 2. Indeed, the authors of this study state “(…) it is undoubtedly 
also the case that authentic genetic associations might be missed by multi-centre 
studies if the effect is weak and there is heterogeneity of effect across different 
study sites.” 
6.2.2 Limitations of laboratory-based studies 
In addition to the limitations of the genetic association analysis, there are important 
limitations to the laboratory work carried out in this thesis. As noted in Chapter 3, 
the immunofluorescent assay for measuring clusters on erythrocytes of different Sl 
and McC genotypes could be argued not to be physiologically relevant as it was 
performed at 4oC and used the α-CR1 antibody J3D3 rather than physiological 
ligands such as immune complexes. Another criticism of this work might be that the 
distances between the z-stacks on confocal imaging were too large to sufficiently 
image the size of the clusters. Both of these criticisms are valid and may potentially 




different if conditions were altered, some concessions must be made to practicality 
when designing experiments with field samples. 
Two limitations stand out clearly from the investigation of CR1 expression on HBEC-
5i in Chapter 4. Firstly, whilst an immortalised cell line is a good representation of 
human brain endothelium, is it not the same and findings should automatically not 
be extrapolated from one to the other. Examination of a reliable source of primary 
HBEC will be very important for clarification of these findings.  It would also be 
valuable to use the same methods to examine the expression of CR1 on HUVECs 
and compare this to the published findings (Collard et al., 1999; Langeggen et al., 
2002). The other obvious limitation of the work in this chapter was the confusion 
caused by using pool of multiple α-CR1 antibodies. The error here was to presume 
that the signal seen was coming from all antibodies equally and not examining their 
individual staining patterns earlier in the course of these experiments. It also 
became clear that a single isotype control was not a suitable comparison to a pool 
of antibodies, but that the control should have comprised the same number of 
separate antibodies as the α-CR1 pool. These errors were costly in terms of the 
time, but have been valuable on a personal level. Undertaking a PhD is as much 
about understanding what constitutes robust methodology as contributing to new 
knowledge. These errors will influence my future approaches to research questions.  
Time did not permit completion of the work in Chapter 5 and I was unable to 
express the mutant LHR-D regions in HEK 293-F cells as hoped. Progress was 
hampered by problems with restriction digests, which prevented effective digestion 
of the mutated inserts and subsequent subcloning into the expression vector. The 
fact that the PasI enzyme was hard to source may have hinted at its unpopularity 
due to technical difficulties. Again, whilst this problem was time-consuming, it was 
instructive in how to problem-shoot sub-cloning strategies, a skill that will be useful 




6.3 Questions remaining and future work 
6.3.1 What are the functional effects of the Sl and McC polymorphisms? 
Although the Sl and McC polymorphisms are sufficient to alter blood group, their 
function remains undefined. Production of the CCP 22-30 region of CR1 containing 
the mutations will permit detailed investigation into whether they alter the binding 
of MBL, C1q or ficolins. Experiments will be performed as outlined in section 5.6.5, 
with initial characterisation of the mutants by SDS-PAGE and circular dichromism 
and binding to the ligands assessed by SPR. Limitations of the previous work using 
short recombinant proteins spanning CCP 15-25 with the Sl and McC polymorphisms 
has been discussed in section 5.2.3 (primarily concerns regarding correct 
glycosylation of the proteins in a P. pastoris system) (Tetteh-Quarcoo et al., 2012). 
As such, it may also be prudent to repeat experiments from this study using 
recombinant proteins expressed in a mammalian system, including investigation of 
the recombinant mutant proteins’ ability to inhibit invasion by P. falciparum or 
rosetting of infected cells.  
If initial investigations suggest differences in binding to complement components, 
further parallel experiments could be performed to assess the complement 
activation. Precise experiments would be guided by the findings, but may include 
assays to determine the mutant effects on activation of the classical and lectin 
pathways. Such approaches might include wells pre-coated with immune complexes 
(for C1q investigation) or mannan (for MBL investigation) and incubation with 
normal human serum and transfected 293-F cells expressing different CCP 22-30 
mutants, with the subsequent deposition of C3b and the MAC on cell surfaces 
measured by measured by α-C3 and α-C5-9 antibodies respectively and flow 
cytometry (Palarasah et al., 2011). Experiments should be performed in factor B 
depleted serum to restrict the influence of the alternative pathway on the findings 




6.3.2 Why are the Sl and McC associations specific to cerebral malaria? 
The protective association between the Sl2/Sl2 genotype and severe malaria 
described in Chapter 2 is specific to the cerebral form of the disease and not 
associated with severe malarial anaemia or respiratory distress. This finding 
replicates that of Thathy et al. who described a CM-specific protective association 
for the Sl2/Sl2 genotype in a smaller study in Western Kenya in 2005 (Thathy et al., 
2005). This CM-specificity may provide a crucial route of investigation into the 
pathogenesis of the disease. The findings of Chapters 3 and 4 suggest that this is not 
due to a difference in clustering of CR1 on erythrocytes or to the expression of 
functional CR1 by human brain endothelial cells. While there is evidence that the 
Sl2/Sl2 genotype is associated with reduced rosetting (analysis of ex-vivo parasite 
samples from Mali in Chapter 2 and (Rowe et al., 1997)), further investigation is 
needed.  
If experiments outlined in 6.3.1 do suggest differences in MBL or C1q binding 
between the mutants, this could direct further investigation into rosetting. The Sl2 
mutation site is distant from the CR1 site involved in rosetting (CCPs 15-17) (Rowe 
et al., 2000) making it unlikely that it could directly influence rosetting. However, it 
is possible that MBL could act as a mediator of rosetting. Both natural IgM and α2-
macroglobulin have been identified as serum rosetting factors for subsets of P. 
falciparum parasites (Akhouri et al., 2016; Rowe et al., 2002a; Stevenson et al., 
2015b). MBL can bind to both the glycosylated fraction of natural IgM and to α2-
macroglobulin (Arnold et al., 2005, 2006a, 2006b). As such, MBL bound to CR1 on 
erythrocytes could be important in stabilising rosette formation. Individuals with 
different MBL-CR1 binding affinities (owing to different Sl/McC genotypes) could 
therefore produce stronger or weaker rosettes during malaria infection, potentially 
affecting disease severity. This possibility could be examined by performing 
rosetting assays with the ITvar60 rosetting strain of P. falciparum which binds IgM 
(Ghumra et al., 2012). Experiments could be repeated using primary erythrocytes of 




Alternatively, immune complexes may provide another important route of enquiry. 
As discussed in section 5.2, high levels of ICs have been reported in children with 
CM in a small Kenyan study (Mibei et al., 2008). The class and subclass of 
immunoglobulins making up these ICs differed significantly between CM and SMA, 
with children with CM displaying higher levels of IgG ICs than those with SMA. 
However, it is worth noting that IC-quantification in this study was performed using 
a C1q-based ELISA, which could bias against detecting ICs opsonised by MBL. In 
addition, the ability of this C1q-based assay to detect ICs containing IgM has been 
questioned. IgM has a high C1q affinity, potentially blocking further binding of C1q 
in the ELISA and leading to misleadingly low levels of identification of IgM-ICs 
(Pleass, 2009). As such, whilst these data linking severe malaria to IC subtypes are 
interesting, these findings require further investigation.  
MBL binds to human immunoglobulins; agalactosylated IgG (which comprise 35% of 
the IgG pool (Butler et al., 2003)), IgA and IgM (Malhotra et al., 1995; McMullen et 
al., 2006; Roos et al., 2001). Evidence suggests that MBL plays a role in clearing 
these ICs (Saevarsdottir et al., 2004, 2007) with the avidity of the MBL-
immunoglobulin interaction increased in immune complexes containing multiple 
immunoglobulin molecules (Arnold et al., 2006c). If, for example, CR1 with the Sl2 
polymorphism was found to bind MBL more strongly, it might help clear MBL-
opsonised IgG ICs more readily, potentially reducing IC deposition in the cerebral 
endothelium, lowering the production of pro-inflammatory cytokines.  
Experiments examining the effect of Sl and McC polymorphisms on IC binding and 
transfer to macrophages/monocytes could help investigate this possibility. 
Erythrocytes and PBMCs collected from the Immunology Cohort annual 
venepuncture in Kilifi, Kenya would represent a source of primary cells with the Sl 
and Mc genotypes of interest (collected in children with normal α-globin) and the 
capacity of erythrocytes of each genotype to transfer ICs to monocytes investigated. 
Erythrocytes carrying MBL-opsonised fluorescently-labelled ICs could be co-




quantified by flow cytometry (Emlen et al., 1992). The experiment could be 
performed with ICs of different classes. Influence of Sl/McC genotype on MBL-IC 
opsonophagocytosis could be also be studied by quantifying fluorescent ICs taken 
up by the monocytes using flow cytometry and cytokine multiplex assays 
(MacMullin et al., 2012). 
A number of other human red blood cell polymorphisms have been associated 
specifically with protection against CM and review of these may prompt alternative 
explanations for the association seen with Sl and McC.  Example include Southeast 
Asian ovalocytosis (SAO), HbC and G6PD have been discussed previously 
(section1.3.3) and may provide other potential CM-specific mechanisms to 
investigate. However, it should be recalled that associations between the Sl and 
McC polymorphisms were also seen for UM and other common childhood 
infections. As such, they may have broader effects, potentially affecting 
complement pathways as hypothesised above.  
6.3.3 What is the underlying mechanism of the Sl/α+thalassaemia 
interaction? 
The third outstanding question focuses on the mechanism of the Sl/α+thalassaemia 
interaction. It is worth reiterating that the novel interaction between Sl and 
α+thalassaemia reported in this chapter will need to be replicated in a separate 
population. If this is the possible, attempting to understand the mechanism 
underpinning it may help clarify the functional effects of both the Sl polymorphism 
and α+thalassaemia in CM.  
One point from the analysis in Chapter 2 that may be important is that the negative 
epistasis between α+thalassaemia/sickle cell trait was confined to cases without 
CM, whereas the Sl/α+thalassaemia interaction was only significant in cases with 
CM (section 2.7.4). This pair of interactions appear to have mutually exclusive 





Potential protective mechanisms for sickle cell and α+thalassaemia have been 
described in section 1.3.The geographical distribution of the two variants overlap 
and as such, they are often inherited together (Flint et al., 1998). However, the 
protective effects are not additive, instead coinheritance of HbAS and 
α+thalassaemia appears to cancel out their malaria-protective traits (negative 
epistasis) (Crompton et al., 2008; May et al., 2007; Williams et al., 2005c). Biological 
mechanisms for this unexpected interaction appear to be due to the properties of 
reduced rosetting, cytoadherence and PfEMP1 expression levels which are enjoyed 
by HbAS-IEs being nullified by co-inheritance with α+thalassaemia (Opi et al., 2014). 
Indeed, erythrocytes with both variants were indistinguishable from normal 
erythrocytes in terms of the above properties. 
The studies reporting negative epistasis between α+thalassaemia and HbAS did not 
examine the interaction by clinical outcome, instead considering all cases of severe 
malaria together (Crompton et al., 2008; May et al., 2007; Williams et al., 2005c). In 
Chapter 2, this interaction was examined by clinical outcome and found to only be 
pertinent to cases of severe malaria without CM. This was in contrast to the 
Sl/α+thalassaemia interaction which was only seen in cases with CM. We can read 
important points into these contrasting findings; firstly that the Sl/α+thalassaemia 
interaction is very unlikely to be attributable to the HbAS/α+thalassaemia 
interaction as the groups affected are mutually exclusive. Secondly, it would appear 
that these interactions have distinct biological effects as they affect different clinical 
outcomes.  
In contrast to the HbAS/α+thalassaemia negative epistasis, where addition of the 
two variants results in loss of malaria protection, the Sl/α+thalassaemia interaction 
is not simply additive. This might suggest that whilst the effects of HbAS and 
α+thalassaemia are biologically different (and not complimentary), the effects of Sl2 
and α+thalassaemia are biologically similar, but not additive as a “saturation point” 
of the effect is reached with either variant alone. An important consideration of this 




Erythrocytes with α+thalassaemia have fewer CR1 molecules on their membranes 
(Cockburn et al., 2004; Opi et al., 2016).  Erythrocytes with low CR1 copy numbers 
(<100) show greatly reduced rosetting when infected with P. falciparum (Rowe et 
al., 1997), which may be one of the protective mechanisms of α+thalassaemia. As 
such, it might be proposed that the Sl2 polymorphism has a similar effect on CR1 
copy number. However, the Sl2/Sl2 is actually associated with a very modest 
increase in CR1 copy number when compared with Sl1/Sl1 genotype (303 CR1 
copies, 95% CI 294–313 vs 256 CR1 copies; 95% CI 236–276 p<0.001) (Opi et al., 
2016), suggesting the effect is not due to absolute CR1 copy number.  
Instead, it is possible that the Sl2 polymorphism reduces one of the functions of 
CR1, thus while the absolute number of CR1 copies on the erythrocyte is static, the 
functional ability of CR1 on the erythrocyte is reduced to that of a cell with a lower 
CR1 copy number. If this were the case, co-inheritance with α+thalassaemia would 
further lower the absolute number of CR1 molecules on an erythrocyte, but with no 
additive protection, as a functional threshold had already been reached. 
Importantly, as with Sl2, α+thalassaemia has been reported to be associated with 
protection out-with malaria (respiratory infection, gastroenteritis and meningitis) 
(Allen et al., 1997; Wambua et al., 2006). As such, Sl2 and α+thalassaemia appear to 
mirror each other in both associated with protection against severe malaria and 
other childhood infections but not affecting parasite density. Further investigation 
into the function of the Sl2 polymorphism might in turn shed light on the protective 









This thesis presents evidence that Sl2, a common African polymorphism in 
complement receptor 1, is strongly associated with protection against CM and 
death. This association was made apparent by considering an interaction with 
α+thalassaemia. Previous studies have been contradictory in terms of associations 
between Sl/McC and severe malaria, but they did not consider the 
Sl2/α+thalassaemia interaction. The work in this thesis suggests that far from being 
inconsistent in their findings, previous studies may have simply been incomplete.  
The mechanism of how Sl2 might protect against CM has yet to be solved. This 
relationship does not appear to be explained by the expression of CR1 on human 
brain endothelium or through Sl/McC altering how CR1 clusters on the surface of 
erythrocytes. However, there are many possible threads to follow to determine the 
function of these polymorphisms and their influence on the malarial infection. In 
addition, determining the biological basis of the interaction between Sl2 and 
α+thalassaemia may also help explain how the latter confers protection against 
severe malaria.  
The work in this thesis also serves as a reminder that no gene acts alone, and that 
conflicting studies may be trying to tell you something important. Interactions with 
other biologically relevant genes should always be considered. 
 
We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started 
And know the place for the first time. 
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8.1 Mass spectrometry data 




Then “Home” “Search Log” under the heading “Mascot Utilities”. 
With reference to Figure 4-18 
Human matched proteins (matched against NCBIprot database) 
Job # 14467 = Band A (upper HBEC-5i lysate gel band) 
Job # 14468 = Band B (middle HBEC-5i lysate gel band) 
Job # 14470 = Band C (lower HBEC-5i lysate gel band) 
Job # 14483 = Band D (CR1-CHO lysate gel band) 
 
Restricted matching (matched against small internal database including CR1) 
Job # 14554 = Band A (upper HBEC-5i lysate gel band) 
Job # 14555 = Band B (middle HBEC-5i lysate gel band) 
Job # 14556 = Band C (lower HBEC-5i lysate gel band) 
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8.7 Grants arising from this thesis 
2016 Vacation Scholarship for Mr Alexandros Constaninou (£2000) – Medical 
Research Scotland (for work outlined in Chapter 4). 
 
8.8 Public engagement projects arising from this thesis 
2017  Meet the Researcher Day for sixth form students. Presentation of work 
funded by Medical Research Scotland at the Science Centre, Glasgow. 
 
2018 Edinburgh International Science Festival. Designing, producing and running 
an exhibit about rosetting and sequestration in severe malaria for primary 
and secondary school students. Plush toy erythrocytes and Velcro were used 
to explain the process. This project was carried out together with colleagues 






2017 “Visualising the Unseen” with Edinburgh College of Art. Working with 
undergraduate art students and ECAT scientists to create visual responses to 
scientists’ work. Conception, planning and execution. 
 
Themes from my thesis depicted on children’s T-shirts 
 




    
Artistic representations of cloning (left panel) and rosetting (right panel) 
 
    
Artistic representations of genetic mutations influencing the risk of cerebral malaria 
(Artists: Claudia Carreras, Vivian Chen, Katie Forrest-Smith and Rebecca Raper) 
 
